小松 嘉人 (コマツ ヨシト)

北海道大学病院 腫瘍センター准教授

各種企業治験、医師主導治験にも精力的に参加し活動しています。地元北海道においても臨床試験グループを立ち上げ、新規消化器癌薬物療法の開発を中心にこの分野での研究を中心に活動しています。抗がん療法の開発のみならず、支持療法や緩和ケアなど、幅広く包括的にOncologyに携わっております。

研究者基本情報

■ 学位
  • 医学博士, 北海道大学
■ URL
researchmap URLホームページURL■ ID 各種
J-Global ID■ 研究キーワード・分野
研究キーワード
  • 膵臓癌
  • 免疫療法
  • 胆道癌
  • 食道癌
  • 大腸癌
  • 胃癌
  • 消化管間質腫瘍
  • 化学療法
  • 緩和ケア
  • 支持療法
  • ゲノム医療
  • 免疫チェックポイント阻害薬
  • 薬物療法
  • 消化器癌(腫瘍学)
  • 消化器病学
  • 臨床試験
研究分野
  • ライフサイエンス, 腫瘍診断、治療学, 消化器癌薬物療法、消化器内科、GIST
■ 担当教育組織

経歴

■ 経歴
経歴
  • 2018年10月 - 現在
    北海道大学病院腫瘍センター, 化学療法部・CancerBoard部, 部長・診療教授
  • 2011年04月 - 現在
    北海道大学病院腫瘍センター, 化学療法部, 副センター長・部長・診療教授
  • 2008年01月 - 2011年03月
    北海道大学病院腫瘍センター, 化学療法部, 副センター長・部長・准教授
  • 2007年12月 - 2008年01月
    北海道大学病院外来治療センター, 化学療法部, センター長・准教授
  • 2008年
    - 腫瘍センター 准教授
  • 2006年 - 2007年
    地域医療連携センター 講師
  • 2006年 - 2007年
    Lecturer,Community Service Network Center
  • 2007年
    外来治療センター 准教授
  • 2004年 - 2006年
    北大癌診断治療学講座 腫瘍内科 助手 助手
  • 2004年 - 2006年
    Research Associate
  • 2001年 - 2004年
    北大病態内科学講座 第三内科 助手 助手
  • 2001年 - 2004年
    Research Associate
  • 1998年 - 2001年
    第三内科 研究員
  • 1998年 - 2001年
    Researcher
  • 1993年 - 1996年
    国立がんセンター 中央病院 薬物療法部 職員(医療系)
学歴
  • 2001年06月 - 現在, 北海道大学大学院医学研究科博士号取得, Graduate School of Medicine
  • 1989年03月 - 現在, 東京医科大学卒業
  • 1989年04月 - 2001年05月, 北海道大学, 医学部, 第三内科研究生
委員歴
  • 現在
    日本消化器内視鏡学会, 支部評議員, 学協会
  • 現在
    日本消化器病学会, 評議員, 学協会
  • 現在
    日本大腸肛門病学会, 代議員, 学協会
  • 現在
    日本胃癌学会, 評議員, 学協会
  • 現在
    日本臨床腫瘍学会, 協議委員, 学協会
  • 現在
    日本癌治療学会, 代議員, 学協会
  • 現在
    日本癌治療学会, PAL委員, 学協会
  • 現在
    日本癌治療学会, ガイドライン(GIST)WG委員, 学協会
  • 現在
    日本消化器病学会, 広報委員, 学協会
  • 現在
    日本臨床腫瘍学会, 認定施設審査部会委員, 学協会

研究活動情報

■ 受賞
  • 2009年10月, 日本癌治療学会, 優秀演題賞
    小松 嘉人
  • 2003年10月, 17th Asia Pacific Cancer Conference, Best Poster AWARD
    小松 嘉人
■ 論文
  • RAS/BRAF wild-type metastatic high-methylated colorectal cancer has gene expression patterns related to MSI-H and BRAF V600E mutant: a translational research.
    Shonosuke Wakayama; Shin Takahashi; Kota Ouchi; Yasuhiro Sakamoto; Tadamichi Denda; Atsuo Takashima; Yoshito Komatsu; Masato Nakamura; Hisatsugu Ohori; Tatsuro Yamaguchi; Yoshimitsu Kobayashi; Hideo Baba; Masanori Kotake; Kenji Amagai; Hitoshi Kondo; Ken Shimada; Yasuhide Yamada; Atsushi Sato; Satoshi Yuki; Akira Okita; Keigo Komine; Mika Watanabe; Satoshi Morita; Chikashi Ishioka
    Scientific reports, 2026年03月08日, [国際誌]
    英語, 研究論文(学術雑誌)
  • Prognostic Biomarkers and Immunotherapeutic Insights of Circulating Tumor DNA Analysis in Advanced Esophageal Squamous Cell Carcinoma From SCRUM-MONSTAR GOZILA Substudy.
    Yuqing Duan; Tadayoshi Hashimoto; Taro Shibuki; Hiroya Taniguchi; Yu Sunakawa; Yoshito Komatsu; Naoki Takahashi; Yuta Sato; Kensei Yamaguchi; Tomohiro Nishina; Tomonori Nakanoko; Shogen Boku; Taroh Satoh; Hisateru Yasui; Taito Esaki; Mitsuho Imai; Takao Fujisawa; Yoshiaki Nakamura; Hideaki Bando; Takayuki Yoshino
    JCO precision oncology, 10, 3, e2500971, 2026年03月, [国際誌]
    英語, 研究論文(学術雑誌), PURPOSE: Advanced esophageal squamous cell carcinoma (ESCC) has a poor prognosis, and current treatments provide limited survival benefits. This study aimed to identify prognostic biomarkers and therapeutic targets by genomic profiling of advanced ESCC using circulating tumor DNA (ctDNA). METHODS: The SCRUM-MONSTAR GOZILA study is a nationwide, plasma-based molecular profiling project using Guardant360, involving 31 core cancer institutions in Japan. We evaluated the genomic landscape of advanced ESCC and investigated associations between specific alterations and overall survival (OS). The correlation between blood tumor mutation burden (bTMB) and clinical outcomes in patients with PD-1 inhibitors was also assessed using multiple cutoff values (2, 4, 6, 8, and 10 mutations/Mb). RESULTS: Among 313 patients, alterations predominantly consisted of single nucleotide variants (SNVs, 68.9%) and copy number alterations (20.7%). TP53 was the most frequent alterations (88.5%), followed by PIK3CA (36.4%), NFE2L2 (24.3%), CCND1 (22.4%), and EGFR (20.1%). Amplifications in PIK3CA, FGFR1, CCND1, and EGFR, as well as mutations in NFE2L2, FGFR1, and RB1 were associated with worse OS (any P < .05). Multivariable analysis confirmed mutations in NFE2L2 or FGFR1 and amplifications in EGFR or PIK3CA as independent poor prognostic factors (all P < .05). In 142 patients treated with PD-1 inhibitors, no significant differences in objective response rate or progression-free survival were observed at different bTMB cutoff values (all P > .1). CONCLUSION: ctDNA analysis identified key genomic alterations linked to poor outcomes in advanced ESCC, revealing potential prognostic biomarkers and therapeutic targets. In contrast, bTMB did not show predictive value for the efficacy of PD-1 inhibitors in this study.
  • Predictors of the early discontinuation of anamorelin hydrochloride in gastrointestinal cancer-related cachexia: a multicenter retrospective cohort study (HGCSG2201).
    Kazuaki Harada; Shinya Kajiura; Kentaro Sawada; Kazuteru Hatanaka; Atsushi Sato; Ken Ito; Hotaka Tamura; Ayako Doi; Takayuki Ando; Michio Nakamura; Hiroshi Nakatsumi; Tetsuhito Muranaka; Susumu Sogabe; Takahiro Ishii; Shintaro Nakano; Masayoshi Dazai; Yusuke Sasaki; Yasuyuki Kawamoto; Satoshi Yuki; Yuh Sakata; Yoshito Komatsu
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 34, 3, 221, 221, 2026年02月19日, [国際誌]
    英語, 研究論文(学術雑誌), PURPOSE: Anamorelin hydrochloride (ANAM), used to treat cancer cachexia, is often discontinued early in clinical practice. Herein, we explored the clinical factors associated with the early discontinuation (Ed) of ANAM and examined its effect on treatment outcomes. METHODS: Clinical data of patients with gastrointestinal cancers who were administered ANAM between April and November 2021 from 16 institutions were retrospectively collected. Ed was defined as ANAM discontinuation within 4 weeks of initiation. ANAM efficacy was compared between the continuation (Co) and Ed groups. RESULTS: Of the 123 patients, 50 had an Ed of ANAM. The most common reasons were cancer progression (36%), adverse events (30%), and insufficient efficacy (22%). Age ≥ 75 years (odds ratio [OR] 4.11, 95% confidence interval [CI] 1.418-11.952, p = 0.009), no concomitant anticancer chemotherapy (OR 8.84, 95% CI 1.900-41.151, p = 0.006), and modified Glasgow prognostic score 2 (OR 2.65, 95% CI 1.065-6.604, p = 0.036) were significant risk factors for Ed. At 3 ± 1 weeks after ANAM initiation, the number of patients with increased appetite (Co 50.8% vs Ed 14.3%, p = 0.012) and food intake (Co 59.2% vs Ed 20.0%, p = 0.002) were significantly higher in the Co group than in the Ed group. CONCLUSION: Initiating ANAM while patients can still receive concurrent chemotherapy may help prevent Ed and achieve better therapeutic benefit. Trial registration The registration number in the UMIN Clinical Trial Registry is UMIN000051550. The date of registration is July 7, 2023.
  • Comparison of chemoradiotherapy and gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer: an integrated analysis of two randomized phase II trials (JCOG2408A).
    Yusuke Sano; Riku Kajikawa; Junki Mizusawa; Tatsuya Ioka; Masato Ozaka; Satoaki Nakamura; Yoshinori Ito; Junji Furuse; Satoshi Kobayashi; Haruhiko Fukuda; Takuji Okusaka; Masafumi Ikeda; Haruo Miwa; Naoki Sasahira; Fumio Nagashima; Kazuyoshi Ohkawa; Kentaro Yamazaki; Masashi Kanai; Taro Yamashita; Kazuo Hara; Yukiko Takayama; Yoshito Komatsu; Nao Fujimori; Naoki Hama; Ken Kamata; Terumasa Hisano; Satoshi Shimizu; Kazutoshi Tobimatsu; Shin Maeda; Makoto Ueno
    BMC cancer, 26, 1, 2026年02月10日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Two main therapeutic approaches are currently used for locally advanced pancreatic cancer (LAPC): chemoradiotherapy and systemic chemotherapy. It remains unclear which approach may be more promising, or whether these strategies should be considered alternative or complementary therapeutic options in the management of LAPC. Clinical outcomes and safety were assessed for S-1 plus concurrent radiotherapy (S-1 + RT) and gemcitabine plus nab-paclitaxel (GnP) in patients with LAPC. METHODS: We conducted a pooled exploratory analysis of individual patient data derived from two multi-institutional randomized phase II trials conducted by the Japan Clinical Oncology Group (JCOG1106 and JCOG1407). JCOG1106 evaluated S-1 + RT with or without induction chemotherapy. JCOG1407 compared GnP with modified FOLFIRINOX. Based on the results of these trials, S-1 + RT and GnP were selected as promising regimens for chemoradiotherapy and systemic chemotherapy, respectively. The primary endpoint of this study was progression-free survival (PFS). Inverse probability of treatment weighting (IPTW) with stabilized weights was applied based on the propensity score to account for baseline imbalances between the two groups. RESULTS: A total of 113 patients were included. After adjustment for patient characteristics, Kaplan–Meier curves showed median PFS, overall survival (OS), and distant metastasis-free survival (DMFS) of 10.2 vs. 9.3 (hazard ratio [HR], 0.88; 95% confidence interval [CI], 0.60–1.30), 19.1 vs. 21.2 (HR, 0.73; 95% CI, 0.48–1.11), and 11.5 vs. 13.1 months (HR, 0.73; 95% CI, 0.49–1.08) for S-1 + RT and GnP, respectively. Treatment received after protocol therapy differed substantially: 77.5% in the S-1 + RT group received single-agent chemotherapy, whereas 50.0% in the GnP group, received more intensive regimens, including multi-agent chemotherapy or chemoradiotherapy. CONCLUSIONS: GnP may offer advantages in suppressing micrometastatic disease, whereas S-1 + RT may provide benefits in local disease control. These findings suggest that both approaches represent important and complementary therapeutic options for LAPC. Prospective randomized studies are warranted to determine the optimal initial strategy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-026-15699-8.
  • HER2 Protein Overexpression, mRNA Expression, and DNA Amplification Across Solid Tumors: Comparison of Next-Generation Sequencing-Based Assays With Immunohistochemistry.
    Michiko Nagamine; Takao Fujisawa; Naoya Sakamoto; Yoshiaki Nakamura; Shigenori Kadowaki; Makoto Ueno; Shogen Boku; Yoshito Komatsu; Eiji Oki; Akitaka Makiyama; Norio Nonomura; Chigusa Morizane; Hidemichi Watari; Susumu Okano; Hiroji Iwata; Kenjiro Namikawa; Yutaka Hatanaka; Kanako C Hatanaka; Kenichi Taguchi; David Spetzler; Milan Radovich; Daniel Magee; Takayuki Yoshino; Matthew Oberley; Takeshi Kuwata
    JCO precision oncology, 10, e2500413, 2026年01月, [国際誌]
    英語, 研究論文(学術雑誌), PURPOSE: The tumor-agnostic approach has been increasingly adopted in precision oncology. Immunohistochemistry (IHC) is the standard biomarker testing for human epidermal growth factor receptor 2 (HER2)-targeted therapies, whereas next-generation sequencing (NGS) has been widely incorporated in routine clinical practices. Here, we investigated the concordance between NGS-based assays and IHC in HER2 testing. Interfering factors leading to discordant results between the assays were also studied. MATERIALS AND METHODS: Over 78,000 solid tumors across various types from two independent cohorts in the United States and Japan were investigated for HER2 DNA copy number, mRNA expression, and protein overexpression by whole-exome sequencing (WES), whole-transcriptome sequencing (WTS), and IHC, respectively. RESULTS: In the US cohort (n = 77,267), HER2 DNA amplification, mRNA overexpression, and IHC-positive (IHC-P) were detected in 4.9%, 10.1%, and 4.7% of the tumors, respectively. Positive results in at least one of the three assays were observed in 10.7% of tumors, while 3.9% were positive for all three assays. Using IHC as a comparator, WTS showed better sensitivity than WES but a lower positive predictive value. These results were consistent in the Japanese cohort (n = 1,225). Although the overall HER2 RNA expression level correlated well with IHC score and DNA copy number, the degree of correlation varied among tumor types. Heterogeneous distribution of IHC-P tumor cells was associated with discordant results between NGS-based assays and IHC. CONCLUSION: HER2-positive status in protein, mRNA, and DNA showed concordance in general but varied among tumor types. NGS-based assays, especially WTS, could be a useful predictive tool for HER2 testing in tumor-agnostic settings. Intratumor heterogeneity in HER2 protein expression should be considered when bringing bulk sequencing tests into clinical settings.
  • Successful re-administration after nano-liposomal irinotecan-induced severe hypersensitivity reaction: a case report.
    Ryota Kanno; Yoshitaka Saito; Yoh Takekuma; Kazuaki Harada; Yoshito Komatsu; Mitsuru Sugawara
    Journal of pharmaceutical health care and sciences, 11, 1, 110, 110, 2025年12月22日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Nano-liposomal irinotecan (nal-IRI) combined with 5-fluorouracil (5-FU) and levofolinate has been reported to extend the survival of patients with pancreatic cancer and represents an effective second-line treatment. Nal-IRI encapsulates IRI in liposomes modified with polyethylene glycol (PEGylation), which can lead to infusion reactions. Hypersensitivity reactions (HSR) to chemotherapeutic agents include both allergic and infusion reactions, which are difficult to distinguish. Severe HSR can be fatal; however, discontinuation of the suspected drug directly affects the treatment strategy. We report a case of severe HSR during the first nal-IRI administration, in which treatment was successfully continued with supportive management. CASE PRESENTATION: A woman in her early 80s with metastatic pancreatic cancer received nal-IRI + 5-FU + levofolinate as second-line treatment. Five minutes after the initiation of the first nal-IRI infusion, the patient developed a tightening sensation in the head, respiratory distress, convulsions, and loss of consciousness, with percutaneous oxygen saturation dropping to the 80% range. The nal-IRI infusion was immediately discontinued, and emergency management was initiated with intravenous infusion of hydrocortisone, famotidine, d-chlorpheniramine maleate, and oxygen administration, resulting in symptom improvement. Given the limited treatment options for metastatic pancreatic cancer and the patient's strong desire to continue therapy, we decided to re-administer the regimen with intensified management, increasing dexamethasone to 19.8 mg and adding famotidine 20 mg and d-chlorpheniramine maleate 5 mg. Furthermore, we adopted a three-step dose-escalation method. The infusion was started at one-third of the standard rate, increased to two-thirds after 30 min, and finally adjusted to the full rate after another 30 min, after confirming the absence of HSR symptoms. Consequently, the patient did not exhibit any signs of HSR, and the same administration method was continued for 11 cycles until disease progression. CONCLUSIONS: The novelty of this report lies in presenting, for the first time, the detailed course and process by which treatment was successfully continued in a patient experiencing severe HSR upon initial nal-IRI administration, through enhanced supportive care tailored to the characteristics of the drug and stepwise dose adjustment.
  • Combination chemotherapy for older patients with unresectable biliary tract cancer: a prospective observational study using propensity-score matched analysis (JON2104-B).
    Satoshi Kobayashi; Kohei Nakachi; Kouji Yamamoto; Makoto Ueno; Yuta Maruki; Kenji Ikezawa; Takeshi Terashima; Satoshi Shimizu; Kotoe Oshima; Kunihiro Tsuji; Yoshiharu Masaki; Hidetaka Tsumura; Taro Shibuki; Masato Ozaka; Naohiro Okano; Yukiyasu Okamura; Kumiko Umemoto; Tatsunori Satoh; Yasushi Kojima; Kazuhiko Shioji; Hiroko Nebiki; Toshifumi Doi; Atsushi Naganuma; Shigeki Kataoka; Emiri Kita; Hiroyuki Asama; Kaoru Tsuchiya; Michiaki Unno; Reiko Ashida; Kazuyuki Matsumoto; Izumi Ohno; Takao Itoi; Yuji Negoro; Yasunari Sakamoto; Shiho Arima; Akinori Asagi; Hiroyuki Okuyama; Yoshito Komatsu; Noritoshi Kobayashi; Hiroaki Nagano; Junji Furuse
    Journal of gastroenterology, 60, 12, 1584, 1595, 2025年12月, [国内誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Systemic chemotherapy with gemcitabine plus S-1 (GEM + S-1), GEM + CDDP plus S-1 (GEM + CDDP + S-1), or gemcitabine plus cisplatin (GEM + CDDP) is standard treatment for advanced biliary tract cancer (aBTC). We aimed to evaluate the efficacy and safety of combination chemotherapy in older patients with aBTC. METHODS: This multicenter prospective observational study (JON2104-B, UMIN000045156) included patients aged ≥ 70 years with aBTC. Inverse-probability weighting propensity-score analyses (IPW) were used to compare overall survival (OS) as the primary endpoint and progression-free survival (PFS) across treatment groups. RESULTS: This study included 305 patients between August 2021 and January 2023. Of them, 75, 131, 26, 52, and 10 received GEM + CDDP + S-1, GEM + CDDP, GEM + S-1, gemcitabine, and S-1; their median ages were 74, 75, 77.5, 80, and 80 years, and approximately 24%, 16.8%, 23.1%, 9.6%, and 0% had G-8 scores of > 14, respectively. GEM + CDDP had a safety profile comparable to that of GEM + CDDP + S-1 but was more toxic than gemcitabine. Per IPW, the hazard ratio (HR) for GEM + CDDP + S-1 versus GEM + CDDP was 0.80 for OS (95% confidence interval [CI], 0.55-1.17) and 0.55 for PFS (95% CI 0.38-0.80). The HR for GEM + CDDP versus gemcitabine was 0.74 for OS (95% CI 0.42-1.29) and 0.79 for PFS (95% CI 0.42-1.49). CONCLUSIONS: GEM + CDDP + S-1 was associated with longer PFS without additional toxicity than GEM + CDDP for fit older patients. However, the OS for both were not statistically different. The efficacies of GEM + CDDP and gemcitabine for vulnerable older patients did not also differ significantly. These findings highlight the importance of vulnerability in patients with aBTC.
  • Evaluation of factors associated with drug fever following gemcitabine and nanoparticle albumin-bound paclitaxel treatment for pancreatic cancer.
    Yoshitaka Saito; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 33, 11, 1006, 1006, 2025年11月01日, [国際誌]
    英語, 研究論文(学術雑誌), PURPOSE: Gemcitabine (GEM) + nanoparticle albumin-bound paclitaxel (nab-PTX) is an effective treatment for advanced pancreatic cancer. However, drug fever is a frequently observed adverse effect of GEM, and PTX can also induce symptoms. This study aimed to identify factors for drug fever in the real-world treatment of pancreatic cancer with GEM + nab-PTX. METHODS: We retrospectively assessed patients with pancreatic cancer who received GEM + nab-PTX (n = 386). The primary endpoint was the identification of factor(s) associated with the incidence of drug fever following the first administration. We also assessed symptoms between specific patient groups. RESULTS: The incidence of drug fever following the first GEM + nab-PTX treatment was 12.7%. The median onset time was day 3 (range: 1-4) with a symptom duration of 1 (1-6) day. Unresectable setting (adjusted odds ratio [95% confidence interval]: 3.35 [1.35-8.32], P = 0.009) and elevated baseline C-reactive protein (CRP) levels (≥ 1.0 mg/dL) (3.55 [1.80-6.98], P = 0.0002) were identified as risk factors using the multivariable logistic regression analysis. Patients receiving regular antipyretic treatment with non-steroidal anti-inflammatory drugs (NSAIDs) and/or acetaminophen had a lower risk (0.42 [0.20-0.87], P = 0.02). No difference was observed in the impact of the type of antipyretics on drug fever between NSAIDs and acetaminophen. CONCLUSION: An unresectable disease status and high baseline CRP levels are risk factors for drug-induced fever, while patients receiving regular antipyretics are at lower risk of developing these symptoms during real-world treatment of pancreatic cancer with GEM + nab-PTX.
  • Baseline hypoalbuminemia enhances regorafenib-induced problematic fatigue development in real-world metastatic colorectal cancer treatment.
    Yoshitaka Saito; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 33, 11, 990, 990, 2025年10月29日, [国際誌]
    英語, 研究論文(学術雑誌), PURPOSE: Regorafenib, a multikinase inhibitor for treating metastatic colorectal cancer (mCRC), induces fatigue in 40-50% of administered patients, including approximately 10% of grade ≥ 3 cases. Additionally, hypoalbuminemia is associated with cancer- and chemotherapy-induced fatigue and frequently observed in patients with advanced cancers. This study aimed to assess the impact of baseline hypoalbuminemia on the development of clinically problematic fatigue in a real-world regorafenib treatment for mCRC. METHODS: Patients with mCRC who underwent regorafenib (n = 102) were divided into the control (baseline serum albumin levels ≥ 3.5 g/dL) and hypoalbuminemia (baseline serum albumin levels < 3.5 g/dL) groups, and retrospectively evaluated. The primary endpoint was comparison of grade ≥ 2 fatigue incidence during all treatment cycles. We also assessed the impact of grade ≥ 2 symptoms on the treatment efficacy. RESULTS: Incidence of grade ≥ 2 fatigue in all treatment cycles in the hypoalbuminemia group was 41.7%, which was significantly higher than that in the control group (14.1%, P = 0.008). In addition, grade ≥ 2 fatigue within the first cycle was significantly more confirmed in the hypoalbuminemia group than in the control group (37.5% vs. 11.5%, P = 0.01). Additionally, patients with early grade ≥ 2 fatigue within 14 days from treatment initiation had a significantly shorter time to treatment failure or overall survival than those without the symptoms. CONCLUSION: Patients with baseline hypoalbuminemia developed clinically problematic fatigue after regorafenib monotherapy for mCRC. Because regorafenib is a later-line mCRC treatment, successful management of emerging fatigue is crucial and requires further evaluation.
  • Factors associated with taxane-associated acute pain syndrome in pancreatic cancer patients receiving gemcitabine and nab-paclitaxel.
    Yoshitaka Saito; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
    Discover oncology, 16, 1, 1967, 1967, 2025年10月27日, [国際誌]
    英語, 研究論文(学術雑誌), PURPOSE: Taxane-associated acute pain syndrome (T-APS) is a common adverse event in patients treated with gemcitabine (GEM) + nanoparticle albumin-bound paclitaxel (nab-PTX) for pancreatic cancer. As several T-APS risk factors, such as age, cancer type, and taxane dose or formulation, differ between pancreatic cancer and other malignancies in previous studies, we aimed to identify factors associated with T-APS in a real-world setting of GEM + nab-PTX treatment for pancreatic cancer. METHODS: We retrospectively analyzed 394 patients with pancreatic cancer receiving GEM + nab-PTX. The primary endpoint was the identification of factors associated with all-grade T-APS. Symptom incidence was also compared across specific patient groups. RESULTS: T-APS occurred in 26.1% of patients after the first GEM + nab-PTX administration (grade 1: 21.6%; grade 2: 4.6%). Among patients with T-APS, 39.8% received medication, with more than two-thirds reporting symptom relief. Multivariable logistic regression analyses identified body mass index (BMI) ≥ 25 kg/m2 as a risk factor and baseline use of mild analgesics (non-steroidal anti-inflammatory drugs [NSAIDs] and/or acetaminophen) as a preventive factor (adjusted odds ratio, 2.98; 95% confidence interval, 1.68-5.31; P = 0.0002 for BMI, 0.48; 0.26-0.89; P = 0.02 for mild analgesics). A subgroup analysis comparing baseline NSAIDs and acetaminophen in patients receiving mild analgesic monotherapy showed no significant difference (P = 0.49). CONCLUSION: Our study identified BMI ≥ 25 kg/m2 as a risk factor and baseline use of mild analgesics as a preventive factor for T-APS development in a real-world GEM + nab-PTX regimen for pancreatic cancer.
  • Impact of baseline hypoalbuminemia on peripheral edema induced by gemcitabine and nab-paclitaxel for pancreatic cancer treatment.
    Yoshitaka Saito; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 33, 11, 938, 938, 2025年10月13日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Gemcitabine (GEM) + nanoparticle albumin-bound paclitaxel (nab-PTX), which is effective in treating pancreatic cancer, frequently induces peripheral edema. Hypoalbuminemia causes generalized peripheral edema and occasionally occurs in patients with cancer, but reports evaluating its interaction with chemotherapy-induced symptoms are lacking. Therefore, we aimed to assess the effect of baseline hypoalbuminemia on peripheral edema following real-world GEM + nab-PTX therapy. METHODS: Patients with pancreatic cancer receiving GEM + nab-PTX (n = 212) were divided into a hypoalbuminemia group (serum albumin levels < 3.5 g/dL), and a control group without hypoalbuminemia, and retrospectively evaluated. The primary endpoint was the incidence of grade ≥ 2 peripheral edema within 6 months of treatment initiation. RESULTS: The incidence of grade ≥ 2 peripheral edema within 6 months was 5.7% in the control group and 22.6% in the hypoalbuminemia group, with a significant difference (P = 0.0009), meeting the primary endpoint. The onset time of grade ≥ 2 peripheral edema was significantly earlier in the hypoalbuminemia group than in the control group (P = 0.0003). In contrast, the incidence of all-grade symptoms was 20.1% in the control group and 30.2% in the hypoalbuminemia group, which was not significantly different (P = 0.13). These results were confirmed in the propensity score-matched population. Multivariate Cox proportional hazard regression analyses showed that baseline hypoalbuminemia was a significant risk factor for grade ≥ 2 peripheral edema (adjusted hazard ratio, 3.84; 95% confidence interval, 1.60-9.23; P = 0.003). CONCLUSION: Our study revealed that patients with baseline hypoalbuminemia who received GEM + nab-PTX therapy for pancreatic cancer developed problematic peripheral edema.
  • A multicenter phase II study of eribulin for BRAF V600E mutant metastatic colorectal cancer: the BRAVERY study (EPOC1701).
    T Masuishi; H Taniguchi; D Kotani; H Bando; Y Komatsu; E Shinozaki; Y Sunakawa; T Satoh; T Nishina; T Esaki; M Wakabayashi; S Nomura; K Takahashi; H Ono; N Hirano; N Fujishiro; N Fuse; A Sato; Y Sakamoto; N Kuramoto; I Miki; H Ichiki; Y Nakamura; G Sharma; S Skrzypczak; E Schultz; C Kingsford; A Ohtsu; T Yoshino
    ESMO open, 10, 11, 105839, 105839, 2025年10月09日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Based on the reported antitumor effects of microtubule inhibitors in xenograft models of BRAF V600E mutant colorectal cancer, this multicenter phase II study aimed to evaluate the efficacy and safety of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer (mCRC). PATIENTS AND METHODS: Patients with BRAF V600E mutant mCRC who received at least one prior regimen were administered intravenous eribulin. The primary endpoint was the objective response rate (ORR). Biomarker analyses were carried out using tumor and serial blood samples. Patients with reduced tumor size and/or progression-free survival (PFS) of >6 months were classified into the good response group, and the remaining patients were classified into the poor response group. RESULTS: Among the 27 patients enrolled, the ORR was 0% (95% confidence interval 0.0% to 12.8%), the disease control rate was 41%, the median PFS was 1.4 months, and the median survival time was 5.3 months (median follow-up, 5.3 months). Of 26 patients for whom tumors for RNA sequencing were available, all four patients in the good response group had the BRAF mutant (BM)2 subtype on gene expression analysis of BM subtype, whereas 22 patients in the poor response group had the BM1 (n = 8) or BM2 (n = 14) subtypes (P = 0.07). The proportion of patients with decreasing BRAF V600E relative clonality at the start of the second cycle was 75% and 11% in the good response and poor response groups, respectively (P = 0.02). Grade 3 and 4 adverse events included neutropenia (63%) and febrile neutropenia (22%). CONCLUSIONS: This phase II study of eribulin for patients with BRAF V600E mutant mCRC did not meet the primary endpoint. Although BM2 on gene expression analysis of BM subtype may be a predictive marker of eribulin efficacy, further studies are required to validate this hypothesis.
  • Efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer: a FRESCO-2 subgroup analysis of patients enrolled in Japan.
    Daisuke Kotani; Takayuki Yoshino; Toshiki Masuishi; Yu Sunakawa; Atsuo Takashima; Kentaro Yamazaki; Hisato Kawakami; Tomohiro Nishina; Yoshito Komatsu; Taito Esaki; Cathy Eng; Stacey Ukrainskyj; Rajash Pallai; Shivani Nanda; Zhao Yang; William Schelman; Marek Kania; Taroh Satoh
    International journal of clinical oncology, 30, 10, 2043, 2052, 2025年10月, [国内誌]
    英語, 研究論文(学術雑誌), BACKGROUND: In the phase 3 FRESCO-2 study, fruquintinib plus best supportive care (BSC) significantly improved overall survival (OS) versus placebo plus BSC in patients with refractory metastatic colorectal cancer (mCRC). We present the results of a FRESCO-2 post hoc subgroup analysis evaluating outcomes of patients enrolled in Japan. METHODS: In FRESCO-2, patients had previously received all standard chemotherapies, anti-VEGF and anti-EGFR therapies if indicated, and had progressed on, or were intolerant to trifluridine-tipiracil and/or regorafenib. Patients were randomized 2:1 to receive fruquintinib 5 mg or matching placebo by mouth once daily on days 1-21 in 28-day cycles, plus BSC. The primary endpoint was OS; secondary endpoints included progression-free survival (PFS) and safety. RESULTS: Of the 56 patients enrolled in Japan, 40 (71.4%) and 16 (28.6%) were randomized to fruquintinib and placebo, respectively. OS was improved with fruquintinib versus placebo (median 6.9 vs. 5.6 months; hazard ratio [HR], 0.42; 95% confidence interval [CI] 0.19 - 0.92). PFS was also improved with fruquintinib versus placebo (median 3.6 vs. 1.8 months; HR, 0.27; 95% CI 0.13 - 0.56). The incidence of grade ≥ 3 treatment-emergent adverse events (TEAEs) with fruquintinib versus placebo was 71.8% versus 29.4%; the most common grade ≥ 3 TEAEs with fruquintinib were hypertension (23.1%) and palmar-plantar erythrodysesthesia (17.9%). CONCLUSIONS: Fruquintinib improved OS and PFS versus placebo in FRESCO-2 patients enrolled in Japan and demonstrated a manageable safety profile. Results from the Japan subgroup were consistent with the global FRESCO-2 population, thus supporting fruquintinib as a novel treatment option for patients in Japan with refractory mCRC. CLINICAL TRIAL DETAILS: ClinicalTrials.gov; NCT04322539.
  • Urinary Titin as a Non-Invasive Biomarker for Sarcopenia Sex Differences in Unresectable Digestive Malignancies: A Retrospective Cohort Study.
    Shiho Kaneko; Kazuaki Harada; Masatsugu Ohara; Shintaro Sawaguchi; Tatsuya Yokoyama; Koichi Ishida; Yasuyuki Kawamoto; Satoshi Yuki; Yoshito Komatsu; Naoya Sakamoto
    International journal of molecular sciences, 26, 14, 2025年07月15日, [国際誌]
    英語, 研究論文(学術雑誌), The prognosis of sarcopenia is poor in cancer patients. Recently, urinary titin, a biomarker of muscle damage, has been suggested as a potential marker for sarcopenia. However, its utility in patients with unresectable digestive malignancies remains unclear. In addition, sex differences have been reported in the association between sarcopenia and urinary titin levels. This study aimed to evaluate urinary titin as a diagnostic marker for unresectable digestive malignancies, focusing on sex differences. This retrospective study enrolled 96 patients (58 males, 38 females; median age 70), and urinary titin was evaluated as a diagnostic biomarker in relation to clinical factors (e.g., age, Eastern Cooperative Oncology Group performance status [ECOG PS], albumin [Alb]) and muscle indicators (e.g., psoas muscle index [PMI], handgrip strength). In male patients, urinary titin levels were significantly higher in the sarcopenia subgroup (5.78 vs. 2.79 pmol/mgCr, p = 0.008), and multivariate analyses identified urinary titin as an independent predictor of sarcopenia (odds ratio 13.4, p = 0.028). The receiver operating characteristic (ROC) analysis demonstrated fair diagnostic performance (area under the curve [AUC] 0.729), with an optimal cutoff value of 3.676 pmol/mgCr. Urinary titin may serve as a useful non-invasive diagnostic biomarker for sarcopenia in patients with unresectable digestive malignancies, particularly in males. These findings suggest that sex-specific approaches are required for sarcopenia assessment with urinary titin.
  • Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High Advanced Gastric or Esophagogastric Junction Cancer.
    Hisato Kawakami; Shigenori Kadowaki; Akitaka Makiyama; Masahiro Tsuda; Kenro Hirata; Naotoshi Sugimoto; Nozomu Machida; Hiroki Hara; Hidekazu Hirano; Taito Esaki; Yoshito Komatsu; Shuichi Hironaka; Yukari Kobayashi; Kazuhiro Kakimi; Yasutaka Chiba; Narikazu Boku; Ichinosuke Hyodo; Kei Muro
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 43, 19, 2184, 2195, 2025年07月, [国際誌]
    英語, 研究論文(学術雑誌), PURPOSE: Microsatellite instability-high (MSI-H) advanced gastric or esophagogastric junction cancer (AGC), accounting for 5%-6% of all AGC cases, has shown an enhanced responsiveness to immunotherapy. We performed a single-arm phase II study to evaluate the combination of nivolumab (NIVO) and low-dose (LD) ipilimumab (IPI) for first-line treatment of MSI-H AGC. PATIENTS AND METHODS: Patients with MSI-H AGC received NIVO (240 mg once every 2 weeks) and IPI (1 mg/kg once every 6 weeks). The primary end point was overall response rate (ORR) assessed by blinded independent central review. Secondary end points included disease control rate (DCR), progression-free survival (PFS), overall survival (OS), safety, and biomarker analysis. MSI-H status was confirmed with an MSI-IVD Kit (Falco). RESULTS: Twenty-nine patients were enrolled. The ORR was 62.1% (95% CI, 42.3 to 79.3), with a complete response rate of 10.3%. The DCR was 79.3% (95% CI, 60.3 to 92.0). Treatment-related adverse events (TRAEs) of any grade occurred in 93.1% of patients, with those of grade ≥3 manifesting in 37.9% of patients. At the data cutoff (median follow-up of 9.0 months), treatment had been discontinued in 21 patients, with such discontinuation being due to TRAEs in 12 (41.4%) patients. However, after exclusion of one patient with progressive disease, the remaining 11 patients showed long-term antitumor efficacy after treatment discontinuation (range of response duration, 0.9+ to 15.6+ months). The median PFS was 13.8 months (95% CI, 13.7 months to not reached [NR]) and the median OS was NR (95% CI, 13.7 months to NR), with a 12-month OS rate of 79.5%. CONCLUSION: NIVO plus LD-IPI showed robust and durable antitumor efficacy as a first-line treatment for MSI-H AGC. Although TRAEs often led to treatment discontinuation, treatment efficacy was subsequently sustained in most patients.
  • Landscape Analysis of CLDN18 Expression and Isoform Distribution in Solid Tumors: Insights From MONSTAR‐SCREEN‐2 Study
    Tadayoshi Hashimoto; Naoko Iida; Yoshiaki Nakamura; Norio Nonomura; Chigusa Morizane; Hiroji Iwata; Susumu Okano; Wataru Yamagami; Naoya Yamazaki; Shigenori Kadowaki; Makoto Ueno; Shogen Boku; Eiji Oki; Yoshito Komatsu; Satoshi Yuki; Akitaka Makiyama; Takatsugu Ogata; Naoki Takahashi; Naohiro Okano; Tomohiro Nishina; Naoya Sakamoto; Takeshi Kuwata; Riu Yamashita; Taro Shibuki; Mitsuho Imai; Takao Fujisawa; Hideaki Bando; Kohei Shitara; Takayuki Yoshino
    Cancer Science, 116, 8, 2218, 2231, Wiley, 2025年06月02日
    研究論文(学術雑誌), ABSTRACT

    Claudin 18.2 (CLDN18.2), a tight junction protein isoform, is an emerging therapeutic target in oncology. CLDN18 is well‐characterized in gastric cancer, but its pan‐cancer expression profiles and isoform distributions are poorly documented. In the present study, we analyzed CLDN18 expression in patients with solid tumors enrolled in the MONSTAR‐SCREEN‐2 study using immunohistochemistry (IHC, n = 349) and whole‐transcriptome sequencing (WTS, n = 2191). A splice junction analysis algorithm characterized isoform distribution patterns in WTS data and evaluated temporal changes using paired pre‐ and postchemotherapy specimens. IHC detected CLDN18.2 (≥ 40% of tumor cells showing any staining intensity) in 16.3% of patients, with highest prevalence in gastric (54.5%), biliary tract (21.7%), pancreatic (20.7%), and small intestinal (18.2%) cancers. WTS and IHC findings were significantly correlated (p < 0.001). WTS analysis with optimized transcript thresholds (n = 2191) demonstrated the CLDN18‐high population to be 13.8%, with highest proportions in gastric (64.5%), small intestinal (40.0%), pancreatic (37.8%), and biliary tract (20.0%) cancers. Isoform analysis of 364 patients revealed CLDN18.2 predominance (mean 18.2/18.1 proportion 0.945), with CLDN18.1 predominance observed in only 4.9% of patients. Longitudinal analysis of 27 paired gastric cancer samples revealed a significant reduction in CLDN18 expression and a nonsignificant decrease in the CLDN18.2 proportion following chemotherapy. This analysis validates WTS as a complementary approach to IHC for CLDN18 assessment and demonstrates significant CLDN18 expression across multiple cancer types. The predominance of CLDN18.2 supports the expansion of targeted therapeutic approaches beyond gastric cancer and indicates the potential of RNA‐based screening.
  • Lack of association between SLFN11 expression and treatment efficacy or survival outcomes in patients with pancreatic ductal adenocarcinoma
    Takeaki Nakamura; Kanako C. Hatanaka; Yasuyuki Kawamoto; Shiho Kaneko; Koichi Ishida; Kazuaki Harada; Satoshi Yuki; Yoshito Komatsu; Yutaka Hatanaka; Naoya Sakamoto
    Journal of Cancer Research and Clinical Oncology, 151, 5, Springer Science and Business Media LLC, 2025年05月10日
    研究論文(学術雑誌)
  • Impact of baseline proteinuria on progression-free survival after regorafenib treatment for metastatic colorectal cancer.
    Yoshitaka Saito; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 33, 5, 443, 443, 2025年05月02日, [国際誌]
    英語, 研究論文(学術雑誌), PURPOSE: Regorafenib improves the survival of patients with metastatic colorectal cancer (mCRC). However, proteinuria frequently occurs in regorafenib treatment, and development of severe hypertension, which is closely related to proteinuria, is associated with better treatment outcomes. We previously reported that patients with baseline proteinuria exhibit regorafenib-induced problematic symptoms. In this study, we aimed to assess the effect of baseline proteinuria on the treatment efficacy of regorafenib for mCRC. METHODS: Patients with mCRC receiving regorafenib (n = 100) were categorized into control (without baseline proteinuria) and pre-existing proteinuria (baseline grades 1-2) groups and retrospectively evaluated. The primary endpoint was the progression-free survival (PFS). RESULTS: Patients in the pre-existing proteinuria group exhibited significantly worse PFS than those in the control group (median with 95% confidence interval [CI] = 51 (46-56) and 56 (49-81) days, respectively; P = 0.04). Overall survival and disease control rate were lower in the pre-existing proteinuria group than in the control group although the difference was not statistically significant (P = 0.11 and 0.10, respectively). Similar results were obtained in the propensity score-matched population. Multivariate Cox hazard regression analyses revealed that baseline pre-existing proteinuria was associated with poor PFS (adjusted hazard ratio = 1.67; 95% CI = 1.03-2.72; P = 0.04). Additionally, ratio of drug suspension duration during all treatment cycles was higher in patients with pre-existing proteinuria than those without symptoms. CONCLUSION: Our results suggest that patients with baseline proteinuria experience poor PFS following regorafenib treatment for mCRC, although we should consider the clinical significance of the difference.
  • イリノテカン誘発性コリン症状に対する抗コリン薬単回予防投与の症状コントロール不良因子の探索
    渡辺 拓也; 齋藤 佳敬; 武隈 洋; 清水 康; 木下 一郎; 小松 嘉人; 菅原 満
    日本臨床腫瘍薬学会雑誌, 41, 137, 137, (一社)日本臨床腫瘍薬学会, 2025年05月
    日本語
  • Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study.
    Kentaro Sawada; Riu Yamashita; Shunsuke A Sakai; Satoshi Horasawa; Ayumu Yoshikawa; Takao Fujisawa; Shigenori Kadowaki; Ken Kato; Makoto Ueno; Eiji Oki; Yoshito Komatsu; Tatsuyuki Chiyoda; Yosuke Horita; Hisateru Yasui; Tadamichi Denda; Hironaga Satake; Taito Esaki; Taroh Satoh; Naoki Takahashi; Kentaro Yamazaki; Nobuhisa Matsuhashi; Tomohiro Nishina; Hiroyuki Takeda; Koushiro Ohtsubo; Takashi Ohta; Akihito Tsuji; Masahiro Goto; Takeshi Kato; Hideaki Bando; Katsuya Tsuchihara; Yoshiaki Nakamura; Takayuki Yoshino
    Cancer research communications, 5, 5, 857, 870, 2025年05月01日, [国際誌]
    英語, 研究論文(学術雑誌), UNLABELLED: Although the gut microbiome is associated with cancer development and progression, little is known about the effects of the gut microbiome landscape and the efficacy of immune checkpoint inhibitors (ICI) across cancer types. We investigated the association between the microbiome, clinical features, and ICI efficacy across cancer types in a large nationwide screening project for solid tumors. Among 2,180 patients with advanced solid tumors enrolled in the SCRUM-Japan MONSTAR-SCREEN between October 2019 and September 2021, in the chemotherapy-naïve cohort (n = 817), a high prevalence of oral bacteria was observed in patients using proton pump inhibitors (PPI) and those with upper gastrointestinal cancers, particularly postoperative patients with gastric or pancreatic cancer. Among patients treated with ICIs (n = 333), a high abundance of sequence variants in the gut microbiome was not significantly associated with ICI efficacy across cancer types (HR = 0.94; 95% confidence interval, 0.73-1.21). However, high oral bacteria in feces significantly correlated with a shorter progression-free survival compared with low oral bacteria (median, 4.34 vs. 6.97 months; HR = 1.38; 95% confidence interval, 1.07-1.78). Notably, in patients using PPIs, a higher proportion of oral bacteria influenced progression-free survival outcomes of ICI treatment (median, 3.15 vs. 2.04 months; P = 0.08), unlike in PPI nonusers (median, 7.13 vs. 5.55 months; P = 0.74). This study of the gut microbiome has unveiled significant insights into its landscape and potential impact on ICI efficacy. It highlights that the abundance of oral bacteria in feces may play a critical role in diminishing ICI efficacy among patients using PPIs. SIGNIFICANCE: As part of the MONSTAR-SCREEN, a prospective nationwide project for patients with solid tumors, we found that although gut microbiome diversity does not consistently predict ICI efficacy across cancer types, a high level of oral bacteria in the gut is linked to reduced ICI effectiveness, especially in patients using PPIs. These findings highlight the potential clinical impact of microbiome variations on cancer treatment outcomes.
  • Evaluation of nausea induced by trifluridine/tipiracil in metastatic colorectal cancer treatment.
    Yoshitaka Saito; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
    Journal of chemotherapy (Florence, Italy), 1, 8, 2025年03月20日, [国際誌]
    英語, 研究論文(学術雑誌), Trifluridine/tipiracil (FTD/TPI) frequently induces chemotherapy-induced nausea and vomiting (CINV). As evidence of factors associated with CINV in oral chemotherapeutic agents is limited, we aimed to assess factors for nausea development in a real-world FTD/TPI-containing treatment for metastatic colorectal cancer (mCRC). Patients with mCRC receiving FTD/TPI with or without bevacizumab (n = 104) were retrospectively evaluated. Nausea occurred in 40.4% of the patients, and the severity was grade 1 for 23.1%, grade 2 for 15.4%, and grade 3 for 1.9%. Multivariable logistic regression analysis suggested that female sex (adjusted odds ratio 2.74, 95% confidence interval 1.02-7.33, p = 0.045) and concomitant bevacizumab (2.68, 1.13-6.37, p = 0.03) were independent risk factors for all-grade nausea during the first cycle as a primary endpoint. Particularly, among patients with FTD/TPI monotherapy, females significantly exhibited nausea compared to males. Our study revealed that concomitant bevacizumab and female sex are independent risk factors for nausea in FTD/TPI-containing treatment for mCRC.
  • Identification of risk factors related to problematic peripheral neuropathy development in gemcitabine and nab-paclitaxel treatment for pancreatic cancer.
    Yoshitaka Saito; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 33, 4, 263, 263, 2025年03月10日, [国際誌]
    英語, 研究論文(学術雑誌), PURPOSE: Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect in patients treated with gemcitabine (GEM) and nanoparticle albumin-bound paclitaxel (nab-PTX) for pancreatic cancer, negatively impacting their quality of life. This study aimed to identify risk factors for significant CIPN development in a real-world setting of GEM + nab-PTX treatment to inform effective management strategies. METHODS: Patients with unresectable pancreatic cancer who received GEM + nab-PTX (n = 140) were retrospectively assessed. The primary endpoint was to identify the risk factor(s) associated with the development of problematic grade ≥ 2 CIPN within six months of treatment initiation. We also evaluated factors associated with all-grade CIPN and compared CIPN incidence across specific patient groups. RESULTS: The incidence of grade ≥ 2 CIPN was 35.0%, with 63.6% of patients experiencing symptoms of any grade. Multivariate Cox proportional hazard regression analysis identified baseline preexisting neuropathy as an independent risk factor for developing grade ≥ 2 CIPN (adjusted hazard ratio 4.03, 95% confidence interval 1.82-8.96, P = 0.0006). Conversely, dose modification of nab-PTX at or within 4 weeks of treatment initiation emerged as a protective factor (0.45, 0.22-0.91, P = 0.03). Additionally, the cumulative incidence of grade ≥ 2 CIPN was significantly lower and delayed in patients who underwent dose modification within 4 weeks compared to those who did not in the population with preexisting neuropathy (P = 0.01). CONCLUSION: Baseline preexisting neuropathy significantly increases the risk, while early dose modification of nab-PTX serves as a protective factor against developing grade ≥ 2 CIPN in patients receiving GEM + nab-PTX treatment for pancreatic cancer.
  • ゾルベツキシマブ投与中に腹部超音波検査で胃壁構造変化を認めた胃癌の1例
    石田 浩一; 原田 一顕; 横山 達也; 金子 志帆; 中村 赳晶; 川本 泰之; 結城 敏志; 小松 嘉人; 西田 睦; 坂本 直哉
    日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 136回・130回, 45, 45, 日本消化器病学会-北海道支部, 2025年03月
    日本語
  • 進行/再発胃癌に対するFTD/TPI+RAM療法の多施設共同後方視的観察研究(HGCSG2302)
    中村 赳晶; 澤田 憲太郎; 川本 泰之; 石黒 敦; 元尾 伊織; 園田 悠紀; 吉河 歩; 鈴木 一広; 中積 宏之; 細川 歩; 石井 貴大; 畑中 一映; 中村 路夫; 中野 真太郎; 村中 徹人; 太宰 昌佳; 生本 太郎; 佐藤 温; 結城 敏志; 坂本 直哉; 小松 嘉人
    日本胃癌学会総会記事, 97回, 249, 249, (一社)日本胃癌学会, 2025年03月
    日本語
  • 転移性結腸直腸癌におけるレゴラフェニブ減量開始の有用性を検討する多施設共同後方視的解析
    原田 一顕; 川上 武志; 伏木 邦博; 山崎 健太郎; 舛石 俊樹; 谷口 浩也; 室 圭; 胡 慶江; 安藤 幸滋; 沖 英次; 小松 嘉人; 坂本 直哉; 結城 敏志
    日本大腸肛門病学会雑誌, 78, 2, 86, 86, (一社)日本大腸肛門病学会, 2025年02月
    日本語
  • Ultrasound-detected gastric changes related to zolbetuximab-induced emesis: a case series.
    Kazuaki Harada; Koichi Ishida; Shiho Kaneko; Tatsuya Yokoyama; Shintaro Sawaguchi; Takeaki Nakamura; Yasuyuki Kawamoto; Satoshi Yuki; Mutsumi Nishida; Naoya Sakamoto; Yoshito Komatsu
    Frontiers in oncology, 15, 1686245, 1686245, 2025年, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Zolbetuximab prolongs survival in patients with claudin18.2 (CLDN18.2)-positive gastric cancer (GC) and gastroesophageal junction cancer. However, it is associated with an increased risk of emesis, and its underlying mechanism remains unclear. CASE PRESENTATION: This report presents three cases of advanced GC that underwent abdominal ultrasonography (US) during zolbetuximab administration. In two patients with primary gastric lesions, severe nausea occurred during the first treatment cycle. US findings revealed increased echogenicity of the submucosal layer, enhanced layer stratification, and increased blood flow signals, which improved as the emesis subsided. During the second cycle, emesis was milder, and US findings revealed only slight changes. In the third patient who underwent total gastrectomy, no nausea or abnormal US findings were observed. CONCLUSION: These US findings indicate gastric tumor tissue injury due to zolbetuximab, which is associated with emesis. US is a valuable tool for further elucidating the mechanisms underlying zolbetuximab-induced emesis and may also contribute to the prediction and prevention of this adverse event. STATEMENT: Zolbetuximab treatment has been reported to improve survival in patients with HER2-negative, CLDN18.2-positive advanced, unresectable, or recurrent gastric and gastroesophageal junction cancers. However, it is associated with a high incidence of nausea, particularly during the first infusion, and the underlying mechanism remains unclear. We present three cases of advanced or recurrent gastric cancer treated with zolbetuximab, during which abdominal ultrasonography (US) was performed. In two cases with primary gastric tumors, US revealed characteristic changes in the gastric wall at the onset of nausea, suggestive of edema and inflammation. These changes appeared prior to the symptoms and resolved as nausea improved. Nausea during the second infusion was milder, with less pronounced US changes. The third case includes a patient who had undergone total gastrectomy; the patient did not experience nausea, and no gastrointestinal changes were observed on US. This is the first report to describe US findings associated with zolbetuximab-induced nausea. These observations suggest that gastric wall changes detectable using US are closely linked to nausea and may reflect underlying gastric injury. This report also highlights the potential of bedside US monitoring to help predict and prevent nausea during zolbetuximab therapy.
  • 高齢者における消化管癌の薬物療法の現状 進行再発結腸直腸癌に対するIRIS/Bevの多施設共同後方視的観察研究(HGCSG1901) 高齢者の治療成績
    原田 一顕; 伊藤 憲; 結城 敏志; 川本 泰之; 吉河 歩; 澤田 憲太郎; 石黒 敦; 武藤 理; 畑中 一映; 奥田 博介; 佐藤 温; 笹木 有佑; 中村 路夫; 目黒 高志; 植田 亮; 坂本 直哉; 坂田 優; 小松 嘉人
    日本消化管学会雑誌, 9, Suppl., 204, 204, (一社)日本消化管学会, 2025年01月
    日本語
  • Targeted therapy guided by circulating tumor DNA analysis in advanced gastrointestinal tumors.
    Yoshiaki Nakamura; Hiroshi Ozaki; Makoto Ueno; Yoshito Komatsu; Satoshi Yuki; Taito Esaki; Hiroya Taniguchi; Yu Sunakawa; Kensei Yamaguchi; Ken Kato; Tadamichi Denda; Tomohiro Nishina; Naoki Takahashi; Taroh Satoh; Hisateru Yasui; Hironaga Satake; Eiji Oki; Takeshi Kato; Takashi Ohta; Nobuhisa Matsuhashi; Masahiro Goto; Naohiro Okano; Koushiro Ohtsubo; Kentaro Yamazaki; Riu Yamashita; Naoko Iida; Mihoko Yuasa; Hideaki Bando; Takayuki Yoshino
    Nature medicine, 31, 1, 165, 175, 2025年01月, [国際誌]
    英語, 研究論文(学術雑誌), Although comprehensive genomic profiling has become standard in oncology for advanced solid tumors, the full potential of circulating tumor DNA (ctDNA)-based profiling in capturing tumor heterogeneity and guiding therapy selection remains underexploited, marked by a scarcity of evidence on its clinical impact and the assessment of intratumoral heterogeneity. The GOZILA study, a nationwide, prospective observational ctDNA profiling study, previously demonstrated higher clinical trial enrollment rates using liquid biopsy compared with tissue screening. This updated analysis of 4,037 patients further delineates the clinical utility of ctDNA profiling in advanced solid tumors, showcasing a significant enhancement in patient outcomes with a 24% match rate for targeted therapy. Patients treated with matched targeted therapy based on ctDNA profiling demonstrated significantly improved overall survival compared with those receiving unmatched therapy (hazard ratio, 0.54). Notably, biomarker clonality and adjusted plasma copy number were identified as predictors of therapeutic efficacy, reinforcing the value of ctDNA in reflecting tumor heterogeneity for precise treatment decisions. These new insights into the relationship between ctDNA characteristics and treatment outcomes advance our understanding beyond the initial enrollment benefits. Our findings advocate for the broader adoption of ctDNA-guided treatment, signifying an advancement in precision oncology and improving survival outcomes in advanced solid tumors.
  • Artificial Intelligence-Powered Human Epidermal Growth Factor Receptor 2 and Tumor Microenvironment Analysis in Human Epidermal Growth Factor Receptor 2-Amplified Metastatic Colorectal Cancer: Exploratory Analysis of Phase II TRIUMPH Trial.
    Mitsuho Imai; Yoshiaki Nakamura; Sangwon Shin; Wataru Okamoto; Takeshi Kato; Taito Esaki; Ken Kato; Yoshito Komatsu; Satoshi Yuki; Toshiki Masuishi; Tomohiro Nishina; Kentaro Sawada; Akihiro Sato; Takeshi Kuwata; Riu Yamashita; Takao Fujisawa; Hideaki Bando; Chan-Young Ock; Satoshi Fujii; Takayuki Yoshino
    JCO precision oncology, 9, e2400385, 2025年01月, [国際誌]
    英語, 研究論文(学術雑誌), PURPOSE: Human epidermal growth factor receptor 2 (HER2)-targeted therapies have shown promise in treating HER2-amplified metastatic colorectal cancer (mCRC). Identifying optimal biomarkers for treatment decisions remains challenging. This study explores the potential of artificial intelligence (AI) in predicting treatment responses to trastuzumab plus pertuzumab (TP) in patients with HER2-amplified mCRC from the phase II TRIUMPH trial. MATERIALS AND METHODS: AI-powered HER2 quantification continuous score (QCS) and tumor microenvironment (TME) analysis were applied to the prescreening cohort (n = 143) and the TRIUMPH cohort (n = 30). AI analyzers determined the proportions of tumor cells (TCs) with HER2 staining intensity and the densities of various cells in TME, examining their associations with clinical outcomes of TP. RESULTS: The AI-powered HER2 QCS for HER2 immunohistochemistry (IHC) achieved an accuracy of 86.7% against pathologist evaluations, with a 100% accuracy for HER2 IHC 3+ patients. Patients with ≥50% of TCs showing HER2 3+ staining intensity (AI-H3-high) exhibited significantly prolonged progression-free survival (PFS; median PFS, 4.4 v 1.4 months; hazard ratio [HR], 0.12 [95% CI, 0.04 to 0.38]) and overall survival (OS; median OS, 16.5 v 4.1 months; HR, 0.13 [95% CI, 0.05 to 0.38]) compared with the AI-H3-low (<50% group). Stratification among patients with AI-H3-high included TME-high (all lymphocyte, fibroblast, and macrophage densities in the cancer stroma above the median) and TME-low (anything below the median), showing a median PFS of 1.3 and 5.6 months for TME-high and TME-low respectively, with an HR of 0.04 (95% CI, 0.01 to 0.19) for AI-H3-high with TME-low compared with AI-H3-low. CONCLUSION: AI-powered HER2 QCS and TME analysis demonstrated potential in enhancing treatment response predictions in patients with HER2-amplified mCRC undergoing TP therapy.
  • Trastuzumab Deruxtecan in Advanced Solid Tumors With Human Epidermal Growth Factor Receptor 2 Amplification Identified by Plasma Cell-Free DNA Testing: A Multicenter, Single-Arm, Phase II Basket Trial.
    Masataka Yagisawa; Hiroya Taniguchi; Taroh Satoh; Shigenori Kadowaki; Yu Sunakawa; Tomohiro Nishina; Yoshito Komatsu; Taito Esaki; Daisuke Sakai; Ayako Doi; Takeshi Kajiwara; Hiromi Ono; Masatoshi Asano; Nami Hirano; Justin Odegaard; Satoshi Fujii; Shogo Nomura; Hideaki Bando; Akihiro Sato; Takayuki Yoshino; Yoshiaki Nakamura
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 42, 32, 3817, 3825, 2024年11月10日, [国際誌]
    英語, 研究論文(学術雑誌), PURPOSE: HERALD/EPOC1806 was conducted as a multicenter phase II trial assessing trastuzumab deruxtecan (T-DXd) therapy for patients with human epidermal growth factor receptor 2 (HER2)-amplified progressive stage solid tumors detected by cell-free DNA (cfDNA) testing. PATIENTS AND METHODS: Patients exhibited advanced solid tumors with HER2 amplification that was identified via next-generation sequencing of cfDNA testing, without the requirement for immunohistochemical HER2 testing. The studied group was administered T-DXd at 5.4 mg/kg once every 3 weeks until onset of disease progression or intolerable toxicity. RESULTS: Overall, 4,734 patients underwent cfDNA testing from December 2019 to January 2022, and 252 demonstrated HER2 amplification. Finally, the study included 62 patients with 16 cancer types with a median baseline plasma HER2 copy number (CN) of 8.55 (range, 2.4-73.9). Confirmed overall response rate (ORR) by investigator assessment was 56.5% (95% CI, 43.3 to 69.0), thus showing a value beyond the 5% threshold. Responses were evaluated for 13 cancer types, including KRAS-mutant colorectal (1/3), PIK3CA-mutant endometrial (5/6), and tissue HER2-negative gastric (1/2) cancers. Plasma HER2 CN above versus below the baseline median value did not differ for impact response; however, clearance of HER2 amplification in cfDNA on cycle 2 day 1 had higher response values compared with persistence. Median progression-free survival and response duration were 7.0 (95% CI, 4.9 to 9.7) and 8.8 (95% CI, 5.8 to 11.2) months, respectively, with the majority of complications being mild to moderate. Interstitial lung diseases were identified in 16 (26%) patients, including 14 patients with grade 1 disease, one patient with grade 2 disease, and one patient with grade 3 disease. CONCLUSION: T-DXd treatment demonstrated high ORR with durable response in patients with advanced HER2-amplified solid tumors determined with cfDNA testing.
  • Impact of renal impairment on early development of severe neutropenia with trifluridine/tipiracil treatment for metastatic colorectal cancer.
    Yoshitaka Saito; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
    Scientific reports, 14, 1, 26990, 26990, 2024年11月06日, [国際誌]
    英語, 研究論文(学術雑誌), Trifluridine/tipiracil (FTD/TPI) with or without bevacizumab is an effective treatment for metastatic colorectal cancer (mCRC). As this agent is mainly excreted via the kidney, we aimed to evaluate the impact of renal impairment (RI) on the early development of severe neutropenia, a dose-limiting toxicity and whose development reflects better treatment outcomes, in patients with mCRC treated with FTD/TPI. Patients with mCRC receiving FTD/TPI ± bevacizumab (n = 100) were divided into the RI group (creatinine clearance [CCr] < 90 mL/min) or control group (CCr ≥ 90 mL/min), and retrospectively evaluated. Severe neutropenia during the first two cycles occurred in 57.6% and 34.2% of patients in the RI and control groups, respectively, which was significantly different (P = 0.03) and met our primary endpoint. Furthermore, the incidence during the first cycle also differed significantly (52.5% in the RI group and 17.1% in the control group, P = 0.0004). Multivariate logistic regression analysis suggested that baseline RI and neutropenia were significant risk factors for early severe neutropenia (adjusted odds ratio and 95% confidence interval: 3.07, 1.24-7.59, P = 0.02 for RI, and 9.76, 1.08-88.11, P = 0.04 for neutropenia). In conclusion, our study suggested that patients with RI can exhibit early severe neutropenia during real-world FTD/TPI treatment for mCRC.
  • The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine.
    Tadayoshi Hashimoto; Yoshiaki Nakamura; Takao Fujisawa; Mitsuho Imai; Taro Shibuki; Naoko Iida; Hiroshi Ozaki; Norio Nonomura; Chigusa Morizane; Hiroji Iwata; Susumu Okano; Wataru Yamagami; Naoya Yamazaki; Shigenori Kadowaki; Hiroya Taniguchi; Makoto Ueno; Shogen Boku; Eiji Oki; Yoshito Komatsu; Satoshi Yuki; Akitaka Makiyama; Tomoyuki Otsuka; Hiroki Hara; Naohiro Okano; Tomohiro Nishina; Yasutoshi Sakamoto; Izumi Miki; Shin Kobayashi; Junichiro Yuda; Shun-Ichiro Kageyama; Michiko Nagamine; Shingo Sakashita; Naoya Sakamoto; Riu Yamashita; Yoshikatsu Koga; Hideaki Bando; Genichiro Ishii; Takeshi Kuwata; Woong-Yang Park; Atsushi Ohtsu; Takayuki Yoshino
    Cancer discovery, 14, 11, 2243, 2261, 2024年11月01日, [国際誌]
    英語, 研究論文(学術雑誌), The SCRUM-Japan MONSTAR-SCREEN consortium is a nationwide molecular profiling project employing artificial intelligence-driven multiomics analyses for patients with advanced malignancies, aiming to develop novel therapeutics and diagnostics and deliver effective drugs to patients. Concurrently, studies assessing molecular residual disease-based precision medicine for resectable solid tumors, including CIRCULATE-Japan, are ongoing. The substantial data generated by these platforms are stored within a state-of-the-art supercomputing infrastructure, VAPOR CONE. Since 2015, our project has registered over 24,000 patients as of December 2023. Among 16,144 patients with advanced solid tumors enrolled in MONSTAR-SCREEN projects, 5.0% have participated in matched clinical trials, demonstrating a 29.2% objective response rate and 14.8-month median survival (95% CI, 13.4-16.3) for patients treated in the matched clinical trials. Notably, patients who received matched therapy demonstrated significantly prolonged overall survival compared with those who did not (hazard ratio 0.77; 95% confidence interval, 0.71-0.83). Significance: Our nationwide molecular profiling initiative played pivotal roles in facilitating the enrollment of patients with advanced solid tumors into matched clinical trials and highlighted the substantial survival benefits of patients treated with matched therapy. We aim to facilitate an industry-academia data-sharing infrastructure ecosystem, fostering new drug discovery paradigms and precision medicine.
  • 消化器癌に対するS-1を含む全身化学療法による眼障害に関する前向き観察研究
    八木澤 允貴; 中村 路夫; 澤田 憲太郎; 川本 泰之; 村中 徹人; 中積 宏之; 太宰 昌佳; 辻 靖; 進藤 吉明; 中野 真太郎; 上林 実; 渡邉 桃子; 原田 一顕; 結城 敏志; 小松 嘉人
    日本癌治療学会学術集会抄録集, 62回, P62, 3, (一社)日本癌治療学会, 2024年10月
    英語
  • 消化器癌に対するS-1を含む全身化学療法による眼障害に関する前向き観察研究
    八木澤 允貴; 中村 路夫; 澤田 憲太郎; 川本 泰之; 村中 徹人; 中積 宏之; 太宰 昌佳; 辻 靖; 進藤 吉明; 中野 真太郎; 上林 実; 渡邉 桃子; 原田 一顕; 結城 敏志; 小松 嘉人
    日本癌治療学会学術集会抄録集, 62回, P62, 3, (一社)日本癌治療学会, 2024年10月
    英語
  • がん悪液質に対するアナモレリン塩酸塩の早期中止と関連する因子の検討(HGCSG2201)
    原田 一顕; 梶浦 新也; 澤田 憲太郎; 畑中 一映; 佐藤 温; 伊藤 憲; 田村 穂高; 土井 綾子; 安藤 孝将; 中村 路夫; 中積 宏之; 村中 徹人; 小松 嘉人
    日本癌治療学会学術集会抄録集, 62回, EN3, 6, (一社)日本癌治療学会, 2024年10月
    英語
  • がん悪液質患者におけるアナモレリン塩酸塩の治療効果に関連する因子(HGCSG2201)
    畑中 一映; 原田 一顕; 梶浦 新也; 澤田 憲太郎; 佐藤 温; 伊藤 憲; 田村 穂高; 土井 綾子; 安藤 孝将; 中村 路夫; 中積 宏之; 村中 徹人; 曽我部 進; 石井 貴大; 小松 嘉人
    日本癌治療学会学術集会抄録集, 62回, O68, 4, (一社)日本癌治療学会, 2024年10月
    英語
  • Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial.
    Kanwal Raghav; Salvatore Siena; Atsuo Takashima; Takeshi Kato; Marc Van den Eynde; Filippo Pietrantonio; Yoshito Komatsu; Hisato Kawakami; Marc Peeters; Thierry Andre; Sara Lonardi; Kensei Yamaguchi; Jeanne Tie; Cristina Gravalos Castro; Hung-Chih Hsu; John H Strickler; Tae-You Kim; Yongjun Cha; Daniel Barrios; Qi Yan; Takahiro Kamio; Kojiro Kobayashi; Aislyn Boran; Makito Koga; John D Allard; Takayuki Yoshino
    The Lancet. Oncology, 25, 9, 1147, 1162, 2024年09月, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Trastuzumab deruxtecan has shown encouraging activity in patients with treatment-refractory HER2-positive, RAS wild-type and BRAF wild-type metastatic colorectal cancer. Dose optimisation and further antitumour assessments in patients with RAS mutations and those with previous anti-HER2 therapy are warranted. We aimed to evaluate two doses of trastuzumab deruxtecan (5·4 mg/kg and 6·4 mg/kg) to establish the recommended dose in patients with pretreated HER2-positive, RAS wild-type or mutant metastatic colorectal cancer. METHODS: DESTINY-CRC02 was a multicentre, randomised, two-stage, two-arm, phase 2 study done in 53 research hospitals and medical centres in Australia, Belgium, France, Italy, Japan, South Korea, Spain, Taiwan, the UK, and the USA. Eligible patients were aged 18 years and older or 20 years and older (depending on region) with pretreated pathologically documented, unresectable, recurrent, or metastatic HER2-positive, and RAS wild-type or mutant colorectal cancer. Patients were required to have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and have received previous chemotherapy, and anti-EGFR, anti-VEGF, or anti-PD-L1 therapy, if clinically indicated. In stage 1, patients were randomly assigned (1:1), via a secure interactive response technology system, to receive 5·4 mg/kg or 6·4 mg/kg trastuzumab deruxtecan administered intravenously every 21 days. Stratification factors were ECOG performance status, HER2 status, and RAS status. In stage 2, patients were assigned into the 5·4 mg/kg treatment group only. The primary endpoint was confirmed objective response rate by blinded independent central review, assessed in all patients for whom treatment was assigned (full analysis set). Safety was assessed in all patients who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov, NCT04744831, and is ongoing (not recruiting). FINDINGS: Between March 5, 2021, and March 29, 2022, 135 patients were centrally screened, 122 of whom were enrolled. In stage 1, 40 patients each were randomly assigned to receive trastuzumab deruxtecan 5·4 mg/kg and 6·4 mg/kg. In stage 2, an additional 42 patients were enrolled in the 5·4 mg/kg group. 64 (52%) participants were male and 58 (48%) were female. The median duration of follow-up was 8·9 months (IQR 6·7-10·5) in the 5·4 mg/kg group and 10·3 months (5·9-12·7) in the 6·4 mg/kg group. The confirmed objective response rate by blinded independent central review was 37·8% (31/82 [95% CI 27·3-49·2]) in the 5·4 mg/kg group and 27·5% (11/40 [14·6-43·9]) in the 6·4 mg/kg group. 34 (41%) of 83 patients in the 5·4 mg/kg group and 19 (49%) of 39 in the 6·4 mg/kg group had grade 3 or worse drug-related treatment-emergent adverse events. The most common grade 3 or worse drug-related treatment-emergent adverse events were neutrophil count decreased (13 [16%] of 83 patients), anaemia (six [7%]), nausea (six [7%]), and white blood cell count decreased (five [6%]) in the 5·4 mg/kg group; and were neutrophil count decreased (10 [26%] of 39 patients), anaemia (eight [21%]), platelet count decreased (four [10%]), and white blood cell count decreased (four [10%]) in the 6·4 mg/kg group. Drug-related serious adverse events occurred in 11 (13%) of 83 patients in the 5·4 mg/kg group and six (15%) of 39 patients in the 6·4 mg/kg group; the most common in the 5·4 mg/kg group was nausea (three [4%] patients) and the most common in the 6·4 mg/kg group were fatigue (two [5%] patients), neutropenia (two [5%]), and thrombocytopenia (two [5%]). A drug-related treatment-emergent adverse event related to death occurred in one (1%) patient in the 5·4 mg/kg group (due to hepatic failure). Adjudicated drug-related interstitial lung disease or pneumonitis events were observed in seven (8%) patients in the 5·4 mg/kg group (all grade 1 or 2) and in five (13%) patients in the 6·4 mg/kg group (four grade 1 or 2; one grade 5). INTERPRETATION: The promising antitumour activity and favourable safety profile support trastuzumab deruxtecan 5·4 mg/kg as the optimal single-agent dose for patients with pretreated HER2-positive metastatic colorectal cancer, including those with RAS mutations, previous anti-HER2 therapy, or both. FUNDING: Daiichi Sankyo and AstraZeneca.
  • Perioperative chemotherapy with nivolumab for HER2-negative locally advanced gastric cancer: a case series.
    Yuta Toji; Shintaro Takeuchi; Yuma Ebihara; Yo Kurashima; Kazuaki Harada; Mariko Hayashi; Hirotake Abe; Hideyuki Wada; Satoko Yorinaga; Toshiaki Shichinohe; Utano Tomaru; Yoshito Komatsu; Satoshi Hirano
    Surgical case reports, 10, 1, 200, 200, 2024年08月28日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Nivolumab with chemotherapy has been transformative for metastatic gastric cancer (GC). The potential of this regimen for local tumor control could be utilized for perioperative chemotherapy in locally advanced GC with bulky tumors or lymph node metastasis involving other organs. CASE PRESENTATION: Five patients with HER2-negative advanced GC were treated with nivolumab and oxaliplatin-based chemotherapy. All patients presented with clinical stage III or IVA GC with tumors in contact with either the pancreas or liver. Following chemotherapy, all tumors demonstrated shrinkage, allowing successful radical gastrectomies including four minimally invasive approach without postoperative complications. Four patients avoided combined resection of other organs. CONCLUSIONS: Perioperative chemotherapy with nivolumab was effective for local disease control in this case series. This regimen could be a promising treatment approach for locally advanced GC; however, its survival benefits should be evaluated in clinical trials.
  • Novel ERBB2 Variant Potentially Associated with Resistance against Anti-HER2 Monoclonal Antibody-Based Therapy in ERBB2-Amplified Metastatic Colorectal Cancer.
    Naoko Iida; Mitsuho Imai; Wataru Okamoto; Takeshi Kato; Taito Esaki; Ken Kato; Yoshito Komatsu; Satoshi Yuki; Toshiki Masuishi; Tomohiro Nishina; Hiromichi Ebi; Hiroya Taniguchi; Norio Nonomura; Yu Sunakawa; Manabu Shiozawa; Kentaro Yamazaki; Shogen Boku; Hideaki Bando; Yuichi Shiraishi; Maki Kobayashi; Hiroki Goto; Akihiro Sato; Satoshi Fujii; Takayuki Yoshino; Yoshiaki Nakamura
    Clinical cancer research : an official journal of the American Association for Cancer Research, OF1-OF12, 2024年08月20日, [国際誌]
    英語, 研究論文(学術雑誌), PURPOSE: HER2-targeted therapies in ERBB2-amplified metastatic colorectal cancer (mCRC) are effective; however, a notable portion of patients do not respond to treatment, and secondary resistance occurs in most patients receiving these treatments. The purpose of this study was to investigate determinants of treatment efficacy and resistance in patients with ERBB2-amplified mCRC who received HER2-targeted therapy by analyzing multiomics data. EXPERIMENTAL DESIGN: We investigated genomic data from a nationwide large cancer genomic screening project, the SCRUM-Japan project. We analyzed paired genome and transcriptome data of tissue and genomic data of ctDNA collected pre- and postprogression in patients enrolled in the related trial, TRIUMPH, in ERBB2-amplified mCRC. RESULTS: In 155 patients with ERBB2-amplified solid tumors who received HER2-targeted therapy based on the SCRUM-Japan project, the objective response rate was 50%, 51%, and 35% in ERBB2 wild-type, variant of unknown significance, and pathogenic variant groups, respectively. In the paired genome and transcriptome data analyses in TRIUMPH, we identified the novel splicing-associated variant c.644-66_-2del in one of the 11 patients with paired whole-exome sequencing and whole-transcriptome sequencing data sets, which lacks the binding domain of pertuzumab, in progressed metastatic tumor as a variant with potential pathogenicity. The time-course ctDNA analysis detected c.644-66_-2del as an acquired variant. CONCLUSIONS: This study highlighted the importance of ERBB2 genomic status when evaluating the efficacy of HER2-targeted therapies in ERBB2-amplified mCRC. The identification of a novel splicing-associated variant may provide insights into potential mechanisms of treatment resistance. Furthermore, we demonstrated the utility of ctDNA to follow the acquired genomic status of mCRC tumors.
  • A multicenter, prospective, phase II trial of second-line aflibercept plus FOLFIRI in patients with metastatic colorectal cancer refractory to an anti-EGFR antibody: HGCSG1801.
    Hiroshi Nakatsumi; Yoshito Komatsu; Kazuaki Harada; Yasuyuki Kawamoto; Satoshi Yuki; Kentaro Sawada; Atsushi Ishiguro; Susumu Sogabe; Takayuki Ando; Yusuke Sasaki; Ayumu Yoshikawa; Michio Nakamura; Masayoshi Dazai; Miki Tateyama; Osamu Muto; Masahito Kotaka; Tamotsu Sagawa; Tetsuhito Muranaka; Kazuteru Hatanaka; Ryo Takagi; Yu Sakata
    International journal of cancer, 2024年08月14日, [国際誌]
    英語, 研究論文(学術雑誌), Aflibercept (AFL) plus FOLFIRI prolongs overall survival (OS) in patients with metastatic colorectal cancer (mCRC). However, there is limited evidence on the efficacy and safety of AFL plus FOLFIRI previously treated with anti-epidermal growth factor receptor (EGFR) agents. Therefore, we conducted a prospective open-label phase II trial evaluating the efficacy and safety of AFL plus FOLFIRI in Japanese patients with mCRC failing a prior oxaliplatin-based chemotherapy plus an anti-EGFR agent. AFL (4 mg/kg iv) followed by FOLFIRI (irinotecan 180 mg/m2, leucovorin 200 mg/m2 iv, bolus 5-fluorouracil [5-FU] 400 mg/m2, and infusional 5-FU 2400 mg/m2/46 h) was given every 2 weeks until progression or unacceptable toxicities. The primary endpoint was progression-free survival (PFS) rate at 6 months. Forty three patients were enrolled between November 2019 and October 2022. The primary endpoint was met: 6-month PFS rate was 58.8% (90% confidence interval [CI], 45.7%-72.0%). Median PFS and OS were 7.3 months (95% CI, 5.5-11.0 months) and 18.8 months (95% CI, 12.9-26.6 months), respectively. The overall response rate was 20.9% (95% CI, 10.0-36.0%) and disease control rate was 88.4% (95% CI, 74.9-96.1%). The main grade ≥3 adverse events included hypertension (62.8%), neutropenia (55.8%), leukopenia (25.6%), febrile neutropenia (11.6%), fatigue (9.3%), anorexia (9.3%), proteinuria (9.3%), and diarrhea (7.0%). No deaths and no new safety signals with a causal relation to the study treatment were observed. This study suggests that AFL plus FOLFIRI shows a high response rate and a manageable safety profile in Japanese patients with mCRC who failed prior oxaliplatin-based chemotherapy plus an anti-EGFR agent.
  • Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2-Expressing Biliary Tract Cancer (HERB; NCCH1805): A Multicenter, Single-Arm, Phase II Trial.
    Akihiro Ohba; Chigusa Morizane; Yasuyuki Kawamoto; Yoshito Komatsu; Makoto Ueno; Satoshi Kobayashi; Masafumi Ikeda; Mitsuhito Sasaki; Junji Furuse; Naohiro Okano; Nobuyoshi Hiraoka; Hiroshi Yoshida; Aya Kuchiba; Ryo Sadachi; Kenichi Nakamura; Naoko Matsui; Yoshiaki Nakamura; Wataru Okamoto; Takayuki Yoshino; Takuji Okusaka
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, JCO2302010, 2024年08月05日, [国際誌]
    英語, 研究論文(学術雑誌), PURPOSE: Treatment options for patients with unresectable or recurrent biliary tract cancer (BTC) who progress on a gemcitabine-containing regimen are limited. In addition, the significance of anti-human epidermal growth factor receptor 2 (HER2) therapy in HER2-expressing BTC has not been sufficiently investigated. METHODS: In this phase II trial, participants from five institutions in Japan were enrolled. Eligible patients had pathologically confirmed unresectable or recurrent BTC with centrally confirmed HER2-positive (immunohistochemistry [IHC]3+ or IHC2+ and in situ hybridization [ISH]+) or HER2-low (IHC2+ and ISH-, IHC1+, and IHC0 and ISH+) and were refractory or intolerant to a gemcitabine-containing regimen. The patients received 5.4 mg/kg trastuzumab deruxtecan (T-DXd) once every 3 weeks until disease progression or unacceptable toxicity. The primary end point was the confirmed objective response rate (ORR) in HER2-positive BTC by an independent central review (threshold ORR, 15%; expected ORR, 40%). RESULTS: A total of 32 patients were enrolled and treated. Among these patients, 22 with HER2-positive disease comprised the primary efficacy population and had a confirmed ORR of 36.4% (90% CI, 19.6 to 56.1; P = .01), meeting the primary end point. Eight with HER2-low disease comprised the exploratory population and had a confirmed ORR of 12.5%. The most common ≥grade 3 treatment-related adverse events were anemia (53.1%) and neutropenia (31.3%). Eight patients (25.0%) had interstitial lung disease (ILD), including two grade 5 events. CONCLUSION: T-DXd showed promising activity in patients with HER2-positive BTC and a signal of efficacy in patients with HER2-low BTC. Although the safety profile was generally manageable, ILD requires careful monitoring and early intervention.
  • 当院における切除不能胆道癌に対するゲムシタビン+シスプラチン+デュルバルマブ療法の使用経験
    横山 達也; 川本 泰之; 原田 一顕; 中村 赳晶; 石田 浩一; 金子 志帆; 結城 敏志; 小松 嘉人; 坂本 直哉
    日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 135回・129回, 47, 47, 日本消化器病学会-北海道支部, 2024年08月
    日本語
  • Different efficacy of tyrosine kinase inhibitors by KIT and PGFRA mutations identified in circulating tumor DNA for the treatment of refractory gastrointestinal stromal tumors.
    Tadayoshi Hashimoto; Yoshiaki Nakamura; Yoshito Komatsu; Satoshi Yuki; Naoki Takahashi; Naohiro Okano; Hidekazu Hirano; Koushiro Ohtsubo; Takashi Ohta; Eiji Oki; Tomohiro Nishina; Hisateru Yasui; Hisato Kawakami; Taito Esaki; Nozomu Machida; Ayako Doi; Shogen Boku; Toshihiro Kudo; Yoshiyuki Yamamoto; Akiyoshi Kanazawa; Tadamichi Denda; Masahiro Goto; Naoko Iida; Hiroshi Ozaki; Taro Shibuki; Mitsuho Imai; Takao Fujisawa; Hideaki Bando; Yoichi Naito; Takayuki Yoshino
    BJC reports, 2, 1, 54, 54, 2024年07月25日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: While advanced gastrointestinal stromal tumors (GISTs) are primarily treated with tyrosine kinase inhibitors (TKIs), acquired resistance from specific mutations in KIT or PDGFRA frequently occurs. We aimed to assess the utility of circulating tumor DNA (ctDNA) as a modality of therapeutic decision-making in advanced GIST. METHODS: We conducted a pooled analysis of SCRUM-Japan studies for advanced GIST patients. We compared patient characteristics analyzed with tissue and blood samples, assessed gene alteration profiles, and evaluated prognostic implications from ctDNA status. RESULTS: In 133 patients, tissue and blood samples were analyzed for 89 and 44 patients, respectively. ctDNA was detected in 72.7% of cases; no prior treatment or progressive disease was significantly associated with ctDNA-positivity. ctDNA-positive patients had significantly shorter progression-free survival compared with ctDNA-negative patients (hazard ratio = 3.92; P = 0.007). ctDNA genotyping revealed a complex landscape of gene alterations, characterized by multi-exonic mutations in KIT, compared with tissue-based analysis. Patients who received TKIs matched to the identified KIT mutation in ctDNA demonstrated significantly longer PFS than those with unmatched treatment (median, 8.23 vs. 2.43 months; P < 0.001). CONCLUSIONS: ctDNA-based analysis facilitates assessment of disease status and genomic profiles, thus potentially assisting in identifying optimal therapeutic strategies for advanced GIST patients.
  • Clinical features associated with NeoRAS wild-type metastatic colorectal cancer A SCRUM-Japan GOZILA substudy.
    Hiroki Osumi; Eiji Shinozaki; Yoshiaki Nakamura; Taito Esaki; Hisateru Yasui; Hiroya Taniguchi; Hironaga Satake; Yu Sunakawa; Yoshito Komatsu; Yoshinori Kagawa; Tadamichi Denda; Manabu Shiozawa; Taroh Satoh; Tomohiro Nishina; Masahiro Goto; Naoki Takahashi; Takeshi Kato; Hideaki Bando; Kensei Yamaguchi; Takayuki Yoshino
    Nature communications, 15, 1, 5885, 5885, 2024年07月13日, [国際誌]
    英語, 研究論文(学術雑誌), "NeoRAS WT" refers to the loss of RAS mutations (MTs) following first-line treatment in metastatic colorectal cancer (mCRC). We evaluate the incidence and clinicopathological characteristics of NeoRAS WT mCRC using next-generation sequencing of plasma circulating tumor DNA. Patients with mCRC enrolled in the GOZILA study initially diagnosed with tissue RAS MT mCRC and received subsequent systemic therapy are eligible. NeoRAS WT is defined as the absence of detectable RAS MT in plasma and assessed in all eligible patients (Group A) and in a subgroup with at least one somatic alteration detected in plasma (Group B). Overall, 478 patients are included. NeoRAS WT prevalence is 19.0% (91/478) in Group A and 9.8% (42/429) in Group B. Absence of liver or lymph node metastasis and tissue RAS MTs other than KRAS exon 2 MTs are significantly associated with NeoRAS WT emergence. Overall, 1/6 and 2/6 patients with NeoRAS WT treated with anti-EGFR monoclonal antibodies (mAbs) show partial response and stable disease for ≥6 months, respectively. NeoRAS WT mCRC is observed at a meaningful prevalence, and anti-EGFR mAb-based therapy may be effective.
  • HGCSG1803 進行膵癌オキサリプラチン・イリノテカン・S-1(OX-IRIS療法)の第II相試験
    川本 泰之; 中野 真太郎; 澤田 憲太郎; 宮城島 拓人; 曽我部 進; 陳 豫; 佐藤 温; 太宰 昌佳; 伊藤 憲; 結城 敏志; 横田 勲; 坂本 直哉; 小松 嘉人
    膵臓, 39, 3, A463, A463, (一社)日本膵臓学会, 2024年07月
    日本語
  • QUATTRO-II randomized trial: CAPOXIRI+bevacizumab vs. FOLFOXIRI+bevacizumab as first-line treatment in patients with mCRC.
    Hideaki Bando; Daisuke Kotani; Hironaga Satake; Tetsuya Hamaguchi; Manabu Shiozawa; Masahito Kotaka; Toshiki Masuishi; Hisateru Yasui; Yoshinori Kagawa; Yoshito Komatsu; Eiji Oki; Yoshiyuki Yamamoto; Hisato Kawakami; Toshihiro Misumi; Hiroya Taniguchi; Kentaro Yamazaki; Kei Muro; Takayuki Yoshino; Takeshi Kato; Akihito Tsuji
    Med (New York, N.Y.), 2024年06月14日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: The QUATTRO-II trial examined the efficacy and safety of capecitabine+oxaliplatin+irinotecan (CAPOXIRI)+bevacizumab (BEV) vs. 5-fluorouracil+folinic acid+oxaliplatin+irinotecan (FOLFOXIRI)+BEV in metastatic colorectal cancer (mCRC). METHODS: In this phase II study (ClinicalTrials.gov: NCT04097444; jRCTs041190072), patients were randomized (1:1) to FOLFOXIRI+BEV or CAPOXIRI+BEV. The induction treatment in the FOLFOXIRI+BEV/CAPOXIRI+BEV arms was continued for 8/6 cycles (maximum 12/8 cycles if feasible), and the maintenance treatment was 5-fluorouracil/leucovorin+BEV or capecitabine+BEV at the investigators' discretion. The primary endpoint was progression-free survival (PFS), with the two arms deemed equivalent if the hazard ratio (HR) of the point estimate was 0.80 < HR < 1.25. Secondary endpoints were overall response rate (ORR), overall survival (OS), incidence of adverse events (AEs), and patient-reported outcomes. FINDINGS: Overall, 51 and 52 patients were randomized to FOLFOXIRI+BEV and CAPOXIRI+BEV, respectively. The study met its primary endpoint; PFS at median follow-up of 23.7 months was 10.6 months (95% confidence interval [CI], 7.7-13.3) in the FOLFOXIRI+BEV arm vs. 10.9 months (95% CI, 9.3-14.3) in the CAPOXIRI+BEV arm (HR 1.114 [0.80 < HR < 1.25], p = 0.654). In the FOLFOXIRI+BEV vs. CAPOXIRI+BEV arms, the 2-year OS rate (95% CI) was 65.5% (49.5%-77.6%) vs. 74.3% (59.8%-84.2%), and the ORR (95% CI) was 76.5% (62.5%-87.2%) vs. 84.6% (71.9%-93.1%). Major (grade ≥3) AEs in the FOLFOXIRI+BEV vs. CAPOXIRI+BEV arms were neutropenia (68.6% vs. 40.4%), febrile neutropenia (9.8% vs. 11.5%), diarrhea (7.8% vs. 17.3%), and appetite loss (7.8% vs. 17.3%). CONCLUSION: CAPOXIRI+BEV was well tolerated with reduced hematological toxicity and efficacy comparable to those of FOLFOXIRI+BEV, providing a potentially convenient first-line treatment alternative to FOLFOXIRI+BEV in patients with mCRC. FUNDING: Chugai Pharmaceutical Co., Ltd.
  • English version of Japanese Clinical Practice Guidelines 2022 for gastrointestinal stromal tumor (GIST) issued by the Japan Society of Clinical Oncology.
    Seiichi Hirota; Ukihide Tateishi; Yuji Nakamoto; Hidetaka Yamamoto; Shinji Sakurai; Hirotoshi Kikuchi; Tatsuo Kanda; Yukinori Kurokawa; Haruhiko Cho; Toshirou Nishida; Akira Sawaki; Masato Ozaka; Yoshito Komatsu; Yoichi Naito; Yoshitaka Honma; Fumiaki Takahashi; Hironobu Hashimoto; Midori Udo; Minako Araki; Sumito Nishidate
    International journal of clinical oncology, 29, 6, 647, 680, 2024年06月, [査読有り], [国内誌]
    英語, 研究論文(学術雑誌), The Japan Society of Clinical Oncology Clinical Practice Guidelines 2022 for gastrointestinal stromal tumor (GIST) have been published in accordance with the Minds Manual for Guideline Development 2014 and 2017. A specialized team independent of the working group for the revision performed a systematic review. Since GIST is a rare type of tumor, clinical evidence is not sufficient to answer several clinical and background questions. Thus, in these guidelines, we considered that consensus among the experts who manage GIST, the balance between benefits and harms, patients' wishes, medical economic perspective, etc. are important considerations in addition to the evidence. Although guidelines for the treatment of GIST have also been published by the National Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO), there are some differences between the treatments proposed in those guidelines and the treatments in the present guidelines because of the differences in health insurance systems among countries.
  • ナノリポソーマルイリノテカンとレボホリナートの並列投与における有効性、安全性の評価
    坂本 達彦; 齋藤 佳敬; 渡辺 拓也; 内山 数貴; 武隈 洋; 小松 嘉人; 菅原 満
    日本臨床腫瘍薬学会雑誌, 36, 191, 191, (一社)日本臨床腫瘍薬学会, 2024年05月
    日本語
  • Phase II trial of niraparib for BRCA-mutated biliary tract, pancreatic and other gastrointestinal cancers: NIR-B.
    Yasuyuki Kawamoto; Chigusa Morizane; Yoshito Komatsu; Shunsuke Kondo; Makoto Ueno; Satoshi Kobayashi; Masayuki Furukawa; Lingaku Lee; Taroh Satoh; Daisuke Sakai; Masafumi Ikeda; Hiroshi Imaoka; Arisa Miura; Yutaka Hatanaka; Isao Yokota; Yoshiaki Nakamura; Takayuki Yoshino
    Future oncology (London, England), 1, 7, 2024年04月17日, [国際誌]
    英語, 研究論文(学術雑誌), Due to the widespread use of cancer genetic testing in gastrointestinal cancer, the BRCA1/2 genetic mutation has been identified in biliary tract cancer as well as pancreatic cancer. Niraparib is a poly(ADP-ribose) polymerase (PARP) inhibitor, and PARP inhibitors exert their cytotoxicity against cancer cells in the context of homologous recombination deficiency, such as BRCA mutations, via the mechanism of synthetic lethality. The aim of this phase II NIR-B trial is to evaluate the efficacy and safety of niraparib for patients with unresectable advanced or recurrent biliary tract cancer, pancreatic cancer or other gastrointestinal cancers with germline or somatic BRCA1/2 mutations revealed by genetic testing. The primary end point is an investigator-assessed objective response rate in each cohort.Clinical Trial Registration: jRCT2011200023 (ClinicalTrials.gov).
  • Safety and Efficacy of Encorafenib, Binimetinib, and Cetuximab for BRAFV600E-Mutant Metastatic Colorectal Cancer: Results of the Japanese Expanded Access Program.
    Daisuke Kotani; Atsuo Takashima; Takeshi Kato; Taroh Satoh; Toshiki Masuishi; Yoshito Komatsu; Manabu Shiozawa; Taito Esaki; Naoki Izawa; Shinji Takeuchi; Hideaki Bando; Satoru Iwasa; Hiroko Hasegawa; Toshifumi Yamaguchi; Hiroya Taniguchi; Yasunori Ushida; Toshiya Oizaki; Chiaki Inoue; Takayuki Yoshino
    Clinical colorectal cancer, 2024年03月09日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: The phase 3 BEACON CRC study demonstrated the survival benefits of encorafenib and cetuximab, with or without binimetinib (the BEACON triplet or doublet regimen), for BRAFV600E-mutant metastatic colorectal cancer (mCRC). This expanded access program (EAP) and subsequent follow-up study assessed the efficacy and safety of the BEACON triplet regimen in Japanese patients with BRAFV600E-mutant mCRC. MATERIALS AND METHODS: The EAP was an open-label, single-arm study including Japanese patients with BRAFV600E-mutant mCRC whose disease progressed after 1 to 2 prior regimens. The patients received the BEACON triplet regimen with 28-day cycles. The subsequent follow-up study assessed the survival outcomes following EAP completion. Safety was assessed only during the EAP. RESULTS: Among the 86 enrolled patients, 81 received the BEACON triplet regimen. The objective response rate and median progression-free survival were 27.6% (95% confidence interval [CI], 18.0%-39.1%) and 5.26 (95% CI, 4.14-5.52) months, respectively. Grade 3 to 4 adverse events and treatment-related adverse events occurred in 43.2% and 28.4% of patients, respectively. No new safety signals were observed during the EAP. Among 58 patients with confirmed survival at EAP completion, 57 were included in the follow-up study. With a median observation period of 9.17 months through the EAP and follow-up study, the median overall survival was 10.38 (95% CI, 9.00-16.16) months. CONCLUSION: The efficacy and safety of the BEACON triplet regimen in Japanese patients with BRAFV600E-mutant mCRC were consistent with those reported in the BEACON CRC trial, supporting its use as a standard treatment for pretreated patients with BRAFV600E-mutant mCRC.
  • Evaluation of the risk factors for the failure of a single prophylactic dose of anticholinergic drugs for irinotecan-induced cholinergic symptoms.
    Takuya Watanabe; Yoshitaka Saito; Yoh Takekuma; Yasushi Shimizu; Ichiro Kinoshita; Yoshito Komatsu; Mitsuru Sugawara
    International journal of clinical pharmacology and therapeutics, 2024年03月03日, [国際誌]
    英語, 研究論文(学術雑誌), OBJECTIVE: Irinotecan (IRI) is an anticancer drug that is frequently used to treat colorectal, gastric, and pancreatic cancers. Its side effects include cholinergic symptoms, such as diarrhea, abdominal pain, nausea, and hyperhidrosis. Anticholinergic medicines are frequently used for treatment or prophylaxis; however, the risk factors for the failure of a single prophylactic anticholinergic administration remain unclear. Moreover, an appropriate anticholinergic drug for prophylaxis remains unknown. Thus, we aimed to identify the risk factors associated with the failure of a single prophylactic dose of anticholinergic drugs for IRI-induced cholinergic symptoms and to evaluate the usefulness of multiple prophylactic doses of anticholinergic drugs. MATERIALS AND METHODS: Patients who underwent IRI treatment for colorectal, gastric, or pancreatic cancer and received prophylactic anticholinergic drugs for IRI-induced cholinergic symptoms (n = 135) were retrospectively evaluated. Univariate and multivariate logistic regression analyses were performed to identify the risk factors for failure of a single prophylactic dose of anticholinergic drugs. We also evaluated the efficacy of multiple prophylactic anticholinergic drug administration. RESULTS: Based on univariate and multivariate analyses, colorectal cancer, female sex, and prophylactic use of scopolamine butyl bromide were identified as risk factors for failure of a single prophylactic dose of anticholinergic drugs. The efficacy of multiple prophylactic doses was confirmed to be 95% of the patients who had a single prophylactic failure due to temporary effect but symptom appearance after a certain period of time (wearing-off). CONCLUSION: We determined that colorectal cancer, female sex, and prophylactic use of scopolamine butyl bromide were risk factors associated with the failure of a single prophylactic dose of anticholinergic drugs, and that multiple prophylactic doses for wearing-off can be a promising method.
  • Impact of preexisting proteinuria on the development of regorafenib-induced problematic proteinuria in real-world metastatic colorectal cancer treatment.
    Yoshitaka Saito; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
    Scientific reports, 14, 1, 5153, 5153, 2024年03月02日, [国際誌]
    英語, 研究論文(学術雑誌), Regorafenib is the first multikinase inhibitor for treating metastatic colorectal cancer (mCRC). Proteinuria is a frequently encountered adverse effect, regardless of prior administration of vascular endothelial growth factor inhibitors. Herein, we aimed to assess the impact of baseline preexisting proteinuria on regorafenib-induced problematic proteinuria during real-world mCRC therapy. Patients with mCRC receiving regorafenib (n = 100) were retrospectively assessed and divided into control and preexisting proteinuria (baseline grade of 1-2) groups. The primary endpoint was the development of grade ≥ 2 (grade ≥ 3 in case of baseline grade 2 patients) proteinuria. Propensity score-matching was performed to confirm the robustness of primary analyses. Defined proteinuria occurred in 30.7 and 57.9% of patients in the control and preexisting proteinuria groups, respectively, with significant differences in the all-patient population (P = 0.01). The preexisting proteinuria group exhibited significant defined proteinuria development within 7 days of regorafenib initiation, grade ≥ 3 symptoms, and treatment suspension owing to proteinuria. Similar results were obtained in the propensity score-matched population. According to multivariate logistic regression analysis, baseline proteinuria was a singular risk factor for defined proteinuria development (adjusted odds ratio; 3.76, 95% confidence interval; 1.45-9.75, P = 0.007). Collectively, our study revealed that patients with preexisting proteinuria develop regorafenib-induced proteinuria degradation.
  • Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer.
    Kohei Shitara; Kei Muro; Jun Watanabe; Kentaro Yamazaki; Hisatsugu Ohori; Manabu Shiozawa; Atsuo Takashima; Mitsuru Yokota; Akitaka Makiyama; Naoya Akazawa; Hitoshi Ojima; Yasuhiro Yuasa; Keisuke Miwa; Hirofumi Yasui; Eiji Oki; Takeo Sato; Takeshi Naitoh; Yoshito Komatsu; Takeshi Kato; Ikuo Mori; Kazunori Yamanaka; Masamitsu Hihara; Junpei Soeda; Toshihiro Misumi; Kouji Yamamoto; Riu Yamashita; Kiwamu Akagi; Atsushi Ochiai; Hiroyuki Uetake; Katsuya Tsuchihara; Takayuki Yoshino
    Nature medicine, 30, 3, 730, 739, 2024年03月, [国際誌]
    英語, 研究論文(学術雑誌), Certain genetic alterations and right-sided primary tumor location are associated with resistance to anti-epidermal growth factor (EGFR) treatment in metastatic colorectal cancer (mCRC). The phase 3 PARADIGM trial (n = 802) demonstrated longer overall survival with first-line anti-EGFR (panitumumab) versus antivascular endothelial growth factor (bevacizumab) plus modified FOLFOX6 in patients with RAS wild-type mCRC with left-sided primary tumors. This prespecified exploratory biomarker analysis of PARADIGM (n = 733) evaluated the association between circulating tumor DNA (ctDNA) gene alterations and efficacy outcomes, focusing on a broad panel of gene alterations associated with resistance to EGFR inhibition, including KRAS, NRAS, PTEN and extracellular domain EGFR mutations, HER2 and MET amplifications, and ALK, RET and NTRK1 fusions. Overall survival was prolonged with panitumumab plus modified FOLFOX6 versus bevacizumab plus modified FOLFOX6 in patients with ctDNA that lacked gene alterations in the panel (that is, negative hyperselected; median in the overall population: 40.7 versus 34.4 months; hazard ratio, 0.76; 95% confidence interval, 0.62-0.92) but was similar or inferior with panitumumab in patients with ctDNA that contained any gene alteration in the panel (19.2 versus 22.2 months; hazard ratio, 1.13; 95% confidence interval, 0.83-1.53), regardless of tumor sidedness. Negative hyperselection using ctDNA may guide optimal treatment selection in patients with mCRC. ClinicalTrials.gov registrations: NCT02394834 and NCT02394795 .
  • 消化器癌患者における鉄欠乏性貧血に対するカルボキシマルトース第二鉄の有用性の検討
    川本 泰之; 原田 一顕; 金子 志帆; 石田 浩一; 中村 赳晶; 結城 敏志; 小松 嘉人; 坂本 直哉
    日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 134回・128回, 75, 75, 日本消化器病学会-北海道支部, 2024年03月
    日本語
  • 切除不能進行再発大腸癌の治療戦略 転移性結腸直腸癌におけるレゴラフェニブ減量開始の有用性を検討する多施設共同後方視的解析
    結城 敏志; 原田 一顕; 小松 嘉人; 坂本 直哉; 川上 武志; 山崎 健太郎; 舛石 俊樹; 谷口 浩也; 胡 慶江; 沖 英次
    日本消化器病学会雑誌, 121, 臨増総会, A73, A73, (一財)日本消化器病学会, 2024年03月
    日本語
  • VOLTAGE-2: multicenter phase II study of nivolumab monotherapy in patients with mismatch repair-deficient resectable locally advanced rectal cancer
    H. Bando; Y. Tsukada; S. Kumagai; Y. Miyashita; A. Taketomi; S. Yuki; Y. Komatsu; T. Akiyoshi; E. Shinozaki; Y. Kanemitsu; A. Takashima; M. Shiozawa; A. Shiomi; K. Yamazaki; N. Matsuhashi; H. Hasegawa; T. Kato; E. Oki; M. Fukui; M. Wakabayashi; N. Fuse; H. Nishikawa; M. Ito; T. Yoshino
    ESMO Gastrointestinal Oncology, 3, 100031, 100031, Elsevier BV, 2024年03月
    研究論文(学術雑誌)
  • CA125 Kinetics as a Potential Biomarker for Peritoneal Metastasis Progression following Taxane-Plus-Ramucirumab Administration in Patients with Advanced Gastric Cancer
    Akira Ueda; Satoshi Yuki; Takayuki Ando; Ayumu Hosokawa; Naokatsu Nakada; Yosuke Kito; Iori Motoo; Ken Ito; Miho Sakumura; Yurika Nakayama; Yuko Ueda; Shinya Kajiura; Koji Nakashima; Kazuaki Harada; Yasuyuki Kawamoto; Yoshito Komatsu; Ichiro Yasuda
    Cancers, 16, 5, 2024年03月
    研究論文(学術雑誌)
  • CA125 Kinetics as a Potential Biomarker for Peritoneal Metastasis Progression following Taxane-Plus-Ramucirumab Administration in Patients with Advanced Gastric Cancer.
    Akira Ueda; Satoshi Yuki; Takayuki Ando; Ayumu Hosokawa; Naokatsu Nakada; Yosuke Kito; Iori Motoo; Ken Ito; Miho Sakumura; Yurika Nakayama; Yuko Ueda; Shinya Kajiura; Koji Nakashima; Kazuaki Harada; Yasuyuki Kawamoto; Yoshito Komatsu; Ichiro Yasuda
    Cancers, 16, 5, 2024年02月22日, [国際誌]
    英語, 研究論文(学術雑誌), Currently, no established marker exists for predicting peritoneal metastasis progression during chemotherapy, although they are major interruptive factors in sequential chemotherapy in patients with advanced gastric cancer (AGC). This multicenter retrospective study was conducted from June 2015 to July 2019, analyzing 73 patients with AGC who underwent taxane-plus-ramucirumab (TAX/RAM) therapy and had their serum carbohydrate antigen 125 (CA125) concentrations measured. Of 31 patients with elevated CA125 levels above a cutoff of 35 U/mL, 25 (80.6%) had peritoneal metastasis. The CA125 concentrations before TAX/RAM treatment were associated with ascites burden. The overall survival was significantly shorter in the CA125-elevated group. CA125 kinetics, measured at a median of 28 days after chemotherapy, were associated with the ascites response (complete or partial response: -1.86%/day; stable disease: 0.28%/day; progressive disease: 2.33%/day). Progression-free survival in the CA125-increased group, defined by an increase of 0.0067%/day using receiver operating characteristic curve analysis, was significantly poorer among patients with peritoneal metastases. In conclusion, this study highlights that CA125 kinetics can serve as an early predictor for the progression of peritoneal metastasis during TAX/RAM treatment.
  • Risk Factor Analysis for Anti-epidermal Growth Factor Receptor Monoclonal Antibody-induced Problematic Skin Toxicities in Patients With Liver Metastatic Colorectal Cancer.
    Yoshitaka Saito; Kazuki Uchiyama; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
    In vivo (Athens, Greece), 38, 5, 2390, 2398, 2024年, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND/AIM: We previously reported that patients with metastatic colorectal cancer (mCRC) and baseline liver metastasis are at a higher risk of developing grade ≥2 overall skin toxicities when treated with anti-epidermal growth factor receptor (EGFR) monoclonal antibody. This study aimed to identify additional factors associated with skin toxicities induced by anti-EGFR treatment in patients with liver metastatic CRC. PATIENTS AND METHODS: Patients with liver metastatic CRC who initially received anti-EGFR monoclonal antibody-containing treatment (n=77) were retrospectively assessed. The primary endpoint was to identify the factor(s) responsible for the development of grade ≥2 overall skin toxicities. Additionally, factors for grade ≥2 rash and paronychia were evaluated. RESULTS: The incidence of grade ≥2 overall skin symptoms, rash, and paronychia was 62.3%, 31.2%, and 28.6%, respectively. Multivariate Cox proportional hazard regression analyses revealed that age <65 years and anemia were independent baseline risk factors for grade ≥2 overall skin toxicities (adjusted hazard ratio 2.09, 95% confidence interval=1.10-3.97, p=0.02 for age; 2.36, 1.20-4.61, p=0.01 for anemia). In contrast, combination prophylaxis using systemic minocycline and corticosteroid ointment was a preventive factor (0.47, 0.25-0.88, p=0.02). Males and age <65 years were baseline risk factors for grade ≥2 rash, and combination prophylaxis was identified as a preventive factor. No factors were identified for paronychia. CONCLUSION: Age <65 years and anemia were identified as independent baseline risk factors. Additionally, combination prophylaxis was found to be a preventive factor against anti-EGFR monoclonal antibody-induced grade ≥2 overall skin toxicities in patients with liver metastatic CRC.
  • Evaluation of the additional prophylactic effect of topical steroid ointment to systemic minocycline against anti-epidermal growth factor antibody-induced skin toxicities in metastatic colorectal cancer treatment.
    Yoshitaka Saito; Kazuki Uchiyama; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 32, 1, 8, 8, 2023年12月06日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Anti-epidermal growth factor receptor (EGFR) antibodies often cause skin toxicities. Preemptive skin treatments using systemic antibiotics with or without topical steroid are reportedly effective although the most suitable method remains unclear. This study aimed to determine whether combination prophylaxis using systemic minocycline and topical steroid is superior to minocycline alone in a real-world metastatic colorectal cancer (mCRC) treatment. METHODS: Patients with mCRC (n = 87) who received anti-EGFR monoclonal antibodies were retrospectively assessed. The primary objective was to compare the incidence of grade ≥ 2 overall skin toxicities during all treatment periods between the control group receiving prophylactic minocycline 100 mg/day, and the combination prophylaxis group receiving minocycline 100 mg/day + topical steroid. The incidence of each skin symptom was also evaluated. RESULTS: The incidence of grade ≥ 2 overall skin toxicities was 63.6% in the control and 56.9% in the combination groups, with no significant difference (P = 0.63). Similarly, the incidence of grade ≥ 2 dry skin, fissures, paronychia, and pruritus did not significantly differ. In addition, incidence of all-grade skin toxicities was not different. However, the incidence of grade ≥ 2 papulopustular rashes was significantly lower in the combination group (23.1% vs. 50.0%, P = 0.03). Propensity score-matched analysis supported these results. Multivariate logistic regression analysis showed no significant association between combination prophylaxis and grade ≥ 2 overall skin toxicities, but it did show a reduction in grade ≥ 2 papulopustular rashes. CONCLUSION: Adding topical steroids to systemic minocycline did not mitigate grade ≥ 2 overall skin toxicities induced by anti-EGFR antibodies; however, it significantly improved papulopustular rashes.
  • Association of PD-L1 and PD-L2 expression and tumor-infiltrating lymphocytes in BRAF V600E-mutated metastatic colorectal cancer: GI-SCREEN post-hoc analysis
    M. Imai; Y. Nakamura; T. Denda; Y. Komatsu; S. Yuki; T. Nishina; Y. Hamamoto; H. Hara; T. Esaki; H. Kawakami; K. Kato; T. Satoh; N. Okano; Y. Sunakawa; H. Taniguchi; K. Yamaguchi; T. Yamada; I. Miki; M. Wakabayashi; T. Kuwata; K. Shitara; T. Yoshino
    ESMO Gastrointestinal Oncology, 2, 100008, 100008, Elsevier BV, 2023年12月
    研究論文(学術雑誌)
  • 胸部食道がん化学放射線療法における重症放射線食道炎に関する後方視的研究
    原田 一顕; 中村 赳晶; 渡辺 亮介; 山村 貴洋; 結城 敏志; 坂本 直哉; 川本 泰之; 小松 嘉人; 打浪 雄介; 田口 大志; 加藤 徳雄; 青山 英史
    北海道医学雑誌, 98, 2, 139, 140, 北海道医学会, 2023年11月
    日本語
  • Re-appraisal of the universal definition of tumor rupture among patients with high-risk gastrointestinal stromal tumors.
    Naoto Gotohda; Toshirou Nishida; Shinsuke Sato; Masato Ozaka; Yujiro Nakahara; Yoshito Komatsu; Masato Kondo; Haruhiko Cho; Yukinori Kurokawa; Yuko Kitagawa
    Annals of gastroenterological surgery, 7, 6, 1021, 1031, 2023年11月, [国内誌]
    英語, 研究論文(学術雑誌), AIM: Tumor rupture has been indicated as a risk factor for recurrence of gastrointestinal stromal tumors (GISTs). The universal definition of tumor rupture was proposed. This study evaluated whether the universal definition was more accurate in identification of GISTs with high recurrent risk than subjective judgment. METHODS: The study included 507 patients with high-risk GISTs who underwent complete resection between December 2012 and December 2015. We conducted a questionnaire survey in participating institutes to re-diagnose tumor rupture based on the universal definition according to their surgical and pathological findings. We compared the clinical outcomes of tumor rupture based on the definition to those based on the surgeon's judgment and clarified the clinical importance of the rupture. RESULTS: Sixty-four patients were initially registered to have tumor rupture by surgeon's judgment, and it became 90 patients who had tumor rupture after reevaluation. Although there were significant differences in recurrence-free survival (RFS) between no rupture and rupture for both initial registration and reevaluation (p = 0.002, <0.001, respectively), a significant difference in overall survival was only observed after reevaluation (p = 0.011). Tumor rupture was significantly associated with large tumor size, mixed cell type in histology, R1 resection, frequent adjuvant therapy and recurrence, but not with location, mitosis, and genotype. Adjuvant therapy more than 3 years improved RFS of patients with tumor rupture. CONCLUSION: This study suggested that tumor rupture based on the universal definition more accurately identified GISTs with poor prognostic outcomes than the subjective judgment.
  • 胸部食道がん化学放射線療法における重症放射線食道炎に関する後方視的研究
    原田 一顕; 中村 赳晶; 渡辺 亮介; 山村 貴洋; 結城 敏志; 坂本 直哉; 川本 泰之; 小松 嘉人; 打浪 雄介; 田口 大志; 加藤 徳雄; 青山 英史
    北海道医学雑誌, 98, 2, 139, 140, 北海道医学会, 2023年11月
    日本語
  • Identification of an optimal mutant allele frequency to detect activating KRAS, NRAS, and BRAF mutations in a commercial cell-free DNA next-generation sequencing assay in colorectal and pancreatic adenocarcinomas.
    Bennett A Caughey; Kumiko Umemoto; Michelle F Green; Masafumi Ikeda; Melissa E Lowe; Makoto Ueno; Donna Niedzwiecki; Hiroya Taniguchi; Daniel J Walden; Yoshito Komatsu; Rachel D'Anna; Taito Esaki; Tadamichi Denda; Michael B Datto; Hideaki Bando; Tanios Bekaii-Saab; Takayuki Yoshino; John H Strickler; Yoshiaki Nakamura
    Journal of gastrointestinal oncology, 14, 5, 2083, 2096, 2023年10月31日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Evaluation for activating mutations in KRAS, NRAS, and BRAF in colorectal cancer (CRC) and in KRAS in pancreatic ductal adenocarcinoma (PDAC) is essential for clinical care. Plasma cell-free DNA (cfDNA) next-generation sequencing (NGS) allows convenient assessment of a tumor's molecular profile, however low tumor DNA shedding limits sensitivity. We investigated mutant allele frequency (MAF) of other oncogenic dominant genes to identify a threshold for accurate detection of KRAS, NRAS, and BRAF (RAS/RAF) mutations in cfDNA. METHODS: Molecular and clinical data were obtained from the Duke Molecular Registry of Tumors and the SCRUM-Japan GOZILA study. Patients with CRC or PDAC and a KRAS, NRAS, or BRAF activating single nucleotide variant (SNV) present on tissue NGS and with available cfDNA assays were included. Recursive partitioning and Wilcoxon-rank statistics methods identified potential cut-points for discriminative MAF values. RESULTS: One hundred and thirty-five CRC and 30 PDAC cases with 198 total cfDNA assays met criteria. Greatest non-RAS/RAF dominant gene MAF of 0.34% provided maximum discrimination for predicting RAS/RAF SNV detection. Sensitivity for RAS/RAF SNVs increased with dominant gene MAF, with MAF ≥1% predicting sensitivity >98%, MAF between 0.34 and 1% predicting sensitivity of 84.0%, and MAF £0.34% predicting sensitivity of 50%. For 43 cfDNA assays that did not detect RAS/RAF SNVs, 18 assays detected 34 other oncogenic variants, of which 80.6% were not also detected on tissue. CONCLUSIONS: Non-RAS/RAF dominant oncogenic mutation MAF ≥1% on cfDNA NGS predicts high sensitivity to detect RAS/RAF oncogenic SNVs in CRC and PDAC. MAF £0.34% indicates an assay may not reliably detect RAS/RAF SNVs, despite detection on tissue testing. Most variants from assays that did not detect RAS/RAF had MAF <1% and were not detected on tissue, suggesting potential confounding. These data suggest a practical approach to determining cfDNA assay adequacy, with implications for guiding clinical decisions in CRC and PDAC.
  • UGT1A1遺伝子型がQUATTRO-II試験の有効性と安全性に及ぼす影響
    濱口 哲弥; 小谷 大輔; 塩澤 学; 坂東 英明; 佐竹 悠良; 沖 英次; 小松 嘉人; 谷口 浩也; 室 圭; 小高 雅人; 山崎 健太郎; 三角 俊裕; 吉野 孝之; 加藤 健志; 辻 晃仁
    日本癌治療学会学術集会抄録集, 61回, FR1, 6, (一社)日本癌治療学会, 2023年10月
    英語
  • 進行大腸癌に対するCAPOXIRI+Bev療法とFOLFOXIRI+Bev療法のランダム化第II相臨床研究
    安井 久晃; 板東 英明; 佐竹 悠良; 小谷 大輔; 濱口 哲弥; 小高 雅人; 谷口 浩也; 室 圭; 小松 嘉人; 沖 英次; 山崎 健太郎; 三角 俊裕; 吉野 孝之; 加藤 健志; 辻 晃仁
    日本癌治療学会学術集会抄録集, 61回, EN1, 3, (一社)日本癌治療学会, 2023年10月
    英語
  • 転移性大腸癌におけるレゴラフェニブの開始用量が治療成績に対する影響
    胡 慶江; 原田 一顕; 川上 武志; 緒方 貴次; 伏木 邦博; 谷口 浩也; 室 圭; 安藤 幸滋; 南原 翔; 川本 泰之; 小松 嘉人; 沖 英次; 舛石 俊樹; 山崎 健太郎; 結城 敏志
    日本癌治療学会学術集会抄録集, 61回, O15, 5, (一社)日本癌治療学会, 2023年10月
    英語
  • 当科におけるがん悪液質患者へのアナモレリン塩酸塩の使用経験
    石田 浩一; 川本 泰之; 金子 志帆; 中村 赳晶; 原田 一顕; 結城 敏志; 小松 嘉人; 坂本 直哉
    日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 133回・127回, 59, 59, 日本消化器病学会-北海道支部, 2023年09月
    日本語
  • Risk factor analysis for anti-epidermal growth factor receptor monoclonal antibody-induced skin toxicities in real-world metastatic colorectal cancer treatment.
    Yoshitaka Saito; Kazuki Uchiyama; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 31, 8, 504, 504, 2023年08月02日, [国際誌]
    英語, 研究論文(学術雑誌), PURPOSE: Anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibodies are effective in treating RAS wild-type metastatic colorectal cancer (mCRC). However, their administration induces skin toxicity, markedly reducing patients' quality of life. This study is aimed at identifying the risk factors associated with anti-EGFR monoclonal antibody-induced skin toxicities. METHODS: Patients with mCRC (n = 116) who received anti-EGFR monoclonal antibody treatment were retrospectively evaluated. Primary endpoint was evaluation of the risk factors for grade ≥ 2 overall skin toxicities during all the treatment periods. Furthermore, factors associated with each grade ≥ 2 skin symptoms were assessed. RESULTS: Incidence of total grade ≥ 2 skin toxicity symptoms was 61.2%, and those of grade ≥ 2 rash, dry skin, fissures, and paronychia were 34.5%, 25.9%, 20.7%, and 25.0%, respectively. Multivariate logistic regression analyses revealed that liver metastasis was an independent risk factor for overall grade ≥ 2 skin toxicities (adjusted odds ratio [OR], 2.88; 95% confidence interval [CI], 1.22-6.78; P = 0.02) and prophylactic administration of antibiotics as a preventive factor (OR 0.10; 95%CI 0.01-0.91; P = 0.04). For grade ≥ 2 rash, prophylactic use of systemic antibiotics and topical steroid ointment was a preventive factor (OR 0.37; 95%CI 0.16-0.89; P = 0.03). Moreover, liver metastasis (OR 8.37; 95%CI 1.98-35.47; P = 0.004) and prophylactic administration of antibiotics (OR 0.15; 95%CI 0.03-0.76; P = 0.02) were significantly associated with grade ≥ 2 paronychia. CONCLUSION: Liver metastasis was suggested to be a risk factor for the incidence of overall grade ≥ 2 skin toxicities; moreover, preemptive systemic antibiotic administration drastically decreased this risk during all periods of anti-EGFR treatment for mCRC.
  • 実臨床における切除不能進行・再発胆道癌に対するGEM+CDDP+S-1療法(GCS)と三剤逐次投与のの治療成績に関する検討
    川本 泰之; 原田 一顕; 坂本 直哉; 中村 赳晶; 金子 志帆; 石田 浩一; 結城 敏志; 桑谷 将城; 小松 嘉人
    胆道, 37, 3, 597, 597, (一社)日本胆道学会, 2023年08月
    日本語
  • 腫瘍破裂GISTにおける臨床・病理組織学的特徴の検討
    後藤田 直人; 西田 俊朗; 佐藤 真輔; 尾阪 将人; 中原 裕次郎; 小松 嘉人; 近藤 正人; 長 晴彦; 黒川 幸典; 北川 雄光
    日本消化器外科学会総会, 78回, P015, 1, (一社)日本消化器外科学会, 2023年07月
    日本語
  • Comprehensive review of undifferentiated carcinoma of the pancreas: from epidemiology to treatment.
    Hiroshi Imaoka; Masafumi Ikeda; Kumiko Umemoto; Yu Sunakawa; Makoto Ueno; Hideki Ueno; Masato Ozaka; Takamichi Kuwahara; Naohiro Okano; Masashi Kanai; Terumasa Hisano; Yuko Suzuki; Akinori Asagi; Kazuhiko Shioji; Akiko Todaka; Kunihiro Tsuji; Kenji Ikezawa; Ikuya Miki; Yoshito Komatsu; Noriyuki Akutsu; Tatsuya Yamashita; Hiroyuki Okuyama; Junji Furuse; Hiroaki Nagano
    Japanese journal of clinical oncology, 2023年06月15日, [国際誌]
    英語, 研究論文(学術雑誌), Undifferentiated carcinoma (UC) of the pancreas is a rare subtype of pancreatic cancer displaying no definitive direction of differentiation. UC has been reported as a highly aggressive malignant neoplasm, with a median overall survival of <1 year, except for several surgical series. On the other hand, UC tissue sometimes contains non-neoplastic osteoclast-like giant cells (OGCs), and such cases have been reported to have relatively longer survival. Thus, the World Health Organization (WHO) classification histologically distinguishes UC with OGCs (UCOGCs) from UC, and UCs were subclassified into three subtypes: anaplastic UC, sarcomatoid UC and carcinosarcoma. However, still less is known about UC due to its rarity, and such situations lead to further difficulties in treatment for UC. To date, only surgical resection can offer curative treatment for patients with UC, and no clear evidence for chemotherapy exists for them. However, a retrospective cohort study and case reports showed that relatively promising results paclitaxel-containing regimens for treatment of patients with unresectable UC. Furthermore, high programmed cell death protein 1 expression has been reported in sarcomatoid UCs and UCOGCs, and promising responses to anti-programmed death-ligand 1 therapy have been described in case reports of UCOGCs. Recent advances in chemotherapeutic agents and molecular technologies are opening up the possibilities for expanded treatments.
  • Severe hypertension development significantly improves progression-free survival in regorafenib treatment for metastatic colorectal cancer.
    Yoshitaka Saito; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
    International journal of clinical oncology, 28, 9, 1183, 1190, 2023年06月15日, [国内誌]
    英語, 研究論文(学術雑誌), PURPOSE: Regorafenib is the first multikinase inhibitor used for metastatic colorectal cancer (mCRC) treatment. Reports regarding other multikinase inhibitors have suggested that the development of hypertension is associated with improved clinical benefits. We aimed to reveal the relationship between the development of severe hypertension and regorafenib efficacy in an mCRC real-world setting. METHODS: Patients with mCRC (n = 100) who received regorafenib were assessed retrospectively. The primary endpoint was a comparison of progression-free survival (PFS) between patients with and without ≥ grade 3 hypertension. The secondary endpoints were overall survival (OS), disease control rate (DCR), and adverse effects. RESULTS: Patients developing ≥ grade 3 hypertension accounted for 30%, and obtained significantly longer PFS than control patients (median PFS of 53 and 56 days, 95% confidence interval [CI] of 46-144 and 49-63 days, respectively; P = 0.04). In contrast, OS and DCR were not statistically different between the groups (P = 0.13 and P = 0.46, respectively). The incidence and severity of adverse effects were not significantly different, except for hypertension. Treatment interruption was significantly more frequent in patients with hypertension (P = 0.04). Multivariate Cox hazard analysis suggested that the development of ≥ grade 3 severe hypertension was an independent factor for improved PFS (adjusted hazard ratio 0.57, 95% CI 0.35-0.93; P = 0.02). In contrast, baseline hypoalbuminemia was associated with a worse PFS (1.85, 1.14-3.01; P = 0.01). CONCLUSION: We have revealed that patients who develop severe hypertension after regorafenib treatment for mCRC have improved PFS. Management of hypertension is important for effective treatment with less burden; therefore, further evaluation is needed.
  • TP53 Gain-of-Function Mutation is a Poor Prognostic Factor in High-Methylated Metastatic Colorectal Cancer.
    Shonosuke Wakayama; Kota Ouchi; Shin Takahashi; Yasuhide Yamada; Yoshito Komatsu; Ken Shimada; Tatsuro Yamaguchi; Hidekazu Shirota; Masanobu Takahashi; Chikashi Ishioka
    Clinical colorectal cancer, 2023年06月07日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Neither TP53 mutation nor DNA methylation status has been established as a biomarker alone of metastatic colorectal cancer. We analyzed the association between TP53 mutation functional subtypes and genome-wide DNA methylation status (GWMS) as combined prognostic markers. METHODS: Patient clinical data were obtained from the TRICOLORE study, a randomized phase III trial. The TP53 mutations were classified into wild-type, gain-of-function (GOF) mutations, and non-gain-of-function (non-GOF) mutations. GWMS of the tumor tissues classified them into high-methylated colorectal cancer (HMCC) and low-methylated colorectal cancer (LMCC). Overall survival (OS) was compared based on these subgroups. RESULTS: Of the 209 patients, 60 (28.7%) were HMCC and 149 (71.3%) were LMCC, 35 (16.7%) were TP53 wild-type and 174 (83.3%) were TP53 mutants including 79 (45.4%) GOF mutations and 95 (54.6%) non-GOF mutations. The OS of the HMCC group was shorter than that of the LMCC group (median 25.3 vs. 40.3 months, P < .001, hazard ratio 1.87) in the total cohort. The combined subgroup analyses of GWMS and TP53 mutation subtypes showed that the HMCC/GOF group had significantly shorter OS than the HMCC/non-GOF group, the LMCC/GOF group, and the LMCC/non-GOF group (median 17.7; 35.3, 40.3, and 41.2 months, P = .007, P < .001, and P < .001, respectively), regardless of the primary tumor location. By the multivariate analysis, only HMCC (P = .009) was a poor prognostic factor in the GOF mutation group. CONCLUSIONS: TP53 GOF with HMCC is a newly identified poorest prognostic molecular subset in metastatic colorectal cancer.
  • Clinical Validation of Plasma-Based Genotyping for RAS and BRAF V600E Mutation in Metastatic Colorectal Cancer: SCRUM-Japan GOZILA Substudy.
    Yu Aoki; Yoshiaki Nakamura; Tadamichi Denda; Takashi Ohta; Taito Esaki; Manabu Shiozawa; Kensei Yamaguchi; Kentaro Yamazaki; Yu Sunakawa; Takeshi Kato; Naohiro Okano; Hiroya Taniguchi; Taro Sato; Eiji Oki; Tomohiro Nishina; Yoshito Komatsu; Nobuhisa Matsuhashi; Masahiro Goto; Hisateru Yasui; Koushiro Ohtsubo; Toshikazu Moriwaki; Naoki Takahashi; Yosuke Horita; Shogen Boku; Masashi Wakabayashi; Takashi Ikeno; Ryuta Mitani; Mihoko Yuasa; Takayuki Yoshino
    JCO precision oncology, 7, e2200688, 2023年06月, [国際誌]
    英語, 研究論文(学術雑誌), PURPOSE: Circulating tumor DNA (ctDNA) genotyping on the basis of next-generation sequencing (NGS) may guide targeted therapy for metastatic colorectal cancer (mCRC). However, the validity of NGS-based ctDNA genotyping for RAS/BRAF V600E mutation assessment and the efficacy of anti-EGFR and BRAF-targeted therapies on the basis of ctDNA results remains unclear. PATIENTS AND METHODS: The performance of NGS-based ctDNA genotyping for RAS/BRAF V600E mutation assessment was compared with that of a validated polymerase chain reaction-based tissue testing in patients with mCRC enrolled in the GOZILA study, a nationwide plasma genotyping study. The primary end points were concordance rate, sensitivity, and specificity. The efficacy of anti-EGFR and BRAF-targeted therapies on the basis of ctDNA were also evaluated. RESULTS: In 212 eligible patients, the concordance rate, sensitivity, and specificity were 92.9% (95% CI, 88.6 to 96.0), 88.7% (95% CI, 81.1 to 94.0), and 97.2% (95% CI, 92.0 to 99.4) for RAS and 96.2% (95% CI, 92.7 to 98.4), 88.0% (95% CI, 68.8 to 97.5), and 97.3% (95% CI, 93.9 to 99.1) for BRAF V600E, respectively. In patients with a ctDNA fraction of ≥1.0%, sensitivity rose to 97.5% (95% CI, 91.2 to 99.7) and 100% (95% CI, 80.5 to 100.0) for RAS and BRAF V600E mutations, respectively. In addition to a low ctDNA fraction, previous chemotherapy, lung and peritoneal metastases, and interval between dates of tissue and blood collection were associated with discordance. The progression-free survival of anti-EGFR therapy and BRAF-targeted treatment was 12.9 months (95% CI, 8.1 to 18.5) and 3.7 (95% CI, 1.3 to not evaluated) months, respectively, for matched patients with RAS/BRAF V600E results by ctDNA. CONCLUSION: ctDNA genotyping effectively detected RAS/BRAF mutations, especially with sufficient ctDNA shedding. Clinical outcomes support ctDNA genotyping for determining the use of anti-EGFR and BRAF-targeted therapies in patients with mCRC.
  • Assessment for the timing of comprehensive genomic profiling tests in patients with advanced solid cancers.
    Kanako Hagio; Junko Kikuchi; Kohichi Takada; Hiroki Tanabe; Minako Sugiyama; Yoshihito Ohhara; Toraji Amano; Satoshi Yuki; Yoshito Komatsu; Takahiro Osawa; Kanako C Hatanaka; Yutaka Hatanaka; Takashi Mitamura; Ichiro Yabe; Yoshihiro Matsuno; Atsushi Manabe; Akihiro Sakurai; Atsushi Ishiguro; Masato Takahashi; Hiroshi Yokouchi; Hirohito Naruse; Yusuke Mizukami; Hirotoshi Dosaka-Akita; Ichiro Kinoshita
    Cancer science, 2023年05月19日, [国際誌]
    英語, 研究論文(学術雑誌), Comprehensive genomic profiling (CGP) tests have been covered by public insurance in Japan for patients with advanced solid tumors who have completed or are completing standard treatments or do not have them. Therefore, genotype-matched drug candidates are often unapproved or off-label, and improving clinical trial access is critical, involving the appropriate timing of CGP tests. To address this issue, we analyzed the previous treatment data for 441 patients from an observational study on CGP tests discussed by the expert panel at Hokkaido University Hospital between August 2019 and May 2021. The median number of previous treatment lines was two; three or more lines accounted for 49%. Information on genotype-matched therapies was provided to 277 (63%). Genotype-matched clinical trials were ineligible because of an excess number of previous treatment lines or use of specific agents were found in 66 (15%) patients, with the highest proportion in breast and prostate cancers. Many patients met the exclusion criteria of one to two or more treatment lines across cancer types. In addition, previous use of specific agents was a frequent exclusion criterion for breast, prostate, colorectal, and ovarian cancers. The patients with tumor types with a low median number (two or fewer) of previous treatment lines, including most rare cancers, primary unknown cancers, and pancreatic cancers, had significantly fewer ineligible clinical trials. The earlier timing of CGP tests may improve access to genotype-matched clinical trials, with their proportion varying by cancer type. Each relevant society needs to advocate the desirable timing of CGP testing nationwide.
  • Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial.
    Jun Watanabe; Kei Muro; Kohei Shitara; Kentaro Yamazaki; Manabu Shiozawa; Hisatsugu Ohori; Atsuo Takashima; Mitsuru Yokota; Akitaka Makiyama; Naoya Akazawa; Hitoshi Ojima; Yasuhiro Yuasa; Keisuke Miwa; Hirofumi Yasui; Eiji Oki; Takeo Sato; Takeshi Naitoh; Yoshito Komatsu; Takeshi Kato; Masamitsu Hihara; Junpei Soeda; Toshihiro Misumi; Kouji Yamamoto; Kiwamu Akagi; Atsushi Ochiai; Hiroyuki Uetake; Katsuya Tsuchihara; Takayuki Yoshino
    JAMA, 329, 15, 1271, 1282, 2023年04月18日, [国際誌]
    英語, 研究論文(学術雑誌), IMPORTANCE: For patients with RAS wild-type metastatic colorectal cancer, adding anti-epidermal growth factor receptor (anti-EGFR) or anti-vascular endothelial growth factor (anti-VEGF) monoclonal antibodies to first-line doublet chemotherapy is routine, but the optimal targeted therapy has not been defined. OBJECTIVE: To evaluate the effect of adding panitumumab (an anti-EGFR monoclonal antibody) vs bevacizumab (an anti-VEGF monoclonal antibody) to standard first-line chemotherapy for treatment of RAS wild-type, left-sided, metastatic colorectal cancer. DESIGN, SETTING, AND PARTICIPANTS: Randomized, open-label, phase 3 clinical trial at 197 sites in Japan in May 2015-January 2022 among 823 patients with chemotherapy-naive RAS wild-type, unresectable metastatic colorectal cancer (final follow-up, January 14, 2022). INTERVENTIONS: Panitumumab (n = 411) or bevacizumab (n = 412) plus modified fluorouracil, l-leucovorin, and oxaliplatin (mFOLFOX6) every 14 days. MAIN OUTCOMES AND MEASURES: The primary end point, overall survival, was tested first in participants with left-sided tumors, then in the overall population. Secondary end points were progression-free survival, response rate, duration of response, and curative (defined as R0 status) resection rate. RESULTS: In the as-treated population (n = 802; median age, 66 years; 282 [35.2%] women), 604 (75.3%) had left-sided tumors. Median follow-up was 61 months. Median overall survival was 37.9 months with panitumumab vs 34.3 months with bevacizumab in participants with left-sided tumors (hazard ratio [HR] for death, 0.82; 95.798% CI, 0.68-0.99; P = .03) and 36.2 vs 31.3 months, respectively, in the overall population (HR, 0.84; 95% CI, 0.72-0.98; P = .03). Median progression-free survival for panitumumab vs bevacizumab was 13.1 vs 11.9 months, respectively, for those with left-sided tumors (HR, 1.00; 95% CI, 0.83-1.20) and 12.2 vs 11.4 months overall (HR, 1.05; 95% CI, 0.90-1.24). Response rates with panitumumab vs bevacizumab were 80.2% vs 68.6%, respectively, for left-sided tumors (difference, 11.2%; 95% CI, 4.4%-17.9%) and 74.9% vs 67.3% overall (difference, 7.7%; 95% CI, 1.5%-13.8%). Median duration of response with panitumumab vs bevacizumab was 13.1 vs 11.2 months for left-sided tumors (HR, 0.86; 95% CI, 0.70-1.10) and 11.9 vs 10.7 months overall (HR, 0.89; 95% CI, 0.74-1.06). Curative resection rates with panitumumab vs bevacizumab were 18.3% vs 11.6% for left-sided tumors; (difference, 6.6%; 95% CI, 1.0%-12.3%) and 16.5% vs 10.9% overall (difference, 5.6%; 95% CI, 1.0%-10.3%). Common treatment-emergent adverse events were acneiform rash (panitumumab: 74.8%; bevacizumab: 3.2%), peripheral sensory neuropathy (panitumumab: 70.8%; bevacizumab: 73.7%), and stomatitis (panitumumab: 61.6%; bevacizumab: 40.5%). CONCLUSIONS AND RELEVANCE: Among patients with RAS wild-type metastatic colorectal cancer, adding panitumumab, compared with bevacizumab, to standard first-line chemotherapy significantly improved overall survival in those with left-sided tumors and in the overall population. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02394795.
  • Efficacy of Pembrolizumab Monotherapy in Japanese Patients with Advanced Gastric or Gastroesophageal Junction Cancer.
    Kei Muro; Kohei Shitara; Kensei Yamaguchi; Takaki Yoshikawa; Hironaga Satake; Hiroki Hara; Naotoshi Sugimoto; Nozomu Machida; Masahiro Goto; Hisato Kawakami; Kenji Amagai; Yasushi Omuro; Taito Esaki; Shuichi Hironaka; Tomohiro Nishina; Yoshito Komatsu; Hisahiro Matsubara; Shinichi Shiratori; Shirong Han; Taroh Satoh; Atsushi Ohtsu
    Journal of gastrointestinal cancer, 2023年04月10日, [国際誌]
    英語, 研究論文(学術雑誌), PURPOSE: Pembrolizumab demonstrated antitumor activity in programmed death ligand 1 positive (combined positive score (CPS) ≥ 1) gastric/gastroesophageal junction cancer in KEYNOTE-059 (third line or beyond), KEYNOTE-061 (second line), and KEYNOTE-062 (first line). We characterized efficacy and safety of pembrolizumab monotherapy in Japanese patients across several lines of therapy in these studies. METHODS: This analysis was conducted in 34 patients from KEYNOTE-059 cohort 1 (all pembrolizumab), including 13 patients with CPS ≥ 1, 65 patients with CPS ≥ 1 from KEYNOTE-061 (pembrolizumab, n = 27; chemotherapy, n = 38), and 70 patients with CPS ≥ 1 from KEYNOTE-062 (pembrolizumab, n = 38; chemotherapy, n = 32). Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and safety were evaluated. RESULTS: In KEYNOTE-059, ORR with pembrolizumab was 9%, median PFS was 2 months, and median OS was 10 months. In KEYNOTE-061, median OS was 12 months with pembrolizumab versus 10 months with chemotherapy (hazard ratio (HR), 0.67; 95% confidence interval (CI), 0.39-1.15). Median PFS (pembrolizumab vs. chemotherapy) was 2 months versus 4 months (HR, 1.21; 95% CI, 0.69-2.13); ORR was 7% versus 18%. In KEYNOTE-062, median OS was 20 months with pembrolizumab versus 18 months with chemotherapy (HR, 0.76; 95% CI, 0.43-1.33). Median PFS (pembrolizumab vs. chemotherapy) was 6 months versus 7 months (HR, 1.03; 95% CI, 0.61-1.74); ORR was 29% versus 34%. CONCLUSIONS: The current analysis provides valuable information that anti-PD-1 therapies are worthy of further assessment for gastric cancer. TRIAL REGISTRATION: ClinicalTrials.gov: NCT02335411 (KEYNOTE-059), NCT02370498 (KEYNOTE-061), and NCT02494583 (KEYNOTE-062).
  • HGCSG1901 転移性大腸癌に対するIRIS/Bevの後方視的検討 UGT1A1 single heterozygousが与える影響
    結城 敏志; 伊藤 憲; 原田 一顕; 川本 泰之; 八木澤 允貴; 澤田 憲太郎; 石黒 敦; 武藤 理; 畑中 一映; 奥田 博介; 佐藤 温; 笹木 有佑; 中村 路夫; 目黒 高志; 太宰 昌佳; 中積 宏之; 植田 亮; 坂本 直哉; 坂田 優; 小松 嘉人
    日本消化器病学会雑誌, 120, 臨増総会, A295, A295, (一財)日本消化器病学会, 2023年03月
    日本語
  • S-1による術後補助化学療法中に早期再発しペムブロリズマブが著効したMSI-high胃癌の1例
    渡辺 亮介; 原田 一顕; 中村 赳晶; 山村 貴洋; 川本 泰之; 結城 敏志; 小松 嘉人; 坂本 直哉
    日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 132回・126回, 60, 60, 日本消化器病学会-北海道支部, 2023年03月
    日本語
  • Efficacy of Targeted Trials and Signaling Pathway Landscape in Advanced Gastrointestinal Cancers From SCRUM-Japan GI-SCREEN: A Nationwide Genomic Profiling Program.
    Yoshiaki Nakamura; Riu Yamashita; Wataru Okamoto; Yoshito Komatsu; Satoshi Yuki; Makoto Ueno; Ken Kato; Hiroya Taniguchi; Yoshinori Kagawa; Tadamichi Denda; Hiroki Hara; Taito Esaki; Toshikazu Moriwaki; Yu Sunakawa; Eiji Oki; Fumio Nagashima; Tomohiro Nishina; Taroh Satoh; Hisato Kawakami; Kensei Yamaguchi; Koushiro Ohtsubo; Takeshi Kato; Yosuke Horita; Akihito Tsuji; Hisateru Yasui; Masahiro Goto; Yasuo Hamamoto; Masashi Wakabayashi; Takashi Ikeno; Kohei Shitara; Hideaki Bando; Katsuya Tsuchihara; Izumi Miki; Hiroko Ichiki; Atsushi Ohtsu; Takayuki Yoshino
    JCO precision oncology, 7, e2200653, 2023年03月, [国際誌]
    英語, 研究論文(学術雑誌), PURPOSE: Genomic profiling programs have been implemented to apply next-generation sequencing (NGS) for facilitating trial enrollment. SCRUM-Japan GI-SCREEN is a large-scale genomic profiling program in advanced gastrointestinal cancers using a validated genomic assay with the goal of facilitating enrollment in targeted clinical trials, generating real-world data, and performing clinicogenomic analysis for biomarker discovery. PATIENTS AND METHODS: Genotyping of tumor tissue samples from 5,743 patients with advanced gastrointestinal cancers enrolled in GI-SCREEN was centrally performed with NGS. Patients were enrolled in matched trials of targeted agents affiliated with GI-SCREEN on the basis of genotyping results. RESULTS: A total of 11 gastrointestinal cancers were included, with colorectal cancer being the most common. The median age ranged from 59 to 70.5 years across cancer types. Patients enrolled after initiation of first-line treatment had significantly longer overall survival (OS) than that before treatment initiation with a median survival time difference of 8.9 months and a hazard ratio (HR) ranging from 0.25 to 0.73 across cancer types, demonstrating an immortal time bias. One hundred and forty-nine patients received matched therapies in clinical trials on the basis of their identified alterations. Among patients with colorectal cancer harboring actionable alterations, the median OS was significantly longer in patients who received matched therapies in trials than in those who did not (HR, 0.52; 95% CI, 0.26 to 1.01; P = .049). Cancer-specific pathway alterations were significantly associated with shorter survival and related to primary resistance to matched trial therapies. CONCLUSION: Our genomic profiling program led to patient enrollment in targeted clinical trials and improved survival of patients with colorectal cancer who received matched therapies in clinical trials. To avoid immortal time bias, precautions are needed when using data from patients who have undergone NGS testing after initiation of the evaluated treatment line.
  • Correlation of UGT1A1 Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotecan plus 5-Fluorouracil/Leucovorin for Pancreatic Ductal Adenocarcinoma: A Multicenter, Retrospective Cohort Study (HGCSG2101).
    Kazuaki Harada; Takahiro Yamamura; Osamu Muto; Michio Nakamura; Susumu Sogabe; Kentaro Sawada; Shintaro Nakano; Masataka Yagisawa; Tetsuhito Muranaka; Masayoshi Dazai; Miki Tateyama; Yoshimitsu Kobayashi; Sosuke Kato; Kazuteru Hatanaka; Yasuyuki Kawamoto; Satoshi Yuki; Yuh Sakata; Naoya Sakamoto; Yoshito Komatsu
    Journal of clinical medicine, 12, 4, 2023年02月17日, [国際誌]
    英語, 研究論文(学術雑誌), The effects of UGT1A1 gene polymorphisms or prior irinotecan treatment on treatment outcomes of nanoliposomal-irinotecan plus 5-fluorouracil/leucovorin (nal-IRI+5-FU/LV) in patients with unresectable pancreatic ductal adenocarcinoma (PDAC) are not established. This multicenter, retrospective cohort study compared treatment outcomes in patients with UGT1A1*1/*1 and those with UGT1A1*1/*6 or *1/*28 genotypes. We also analyzed the impact of prior irinotecan treatment on survival outcomes in 54 patients treated with nal-IRI+5-FU/LV. Comparable effectiveness was found regardless of the UGT1A1 genotypes. While no significant differences were found, grade ≥3 neutropenia and febrile neutropenia were more frequent in patients with UGT1A1*1/*6 or *1/*28 than in those with UGT1A1*1/*1 genotypes (grade ≥3 neutropenia, 50.0% vs. 30.8%, p = 0.24; febrile neutropenia, 9.1% vs. 0.0%, p = 0.20, respectively). No significant difference in progression-free survival (PFS) and overall survival (OS) was observed between irinotecan-naïve-patients and other patients. However, irinotecan-resistant patients showed significantly shorter PFS (hazard ratio (HR) 2.83, p = 0.017) and OS (HR 2.58, p = 0.033) than other patients. Our study indicated that patients with UGT1A1*1/*6 or *1/*28 may be prone to neutropenia, though further study is needed. The survival benefit of nal-IRI+5-FU/LV could be maintained in patients without disease progression after irinotecan therapy.
  • Phase I Study of the Liposomal Formulation of Eribulin (E7389-LF): Results from the Advanced Gastric Cancer Expansion Cohort
    Kohei Shitara; Motohiro Hirao; Satoru Iwasa; Takashi Oshima; Yoshito Komatsu; Akihito Kawazoe; Yasuyoshi Sato; Takuya Hamakawa; Kan Yonemori; Nozomu Machida; Satoshi Yuki; Takuya Suzuki; Shiori Okumura; Takao Takase; Taro Semba; Bob Zimmermann; Angela Teng; Kensei Yamaguchi
    Clinical Cancer Research, 29, 8, 1460, 1467, American Association for Cancer Research (AACR), 2023年02月02日
    研究論文(学術雑誌), Abstract

    Purpose:

    In the dose-expansion part of this open-label, phase I study, we explored the efficacy and safety of E7389-LF (liposomal formulation of eribulin) in Japanese patients with advanced gastric cancer.

    Patients and Methods:

    Patients with advanced gastric cancer who had been previously treated with ≥2 lines of chemotherapy received E7389-LF 2.0 mg/m2 every 3 weeks (the previously determined maximum tolerated dose, the primary objective of Study 114). Secondary objectives included objective response rate (ORR), progression-free survival (PFS), and safety; exploratory objectives included disease control rate (DCR) and clinical benefit rate (CBR), as well as pharmacodynamic measurements of serum biomarkers.

    Results:

    As of June 24, 2021, 34 patients were enrolled and treated (10 from the original dose-expansion cohort, expanded to include 24 additional patients). Six patients had partial responses, for an ORR of 17.6% [95% confidence interval (CI), 6.8–34.5], and the median PFS was 3.7 months (95% CI, 2.7–4.8). The DCR was 79.4% (95% CI, 62.1–91.3), and the CBR was 32.4% (95% CI, 17.4–50.5). Overall, 32 patients (94.1%) experienced treatment-related adverse events, and 26 patients (76.5%) experienced grade ≥3 events, most commonly neutropenia (41.2%) and leukopenia (29.4%). Of the 8 endothelial cell/vasculature markers tested in this study, 7 were significantly increased among patients treated with E7389-LF; these changes were generally consistent regardless of best overall response.

    Conclusions:

    E7389-LF 2.0 mg/m2 every 3 weeks was tolerable and showed preliminary activity for the treatment of patients with gastric cancer.
  • 腸内細菌叢に影響を与える薬剤の投与歴と胃癌化学療法の治療効果に関する検討
    中村 赳晶; 渡辺 亮介; 山村 貴洋; 原田 一顕; 川本 泰之; 結城 敏志; 小松 嘉人; 坂本 直哉
    日本胃癌学会総会記事, 95回, 415, 415, (一社)日本胃癌学会, 2023年02月
    日本語
  • Anti-epidermal growth factor receptor treatment for patients with NeoRAS wild-type metastatic colorectal cancer: a case report of two cases.
    Kazuaki Harada; Satoshi Yuki; Yasuyuki Kawamoto; Takeaki Nakamura; Shiho Kaneko; Koichi Ishida; Naoya Sakamoto; Yoshito Komatsu
    Therapeutic advances in medical oncology, 15, 17588359231216090, 17588359231216090, 2023年, [国際誌]
    英語, The NeoRAS phenomenon is defined as the conversion of tumor RAS status from mutant-type (MT) to wild-type (WT) after systemic chemotherapy in metastatic colorectal cancer (mCRC). Cetuximab, an anti-epidermal growth factor receptor (EGFR) antibody, is effective in patients with RAS WT mCRC but ineffective in those with RAS MT mCRC; however, its outcome in patients with NeoRAS WT mCRC is unclear. Herein, we report two cases of NeoRAS WT mCRC that responded clinically to anti-EGFR treatment. The first was a 40-year-old man with synchronous peritoneal metastatic rectosigmoid cancer. The first RAS testing on tumor tissue revealed a KRAS G12C mutation, which was converted to RAS WT after two lines of chemotherapy, as assessed by liquid biopsy. After initiating irinotecan plus cetuximab treatment, a computed tomography (CT) scan revealed that malignant ascites had resolved. The treatment was discontinued after 4 months because of disease progression. The second was a 68-year-old male patient with synchronous liver metastasis from sigmoid colon cancer. The KRAS G12D mutation, initially detected in tumor tissue, was not detected by liquid biopsy after six lines of chemotherapy. Cetuximab monotherapy was initiated, and the liver metastases shrank significantly. The patient continued cetuximab monotherapy for 8 months without disease progression. Our cases demonstrate the efficacy of anti-EGFR therapy for NeoRAS WT mCRC and highlight the importance of capturing the gene mutation profile throughout the clinical course for optimal treatment selection.
  • Characteristics and usefulness of transabdominal ultrasonography in immune-mediated colitis.
    Kensuke Sakurai; Takehiko Katsurada; Mutsumi Nishida; Satomi Omotehara; Shinya Fukushima; Shinsuke Otagiri; Kazunori Nagashima; Reizo Onishi; Ryo Takagi; Yoshito Komatsu; Naoya Sakamoto
    Intestinal research, 21, 1, 126, 136, 2023年01月, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND/AIMS: The usefulness of ultrasonography (US) in diseases of the gastrointestinal tract has been reported recently. This prospective study aimed to determine the features of US findings in immune-mediated colitis (IMC), an adverse event induced by immune checkpoint inhibitor, and examine the correlation between US findings, colonoscopy (CS) findings, and severity of colitis. METHODS: We studied patients examined using CS and US upon suspicion of IMC in Hokkaido University Hospital between April 2018 and February 2021. Endoscopic findings of IMC were assessed using the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). The severity of US findings in IMC was evaluated using US grade, which is the ultrasonographic grading scale in ulcerative colitis. Bowel wall thickness and the intensity of the color Doppler signal were also analyzed. Severity of colitis was evaluated using Common Terminology Criteria for Adverse Events (CTCAE) grade version 5. RESULTS: Fourteen patients with IMC were enrolled. The US findings were bowel wall thickening, loss of stratification, ulceration and increased blood flow signal. The US grade was moderately correlated with the UCEIS (r=0.687, p=0.009) and CTCAE grade (r=0.628, p=0.035). Bowel wall thickness and UCEIS (r=0.628, p=0.020), as well as color Doppler signal grade and CTCAE grade (r=0.724, p=0.008), were significantly correlated. CONCLUSIONS: US findings in IMC were mainly similar to those of ulcerative colitis, but there were some findings that were characteristic only of IMC. Significant correlation was found between US findings, CS findings, and severity of colitis. Hence, US could be useful for the evaluation of IMC.
  • A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407).
    Masato Ozaka; Kohei Nakachi; Satoshi Kobayashi; Akihiro Ohba; Hiroshi Imaoka; Takeshi Terashima; Hiroshi Ishii; Junki Mizusawa; Hiroshi Katayama; Tomoko Kataoka; Takuji Okusaka; Masafumi Ikeda; Naoki Sasahira; Haruo Miwa; Eishiro Mizukoshi; Naohiro Okano; Nobumasa Mizuno; Tomohisa Yamamoto; Yoshito Komatsu; Akiko Todaka; Ken Kamata; Masayuki Furukawa; Nao Fujimori; Akio Katanuma; Yukiko Takayama; Hidetaka Tsumura; Haruhiko Fukuda; Makoto Ueno; Junji Furuse
    European journal of cancer (Oxford, England : 1990), 181, 135, 144, 2022年12月27日, [国際誌]
    英語, 研究論文(学術雑誌), AIM: We compared the efficacy of modified 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFIRINOX) with that of gemcitabine plus nab-paclitaxel (GnP) for locally advanced pancreatic cancer (LAPC). METHODS: Patients with untreated LAPC were randomly assigned (1:1) to receive mFOLFIRINOX or GnP. One-year overall survival (OS) was the primary endpoint. The major secondary end-points included progression-free survival (PFS), response rate (RR), carbohydrate antigen 19-9 (CA19-9) response, and adverse events. The sample size was 124 patients to select a more effective regimen with a minimum probability of 0.85 and to examine the null hypothesis of the 1-year OS <53%. RESULTS: Of the 126 patients enrolled from 29 institutions, 125 were deemed eligible. The 1-year OS was 77.4% (95% CI, 64.9-86.0) and 82.5% (95% CI, 70.7-89.9) in the mFOLFIRINOX and GnP arms, respectively. The median PFS was 11.2 (95% CI, 9.9-15.9) and 9.4 months (95% CI, 7.4-12.8) in the mFOLFIRINOX and GnP arms, respectively. The RR and CA19-9 response rate were 30.9% (95% CI, 19.1-44.8) and 57.1% (95% CI, 41.0-72.3) and 42.1% (95% CI 29.1-55.9) and 85.0% (95% CI, 70.2-94.3) in the mFOLFIRINOX and GnP arms, respectively. Grade 3-4 diarrhoea and anorexia were predominant in the mFOLFIRINOX arm. CONCLUSION: GnP was considered the candidate for a subsequent phase III trial because of its better RR, CA19-9 response, and mild gastrointestinal toxicities. Both regimens displayed higher efficacy in the 1-year survival than in the historical data of gemcitabine monotherapy.
  • Feasibility of edoxaban for asymptomatic cancer-associated thrombosis in Japanese patients with gastrointestinal cancer: ExCAVE study.
    Michio Nakamura; Atsushi Ishiguro; Masayoshi Dazai; Yasuyuki Kawamoto; Satoshi Yuki; Susumu Sogabe; Ayumu Hosokawa; Kentaro Sawada; Osamu Muto; Naoki Izawa; Koji Nakashima; Yoshiki Horie; Masataka Yagisawa; Shinya Kajiura; Takayuki Ando; Yosuke Mitsuhashi; Yu Sunakawa; Yasuka Kikuchi; Yoshito Komatsu
    BMC cancer, 22, 1, 1322, 1322, 2022年12月16日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Although initial therapy with a parenteral anticoagulant is required before edoxaban, this strategy is frequently avoided in actual clinical practice because of its complexity. This study assessed the feasibility of edoxaban without initial heparin usage for asymptomatic cancer-associated thrombosis (CAT) in Japanese patients with gastrointestinal cancer (GIC) at high risk of bleeding. METHODS: In this multicenter prospective feasibility study conducted at 10 Japanese institutions, patients with active GIC who developed accidental asymptomatic CAT during chemotherapy were recruited. Edoxaban was orally administered once daily without initial parenteral anticoagulant therapy within 3 days after detecting asymptomatic CAT. The primary outcome was the incidence of major bleeding (MB) or clinically relevant non-major bleeding (CRNMB) during the first 3 months of edoxaban administration. RESULTS: Of the 54 patients enrolled from October 2017 to September 2020, one was excluded because of a misdiagnosis of CAT. In the remaining 53 patients, the primary outcome occurred in six patients (11.3%). MB occurred in four patients (7.5%), including gastrointestinal bleeding in three patients and intracranial hemorrhage in one patient. CRNMB occurred in two patients (3.8%), including bleeding from the stoma site and genital bleeding in one patient each. There were no deaths attributable to bleeding, and all patients who experienced MB or CRNMB recovered. CONCLUSIONS: The risk of bleeding after edoxaban without heparin pretreatment was acceptable, demonstrating new treatment options for asymptomatic CAT in patients with GIC.
  • Risk factor analysis for regorafenib-induced severe hypertension in metastatic colorectal cancer treatment.
    Yoshitaka Saito; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 30, 12, 10203, 10211, 2022年10月11日, [国際誌]
    英語, 研究論文(学術雑誌), Regorafenib, a multikinase inhibitor, is effective in treating metastatic colorectal cancer (mCRC). Hypertension is a frequently occurring adverse effect caused by regorafenib regardless of previous treatment with vascular endothelial growth factor (VEGF) inhibitors in almost all patients. We identified the risk factors associated with regorafenib-induced severe hypertension. Patients with mCRC (n = 100) who received regorafenib were evaluated retrospectively. The primary endpoint was the evaluation of the risk factors for grade ≥ 3 hypertension. The association between pre-existing hypertension at baseline and grade ≥ 3 hypertension symptoms was also assessed. Patients with pre-existing hypertension at baseline accounted for 55% of the total patients. The starting doses of regorafenib were 160 mg (49.0% of patients), 120 mg (29.0%), and 80 mg (22.0%). The incidence of grade ≥ 3 hypertension was 30.0%. The median time to grade ≥ 3 symptom development was 7 days (range: 1-56 days). Additional antihypertensive treatment was administered to 83.6% of patients who developed hypertension. Logistic regression analyses revealed that baseline pre-existing hypertension complications and previous anti-VEGF treatment for ≥ 700 days were independent risk factors for grade ≥ 3 hypertension development. Further analyses revealed that pre-existing hypertension before anti-VEGF treatment (primary hypertension) was significantly related to the symptom development (adjusted odds ratio, 8.74; 95% confidence interval, 2.86-26.72; P = 0.0001). Our study suggests that pre-existing primary hypertension and previous anti-VEGF treatment for ≥ 700 days are independent risk factors for regorafenib-induced severe hypertension. Deeper understanding of the symptom nature and management can significantly contribute to safer interventions, necessitating further studies.
  • 再発高リスクGISTに対する術後長期補助療法の有用性(STAR ReGISTry)
    佐藤 真輔; 西田 俊朗; 尾阪 将人; 中原 裕次郎; 小松 嘉人; 近藤 正人; 長 晴彦; 廣田 誠一; 鍵村 達夫; 黒川 幸典; 北川 雄光
    日本消化器病学会雑誌, 119, 臨増大会, A759, A759, (一財)日本消化器病学会, 2022年10月
    日本語
  • 進行胃癌・大腸癌における治療前の血中循環腫瘍DNA検出の臨床的妥当性
    青木 優; 中村 能章; 谷口 浩也; 小松 嘉人; 砂川 優; 塩澤 学; 太田 高志; 江崎 泰斗; 山崎 健太郎; 佐竹 悠良; 松橋 延壽; 後藤 昌弘; 賀川 義規; 仁科 智裕; 吉野 孝之
    日本癌治療学会学術集会抄録集, 60回, PS, 1, (一社)日本癌治療学会, 2022年10月
    英語
  • Fecal microbiota in patients with a stoma decreases anaerobic bacteria and alters taxonomic and functional diversities
    Shunsuke A. Sakai; Masato Aoshima; Kentaro Sawada; Satoshi Horasawa; Ayumu Yoshikawa; Takao Fujisawa; Shigenori Kadowaki; Tadamichi Denda; Nobuhisa Matsuhashi; Hisateru Yasui; Masahiro Goto; Kentaro Yamazaki; Yoshito Komatsu; Ryota Nakanishi; Yoshiaki Nakamura; Hideaki Bando; Yamato Hamaya; Shun-Ichiro Kageyama; Takayuki Yoshino; Katsuya Tsuchihara; Riu Yamashita
    Frontiers in Cellular and Infection Microbiology, 12, Frontiers Media SA, 2022年09月14日
    研究論文(学術雑誌), Colorectal cancer (CRC) is one of the most common malignant diseases. Generally, stoma construction is performed following surgery for the resection of the primary tumor in patients with CRC. The association of CRC with the gut microbiota has been widely reported, and the gut microbiota is known to play an important role in the carcinogenesis, progression, and treatment of CRC. In this study, we compared the microbiota of patients with CRC between with and without a stoma using fecal metagenomic sequencing data from SCRUM-Japan MONSTAR-SCREEN, a joint industry-academia cancer research project in Japan. We found that the composition of anaerobes was reduced in patients with a stoma. In particular, the abundance of Alistipes, Akkermansia, Intestinimonas, and methane-producing archaea decreased. We also compared gene function (e.g., KEGG Orthology and KEGG pathway) and found that gene function for methane and short-chain fatty acids (SCFAs) production was underrepresented in patients with a stoma. Furthermore, a stoma decreased Shannon diversity based on taxonomic composition but increased that of the KEGG pathway. These results suggest that the feces of patients with a stoma have a reduced abundance of favorable microbes for cancer immunotherapy. In conclusion, we showed that a stoma alters the taxonomic and functional profiles in feces and may be a confounding factor in fecal microbiota analysis.
  • Long-term adjuvant therapy for high-risk gastrointestinal stromal tumors in the real world.
    Toshirou Nishida; Shinsuke Sato; Masato Ozaka; Yujiro Nakahara; Yoshito Komatsu; Masato Kondo; Haruhiko Cho; Seiichi Hirota; Tatsuo Kagimura; Yukinori Kurokawa; Yuko Kitagawa
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 25, 5, 956, 965, 2022年09月, [国内誌]
    英語, 研究論文(学術雑誌), PURPOSE: Three years of adjuvant imatinib is the standard therapy for gastrointestinal stromal tumors (GISTs) with high-risk features. The prognostic effects of long-term adjuvant therapy are unknown. PATIENTS AND METHODS: The prospective registry study recruited 515 patients with high-risk GISTs between Dec. 2012 and Dec. 2015 were analyzed. The primary endpoint was recurrence-free survival (RFS), and secondary endpoints include overall survival (OS) and safety. The study was designed to compare RFS after 3.5 years of 3-year adjuvant therapy (3.0 ± 0.5 years: 3-year group) with that of more than 3.5 years (median 5.2 years: longer group). RESULTS: Five-year RFS and 5-year OS were 68.2% (95% confidence interval [CI] 63.8-72.1) and 92.3% (95% CI 89.5-94.4), respectively. The recurrence rate during adjuvant was estimated to be 2.9/100 person-years (95% CI 2.0-4.1) and those after the end of adjuvant, which appeared similar irrespective of the adjuvant duration or reason to stop adjuvant, were estimated 12.0/100 person-years (95% CI 10.2-14.0). The 5-year RFS rates of 3-year and longer groups were 78.7% (95% CI 70.8-84.7) and 92.7% (95% CI 85.2-96.4), respectively. RFS after 3.5 years of the longer group was significantly better than that of the 3-year group (adjusted hazard ratio [HR] 0.56; 95% CI 0.39-0.78; P < 0.001). CONCLUSION: The recurrence risk of high-risk GISTs after adjuvant therapy is similar irrespective of the adjuvant duration and imatinib adjuvant may not cure but may delay recurrence. RFS after long-term adjuvant therapy appeared better than that after 3-year adjuvant.
  • 内科・外科による消化器病共同診療の現況と展望 局所進行直腸癌における術前FOLFOX療法の有効性の検討(RNAC01試験)の解釈とその発展
    藤好 直; 本間 重紀; 市川 伸樹; 結城 敏志; 川本 泰之; 原田 一顕; 吉田 雅; 柴田 賢吾; 松井 博紀; 小松 嘉人; 坂本 直哉; 武冨 紹信
    日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 131回・125回, 26, 26, 日本消化器病学会-北海道支部, 2022年09月
    日本語
  • 内科・外科による消化器病共同診療の現況と展望 当科における切除可能境界膵癌に対する術前治療の現状
    原田 一顕; 中村 赳晶; 渡辺 亮介; 山村 貴洋; 川本 泰之; 結城 敏志; 桑谷 将城; 田口 大志; 加藤 徳雄; 浅野 賢道; 中村 透; 平野 聡; 小松 嘉人; 坂本 直哉
    日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 131回・125回, 28, 28, 日本消化器病学会-北海道支部, 2022年09月
    日本語
  • Usefulness of ultrasonography and elastography in diagnosing oxaliplatin-induced sinusoidal obstruction syndrome.
    Rika Saito; Yasuyuki Kawamoto; Mutsumi Nishida; Takahito Iwai; Yasuka Kikuchi; Isao Yokota; Ryo Takagi; Takahiro Yamamura; Ken Ito; Kazuaki Harada; Satoshi Yuki; Yoshito Komatsu; Naoya Sakamoto
    International journal of clinical oncology, 27, 11, 1780, 1790, 2022年08月30日, [国内誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Sinusoidal obstruction syndrome (SOS) refers to liver injury caused by hematopoietic stem cell transplantation (HSCT) and anticancer drugs including oxaliplatin. Increased splenic volume (SV) on computed tomography (CT) indicates oxaliplatin-induced SOS. Similarly, ultrasonography and liver stiffness measurement (LSM) by shear-wave elastography (SWE) can help diagnose SOS after HSCT; however, their usefulness for diagnosing oxaliplatin-induced SOS remains unclear. We investigated the usefulness of the Hokkaido ultrasonography-based scoring system with 10 ultrasonographic parameters (HokUS-10) and SWE in diagnosing oxaliplatin-induced SOS early. METHODS: In this prospective observational study, ultrasonography and SWE were performed before and at 2, 4, and 6 months after oxaliplatin-based chemotherapy. HokUS-10 was used for assessment. CT volumetry of the SV was performed in clinical practice, and an SV increase ≥ 30% was considered the diagnostic indicator of oxaliplatin-induced SOS. We assessed whether HokUS-10 and SWE can lead to an early detection of oxaliplatin-induced SOS before an increased SV on CT. RESULTS: Of the 30 enrolled patients with gastrointestinal cancers, 12 (40.0%) with an SV increase  ≥ 30% on CT were diagnosed with SOS. The HokUS-10 score was not correlated with an SV increase ≥ 30% (r = 0.18). The change in rate of three HokUS-10 parameters were correlated with an SV increase ≥ 30% (r = 0.32-0.41). The change in rate of LSM by SWE was correlated with an SV increase  ≥ 30% (r = 0.40). CONCLUSIONS: The usefulness of HokUS-10 score was not demonstrated; however, some HokUS-10 parameters and SWE could be useful for the early diagnosis of oxaliplatin-induced SOS.
  • An open-label, crossover study to compare different formulations and evaluate effect of food on pharmacokinetics of pimitespib in patients with advanced solid tumors.
    Yoshito Komatsu; Tsuneo Shimokawa; Kohei Akiyoshi; Masato Karayama; Akihiko Shimomura; Yasuyuki Kawamoto; Satoshi Yuki; Yuichi Tambo; Kazuo Kasahara
    Investigational new drugs, 40, 5, 1011, 1020, 2022年08月06日, [国際誌]
    英語, 研究論文(学術雑誌), This study compared the bioavailability of two pimitespib formulations (Formulations A and B), evaluated the food effect on Formulation A, and evaluated the safety and efficacy of multiple pimitespib doses in patients with solid tumors. This clinical, pharmacological multicenter study had two cohorts and periods. A single dose of Formulation A or B was administered in a crossover design to compare the pharmacokinetics in Cohort 1. In Cohort 2, the effects of fed vs fasting conditions were evaluated among those receiving Formulation A. Subsequently, multiple Formulation A doses were administered to all patients for safety and efficacy assessments. In Cohorts 1 and 2, 12 and 16 patients, respectively, were analyzed for pharmacokinetics. Thirty patients were analyzed for safety and efficacy. Maximum concentration (Cmax), area under the curve (AUC)last, and AUCinf geometric mean ratios for Formulations A and B (90% confidence interval [CI]) were 0.8078 (0.6569-0.9933), 0.7973 (0.6672-0.9529), and 0.8094 (0.6697-0.9782), respectively; 90% CIs were not within the bioequivalence range (0.80-1.25). In Cohort 2, mean Cmax, AUClast, and AUCinf were higher in fed vs fasting conditions. No safety concerns emerged with single or multiple administration. Overall response rate, disease control rate, and median progression-free survival were 0%, 33%, and 1.5 months, respectively. Four patients had stable disease ≥ 5 months. Bioequivalence of the two formulations was unconfirmed. Systemic exposure of Formulation A was approximately 20% less than Formulation B. A high-fat/calorie meal increased the relative pharmacokinetics and bioavailability of a single 160-mg dose. Trial Registration: JapicCTI-184191 (Japan Pharmaceutical Information Center) registered on November 5, 2018.
  • Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603.
    Yasuyuki Kawamoto; Satoshi Yuki; Kentaro Sawada; Michio Nakamura; Osamu Muto; Susumu Sogabe; Yoshiaki Shindo; Atsushi Ishiguro; Atsushi Sato; Yasushi Tsuji; Masayoshi Dazai; Hiroyuki Okuda; Takashi Meguro; Kazuaki Harada; Mari Sekiguchi; Kazufumi Okada; Yoichi M Ito; Yuh Sakata; Naoya Sakamoto; Yoshito Komatsu
    The oncologist, 27, 8, e642-e649, 2022年08月05日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Ramucirumab is a human IgG1 monoclonal vascular endothelial growth factor receptor-2 antibody that inhibits tumor cell growth and affects the tumor cell microenvironment. We assessed the efficacy and safety of ramucirumab plus irinotecan combination therapy as second-line treatment in patients with previously treated advanced gastric cancer. MATERIALS AND METHODS: Patients with advanced gastric cancer refractory or intolerant to primary chemotherapy were included. Ramucirumab 8 mg/kg plus irinotecan 150 mg/m2 combination therapy was administered every 2 weeks. The primary endpoint was progression-free survival rate at 6 months and secondary endpoints were overall survival, progression-free survival, response rate, safety, and dose intensity for each drug. RESULTS: Thirty-five patients were enrolled between January 2018 and September 2019. The progression-free survival rate at 6 months was 26.5% [95%CI, 13.2%-41.8%, P = .1353)]. Median progression-free and overall survivals were 4.2 months (95%CI, 2.5-5.4 months) and 9.6 months (95%CI, 6.4-16.6 months), respectively. The overall response rate was 25.9% (95%CI, 11.1-36.3%) and disease control rate was 85.2% (95%CI, 66.3-95.8%). Grade ≥3 adverse events that occurred in >10% of patients included neutropenia, leucopenia, anemia, anorexia, and febrile neutropenia. No death or new safety signals with a causal relation to the study treatment were observed. CONCLUSION: Although the primary endpoint was not achieved statistically, combination therapy of ramucirumab plus irinotecan showed anticancer activity and a manageable safety profile for second-line treatment of patients with advanced gastric cancer.
  • Rapid Screening Using Pathomorphologic Interpretation to Detect BRAFV600E Mutation and Microsatellite Instability in Colorectal Cancer.
    Satoshi Fujii; Daisuke Kotani; Masahiro Hattori; Masato Nishihara; Toshihide Shikanai; Junji Hashimoto; Yuki Hama; Takuya Nishino; Mizuto Suzuki; Ayatoshi Yoshidumi; Makoto Ueno; Yoshito Komatsu; Toshiki Masuishi; Hiroki Hara; Taito Esaki; Yoshiaki Nakamura; Hideaki Bando; Tomoyuki Yamada; Takayuki Yoshino
    Clinical cancer research : an official journal of the American Association for Cancer Research, 28, 12, 2623, 2632, 2022年06月13日, [国際誌]
    英語, 研究論文(学術雑誌), PURPOSE: Rapid decision-making is essential in precision medicine for initiating molecular targeted therapy for patients with cancer. This study aimed to extract pathomorphologic features that enable the accurate prediction of genetic abnormalities in cancer from hematoxylin and eosin images using deep learning (DL). EXPERIMENTAL DESIGN: A total of 1,657 images (one representative image per patient) of thin formalin-fixed, paraffin-embedded tissue sections from either primary or metastatic tumors with next-generation sequencing-confirmed genetic abnormalities-including BRAFV600E and KRAS mutations, and microsatellite instability high (MSI-H)-that are directly relevant to therapeutic strategies for advanced colorectal cancer were obtained from the nationwide SCRUM-Japan GI-SCREEN project. The images were divided into three groups of 986, 248, and 423 images to create one training and two validation cohorts, respectively. Pathomorphologic feature-prediction DL models were first developed on the basis of pathomorphologic features. Subsequently, gene-prediction DL models were constructed for all possible combinations of pathomorphologic features that enabled the prediction of gene abnormalities based on images filtered by the combination of pathomorphologic feature-prediction models. RESULTS: High accuracies were achieved, with AUCs > 0.90 and 0.80 for 12 and 27, respectively, of 33 analyzed pathomorphologic features, with high AUCs being yielded for both BRAFV600E (0.851 and 0.859) and MSI-H (0.923 and 0.862). CONCLUSIONS: These findings show that novel next-generation pathology methods can predict genetic abnormalities without the need for standard-of-care gene tests, and this novel next-generation pathology method can be applied for colorectal cancer treatment planning in the near future.
  • Analysis of the Pancreatic Cancer Microbiome Using Endoscopic Ultrasound–Guided Fine-Needle Aspiration–Derived Samples
    Shintaro Nakano; Yasuyuki Kawamoto; Yoshito Komatsu; Rika Saito; Ken Ito; Takahiro Yamamura; Kazuaki Harada; Satoshi Yuki; Kazumichi Kawakubo; Ryo Sugiura; Shin Kato; Koji Hirata; Hajime Hirata; Masahito Nakajima; Ryutaro Furukawa; Yunosuke Takishin; Kousuke Nagai; Isao Yokota; Keisuke H. Ota; Shinji Nakaoka; Masaki Kuwatani; Naoya Sakamoto
    Pancreas, Publish Ahead of Print, 4, 351, 357, Ovid Technologies (Wolters Kluwer Health), 2022年06月13日
    研究論文(学術雑誌)
  • Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial).
    Akihiro Ohba; Chigusa Morizane; Yasuyuki Kawamoto; Yoshito Komatsu; Makoto Ueno; Satoshi Kobayashi; Masafumi Ikeda; Mitsuhito Sasaki; Junji Furuse; Naohiro Okano; Nobuyoshi Hiraoka; Hiroshi Yoshida; Aya Kuchiba; Ryo Sadachi; Kenichi Nakamura; Naoko Matsui; Yoshiaki Nakamura; Wataru Okamoto; Takayuki Yoshino; Takuji Okusaka
    Journal of Clinical Oncology, 40, 16_suppl, 4006, 4006, American Society of Clinical Oncology (ASCO), 2022年06月01日
    研究論文(学術雑誌), 4006

    Background: BTCs have an aggressive tumor biology with limited treatment options. With a HER2-positivity rate of 5–20% in BTCs, case series and small clinical trials have shown signs of activity for HER2 blockade in these pts. T-DXd is an antibody-drug conjugate composed of a humanized monoclonal anti-HER2 antibody, a cleavable linker, and a topoisomerase I inhibitor. The HERB trial is an investigator-initiated, multicenter, single-arm phase 2 trial of T-DXd in pts with HER2-expressing BTCs. Methods: Centrally confirmed HER2-expressing (HER2-positive: IHC3+ or IHC2+/ISH+, and HER2-low-expressing [HER2-low]: IHC/ISH status of 0/+, 1+/-, 1+/+, or 2+/-) pts with BTCs who were refractory or intolerant to gemcitabine containing regimen received 5.4 mg/kg of T-DXd every 3 weeks. The primary endpoint was the confirmed objective response rate (ORR) in HER2-positive pts by independent central review. The sample size of 22 had 80% power with one-sided alpha error of 5%; threshold ORR, 15%; and expected ORR, 40%. The ORR, disease control rate (DCR), progression-free survival (PFS), overall survival (OS) in HER2-positive/-low pts, and incidence of treatment-emergent adverse events (TEAEs) were assessed as secondary endpoints. Results: A total of 32 pts, 24 with HER2-positive and 8 with HER2-low BTCs, received T-DXd. Twenty-two pts with HER2-positive, excluding 2 ineligible pts, were identified for primary efficacy analysis. Among the 22 pts, IHC3+ and IHC2+/ISH+ were 45.5% and 54.5%, primary sites: gallbladder/extrahepatic/intrahepatic/Vater were 11/6/3/2, median number of prior regimens was 2 (range, 1–4). The confirmed ORR in HER2-positive pts was 36.4% (8/22; 2 CR and 6 PR; 90% CI, 19.6–56.1), indicating statistically significant improvement in ORR (P = 0.01). The DCR, median (m) PFS, mOS were 81.8% (95% CI, 59.7–94.8), 4.4 months (mo) (95% CI, 2.8–8.3), 7.1 mo (95% CI, 4.7–14.6), respectively. In addition, encouraging efficacy were seen even in HER2-low pts; ORR, DCR, mPFS, and mOS were 12.5% (1/8; 1 PR; 95% CI, 0.3–52.7), 75.0% (95% CI, 34.9–96.8), 4.2 mo (95% CI, 1.3–6.2), and 8.9 mo (95% CI, 3.0–12.8), respectively. In the safety analysis set (n = 32), TEAEs of > = grade (G) 3 occurred in 81.3% (26/32); the common TEAEs were anemia (53.1%), neutropenia (31.3%), and leukopenia (31.3%). TEAEs leading to drug discontinuation occurred in 8 pts (25.0%). Eight pts (25.0%) had interstitial lung disease (ILD; G1/G2/G3/G5 were 3/1/2/2) not adjudicated by an independent committee. Conclusions: T-DXd showed promising activity in pts with HER2-expressing BTCs. Although the safety profile was generally consistent with other T-DXd studies, ILD, an important identified risk of T-DXd, requires more careful monitoring and intervention. These results support further exploration of T-DXd in this patient population. Clinical trial information: JMA-IIA00423.
  • Multicenter, prospective, observational study of chemotherapy-induced dysgeusia in gastrointestinal cancer.
    Ken Ito; Satoshi Yuki; Hiroshi Nakatsumi; Yasuyuki Kawamoto; Kazuaki Harada; Shintaro Nakano; Rika Saito; Takayuki Ando; Kentaro Sawada; Masataka Yagisawa; Atsushi Ishiguro; Masayoshi Dazai; Ichiro Iwanaga; Kazuteru Hatanaka; Atsushi Sato; Ryusuke Matsumoto; Yoshiaki Shindo; Miki Tateyama; Tetsuhito Muranaka; Masaki Katagiri; Isao Yokota; Yuh Sakata; Naoya Sakamoto; Yoshito Komatsu
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 30, 6, 5351, 5359, 2022年06月, [国際誌]
    英語, 研究論文(学術雑誌), PURPOSE: Dysgeusia is an adverse event caused by chemotherapy. Although retrospective studies have shown zinc administration improves dysgeusia, there have been no prospective studies. The present study examined effects of zinc therapy on dysgeusia in patients with gastrointestinal cancer. METHODS: This multicenter, prospective, observational study enrolled patients with dysgeusia during chemotherapy treatment. Patients received no intervention (control), polaprezinc p.o., or zinc acetate hydrate p.o., and serum zinc levels were measured at 0 (baseline), 6, and 12 weeks. Dysgeusia was assessed using CTCAE v5.0 and subjective total taste acuity (STTA) criteria using questionnaires at baseline and 12 weeks. RESULTS: From February 2020 to June 2021, 180 patients were enrolled from 17 institutes. There were no differences in mean baseline serum zinc levels among the groups (67.3, 66.6, and 67.5 μg/dL in the no intervention, polaprezinc, and zinc acetate hydrate groups, respectively. P = 0.846). The changes in mean serum zinc levels after 12 weeks were - 3.8, + 14.3, and + 46.6 μg/dL, and the efficacy rates of dysgeusia were 33.3%, 36.8%, and 34.6% using CTCAE and 33.3%, 52.6%, 32.7% using STTA in the no intervention, polaprezinc, and zinc acetate hydrate groups, respectively. The STTA scores improved in all groups, with significant improvement observed in the polaprezinc group compared with the no intervention group (P = 0.045). CONCLUSION: There was no significant correlation between the degree of serum zinc elevation and improvement in dysgeusia, suggesting that polaprezinc, but not zinc acetate hydrate, was effective in improving chemotherapy-induced dysgeusia. TRIAL REGISTRATION: UMIN000039653. Date of registration: March 2, 2020.
  • Study protocol of the HGCSG1803: a phase II multicentre, non-randomised, single-arm, prospective trial of combination chemotherapy with oxaliplatin, irinotecan and S-1 (OX-IRIS) as first-line treatment for metastatic or relapsed pancreatic cancer.
    Shintaro Nakano; Yasuyuki Kawamoto; Satoshi Yuki; Kazuaki Harada; Takuto Miyagishima; Susumu Sogabe; Masayoshi Dazai; Atsushi Sato; Atsushi Ishiguro; Michio Nakamura; Shinya Kajiura; Yasuo Takahashi; Miki Tateyama; Kazuteru Hatanaka; Yasushi Tsuji; Takahide Sasaki; Yoshiaki Shindo; Tomoe Kobayashi; Isao Yokota; Naoya Sakamoto; Yuh Sakata; Yoshito Komatsu
    BMJ open, 12, 5, e048833, 2022年05月09日, [国際誌]
    英語, 研究論文(学術雑誌), INTRODUCTION: Combination chemotherapy with oxaliplatin, irinotecan, fluorouracil and leucovorin (FOLFIRINOX) has become one of the standard treatments for metastatic pancreatic cancer. However, the use of FOLFIRINOX requires prolonged infusion. Therefore, we planned to develop a new combination chemotherapy regimen with oxaliplatin, irinotecan and S-1 (OX-IRIS) for advanced pancreatic cancer. In the phase Ⅰ study that was conducted previously, the safety and recommended dose of OX-IRIS were assessed. In this study, we will evaluate the efficacy and safety of OX-IRIS. METHODS AND ANALYSIS: The HGCSG1803 study started as a multicentre, non-randomised, single-arm, prospective, phase II study in December 2019. Eligible subjects were patients with untreated metastatic or relapsed pancreatic cancer. OX-IRIS is administered as follows: 30 min infusion of antiemetic; 2-hour infusion of oxaliplatin (65 mg/m2); 1.5-hour infusion of irinotecan (100 mg/m2) on day 1 and 15 of each 4-week cycle; and oral S-1 (40 mg/m2) twice daily from after dinner on day one to after breakfast on day 15, followed by a 14-day rest, to be repeated every 2 weeks until disease progression, unacceptable toxicity or patient refusal. The primary endpoint is response rate. The secondary endpoints are overall and progression-free survival, safety and dose for each drug. Using a binomial test, a sample size of 40 patients was set with a threshold value of 10% and expected value of 30%. Registration of 40 cases is planned from 18 institutions in Japan. ETHICS AND DISSEMINATION: All the procedures will be conducted in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Declaration of Helsinki of 1964 and its later versions. All the patients will receive written information about the trial and will provide informed consent before enrolment. This trial was approved by the Hokkaido University Certified Review Board (approval No: 018-037). TRIAL REGISTRATION NUMBER: jRCTs011190008.
  • Phase II Study of Continued Trastuzumab Plus Irinotecan in Patients with HER2-positive Gastric Cancer Previously Treated with Trastuzumab (HGCSG 1201).
    Yasuyuki Kawamoto; Satoshi Yuki; Takashi Meguro; Kazuteru Hatanaka; Minoru Uebayashi; Michio Nakamura; Hiroyuki Okuda; Ichiro Iwanaga; Takashi Kato; Shintaro Nakano; Atsushi Sato; Kazuaki Harada; Koji Oba; Yuh Sakata; Naoya Sakamoto; Yoshito Komatsu
    The oncologist, 27, 5, 340-e374, 2022年05月06日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: The efficacy of irinotecan plus continuous trastuzumab beyond progression in patients with gastric cancer previously treated with trastuzumab plus standard first-line chemotherapy has not been reported. METHODS: Patients with human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer who were previously treated with trastuzumab received trastuzumab every 3 weeks and irinotecan every 2 weeks. The primary endpoint was the overall response rate (ORR), and the secondary endpoints included progression-free survival (PFS), 6-month survival rates, safety, and subgroup analysis by HER2 status. RESULTS: Sixteen patients were enrolled in a 3-year pre-planned registration period. This study was prematurely closed due to poor patient accrual. The ORR and disease control rate were 6.7% (95% CI, 0.2-32.0) and 53.3% (95% CI, 26.6-78.7). The median PFS and overall survival (OS) were 2.4 months (95% CI, 0.0-5.2) and 9.7 months (95% CI, 8.2-11.2), respectively. The most frequently reported grades 3-4 adverse events were neutropenia (40%), anemia (27%), anorexia (33%), and fatigue (33%). CONCLUSION: With only 16 patients enrolled, the present study has very low power to detect any clinical benefit of trastuzumab plus irinotecan beyond disease progression in patients with HER2-positive advanced gastric cancer who previously received trastuzumab.Trial Identifier: UMIN000007636.
  • Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial.
    Akihiro Ohba; Chigusa Morizane; Makoto Ueno; Satoshi Kobayashi; Yasuyuki Kawamoto; Yoshito Komatsu; Masafumi Ikeda; Mitsuhito Sasaki; Naohiro Okano; Junji Furuse; Nobuyoshi Hiraoka; Hiroshi Yoshida; Aya Kuchiba; Ryo Sadachi; Kenichi Nakamura; Naoko Matsui; Yoshiaki Nakamura; Wataru Okamoto; Takayuki Yoshino; Takuji Okusaka
    Future oncology (London, England), 18, 19, 2351, 2360, 2022年05月05日, [国際誌]
    英語, 研究論文(学術雑誌), Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate composed of a humanized monoclonal anti-HER2 antibody, a cleavable tetrapeptide-based linker and a potent topoisomerase I inhibitor. The drug's efficacy has been proven in HER2-positive breast and gastric cancers. The rate of HER2 positivity in biliary tract cancer (BTC) has been reported to be 5-20%, and case reports and clinical trials have suggested that HER2 inhibitors might be active in HER2-positive BTC. Here we describe the rationale and design of the phase II HERB trial that will evaluate the efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing unresectable or recurrent BTC. The primary end point will be the centrally assessed objective response rate in HER2-positive patients.
  • 個別化医療を見据えた消化器診療の現状 超音波内視鏡下穿刺吸引法で得られた検体を用いた膵腫瘍内細菌叢の検討
    中野 真太郎; 川本 泰之; 小松 嘉人; 伊藤 憲; 原田 一顕; 結城 敏志; 川久保 和道; 杉浦 諒; 加藤 新; 平田 幸司; 平田 甫; 中島 正人; 古川 龍太郎; 滝新 悠之介; 永井 孝輔; 横田 勲; 太田 圭祐; 中岡 慎治; 桑谷 将城; 坂本 直哉
    日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 130回・124回, 36, 36, 日本消化器病学会-北海道支部, 2022年03月
    日本語
  • The survival benefit of increasing the number of active drugs for metastatic colorectal cancer: A multicenter retrospective study
    Takeshi Kawakami; Toshiki Masuishi; Yasuyuki Kawamoto; Hirofumi Go; Kyoko Kato; Ryosuke Kumanishi; Kentaro Sawada; Satoshi Yuki; Kouji Yamamoto; Yoshito Komatsu; Kei Muro; Kunihiro Fushiki; Hiromichi Shirasu; Kentaro Yamazaki
    Cancer Medicine, Wiley, 2022年02月19日
    研究論文(学術雑誌)
  • 進行固形がん患者に対する保険診療による包括的がんゲノムプロファイリング検査の実施時期についての検討
    菊地 順子; 大原 克仁; 天野 虎次; 矢部 一郎; 小松 嘉人; 松野 吉宏; 石黒 敦; 水上 裕輔; 櫻井 晃洋; 木下 一郎
    日本内科学会雑誌, 111, Suppl., 190, 190, (一社)日本内科学会, 2022年02月
    日本語
  • Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA Substudy.
    Yoshiaki Nakamura; Wataru Okamoto; Tadamichi Denda; Tomohiro Nishina; Yoshito Komatsu; Satoshi Yuki; Hisateru Yasui; Taito Esaki; Yu Sunakawa; Makoto Ueno; Eiji Shinozaki; Nobuhisa Matsuhashi; Takashi Ohta; Ken Kato; Koushiro Ohtsubo; Hideaki Bando; Hiroki Hara; Taroh Satoh; Kentaro Yamazaki; Yoshiyuki Yamamoto; Naohiro Okano; Tetsuji Terazawa; Takeshi Kato; Eiji Oki; Akihito Tsuji; Yosuke Horita; Yasuo Hamamoto; Akihito Kawazoe; Hiromichi Nakajima; Shogo Nomura; Ryuta Mitani; Mihoko Yuasa; Kiwamu Akagi; Takayuki Yoshino
    JCO precision oncology, 6, e2100383, 2022年02月, [国際誌]
    英語, 研究論文(学術雑誌), PURPOSE: Circulating tumor DNA (ctDNA) genotyping may guide targeted therapy for patients with advanced GI cancers. However, no studies have validated ctDNA genotyping for microsatellite instability (MSI) assessment in comparison with a tissue-based standard. PATIENTS AND METHODS: The performance of plasma-based MSI assessment using Guardant360, a next-generation sequencing-based ctDNA assay, was compared with that of tissue-based MSI assessment using a validated polymerase chain reaction-based method in patients with advanced GI cancers enrolled in GOZILA study, a nationwide ctDNA profiling study. The primary end points were overall percent agreement, positive percent agreement (PPA), and negative percent agreement. The efficacy of immune checkpoint inhibitor therapy was also evaluated. RESULTS: In 658 patients with advanced GI cancers who underwent both plasma and tissue testing for MSI, the overall percent agreement, PPA, and negative percent agreement were 98.2% (95% CI, 96.8 to 99.1), 71.4% (95% CI, 47.8 to 88.7), and 99.1% (95% CI, 98.0 to 99.7), respectively. In patients whose plasma samples had a ctDNA fraction ≥ 1.0%, the PPA was 100.0% (15/15; 95% CI, 78.2 to 100.0). Three patients with MSI-high (MSI-H) tumors detected only by ctDNA genotyping achieved clinical benefits after receiving anti-programmed cell death 1 therapy with the progression-free survival ranging from 4.3 to 16.7 months. One patient with an aggressive cancer of an unknown primary site benefited from pembrolizumab after rapid detection of MSI-H by ctDNA genotyping. CONCLUSION: ctDNA genotyping was able to detect MSI with high concordance to validated tissue-based MSI testing, especially in patients with tumors that have sufficient ctDNA shedding. Furthermore, ctDNA genotyping enabled identification of patients with MSI-H tumors who benefited from immune checkpoint inhibitor treatment.
  • Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instability-High Locally Advanced Rectal Cancer.
    Hideaki Bando; Yuichiro Tsukada; Koji Inamori; Yosuke Togashi; Shohei Koyama; Daisuke Kotani; Shota Fukuoka; Satoshi Yuki; Yoshito Komatsu; Shigenori Homma; Akinobu Taketomi; Mamoru Uemura; Takeshi Kato; Makoto Fukui; Masashi Wakabayashi; Naoki Nakamura; Motohiro Kojima; Hiroshi Kawachi; Richard Kirsch; Tsutomu Yoshida; Yutaka Suzuki; Akihiro Sato; Hiroyoshi Nishikawa; Masaaki Ito; Takayuki Yoshino
    Clinical cancer research : an official journal of the American Association for Cancer Research, 28, 6, 1136, 1146, 2022年01月21日, [国際誌]
    英語, 研究論文(学術雑誌), PURPOSE: Preoperative chemoradiotherapy (CRT) and surgical resection are the standard treatment for locally advanced rectal cancer (LARC). Combining immune checkpoint inhibitors with radiation suggests a promising approach for enhancing efficacy. We investigated the efficacy of CRT followed by nivolumab and surgery in patients with LARC. PATIENTS AND METHODS: In phase I, we investigated the feasibility of sequentially combined CRT, 5 cycles of nivolumab, and radical surgery. In phase II, patients with microsatellite stable (MSS) and microsatellite instability-high (MSI-H) LARC were evaluated. RESULTS: Three patients in phase I received full courses of CRT and nivolumab without dose modification; the schedule was recommended for phase II. A pathologic complete response (pCR) was centrally confirmed in 30% [11/37; 90% confidence interval (CI), 18%-44%] and 60% (3/5) of the MSS and exploratory MSI-H cohorts, respectively. While immune-related severe adverse events were observed in 3 patients, no treatment-related deaths were observed. In 38 patients with MSS who underwent surgery, pCR rates of 75% (6/8) and 17% (5/30; P = 0.004, Fisher exact test) were observed in those with programmed cell death ligand 1 (PD-L1) tumor proportion score ≥1% and <1%, respectively; IHC staining was performed using pre-CRT samples. In 24 patients with MSS, pre-CRT samples were analyzed by flow cytometry; pCR rates of 78% (7/9) and 13% (2/15; P = 0.003, Fisher exact test) were observed for CD8+ T cell/effector regulatory T cell (CD8/eTreg) ratios of ≥2.5 and <2.5, respectively, in tumor-infiltrating lymphocytes. CONCLUSIONS: CRT followed by consolidation nivolumab could increase pCR. PD-L1 expression and an elevated CD8/eTreg ratio were positive predictors in patients with MSS LARC.
  • がん治療医・緩和ケアスタッフを対象としたターミナルケア態度尺度を用いた意識調査
    熊井 正貴; 加藤 信太郎; 小柳 遼; 敦賀 健吉; 伊藤 陽一; 山田 武宏; 武隈 洋; 菅原 満; 川本 泰之; 小松 嘉人
    Palliative Care Research, 17, 2, 51, 58, (NPO)日本緩和医療学会, 2022年
    日本語
  • Study protocol for HGCSG1801: A multicenter, prospective, phase II trial of second-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer refractory to anti-EGFR antibodies.
    Hiroshi Nakatsumi; Yoshito Komatsu; Tetsuhito Muranaka; Satoshi Yuki; Yasuyuki Kawamoto; Kazuaki Harada; Masayoshi Dazai; Miki Tateyama; Yusuke Sasaki; Takuto Miyagishima; Yasushi Tsuji; Masaki Katagiri; Michio Nakamura; Susumu Sogabe; Kazuteru Hatanaka; Takashi Meguro; Tomoe Kobayashi; Atsushi Ishiguro; Osamu Muto; Yoshiaki Shindo; Masahito Kotaka; Takayuki Ando; Ryo Takagi; Naoya Sakamoto; Yu Sakata
    Frontiers in oncology, 12, 939425, 939425, 2022年, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: The first-line chemotherapy for patients with RAS and BRAF wild-type metastatic colorectal cancer (mCRC) commonly involves cytotoxic regimens, such as FOLFOX and FOLFIRI, combined with epidermal growth factor receptor (EGFR) antibodies. When progression occurs following anti-EGFR antibody-combined chemotherapy, anti-angiogenic inhibitors can be used as second-line treatment. Although randomized controlled trials have shown that anti-angiogenic inhibitors [bevacizumab, ramucirumab, and aflibercept (AFL)] carry survival benefit when combined with FOLFIRI as second-line chemotherapy, such trials did not provide data on patients with mCRC refractory to anti-EGFR antibody-combined chemotherapy. Therefore, our group planned a multicenter, nonrandomized, single-arm, prospective, phase II study to investigate the safety and efficacy of FOLFIRI plus AFL as a second-line chemotherapy for patients with mCRC refractory to oxaliplatin-based chemotherapy combined with anti-EGFR antibodies. METHODS: FOLFIRI (irinotecan 180 mg/m2, l-leucovorin 200 mg/m2, bolus 5-FU 400 mg/m2, and infusional 5-FU 2400 mg/m2/46 h) and AFL (4 mg/kg) will be administered every 2 weeks until progression or unacceptable toxicities occur. The primary endpoint will be the 6-month progression-free survival (PFS) rate, whereas the secondary endpoints will include overall survival, PFS, response rate, disease control rate, adverse events, and relative dose intensity for each drug. A sample size of 41 participants will be required. This study will be sponsored by the Non-Profit Organization Hokkaido Gastrointestinal Cancer Study Group and will be supported by a grant from Sanofi. DISCUSSION: There is only an observational study reporting data on FOLFIRI plus AFL for patients with mCRC who previously received anti-EGFR antibodies; therefore, a prospective clinical trial is needed. This study will prospectively evaluate the efficacy and safety of FOLFIRI plus AFL in patients with mCRC who are resistant to anti-EGFR antibodies and have limited data. Moreover, this study will reveal predictive biomarkers for AFL-based chemotherapy. CLINICAL TRIAL REGISTRATION: Japan Registry of Clinical Trials, jRCTs011190006. Registered 19 November, 2019, https://jrct.niph.go.jp/latest-detail/jRCTs011190006.
  • がん治療医・緩和ケアスタッフを対象としたターミナルケア態度尺度を用いた意識調査
    熊井 正貴; 加藤 信太郎; 小柳 遼; 敦賀 健吉; 伊藤 陽一; 山田 武宏; 武隈 洋; 菅原 満; 川本 泰之; 小松 嘉人
    Palliative Care Research, 17, 2, 51, 58, (NPO)日本緩和医療学会, 2022年
    日本語
  • A 5% Glucose Solution for the Liquid Formulation Gemcitabine Solvent Decreases Gemcitabine-induced Vascular Pain.
    Kazuki Uchiyama; Yoshitaka Saito; Tatsuhiko Sakamoto; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
    Anticancer research, 42, 1, 343, 348, 2022年01月, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND/AIM: Gemcitabine (GEM)-induced vascular pain often occurs in patients. A 5% glucose solution for the lyophilized formulation of GEM solvent is known to decrease the frequency of GEM-induced vascular pain compared with saline. In this study, we aimed to examine the availability of glucose for a liquid formulation GEM solvent for the prevention of GEM-induced vascular pain. PATIENTS AND METHODS: In total, 214 patients with bile tract or pancreatic cancer, who received GEM-containing regimens, were enrolled in this retrospective study. The patients were divided into a glucose group, which was administered the liquid formation GEM diluted with glucose, and a saline group. The frequency of GEM-induced vascular pain was compared between them. RESULTS: Glucose significantly decreased the frequency of GEM-induced vascular pain during the first GEM administration (36% vs. 55%, p=0.005). CONCLUSION: Switching the solution for liquid formulation GEM from saline to glucose significantly decreased the frequency of vascular pain.
  • A prognostic biomarker study in patients with clinical stage I esophageal squamous cell carcinoma: JCOG0502‐A1
    Kotoe Oshima; Ken Kato; Yoshinori Ito; Hiroyuki Daiko; Isao Nozaki; Satoru Nakagawa; Yuichi Shibuya; Takashi Kojima; Yasushi Toh; Morihito Okada; Shuichi Hironaka; Yuji Akiyama; Yoshito Komatsu; Kazuhiro Maejima; Hidewaki Nakagawa; Ritsuko Onuki; Momoko Nagai; Mamoru Kato; Keisuke Kanato; Aya Kuchiba; Kenichi Nakamura; Yuko Kitagawa
    Cancer Science, 113, 3, 1018, 1027, Wiley, 2021年12月28日
    研究論文(学術雑誌)
  • Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial.
    Yoshiaki Nakamura; Wataru Okamoto; Takeshi Kato; Taito Esaki; Ken Kato; Yoshito Komatsu; Satoshi Yuki; Toshiki Masuishi; Tomohiro Nishina; Hiromichi Ebi; Kentaro Sawada; Hiroya Taniguchi; Nozomu Fuse; Shogo Nomura; Makoto Fukui; Seiko Matsuda; Yasutoshi Sakamoto; Hiroshi Uchigata; Kana Kitajima; Naomi Kuramoto; Takashi Asakawa; Steve Olsen; Justin I Odegaard; Akihiro Sato; Satoshi Fujii; Atsushi Ohtsu; Takayuki Yoshino
    Nature medicine, 27, 11, 1899, 1903, 2021年11月, [国際誌]
    英語, 研究論文(学術雑誌), The applicability of circulating tumor DNA (ctDNA) genotyping to inform enrollment of patients with cancer in clinical trials has not been established. We conducted a phase 2 trial to evaluate the efficacy of pertuzumab plus trastuzumab for metastatic colorectal cancer (mCRC), with human epidermal growth factor receptor 2 (HER2) amplification prospectively confirmed by tumor tissue or ctDNA analysis ( UMIN000027887 ). HER2 amplification was confirmed in tissue and/or ctDNA in 30 patients with mCRC. The study met the primary endpoint with a confirmed objective response rate of 30% in 27 tissue-positive patients and 28% in 25 ctDNA-positive patients, as compared to an objective response rate of 0% in a matched real-world reference population treated with standard-of-care salvage therapy. Post hoc exploratory analyses revealed that baseline ctDNA genotyping of HER2 copy number and concurrent oncogenic alterations adjusted for tumor fraction stratified patients according to efficacy with similar accuracy to tissue genotyping. Decreased ctDNA fraction 3 weeks after treatment initiation associated with therapeutic response. Pertuzumab plus trastuzumab showed similar efficacy in patients with mCRC with HER2 amplification in tissue or ctDNA, showing that ctDNA genotyping can identify patients who benefit from dual-HER2 blockade as well as monitor treatment response. These findings warrant further use of ctDNA genotyping in clinical trials for HER2-amplified mCRC, which might especially benefit patients in first-line treatment.
  • 進行性固形癌患者における腸内細菌叢と免疫チェックポイント阻害剤の有効性
    洞澤 智至; 澤田 憲太郎; 山下 理宇; 藤澤 孝夫; 吉河 歩; 中村 能章; 谷口 浩也; 門脇 重憲; 加藤 健; 佐藤 太郎; 小松 嘉人; 沖 英二; 安井 久晃; 山崎 健太郎; 吉野 孝之
    日本癌治療学会学術集会抄録集, 59回, PS, 8, (一社)日本癌治療学会, 2021年10月
    英語
  • 胃癌の血中循環腫瘍DNAにおけるFGFR2増幅及びFGFR阻害薬に対する治療効果の検討
    城後 友望子; 中村 能章; 設樂 紘平; 坂東 英明; 安井 久晃; 江崎 泰斗; 寺澤 哲志; 佐藤 太郎; 篠崎 英司; 仁科 智裕; 小倉 孝; 小松 嘉人; 谷口 浩也; 藤井 誠志; 吉野 孝之
    日本癌治療学会学術集会抄録集, 59回, O47, 7, (一社)日本癌治療学会, 2021年10月
    英語
  • HGCSG2101 実臨床における進行膵癌に対するnal/IRI+5-FU/LVの治療成績
    山村 貴洋; 原田 一顕; 曽我部 進; 澤田 憲太郎; 八木澤 允貴; 中野 真太郎; 太宰 昌佳; 舘山 美樹; 伊藤 憲; 斎藤 里佳; 川本 泰之; 結城 敏志; 坂本 直哉; 坂田 優; 小松 嘉人
    日本癌治療学会学術集会抄録集, 59回, O43, 2, (一社)日本癌治療学会, 2021年10月
    英語
  • HGCSG1901 切除不能結腸直腸癌におけるIRIS/Bevの後方視的研究 抗EGFR抗体後の検討
    斎藤 絢介; 伊藤 憲; 結城 敏志; 川本 泰之; 八木澤 允貴; 澤田 憲太郎; 佐藤 温; 辻 靖; 安藤 孝将; 中野 真太郎; 若林 俊樹; 小高 雅人; 高橋 康雄; 坂田 優; 小松 嘉人
    日本癌治療学会学術集会抄録集, 59回, O56, 4, (一社)日本癌治療学会, 2021年10月
    英語
  • がん治療医・緩和ケアスタッフを対象としたターミナルケア態度尺度を用いた意識調査
    熊井 正貴; 加藤 信太郎; 小柳 遼; 敦賀 健吉; 伊藤 陽一; 山田 武宏; 川本 泰之; 武隈 洋; 菅原 満; 小松 嘉人
    Palliative Care Research, 16, Suppl._Hokkaido, S492, S492, (NPO)日本緩和医療学会, 2021年10月
    日本語
  • がん治療医・緩和ケアスタッフを対象としたターミナルケア態度尺度を用いた意識調査
    熊井 正貴; 加藤 信太郎; 小柳 遼; 敦賀 健吉; 伊藤 陽一; 山田 武宏; 川本 泰之; 武隈 洋; 菅原 満; 小松 嘉人
    Palliative Care Research, 16, Suppl._Hokkaido, S492, S492, (NPO)日本緩和医療学会, 2021年10月
    日本語
  • 大腸癌周術期治療の臨床開発と将来展望 進行直腸癌に対する化学放射線療法と免疫チェックポイント阻害剤を用いた術前治療
    塚田 祐一郎; 坂東 英明; 稲守 宏冶; 冨樫 庸介; 結城 敏志; 小松 嘉人; 本間 重紀; 武冨 紹信; 植村 守; 加藤 健志; 若林 将史; 佐藤 暁洋; 西川 博嘉; 伊藤 雅昭; 吉野 孝之
    日本癌治療学会学術集会抄録集, 59回, SY2, 4, (一社)日本癌治療学会, 2021年10月
    英語
  • A Phase I Trial of Oxaliplatin, Irinotecan, and S-1 Combination Therapy (OX-IRIS) as Chemotherapy for Unresectable Pancreatic Cancer (HGCSG 1403).
    Yasuyuki Kawamoto; Hiroshi Nakatsumi; Kazuaki Harada; Tetsuhito Muranaka; Atsushi Ishiguro; Yoshimitsu Kobayashi; Hideyuki Hayashi; Satoshi Yuki; Kentaro Sawada; Masataka Yagisawa; Shintaro Nakano; Naoya Sakamoto; Yoshito Komatsu
    The oncologist, 26, 10, e1675-e1682, 2021年10月, [国際誌]
    英語, 研究論文(学術雑誌), LESSONS LEARNED: Because S-1 is orally administered, OX-IRIS does not necessitate the continuous infusion of 5-FU and is more convenient. The recommended dose of OX-IRIS was determined to be level -1 (oxaliplatin, 65 mg/m2 ; irinotecan, 100 mg/m2 ; S-1, 80 mg/m2 ), which has manageable safety and promising anticancer activities. BACKGROUND: OX-IRIS is a new combination therapy of oxaliplatin, irinotecan, and S-1 for unresectable pancreatic ductal adenocarcinoma (PDAC), which may be beneficial because S-1 is administered orally and continuous infusion of 5-fluorouracil (5-FU) is not needed. METHODS: Patients who had not received prior therapy for unresectable PDAC were enrolled. Adenocarcinoma or adenosquamous histology was required. Oxaliplatin and irinotecan were administered on days 1 and 15; S-1 was administered orally twice a day on days 1-14, followed by 14 days of rest (one cycle). Primary endpoints were dose-limiting toxicity (DLT) and maximum tolerated dose (MTD). Secondary endpoints were safety, overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). RESULTS: In level 0 (oxaliplatin, 85 mg/m2 ; irinotecan, 100 mg/m2 ; S-1, 80 mg/m2 ), two of five patients experienced DLT. In level -1 (oxaliplatin, 65 mg/m2 ; irinotecan, 100 mg/m2 ; S-1, 80 mg/m2 ), DLT could not be evaluated in two of eight patients because one cycle was not completed; one of the remaining six patients experienced DLT. Anemia, thrombocytopenia, fatigue, nausea, anorexia, diarrhea, and peripheral sensory neuropathy were seen frequently in levels 0 and -1. ORR was 30% in levels 0 and -1. Median progression-free survival and median overall survival were 4.1 months (95% confidence interval [CI], 0.0-8.9 months) and 13.7 months (95% CI, 4.8-22.6 months), respectively. CONCLUSION: MTD of OX-IRIS therapy was estimated to be level 0, and the recommended dose (RD) for future trial was level -1.
  • The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational Study.
    Keigo Chida; Daisuke Kotani; Toshiki Masuishi; Takeshi Kawakami; Yasuyuki Kawamoto; Kyoko Kato; Kunihiro Fushiki; Kentaro Sawada; Ryosuke Kumanishi; Hiromichi Shirasu; Yuki Matsubara; Satoshi Yuki; Yoshito Komatsu; Kentaro Yamazaki; Takayuki Yoshino
    The oncologist, 26, 10, 845, 853, 2021年10月, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: KRAS is one of the most frequently mutated oncogenes in colorectal cancer (CRC). Recently, a novel therapy targeting KRAS G12C mutation has demonstrated promising activities for corresponding advanced solid tumors, including metastatic CRC (mCRC). However, the prognostic impact of the KRAS G12C mutation remains unclear in patients with mCRC. MATERIALS AND METHODS: We retrospectively reviewed medical records of patients with mCRC who received first-line chemotherapy between January 2005 and December 2017 at four large oncology facilities in Japan. Survival outcomes were compared between patients with KRAS G12C and those with non-G12C mutations. RESULTS: Among 2,457 patients with mCRC, 1,632 met selection criteria, and of these, 696 had KRAS exon 2 mutations, including 45 with KRAS G12C mutation tumors. Patient characteristics were not significantly different between the KRAS G12C and non-G12C groups. At a median follow-up of 64.8 months, patients with the KRAS G12C mutation showed significantly shorter first-line progression-free survival (PFS; median, 9.4 vs. 10.8 months; p = .015) and overall survival (OS; median, 21.1 vs. 27.3 months; p = .015) than those with non-G12C mutations. Multivariate analysis also showed that KRAS G12C mutation was significantly associated with shorter PFS (hazard ratio [HR], 1.43; 95% confidence interval [CI], 1.04-1.96, p = .030) and OS (HR, 1.42; 95% CI, 1.01-2.00; p = .044). CONCLUSION: We demonstrate that, compared with non-G12C mutations, KRAS G12C mutation is significantly correlated with shorter first-line PFS and OS. These findings indicate the relevance of a stratified treatment targeting KRAS G12C mutation in mCRC. IMPLICATIONS FOR PRACTICE: Among patients with KRAS exon 2 mutated metastatic colorectal cancer (mCRC), median progression-free survival (PFS) and overall survival (OS) were 9.4 and 21.1 months, respectively, for G12C mutation and 10.8 and 27.3 months, respectively, for patients with non-G12C mutations, indicating significantly shorter PFS (hazard ratio [HR], 1.47; 95% confidence interval [CI], 1.08-2.01; p = .015) and OS (HR, 1.50; 95% CI, 1.08-2.08; p = .015) in patients with G12C mutation than in those with non-G12C mutations. Furthermore, multivariate analysis showed that KRAS G12C mutation was independently associated with shorter first-line PFS and OS. Thus, these findings underscore the relevance of a stratified treatment targeting KRAS G12C mutation in mCRC.
  • Severe hypertriglyceridemia induced by S-1: Subsequent case series of four patients and further review of the literature.
    Yoshitaka Saito; Yoh Takekuma; Satoshi Takeuchi; Yoshito Komatsu; Mitsuru Sugawara
    International journal of clinical pharmacology and therapeutics, 59, 12, 787, 793, 2021年09月10日, [国際誌]
    英語, 研究論文(学術雑誌), OBJECTIVE: We previously reported a case where S-1, containing tegafur, gimeracil, and oteracil potassium, induced severe hypertriglyceridemia. After the case, we regularly monitored serum lipid levels and surprisingly observed an additional 4 cases within 1.5 years. We here report the treatment process. CASE REPORT: At least 3 patients exhibited hyperlipidemia at baseline; in 2 of them, this was caused by previous fluoropyrimidine treatment. One patient experienced grade 4 hypertriglyceridemia, and the other 3 grade 3 hypertriglyceridemia. One patient developed temporary serum triglyceride elevation during the S-1 administration period, and the 3 experienced persistent elevation. The severity of serum triglyceride level worsened with increasing administration and peaked in cycles 2 - 6. Fenofibrate 80 - 160 mg/day and S-1 dose reduction were effective, with some significantly and others gradually decreasing to grade 0 - 1. DISCUSSION: The summarized clinical features are as follows: (1) Severe hypertriglyceridemia tends to appear after several treatment cycles and worsens with increasing administration. (2) It tends to occur in patients with hyperlipidemia at baseline. (3) Patients previously affected with fluoropyrimidines-induced hypertriglyceridemia can experience S-1 symptoms. (4) In some cases, it might decrease after the S-1 suspension period. (5) Fibrates and S-1 dose reductions were effective. As the final fluoropyrimidine product is fluorouracil, its presence or that of its metabolizing enzymes and the genetic background of the patients might have affected the results. We should be aware of the risk of temporal and asymptomatic occurrence of S-1-induced hypertriglyceridemia for early detection with appropriate treatment.
  • Infusion-related reaction to ramucirumab plus FOLFIRI in patients with advanced colorectal cancer.
    Hiroyuki Okuyama; Yoshinori Kagawa; Toshiki Masuishi; Saori Mishima; Hiromichi Shirasu; Koji Ando; Satoshi Yuki; Kei Muro; Takayuki Yoshino; Kentaro Yamazaki; Eiji Oki; Yoshito Komatsu; Akihito Tsuji
    International journal of clinical oncology, 26, 11, 2025, 2028, 2021年09月02日, [国内誌]
    英語, 研究論文(学術雑誌), BACKGROUND: An infusion-related reaction (IRR) is a well-known adverse event related to monoclonal antibodies, and antihistamine premedication is recommended to prevent IRRs. Ramucirumab plus FOLFIRI therapy is the standard second-line treatment for metastatic colorectal cancer (CRC). Ramucirumab is a fully human antibody, suggesting that the incidence of IRRs is lower, however, the current recommendation for the proper use of ramucirumab is antihistamine premedication, but the incidence and severity of ramucirumab-induced IRR without antihistamine premedication have not been elucidated. METHODS: A retrospective study to evaluate the incidence of ramucirumab-induced IRRs in unresectable CRC patients treated by ramucirumab plus FOLFIRI therapy. If the incidence of IRR without antihistamine premedication was not higher than that of cetuximab in a previous report (5.7%), planning a prospective study was considered. RESULTS: A total of 147 patients with unresectable CRC who had been treated by ramucirumab plus FOLFIRI therapy were identified. Of them, 106 (72%) patients received intravenous antihistamine premedication. An IRR occurred in 2 patients (1.4%), 1 grade 2 and 1 grade 3. They received antihistamine and steroid premedication. On the other hand, IRRs were not observed in 41 patients without antihistamine premedication, and the incidence of IRRs was significantly lower compared with the previous report of cetuximab (p < 0.001). CONCLUSION: The incidence of ramucirumab-induced IRRs without antihistamine premedication is low. Not using antihistamine premedication can decrease medical costs. These findings warrant further investigation in large-scale cohorts to clarify the incidence and severity of ramucirumab-induced IRRs and further clarify the proper use of ramucirumab.
  • Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trial.
    Tadamichi Denda; Atsuo Takashima; Makio Gamoh; Ichiro Iwanaga; Yoshito Komatsu; Masanobu Takahashi; Masato Nakamura; Hisatsugu Ohori; Akiko Sakashita; Masahiro Tsuda; Yoshimitsu Kobayashi; Hideo Baba; Masanori Kotake; Chikashi Ishioka; Yasuhide Yamada; Atsushi Sato; Satoshi Yuki; Satoshi Morita; Shin Takahashi; Tatsuro Yamaguchi; Ken Shimada
    European journal of cancer (Oxford, England : 1990), 154, 296, 306, 2021年09月, [国際誌]
    英語, 研究論文(学術雑誌), AIM: The TRICOLORE trial previously demonstrated that S-1 and irinotecan plus bevacizumab was non-inferior, based on progression-free survival (PFS), to 5-fluorouracil, leucovorin and oxaliplatin (mFOLFOX6)/capecitabine and oxaliplatin (CapeOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer (mCRC). Overall survival (OS) data were immature at the time of the primary analysis. METHODS: In total, 487 patients from 53 institutions with previously untreated mCRC were randomly assigned (1:1) to receive either mFOLFOX6/CapeOX plus bevacizumab (control group) or S-1 and irinotecan plus bevacizumab (experimental group; 3- or 4-week regimen). The final OS data were analysed from follow-up data collected until 30th September 2017. RESULTS: With a median follow-up period of 48.7 months, median survival times were 32.6 and 34.3 months (hazard ratio [HR]: 0.89, 95% confidence interval [CI]: 0.72-1.10, P = 0.293) and median PFS durations were 10.8 and 14.0 months in the control and experimental groups, respectively (HR: 0.86, 95% CI: 0.71-1.04, P < 0.0001 for non-inferiority). In patients with left-sided RAS wild-type tumours, median PFS durations were 11.4 and 16.9 months in the control and experimental groups, respectively (HR: 0.68, 95% CI: 0.48-0.96, P = 0.028). CONCLUSION: S-1 and irinotecan plus bevacizumab resulted in comparable OS and non-inferior PFS with that of mFOLFOX6/CapeOX plus bevacizumab treatment as first-line chemotherapy for patients with mCRC. We recommend the use of S-1 and irinotecan plus bevacizumab as a standard first-line regimen independent of tumour sidedness or RAS status in mCRC. TRIAL REGISTRATION: UMIN-CTR: 000007834.
  • Circulating Tumor DNA Analysis Detects FGFR2 Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer.
    Tomoko Jogo; Yoshiaki Nakamura; Kohei Shitara; Hideaki Bando; Hisateru Yasui; Taito Esaki; Tetsuji Terazawa; Taroh Satoh; Eiji Shinozaki; Tomohiro Nishina; Yu Sunakawa; Yoshito Komatsu; Hiroki Hara; Eiji Oki; Nobuhisa Matsuhashi; Takashi Ohta; Takeshi Kato; Koushiro Ohtsubo; Takeshi Kawakami; Naohiro Okano; Yoshiyuki Yamamoto; Takanobu Yamada; Akihito Tsuji; Justin I Odegaard; Hiroya Taniguchi; Toshihiko Doi; Satoshi Fujii; Takayuki Yoshino
    Clinical cancer research : an official journal of the American Association for Cancer Research, 27, 20, 5619, 5627, 2021年08月10日, [国際誌]
    英語, 研究論文(学術雑誌), PURPOSE: FGFR2 amplification is associated with poor prognosis in advanced gastric cancer and its subclonal heterogeneity has been revealed. Here, we examined whether circulating tumor DNA (ctDNA) was useful for detecting FGFR2 amplification and co-occurring resistance mechanisms in advanced gastric cancer. EXPERIMENTAL DESIGN: We assessed genomic characteristics of FGFR2-amplified advanced gastric cancer in a nationwide ctDNA screening study. We also analyzed FGFR2 amplification status in paired tissue and plasma samples with advanced gastric cancer. In addition, we examined patients with FGFR2-amplified advanced gastric cancer identified by ctDNA sequencing who received FGFR inhibitors. RESULTS: FGFR2 amplification was more frequently detected by ctDNA sequencing in 28 (7.7%) of 365 patients with advanced gastric cancer than by tissue analysis alone (2.6%-4.4%). FGFR2 amplification profiling of paired tissue and plasma revealed that FGFR2 amplification was detectable only by ctDNA sequencing in 6 of 44 patients, which was associated with a worse prognosis. Two patients in whom FGFR2 amplification was detected by ctDNA sequencing after tumor progression following previous standard chemotherapies but not by pretreatment tissue analysis had tumor responses to FGFR inhibitors. A third patient with FGFR2 and MET co-amplification in ctDNA showed a limitation of benefit from FGFR inhibition, accompanied by a marked increase in the MET copy number. CONCLUSIONS: ctDNA sequencing identifies FGFR2 amplification missed by tissue testing in patients with advanced gastric cancer, and these patients may respond to FGFR inhibition. The utility of ctDNA sequencing warrants further evaluation to develop effective therapeutic strategies for patients with FGFR2-amplified advanced gastric cancer.
  • 切除不能進行再発大腸癌に対する一次治療としてのCAPOXIRI+BEV療法の薬剤用量確認Stepの結果 QUATTRO-II
    小高 雅人; 沖 英次; 佐竹 悠良; 坂東 英明; 山崎 健太郎; 山中 竹春; 小松 嘉人; 吉野 孝之; 辻 晃仁; 加藤 健志
    日本消化器外科学会総会, 76回, P010, 1, (一社)日本消化器外科学会, 2021年07月
    日本語
  • P4-10 The impact of neutrophil/lymphocyte ratio (NLR) on overall survival for patients with metastatic colorectal cancer
    Kazuaki Harada; Takeshi Kawakami; Toshiki Masuishi; Yasuyuki Kawamoto; Hirohumi Go; Kyoko Kato; Ryosuke Kumanishi; Satoshi Yuki; Kouji Yamamoto; Hirofumi Yasui; Yoshito Komatsu; Kei Muro; Takeharu Yamanaka; Kentaro Yamazaki
    Annals of Oncology, 32, S332, S332, Elsevier BV, 2021年07月
    研究論文(学術雑誌)
  • A case of immune checkpoint inhibitor-associated gastroenteritis detected by ultrasonography.
    Satomi Omotehara; Mutsumi Nishida; Kana Yamanashi; Kensuke Sakurai; Takehiko Katsurada; Yoshito Komatsu; Ai Shimizu; Hitoshi Shibuya; Naofumi Shinagawa; Junichi Sugita; Takanori Teshima
    Journal of clinical ultrasound : JCU, 49, 6, 605, 609, 2021年07月, [国際誌]
    英語, While immune checkpoint inhibitors (ICIs) have antitumor effects, they also have characteristic side effects, including colitis. However, gastritis has rarely been reported. We report a case of a patient with lung adenocarcinoma who presented with epigastric pain and diarrhea following pembrolizumab administration. Sonography of the abdomen demonstrated diffuse, although mild, gastric wall thickening (mainly in the submucosa), as well as a slight decrease in echogenicity throughout the gastric wall. While the mucosal surface was relatively smooth, color Doppler examination showed increased vascularity. Esophagogastroduodenoscopy and pathological examination confirmed the diagnosis of ICI-related gastroenteritis.
  • Safety and efficacy of panitumumab in combination with trifluridine/tipiracil for pre-treated patients with unresectable, metastatic colorectal cancer with wild-type RAS: The phase 1/2 APOLLON study.
    Takeshi Kato; Yoshinori Kagawa; Yasutoshi Kuboki; Makio Gamoh; Yoshito Komatsu; Hirofumi Yasui; Hironaga Satake; Eiji Oki; Hiroaki Tanioka; Masahito Kotaka; Akitaka Makiyama; Tadamichi Denda; Masahiro Goto; Takayuki Yoshino; Kentaro Yamazaki; Junpei Soeda; Kazunori Shibuya; Masaru Iwata; Koji Oba; Kensei Yamaguchi
    International journal of clinical oncology, 26, 7, 1238, 1247, 2021年07月, [国内誌]
    英語, 研究論文(学術雑誌), BACKGROUND: We aimed to assess the safety and efficacy of combination treatment with panitumumab plus trifluridine/tipiracil (FTD/TPI) in patients with wild-type RAS metastatic colorectal cancer (mCRC) who were refractory/intolerant to standard therapies other than anti-epidermal growth factor receptor therapy. METHODS: APOLLON was an open-label, multicentre, phase 1/2 trial. In the phase 1 part, 3 + 3 de-escalation design was used to investigate the recommended phase 2 dose (RP2D); all patients in the phase 2 part received the RP2D. The primary endpoint was investigator-assessed progression-free survival (PFS) rate at 6 months. Secondary endpoints included PFS, overall survival (OS), overall response rate (ORR), disease control rate (DCR), time to treatment failure (TTF), and safety. RESULTS: Fifty-six patients were enrolled (phase 1, n = 7; phase 2, n = 49) at 25 Japanese centres. No dose-limiting toxicities were observed in patients receiving panitumumab (6 mg/kg every 2 weeks) plus FTD/TPI (35 mg/m2 twice daily; days 1-5 and 8-12 in a 28-day cycle), which became RP2D. PFS rate at 6 months was 33.3% (90% confidence interval [CI] 22.8-45.3). Median PFS, OS, ORR, DCR, and TTF were 5.8 months (95% CI 4.5-6.5), 14.1 months (95% CI 12.2-19.3), 37.0% (95% CI 24.3-51.3), 81.5% (95% CI 68.6-90.8), and 5.8 months (95% CI 4.29-6.21), respectively. Neutrophil count decreased (47.3%) was the most common Grade 3/4 treatment-emergent adverse event. No treatment-related deaths occurred. CONCLUSION: Panitumumab plus FTD/TPI exhibited favourable anti-tumour activity with a manageable safety profile and may be a therapeutic option for pre-treated mCRC patients.
  • Hypertriglyceridemia induced by S-1: A novel case report and review of the literature.
    Yoshitaka Saito; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 27, 4, 1020, 1025, 2021年06月, [国際誌]
    英語, 研究論文(学術雑誌), INTRODUCTION: S-1, a compounding agent of tegafur, gimeracil, and oteracil potassium, is one of the most effective chemotherapeutic agents for colorectal cancer. In this case, following S-1 administration, we observed predominant elevation of serum triglyceride. CASE REPORT: A 49-year-old man with stage IV transverse colon adenocarcinoma received S-1 + irinotecan + bevacizumab. At the end of the S-1 administration period in every course, his serum triglyceride level was found to be elevated. Finally, it reached grade 4, without any symptoms of acute pancreatitis in the fifth course, and fenofibrate 80 mg once a day was administered.Management & outcome: Interestingly, the elevation spontaneously normalized without any pharmacotherapy 14 days after S-1 withdrawal, and this elevation did not occur when S-1 was not administered. Further, fenofibrate administration attenuated the hypertriglyceridemia to grades 1-3, with no complications. DISCUSSION: S-1 administration induced hypertriglyceridemia owing to the elevated serum triglyceride; however, a contrasting result was observed in the S-1 withdrawal period and during the S-1-cessation cycle. Since dietary intake was poorer during the S-1 administration period, it is considered that S-1 might have disturbed lipid metabolism. Further, we know that capecitabine, which is a prodrug of fluorouracil, also induces hypertriglyceridemia. As the end product of these medicines is fluorouracil, the presence of fluorouracil or its metabolizing enzymes, the genetic background of the patient might have affected the results. We have to be aware of the risk of asymptomatic and temporal occurrence of hypertriglyceridemia by S-1 administration for the early detection with appropriate pre-emptive treatment.
  • Detection of risk factors related to administration suspension and severe neutropenia in gemcitabine and nab-paclitaxel treatment.
    Yoshitaka Saito; Yoh Takekuma; Masaki Kobayashi; Yoshito Komatsu; Mitsuru Sugawara
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 29, 6, 3277, 3285, 2021年06月, [国際誌]
    英語, 研究論文(学術雑誌), PURPOSE: The combination of gemcitabine (GEM) and nanoparticle albumin-bound paclitaxel (nab-PTX) is an effective chemotherapeutic regimen for locally advanced and metastatic pancreatic cancer. The dose-limiting toxicities (DLTs) of this treatment are sepsis and neutropenia, while the relative dose intensity (RDI) of GEM is approximately 75% and of nab-PTX is 70-80%. In this study, we evaluated the risk factor(s) regarding treatment suspension, which leads to reduction in the RDI of these agents, enabling appropriate schedule management. METHODS: Two hundred patients with pancreatic cancer who received GEM + nab-PTX were retrospectively investigated. Frequency and risk factor(s) of suspension of the treatment and grade 3/4 neutropenia in the first course were evaluated. RESULTS: The frequency of treatment suspension in the first course was 61%. The frequency of grade 3/4 neutropenia was 51%, while that of thrombocytopenia was 7.5%. The RDI was 78.0% for GEM and 77.7% for nab-PTX. Univariate and multivariate analyses to identify risk or preventive factors related to treatment suspension suggested that low platelet count at baseline was a risk factor, whereas dose reduction from the treatment initiation was a preventive factor. The most common cause of abeyance was grade 3/4 neutropenia (83.6%), the risk factors of which were low platelet count and age ≥ 65 years at baseline, while dose reduction was a preventive factor. CONCLUSION: We found that a low platelet level at baseline was a risk factor, whereas dose reduction from initiation was a preventive factor in regard to treatment suspension and severe neutropenia occurrence in GEM + nab-PTX treatment.
  • Prognostic Value and Molecular Landscape of HER2 Low-Expressing Metastatic Colorectal Cancer.
    Masataka Yagisawa; Kentaro Sawada; Yoshiaki Nakamura; Satoshi Fujii; Satoshi Yuki; Yoshito Komatsu; Takayuki Yoshino; Naoya Sakamoto; Hiroya Taniguchi
    Clinical colorectal cancer, 20, 2, 113, 120, 2021年06月, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: The prognostic value and molecular landscape of human epidermal growth factor receptor 2 (HER2) low-expressing (HER2-L) metastatic colorectal cancer (mCRC) remain unclear. PATIENTS AND METHODS: This study enrolled patients with mCRC who had undergone surgical resection of primary tumor. Using the specimen, we evaluated HER2 expression by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). HER2 positivity was defined as follows: HER2 positivity (HER2-Pos) as IHC 3 + or IHC 2+/FISH positive, HER2-L as IHC 2+/FISH negative or IHC 1+, and HER2 negativity (HER2-Neg) as IHC 0+. Gene alterations were determined by next-generation sequencing. RESULTS: Between 2005 and 2015, a total of 370 patients were analyzed, comprising 15 patients (4%) with HER2-Pos, 21 (6%) with HER2-L, and 334 (90%) with HER2-Neg disease. The clinicopathologic characteristics among groups had no differences. HER2-L had a significantly higher proportion of coaltered RAS mutation than HER2-Pos (P = .037). With a median follow-up of 101.8 months, HER2-L had a significantly better median overall survival than HER2-Pos (P = .029) (18.2 months in HER2-Pos vs. 33.3 in HER2-L vs. 27.9 in HER2-Neg). In 58 patients harboring wild-type RAS and receiving anti-EGFR antibody therapy, HER2-L had a better median progression-free survival tendency than HER2-Pos, with 2.2 months in HER2-Pos, 7.8 in HER2-L, and 5.1 in HER2-Neg (P = .036). CONCLUSION: HER2-L mCRC showed a better prognosis than HER2-Pos mCRC, and it is similar to HER2-Neg mCRC. Hence, HER2-L mCRC might have different biologic behavior in terms of prognostic value and molecular landscape of mCRC, suggesting the possibility of implementation of HER2-guided clinical development against HER2-expressing mCRC.
  • Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial.
    Salvatore Siena; Maria Di Bartolomeo; Kanwal Raghav; Toshiki Masuishi; Fotios Loupakis; Hisato Kawakami; Kensei Yamaguchi; Tomohiro Nishina; Marwan Fakih; Elena Elez; Javier Rodriguez; Fortunato Ciardiello; Yoshito Komatsu; Taito Esaki; Ki Chung; Zev Wainberg; Andrea Sartore-Bianchi; Kapil Saxena; Eriko Yamamoto; Emarjola Bako; Yasuyuki Okuda; Javad Shahidi; Axel Grothey; Takayuki Yoshino
    The Lancet. Oncology, 22, 6, 779, 789, 2021年06月, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: HER2 amplification has been identified in 2-3% of patients with colorectal cancer, although there are currently no approved HER2-targeted therapies for colorectal cancer. We aimed to study the antitumour activity and safety of trastuzumab deruxtecan (an antibody-drug conjugate of humanised anti-HER2 antibody with topoisomerase I inhibitor payloads) in patients with HER2-expressing metastatic colorectal cancer. METHODS: DESTINY-CRC01 is an open-label, phase 2 study that recruited patients from 25 clinics and hospitals in Italy, Japan, Spain, the UK, and the USA. Eligible patients had centrally confirmed HER2-expressing metastatic colorectal cancer that had progressed on two or more previous regimens (HER2-targeted therapies other than trastuzumab deruxtecan permitted), were aged 18 years or older (≥20 years in Japan), had an Eastern Cooperative Oncology Group score of 0 or 1, and had RAS and BRAFV600E wild-type tumours. Patients were enrolled into one of three cohorts by HER2 expression level: cohort A (HER2-positive, immunohistochemistry [IHC] 3+ or IHC2+ and in-situ hybridisation [ISH]-positive), cohort B (IHC2+ and ISH-negative), or cohort C (IHC1+). Patients received 6·4 mg/kg trastuzumab deruxtecan intravenously every 3 weeks until disease progression, unacceptable adverse events, withdrawal of consent, or death. The primary endpoint was confirmed objective response rate in cohort A by independent central review which was assessed in the full analysis set and safety was assessed in the safety analysis set. Both the full analysis set and the safety analysis set included all patients who received one or more doses of trastuzumab deruxtecan. This ongoing trial is registered with ClinicalTrials.gov, number NCT03384940. FINDINGS: Between Feb 23, 2018, and July 3, 2019, 78 patients were enrolled in the study (53 in cohort A, seven in cohort B, and 18 in cohort C), all of whom received at least one dose of study drug. For the 53 (68%) patients with HER2-positive tumours (cohort A), a confirmed objective response was reported in 24 (45·3%, 95% CI 31·6-59·6) patients after a median follow-up of 27·1 weeks (IQR 19·3-40·1). Grade 3 or worse treatment-emergent adverse events that occurred in at least 10% of all participants were decreased neutrophil count (17 [22%] of 78) and anaemia (11 [14%]). Five patients (6%) had adjudicated interstitial lung disease or pneumonitis (two grade 2; one grade 3; two grade 5, the only treatment-related deaths). INTERPRETATION: Trastuzumab deruxtecan showed promising and durable activity in HER2-positive metastatic colorectal cancer refractory to standard treatment, with a safety profile consistent with that reported in previous trastuzumab deruxtecan trials. Interstitial lung disease and pneumonitis are important risks requiring careful monitoring and prompt intervention. FUNDING: Daiichi Sankyo.
  • Phase II study of cetuximab plus S-1/cisplatin therapy in Japanese patients with advanced gastric cancer.
    Kensei Yamaguchi; Nozomu Fuse; Yoshito Komatsu; Hirofumi Fujii; Shuichi Hironaka; Yasushi Omuro; Kei Muro; Hirofumi Yasui; Shinya Ueda; Tomohiro Nishina; Morihiro Watanabe; Atsushi Ohtsu
    Japanese journal of clinical oncology, 51, 6, 879, 885, 2021年05月28日, [国際誌]
    英語, 研究論文(学術雑誌), OBJECTIVE: We evaluated the efficacy and safety of first-line S-1 plus cisplatin in combination with cetuximab for Japanese patients with advanced gastric cancer, including gastroesophageal junction adenocarcinoma. METHODS: This open-label, single arm, multicenter, phase 2 trial was conducted to assess first-line cetuximab plus S-1 plus cisplatin for advanced gastric cancer. A total of 40 patients from 10 centers were enrolled. Cetuximab was administered weekly, with the initial infusion at 400 mg/m2 and then 250 mg/m2 each subsequent week. S-1 plus cisplatin chemotherapy was concomitantly conducted in a 5-week cycle: S-1 (40-60 mg, adjusted for body surface area) was given twice daily for 3 consecutive weeks, followed by a 2-week rest period, and cisplatin (60 mg/m2) was given on day 8 of each cycle for a maximum of 8 cycles. Treatment continued until the occurrence of radiographically confirmed progressive disease, unacceptable toxicity or withdrawal of consent. The primary endpoint was the best overall response. Secondary endpoints included progression-free survival and safety. RESULTS: A total of 40 patients were evaluable. One patient (2.5%) had a complete response; 15 patients (37.5%) had a partial response. The observed overall response rate according to the independent review committee was 40.0% (95% confidence interval, 24.9-56.7; P = 0.7043 [one-sided null hypothesis: overall response rate ≤ 43%]); median PFS was 5.6 months (95% confidence intervals, 4.2-8.3). No adverse events leading to death were reported during the study, and no specific safety concerns were observed. CONCLUSIONS: Overall, the addition of cetuximab to S-1 plus cisplatin was well tolerated in patients with advanced gastric cancer but provided no additional clinical benefit in this study. ClinicalTrials.gov identifier: NCT01388790.
  • Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first-line treatment for metastatic colorectal cancer: Safety lead-in results from the QUATTRO-II study.
    Daisuke Kotani; Takayuki Yoshino; Masahito Kotaka; Akihito Kawazoe; Toshiki Masuishi; Hiroya Taniguchi; Kentaro Yamazaki; Takeharu Yamanaka; Eiji Oki; Kei Muro; Yoshito Komatsu; Hideaki Bando; Hironaga Satake; Takeshi Kato; Akihito Tsuji
    Investigational new drugs, 39, 6, 1649, 1655, 2021年05月21日, [国際誌]
    英語, 研究論文(学術雑誌), Background FOLFOXIRI plus bevacizumab is the first-line treatment for metastatic colorectal cancer (mCRC) but demonstrates high neutropenia incidence among Asian patients. Hence, we conducted the randomized phase II QUATTRO-II study (ClinicalTrials.gov identifier: NCT04097444; Japan Registry of Clinical Trials identifier: jRTCs041190072) to evaluate the safety and efficacy of capecitabine, oxaliplatin, and irinotecan (CAPOXIRI) combination plus bevacizumab versus FOLFOXIRI plus bevacizumab, expecting a lower incidence of neutropenia without compromising the efficacy. Methods We investigated the recommended doses (RD) of oxaliplatin and irinotecan as a safety lead-in portion of Step 1 before initiating the randomized portion as Step 2. Four dose levels of CAPOXIRI (fixed dose of capecitabine, 1600 mg/m2; escalated/de-escalated doses of oxaliplatin and irinotecan) plus bevacizumab (7.5 mg/kg) were investigated in a 3 + 3 manner. A dose level of ≤ 2/6 of dose-limiting toxicity (DLT) cases was expected as the RD. Results In Step 1, we included nine patients (three and six in levels 0 and + 1, respectively). Level 0 (irinotecan, 200 mg/m2; oxaliplatin, 100 mg/m2) did not demonstrate DLTs. In level + 1 (irinotecan, 200 mg/m2; oxaliplatin, 130 mg/m2), although one patient experienced grade 4 febrile neutropenia, no further safety concerns were observed. As a preliminary efficacy result, the objective response rate in all nine patients was 89 % (100 and 83 % in levels 0 and + 1, respectively). Conclusions The RD of CAPOXIRI plus bevacizumab was 200, 130, and 1600 mg/m2 for irinotecan, oxaliplatin, and capecitabine, respectively, and 7.5 mg/kg for bevacizumab. The randomized portion is still ongoing.
  • Combined Analysis of Concordance between Liquid and Tumor Tissue Biopsies for RAS Mutations in Colorectal Cancer with a Single Metastasis Site: The METABEAM Study.
    Yoshinori Kagawa; Elena Elez; Jesús García-Foncillas; Hideaki Bando; Hiroya Taniguchi; Ana Vivancos; Kiwamu Akagi; Ariadna García; Tadamichi Denda; Javier Ros; Tomohiro Nishina; Iosune Baraibar; Yoshito Komatsu; Davide Ciardiello; Eiji Oki; Toshihiro Kudo; Takeshi Kato; Takeharu Yamanaka; Josep Tabernero; Takayuki Yoshino
    Clinical cancer research : an official journal of the American Association for Cancer Research, 27, 9, 2515, 2522, 2021年05月01日, [国際誌]
    英語, 研究論文(学術雑誌), PURPOSE: OncoBEAM™ is a circulating tumor DNA (ctDNA) test that uses the BEAMing digital PCR technology. We clarified the association between the baseline tumor burden and discordance in the RAS status by metastatic sites in patients with a single metastatic site. EXPERIMENTAL DESIGN: Data from previous Spanish and Japanese studies investigating the concordance of the RAS status between OncoBEAM™ and tissue biopsy in 221 patients with metastatic colorectal cancer (mCRC) were used. We collected data from patients with liver, peritoneal, or lung metastases and evaluated the concordance rates according to the metastatic site and the association between the concordance rate and tumor burden. RESULTS: Patients had metastases in the liver (n = 151), peritoneum (n = 25), or lung (n = 45) with concordance rates of 91% (95% confidence interval, 85%-95%), 88% (68%-97%), and 64% (49%-78%), respectively. Factors associated with concordance included the baseline longest diameter and lesion number (P = 0.004), and sample collection interval (P = 0.036). Concordance rates ≥90% were observed in the following groups: liver metastases alone, regardless of the baseline longest diameter and lesion number; peritoneal metastases alone in patients with a baseline longest diameter ≥20 mm; and lung metastases alone in patients with a baseline longest diameter ≥20 mm and/or number of lesions ≥10. CONCLUSIONS: Plasma ctDNA-based liquid biopsy in patients with mCRC may be useful depending on the metastatic site. The maximum diameter and lesion number should be carefully considered when determining patients' RAS status with only peritoneal or lung metastases.
  • Clinical significance of comprehensive genomic profiling tests covered by public insurance in patients with advanced solid cancers in Hokkaido, Japan.
    Junko Kikuchi; Yoshihito Ohhara; Kohichi Takada; Hiroki Tanabe; Kazuteru Hatanaka; Toraji Amano; Kanako C Hatanaka; Yutaka Hatanaka; Takashi Mitamura; Momoko Kato; Yuka Shibata; Ichiro Yabe; Akira Endoh; Yoshito Komatsu; Yoshihiro Matsuno; Minako Sugiyama; Atsushi Manabe; Akihiro Sakurai; Masato Takahashi; Hirohito Naruse; Yoshihiro Torimoto; Hirotoshi Dosaka-Akita; Ichiro Kinoshita
    Japanese journal of clinical oncology, 51, 5, 753, 761, 2021年04月30日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Comprehensive cancer genomic profiling has been used recently for patients with advanced solid cancers. Two cancer genomic profiling tests for patients with no standard treatment are covered by Japanese public health insurance since June 2019. METHODS: We prospectively analyzed data of 189 patients with solid cancers who underwent either of the two-cancer genomic profiling tests at Hokkaido University Hospital and its liaison hospitals and whose results were discussed in molecular tumor board at Hokkaido University Hospital between August 2019 and July 2020. RESULTS: All 189 patients had appropriate results. Actionable gene alterations were identified in 93 patients (49%). Frequent mutations included PIK3CA (12%) mutation, BRCA1/2 alteration (7%), ERBB2 amplification (6%) and tumor mutation burden-High (4%). The median turnaround time from sample shipping to acquisition by the expert panel was 26 days. Although 115 patients (61%) were provided with information for genotype-matched therapies, only 21 (11%) received them. Notably, four of eight patients below the age of 20 years were provided information for genotype-matched therapies, and three received them. Their response rates and disease control rates were 29% and 67%, respectively. Most patients who did not undergo the genotype-matched therapies were provided information for only investigational drugs in phases I and II at distant clinical trial sites in central Japan. Twenty-six patients were informed of suspected germline findings, while 11 patients (42%) received genetic counseling. CONCLUSIONS: The publicly reimbursed cancer genomic profilings may lead to the modest but favorable therapeutic efficacy of genotype-matched therapy for solid cancer patients with no standard therapy. However, poor access to genotype-matched therapy needs to be resolved.
  • IBD診療における超音波の有用性 免疫チェックポイント阻害薬誘発性大腸炎における体外式超音波検査の有用性
    桜井 健介; 西田 睦; 表原 里実; 小田切 信介; 長島 一哲; 桂田 武彦; 小松 嘉人; 坂本 直哉
    超音波医学, 48, Suppl., S306, S306, (公社)日本超音波医学会, 2021年04月
    日本語
  • Advanced colorectal cancer subtypes (aCRCS) help select oxaliplatin-based or irinotecan-based therapy for colorectal cancer.
    Shin Takahashi; Yasuhiro Sakamoto; Tadamichi Denda; Atsuo Takashima; Yoshito Komatsu; Masato Nakamura; Hisatsugu Ohori; Tatsuro Yamaguchi; Yoshimitsu Kobayashi; Hideo Baba; Masanori Kotake; Kenji Amagai; Hitoshi Kondo; Ken Shimada; Atsushi Sato; Satoshi Yuki; Akira Okita; Kota Ouchi; Keigo Komine; Mika Watanabe; Satoshi Morita; Chikashi Ishioka
    Cancer science, 112, 4, 1567, 1578, 2021年04月, [国際誌]
    英語, 研究論文(学術雑誌), Oxaliplatin (OX) and irinotecan (IRI) are used as key drugs for the first-line treatment of metastatic colorectal cancer (mCRC). However, no biomarkers have been identified to decide which of the drugs is initially used. In this translational research (TR) of the TRICOLORE trial, the advanced colorectal cancer subtype (aCRCS) was analyzed as a potential biomarker for the selection of OX or IRI. We collected 335 (68.8%) formalin-fixed, paraffin-embedded (FFPE) primary tumor specimens from 487 patients registered in the TRICOLORE trial and performed direct sequencing and immunohistochemical staining of CRC-related genes, comprehensive gene-expression analysis, and genome-wide methylation analysis. The progression-free survival (PFS) of the IRI group was significantly better compared with the OX group in BRAF wild-type (WT), PTEN-positive, and aCRCS A1 patients. Among the molecular factors, aCRCS were only associated with the PFS of OX and IRI groups. The PFS of the IRI group was significantly better compared with the OX group in aCRCS A1 + B1 (hazard ratio [HR] = 0.58; 95% confidence interval [CI] = 0.41-0.82; P = .0023). In contrast, the OX group had better PFS compared with the IRI group in aCRCS B2, although this was not statistically significant (HR = 1.66; 95% CI = 0.94-2.96; P = .083). Nearly half of patients with mCRC (46.8%, aCRCS A1 + B1) respond well to IRI, while only about 18.5% (aCRCS B2) of patients with mCRC responded well to OX. In conclusion, the aCRCS might be a predictive factor for the clinical outcomes of OX-based and IRI-based therapies.
  • 進展胃癌に対する薬物治療はこれからどう変わるか? MSI-H進行胃癌に対する1次治療としてのニボルマブと低用量イピリムマブ併用の第II相試験(NO LIMIT試験)(Phase II study of Nivolumab plus Low dose Ipilimumab In gastric MSI-H Tumor(NO LIMIT))
    川上 尚人; 小松 嘉人; 藪崎 裕; 原 浩樹; 平田 賢郎; 平野 秀和; 町田 望; 牧山 明資; 門脇 重憲; 杉本 直俊; 津田 政広; 茶山 一彰; 江崎 泰斗; 廣中 秀一; 室 圭
    日本胃癌学会総会記事, 93回, 210, 210, (一社)日本胃癌学会, 2021年03月
    英語
  • Effect of early tumor response on the health-related quality of life among patients on second-line chemotherapy for advanced gastric cancer in the ABSOLUTE trial.
    Kazumasa Fujitani; Kohei Shitara; Atsuo Takashima; Keisuke Koeda; Hiroki Hara; Norisuke Nakayama; Shuichi Hironaka; Kazuhiro Nishikawa; Yutaka Kimura; Kenji Amagai; Hisashi Hosaka; Yoshito Komatsu; Ken Shimada; Ryohei Kawabata; Hideki Ohdan; Yasuhiro Kodera; Masato Nakamura; Takako Eguchi Nakajima; Yoshinori Miyata; Toshikazu Moriwaki; Tetsuya Kusumoto; Kazuo Nishikawa; Kazuhiro Ogata; Masashi Shimura; Satoshi Morita; Wasaburo Koizumi
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 24, 2, 467, 476, 2021年03月, [国内誌]
    英語, 研究論文(学術雑誌), BACKGROUND: This study evaluated the association between early tumor response at 8 weeks, previously reported as a positive outcome prognosticator, and health-related quality of life (HRQOL) in advanced gastric cancer (AGC) patients enrolled in the ABSOLUTE trial. METHODS: HRQOL was assessed using the EuroQol-5 Dimension (EQ-5D) utility index score in patients with complete response (CR) + partial response (PR) and progressive disease (PD) at 8 weeks, and time-to-deterioration (TtD) of the EQ-5D score, with the preset minimally important difference (MID) of 0.05, was compared between these populations. Among the enrolled patients, 143 and 160 patients were assessable in weekly solvent-based paclitaxel (Sb-PTX) arm and weekly nanoparticle albumin-bound paclitaxel (nab-PTX) arm, respectively. RESULTS: Changes of the EQ-5D score from baseline to 8 weeks in the nab-PTX arm were 0.0009 and - 0.1229 in CR + PR and PD patients, respectively; the corresponding values for the Sb-PTX arm were - 0.0019 and - 0.1549. For both treatments, changes of the EQ-5D score from baseline at 8 weeks were significantly larger in patients with PD than in those with CR + PR. The median TtD was 3.9 and 2.2 months in patients with CR + PR and PD, respectively, for nab-PTX [hazard ratio (HR) = 0.595, 95% confidence interval (CI) 0.358-0.989]. For Sb-PTX, the corresponding values were 4.7 and 2.0 months (HR = 0.494, 95% CI 0.291-0.841). CONCLUSIONS: Early tumor shrinkage was associated with maintained HRQOL in AGC patients on the second-line chemotherapy with taxanes.
  • Correction to: Effect of early tumor response on the health-related quality of life among patients on second-line chemotherapy for advanced gastric cancer in the ABSOLUTE trial.
    Kazumasa Fujitani; Kohei Shitara; Atsuo Takashima; Keisuke Koeda; Hiroki Hara; Norisuke Nakayama; Shuichi Hironaka; Kazuhiro Nishikawa; Yutaka Kimura; Kenji Amagai; Hisashi Hosaka; Yoshito Komatsu; Ken Shimada; Ryohei Kawabata; Hideki Ohdan; Yasuhiro Kodera; Masato Nakamura; Takako Eguchi Nakajima; Yoshinori Miyata; Toshikazu Moriwaki; Tetsuya Kusumoto; Kazuo Nishikawa; Kazuhiro Ogata; Masashi Shimura; Satoshi Morita; Wasaburo Koizumi
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 24, 2, 477, 478, 2021年03月, [国内誌]
    英語
  • A randomized, double-blind, phase II study of oral histone deacetylase inhibitor resminostat plus S-1 versus placebo plus S-1 in biliary tract cancers previously treated with gemcitabine plus platinum-based chemotherapy.
    Makoto Ueno; Chigusa Morizane; Masayuki Furukawa; Daisuke Sakai; Yoshito Komatsu; Yousuke Nakai; Masahiro Tsuda; Masato Ozaka; Nobumasa Mizuno; Manabu Muto; Akira Fukutomi; Masafumi Ikeda; Akihito Tsuji; Akio Katanuma; Toshikazu Moriwaki; Takeshi Kajiwara; Hiroshi Ishii; Yuji Negoro; Satoshi Shimizu; Noriko Nemoto; Shingo Kobayashi; Keigo Makino; Junji Furuse
    Cancer medicine, 10, 6, 2088, 2099, 2021年03月, [国際誌]
    英語, 研究論文(学術雑誌), PURPOSE: Effective second-line chemotherapy options are limited in treating advanced biliary tract cancers (BTCs). Resminostat is an oral histone deacetylase inhibitor. Such inhibitors increase sensitivity to fluorouracil, the active form of S-1. In the phase I study, addition of resminostat to S-1 was suggested to have promising efficacy for pre-treated BTCs. This study investigated the efficacy and safety of resminostat plus S-1 in second-line therapy for BTCs. METHODS: Patients were randomly assigned to receive resminostat or placebo (200 mg orally per day; days 1-5 and 8-12) and S-1 group (80-120 mg orally per day by body surface area; days 1-14) over a 21-day cycle. The primary endpoint was progression-free survival (PFS). Secondary endpoints comprised overall survival (OS), response rate (RR), disease control rate (DCR), and safety. RESULTS: Among 101 patients enrolled, 50 received resminostat+S-1 and 51 received placebo+S-1. Median PFS was 2.9 months for resminostat+S-1 vs. 3.0 months for placebo+S-1 (HR: 1.154, 95% CI: 0.759-1.757, p = 0.502); median OS was 7.8 months vs. 7.5 months, respectively (HR: 1.049, 95% CI: 0.653-1.684, p = 0.834); the RR and DCR were 6.0% vs. 9.8% and 70.0% vs. 78.4%, respectively. Treatment-related adverse events (TrAEs) of grade ≥ 3 occurring more frequently (≥10% difference) in the resminostat+S-1 than in the placebo+S-1 comprised platelet count decreased (18.0% vs. 2.0%) and decreased appetite (16.0% vs. 2.0%). CONCLUSIONS: Resminostat plus S-1 therapy improved neither PFS nor OS for patients with pre-treated BTCs. Addition of resminostat to S-1 was associated with higher incidence of TrAEs, but these were manageable (JapicCTI-183883).
  • An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability-High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT, WJOG13320G/CA209-7W7).
    Hisato Kawakami; Shuichi Hironaka; Taito Esaki; Kazuaki Chayama; Masahiro Tsuda; Naotoshi Sugimoto; Shigenori Kadowaki; Akitaka Makiyama; Nozomu Machida; Hidekazu Hirano; Kenro Hirata; Hiroki Hara; Hiroshi Yabusaki; Yoshito Komatsu; Kei Muro
    Cancers, 13, 4, 2021年02月15日, [国際誌]
    英語, 研究論文(学術雑誌), Nivolumab (NIVO) plus low-dose ipilimumab (IPI) has shown a promising survival benefit in first-line treatment of microsatellite instability-high (MSI-H) colorectal cancer. We hypothesized that this regimen might also be beneficial for MSI-H gastric cancer (GC), which accounts for ~5% of all GC cases. NO LIMIT (WJOG13320G/CA209-7W7) is an investigator-initiated, single-arm, open-label, 14-center phase 2 trial of NIVO plus low-dose IPI for MSI-H GC in the first-line setting. Eligibility criteria include unresectable advanced, recurrent, or metastatic gastric or esophagogastric junction cancer with a histologically confirmed diagnosis of adenocarcinoma; confirmed MSI-H status with the MSI-IVD Kit (FALCO); no prior systemic anticancer therapy; an Eastern Cooperative Oncology Group performance status of 0 or 1; and a measurable lesion per RECIST 1.1. The primary objective of the study is to determine the overall response rate (ORR) for the NIVO+IPI regimen as assessed by blinded independent central review. Secondary end points include progression-free survival, overall survival, duration of response, safety, tolerability, and biomarkers. The number of patients was set at 28 on the basis of the threshold and expected ORR values of 35 and 65%, respectively, with a one-sided alpha error of 0.025 and power of 0.80. Subjects will receive treatment with nivolumab (240 mg) biweekly in combination with ipilimumab (1 mg/kg) every 6 weeks. The results of this study should clarify the therapeutic potential of NIVO+IPI for MSI-H GC in the first-line setting. Trial registration: JapicCTI-205400.
  • Treatment Pattern for Advanced Gastric Cancer in Japan and Factors Associated with Sequential Treatment: A Retrospective Administrative Claims Database Study
    Yoshito Komatsu; Shuichi Hironaka; Yoshinori Tanizawa; Zhihong Cai; Yongzhe Piao; Narikazu Boku
    Advances in Therapy, Adis, 2021年
    英語, 研究論文(学術雑誌)
  • Risk Analysis of Denosumab-Induced Hypocalcemia in Bone Metastasis Treatment: Renal Dysfunction Is Not a Risk Factor for Its Incidence in a Strict Denosumab Administration Management System with Calcium/Vitamin D Supplementation.
    Yoshitaka Saito; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
    Biological & pharmaceutical bulletin, 44, 12, 1819, 1823, 2021年, [国内誌]
    英語, 研究論文(学術雑誌), We have reported that a strict denosumab administration management system with oral calcium/vitamin D supplementation attenuates denosumab-induced hypocalcemia in 158 cancer patients with bone metastasis. In this report, 27.8% of the patients experienced hypocalcemia, including 0.6% with grade 2. So far, the risk factors for ≥grade 2 hypocalcemia incidence have been identified in denosumab-treated cancer patients, including patients without calcium/vitamin D supplementation. Therefore, the present study aimed to reveal the factors that affect all-grade hypocalcemia incidence with calcium/vitamin D supplementation and team medical care according to the management system. A receiver operating characteristic curve analysis suggested that the cutoff of baseline serum calcium level for all-grade hypocalcemia incidence was 9.3 mg/dL. Multivariate analysis revealed that age ≥65 years (odds ratio, 95% confidence interval: 2.57, 1.11-5.95, p = 0.03), grade 1 or higher serum alkaline phosphatase elevation (3.70, 1.71-8.00, p < 0.01), an adjusted serum calcium level of less than 9.3 mg/dL (3.21. 1.25-8.24, p = 0.02) at baseline, and co-administration of cytotoxic agents (2.33, 1.06-7.11, p = 0.03) are risk factors for the incidence of all-grade hypocalcemia. However, renal dysfunction, which has been suggested to be a risk factor in previous reports, was not a factor. In conclusion, we revealed the risk factors for all-grade hypocalcemia in calcium/vitamin D supplementation and awareness, as demonstrated by the management system. Moreover, renal dysfunction was not a risk factor in our strict denosumab administration management system. Our results support the value of early detection of hypocalcemia incidence to guide the selection of an appropriate management strategy.
  • Hypertriglyceridemia Induced by Fluorouracil: A Novel Case Report
    Yoshitaka Saito; Yoh Takekuma; Satoshi Yuki; Yoshito Komatsu; Mitsuru Sugawara
    Case Reports in Oncology, 14, 1, 207, 211, 2021年01月
    研究論文(学術雑誌)
  • Quality of Life Associated with Ramucirumab Treatment in Patients with Advanced Gastric Cancer in Japan: Exploratory Analysis from the Phase III RAINBOW Trial.
    Kensei Yamaguchi; Yasuhiro Shimada; Shuichi Hironaka; Naotoshi Sugimoto; Yoshito Komatsu; Tomohiro Nishina; Yasushi Omuro; Takao Tamura; Yongzhe Piao; Gosuke Homma; Min-Hua Jen; Astra M Liepa; Kei Muro
    Clinical drug investigation, 41, 1, 53, 64, 2021年01月, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND AND OBJECTIVE: Gastric cancer has been associated with notable geographic heterogeneity in previous multi-regional studies. In particular, patients from Japan have better outcomes compared with patients from other regions. Here, we assess patient-focused outcomes for the subgroup of Japanese patients in the global RAINBOW study. METHODS: Quality of life (QoL) was assessed using the European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire-Core 30 (QLQ-C30) at baseline and 6-week intervals. Investigators assessed performance status before each 4-week cycle. Time-to-deterioration in each QLQ-C30 scale was defined as randomization to first worsening of ≥ 10 points (on a 100-point scale). Time-to-deterioration in performance status was defined as first worsening to ≥ 2. Hazard ratios were estimated using Cox proportional hazards models. RESULTS: The Japan subgroup contained 140 patients (ramucirumab plus paclitaxel, n = 68; placebo plus paclitaxel, n = 72); baseline QoL data were available for all patients. At baseline, QLQ-C30 scores were similar between study arms. Of the 15 QLQ-C30 scales, nine had a hazard ratio < 1, indicating similar or numerically longer time-to-deterioration in QoL for ramucirumab plus paclitaxel; all 95% confidence intervals included 1. Best mean change from baseline numerically favored ramucirumab plus paclitaxel in most QoL scales. The hazard ratios for time-to-deterioration of performance status to ≥ 2 were 0.64 in the Japan subgroup and 0.88 in the non-Asian subgroup. The Japan subgroup had better QoL at baseline compared with the non-Asian subgroup. CONCLUSIONS: Treatment with ramucirumab plus paclitaxel maintained QoL and performance status over time compared with placebo plus paclitaxel in the Japan subgroup of the RAINBOW trial. These data suggest that the heterogeneity in gastric cancer between geographic regions includes multiple measures of QoL. TRIAL REGISTRATION NUMBER: NCT01170663 (first submitted 21 July, 2010).
  • Evaluation of Chemotherapy Regimen Management Practice by Oncology-Specialized and Non-specialized Pharmacists Collaboration.
    Yoshitaka Saito; Kazuki Uchiyama; Tatsuhiko Sakamoto; Kosei Kubota; Hiromitsu Oki; Miwako Iwai; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
    Biological & pharmaceutical bulletin, 44, 3, 293, 297, 2021年, [国内誌]
    英語, 研究論文(学術雑誌), Chemotherapy regimen management is one of the most important oncology pharmacy practices, because chemotherapy is conducted according to the registered regimens. In this study, we evaluated the pharmaceutical practice that assumes the initial confirmation of chemotherapy regimens and the quality of practice sharing between oncology-specialized and non-specialized pharmacists in regimen management committee. Pharmacists initially confirmed the applied regimen prescribed by physicians regarding chemotherapeutic agents and prophylactic supportive care medicines. Following confirmation, the regimens were reviewed by the Hokkaido University Hospital Regimen Management Committee. A total of 233 regimens were reviewed by the committee over three years. In total, 110 pharmaceutical inquiries were conducted, 45% of inquiries were concerning chemotherapeutic agents, of which approximately half were regarding supportive care medicines. Most inquiries were regarding premedication, followed by those on administration time, solvent of infusion medicines, and dosage. Correction was performed for 84.5% of inquiries. There was no significant difference in inquiry rates between practice and trial regimens. We have entrusted the first basic regimen review according to the checklist, creation of the chemotherapy plan document, and registry of the adopted regimens in the ordering system from oncology-certified pharmacists to non-certified pharmacists. Basic regimen review was well conducted by a non-certified pharmacist, and a more advanced review was additionally performed by certified pharmacists. In conclusion, we demonstrated the utility of pharmaceutical confirmation in a chemotherapeutic regimen review, suitable review coverage, and quality practice sharing between oncology-certified and non-certified pharmacists, which is one of the recommended methods in chemotherapy regimen review.
  • Safety Evaluation of Initial CT-P6 Administration for 30 min during the Switch from Reference Trastuzumab in Maintenance Infusion: A Multicenter Observational Study.
    Yoshitaka Saito; Shinya Tamaki; Haruka Hasegawa; Kenta Takahashi; Akira Tokutome; Yoh Takekuma; Hiroko Yamashita; Yoshito Komatsu; Mitsuru Sugawara
    Biological & pharmaceutical bulletin, 44, 4, 474, 477, 2021年, [国内誌]
    英語, 研究論文(学術雑誌), CT-P6 is a biosimilar of trastuzumab and is recommended to be administered for 30-90 min in subsequent maintenance infusions to prevent infusion-related reactions (IRRs). We administered CT-P6 for 30 min as the first injection and as an alternative to reference trastuzumab in the maintenance infusion and evaluated the safety of the administration. A total of 140 patients with breast or gastric cancer, who received a switch from tri-weekly reference trastuzumab to CT-P6 for 30 min in maintenance infusions, were retrospectively evaluated. Premedication was administered prior to an infusion of CT-P6 and a cytotoxic agent. However, premedication was not provided when CT-P6 was co-administered with pertuzumab or administered alone. The primary endpoint was the incidence of IRRs. The secondary endpoint was the incidence of diarrhea and skin toxicity. Ninety-five percent of the patients had breast cancer, and 44.3% had advance-stage cancer. The treatment included CT-P6 alone (17.9%) or with cytotoxic agents (23.6%), antihormonal drugs (25.7%), and pertuzumab (62.9%). Median administration time of trastuzumab at the switch was 13 administrations (range 2-140). Premedication was administered to 20.7% patients. One patient (0.7%) experienced grade 3 IRR. The frequency of diarrhea in the reference trastuzumab group and the CT-P6 group was 7.1 and 6.4%, respectively, and that of skin toxicity was 6.4 and 5.0%, respectively, without differences. In conclusion, we first demonstrated that an initial CT-P6 administration for 30 min during the switch from reference trastuzumab in maintenance infusion is an acceptable administration method.
  • [Pharmaceutical Intervention According to Strict Management System Can Normalize Decreased Serum Calcium Level by Denosumab and Prevent Its Aggravation].
    Yoshitaka Saito; Kazuki Uchiyama; Tatsuhiko Sakamoto; Kojiro Yamazaki; Kosei Kubota; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 141, 8, 1023, 1030, 2021年, [国内誌]
    日本語, 研究論文(学術雑誌), Denosumab is a fully monoclonal antibody against the receptor activator of nuclear factor kappa-B ligand (RANKL), and prevents skeletal-related events by bone metastasis. Hypocalcemia is the most typical adverse effect of denosumab use. We have developed a management system for the more efficient and safer management of denosumab administration, and evaluated pharmaceutical interventions for the better control of hypocalcemia. All pharmaceutical interventions in the system from April 2016 to March 2020 were retrospectively evaluated. We have also assessed the incidence of hypocalcemia in 158 patients who were administered denosumab for six months or more in the period. A total of 282 pharmaceutical interventions (7.0% of the total administration) were conducted. The most conducted intervention was regarding hypocalcemia, which involved the suspension of the injection and/or the increase of calcium and vitamin D supplement with 65% adoption and 17% temporary treatment suspensions. Other interventions were about hypercalcemia, request of laboratory examination and ordering supplements, dental consultation, and poor renal function. A total of 199 interventions (70.6%) were adopted, with 33 administrations suspended. The frequency of hypocalcemia was 27.8% with just one patient having grade 2 hypocalcemia, suggesting that there were no severe cases. Moreover, hypocalcemia was significantly normalized following pharmaceutical intervention and/or handling by physicians (p=0.02) according to the system. Conversely, the normalization rate in hypercalcemia did not differ according to the countermeasures. In conclusion, pharmaceutical interventions according to our management system benefit safe denosumab treatment, especially in severe hypocalcemia prevention.
  • Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies.
    Yoshiaki Nakamura; Hiroya Taniguchi; Masafumi Ikeda; Hideaki Bando; Ken Kato; Chigusa Morizane; Taito Esaki; Yoshito Komatsu; Yasuyuki Kawamoto; Naoki Takahashi; Makoto Ueno; Yoshinori Kagawa; Tomohiro Nishina; Takeshi Kato; Yoshiyuki Yamamoto; Junji Furuse; Tadamichi Denda; Hisato Kawakami; Eiji Oki; Takako Nakajima; Naohiro Nishida; Kensei Yamaguchi; Hisateru Yasui; Masahiro Goto; Nobuhisa Matsuhashi; Koushiro Ohtsubo; Kentaro Yamazaki; Akihito Tsuji; Wataru Okamoto; Katsuya Tsuchihara; Takeharu Yamanaka; Izumi Miki; Yasutoshi Sakamoto; Hiroko Ichiki; Masayuki Hata; Riu Yamashita; Atsushi Ohtsu; Justin I Odegaard; Takayuki Yoshino
    Nature medicine, 26, 12, 1859, 1864, 2020年12月, [国際誌]
    英語, 研究論文(学術雑誌), Comprehensive genomic profiling enables genomic biomarker detection in advanced solid tumors. Here, to evaluate the utility of circulating tumor DNA (ctDNA) genotyping, we compare trial enrollment using ctDNA sequencing in 1,687 patients with advanced gastrointestinal (GI) cancer in SCRUM-Japan GOZILA (no. UMIN000016343), an observational ctDNA-based screening study, to enrollment using tumor tissue sequencing in the same centers and network (GI-SCREEN, 5,621 patients). ctDNA genotyping significantly shortened the screening duration (11 versus 33 days, P < 0.0001) and improved the trial enrollment rate (9.5 versus 4.1%, P < 0.0001) without compromising treatment efficacy compared to tissue genotyping. We also describe the clonal architecture of ctDNA profiles in ~2,000 patients with advanced GI cancer, which reinforces the relevance of many targetable oncogenic drivers and highlights multiple new drivers as candidates for clinical development. ctDNA genotyping has the potential to accelerate innovation in precision medicine and its delivery to individual patients.
  • nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients.
    Makoto Ueno; Shoji Nakamori; Kazuya Sugimori; Masashi Kanai; Masafumi Ikeda; Masato Ozaka; Masayuki Furukawa; Takuji Okusaka; Ken Kawabe; Junji Furuse; Yoshito Komatsu; Hiroshi Ishii; Atsushi Sato; Satoshi Shimizu; Priti Chugh; Rui Tang; Tatsuya Ioka
    Cancer medicine, 9, 24, 9396, 9408, 2020年12月, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: In the NAPOLI-1 phase 3 trial, liposomal irinotecan (nal-IRI) +5-fluorouracil/leucovorin (5-FU/LV) significantly increased mPFS versus 5-FU/LV (3.1 vs. 1.5 months [unstratified HR = 0.56, p = 0.0001]) in patients with mPAC that progressed on prior gemcitabine-based therapy. This randomized phase 2 trial evaluated nal-IRI+5-FU/LV tolerability (Part 1), safety, and efficacy (Part 2; outcomes reported here) in Japanese patients with mPAC that progressed on gemcitabine-based therapy. METHODS: Patients were randomized 1:1 and stratified by KPS (70 and 80 vs. ≥90) and baseline albumin (≥4.0 g/dl vs. <4.0 g/dl). Primary endpoint was PFS; secondary endpoints were ORR, DCR, OS, TTF, CA19-9 response, and QoL. The ITT population comprised all randomized patients. RESULTS: Patient characteristics differed between nal-IRI+5-FU/LV (n = 40) and 5-FU/LV (n = 39) arms, including baseline hepatic lesions (63% vs. 51%), stage IV disease at diagnosis (78% vs. 51%), and post-study anticancer therapy (55% vs. 72%). Investigator-assessed mPFS increase with nal-IRI+5-FU/LV was clinically meaningful and statistically significant versus 5-FU/LV (2.7 vs. 1.5 months, HR = 0.60). Independently assessed mPFS showed similar trends (1.7 vs. 1.6 months, HR = 0.79). mOS was 6.3 months with nal-IRI+5-FU/LV and not reached with 5-FU/LV. ORR increased significantly with nal-IRI+5-FU/LV versus 5-FU/LV (18% vs. 0, rate difference 17.5). Commonly reported grade ≥3 treatment-emergent AEs were decreased neutrophil count (37% vs. 3%), decreased white blood cell count (20% vs. 0), and diarrhea (17% vs. 3%). CONCLUSIONS: In conclusion, clinically meaningful and statistically significant gains in investigator-assessed PFS and ORR were observed with nal-IRI+5-FU/LV versus 5-FU/LV in Japanese patients, with no new or unexpected safety signals. (Clinicaltrials.gov ID: NCT02697058).
  • BRAF V600E変異転移性大腸がんにおけるEncorafenib±Binimetinib+Cetuximab併用療法
    吉野 孝之; 加藤 健志; 江崎 泰斗; 高島 淳生; 塩澤 学; 中島 貴子; 竹内 伸司; 佐藤 太郎; 小松 嘉人; 室 圭
    日本癌治療学会学術集会抄録集, 58回, O26, 4, (一社)日本癌治療学会, 2020年10月
    英語
  • FOLFIRI+ラムシルマブ療法におけるインフュージョンリアクションの頻度に関する検討
    賀川 義規; 舛石 俊樹; 三島 沙織; 白数 洋充; 安藤 幸滋; 結城 敏志; 奥山 浩之; 室 圭; 吉野 孝之; 山崎 健太郎; 沖 英次; 小松 嘉人; 辻 晃仁
    日本癌治療学会学術集会抄録集, 58回, O31, 1, (一社)日本癌治療学会, 2020年10月
    日本語
  • Oxaliplatinによる類洞閉塞症候群の診断における腹部超音波検査の有用性の検討
    斎藤 里佳; 西田 睦; 岩井 孝仁; 菊池 穏香; 吉野 裕紀; 横田 勲; 高木 諒; 川本 泰之; 山村 貴洋; 伊藤 憲; 中野 真太郎; 原田 一顕; 結城 敏志; 小松 嘉人; 坂本 直哉
    日本癌治療学会学術集会抄録集, 58回, P, 178, (一社)日本癌治療学会, 2020年10月
    英語
  • 消化管間質腫瘍(GIST)におけるレゴラフェニブ治療と骨格筋量の変化に関する検討
    伊藤 憲; 原田 一顕; 川本 泰之; 中積 宏之; 中野 真太郎; 斎藤 里佳; 山村 貴洋; 結城 敏志; 小松 嘉人; 坂本 直哉
    日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 127回・121回, 62, 62, 日本消化器病学会-北海道支部, 2020年10月
    日本語
  • IRIS/Bev療法時の下痢に対する半夏瀉心湯予防投与の第二相試験 生存期間の解析
    原田 一顕; 中積 宏之; 川本 泰之; 結城 敏志; 石黒 敦; 舘山 美樹; 宮城島 拓人; 中村 路夫; 太宰 昌佳; 奥田 博介; 畑中 一映; 天野 虎次; 小松 嘉人
    日本癌治療学会学術集会抄録集, 58回, P, 122, (一社)日本癌治療学会, 2020年10月
    英語
  • 消化器癌の化学療法で味覚異常を発症した症例の多施設共同医師主導前向き観察研究
    伊藤 憲; 結城 敏志; 中積 宏之; 安藤 孝将; 太宰 昌佳; 畑中 一映; 宮城島 拓人; 久居 弘幸; 石黒 敦; 植田 亮; 佐々木 尚英; 進藤 吉明; 坂本 直哉; 坂田 優; 小松 嘉人
    日本癌治療学会学術集会抄録集, 58回, P, 180, (一社)日本癌治療学会, 2020年10月
    英語
  • 切除不能大腸癌における一次化学療法開始からの生存期間に対する後方治療の影響
    加藤 恭子; 川上 武志; 舛石 俊樹; 川本 泰之; 郷 洋文; 熊西 亮介; 澤田 憲太郎; 結城 敏志; 山本 紘司; 安井 博史; 小松 嘉人; 室 圭; 山中 竹春; 山崎 健太郎
    日本癌治療学会学術集会抄録集, 58回, O25, 3, (一社)日本癌治療学会, 2020年10月
    英語
  • 大腸癌化学療法の治療選択に有用なバイオマーカー 切除不能大腸がんに対するがん薬物療法効果予測バイオマーカーとしてのCMSの意義
    大堀 久詔; 坂本 康寛; 傳田 忠道; 高島 淳生; 高畑 武功; 小松 嘉人; 山口 達郎; 嶋田 顕; 高橋 信; 森田 智視; 石岡 千加史
    日本癌治療学会学術集会抄録集, 58回, WS7, 2, (一社)日本癌治療学会, 2020年10月
    英語
  • Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in Japan.
    Takashi Kitagataya; Goki Suda; Kazunori Nagashima; Takehiko Katsurada; Koji Yamamoto; Megumi Kimura; Osamu Maehara; Ren Yamada; Taku Shigesawa; Kazuharu Suzuki; Akihisa Nakamura; Masatsugu Ohara; Machiko Umemura; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Shunsuke Ohnishi; Yoshito Komatsu; Hiroo Hata; Satoshi Takeuchi; Takashige Abe; Jun Sakakibara-Konishi; Takanori Teshima; Akihiro Homma; Naoya Sakamoto
    Journal of gastroenterology and hepatology, 35, 10, 1782, 1788, 2020年10月, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND AND AIM: Immune checkpoint inhibitors (ICI) have revolutionized anti-malignancy therapy and thus have been increasingly used. Although ICI may cause immune-related adverse events (irAE) in various organs, including the liver, the prevalence and predictive factors of irAE have not been clarified. METHODS: In this retrospective study, consecutive patients who had malignancies and were treated with ICI without other chemotherapeutic agents at Hokkaido University Hospital between 2014 and 2019 were screened. Patients were excluded if they were < 20 years old and had insufficient clinical data. RESULTS: Of the 233 patients screened, 202 patients met the inclusion criteria and were included in the analysis. The patients were aged 25-92 years, and 60.9% were male. The patients received nivolumab (n = 137), pembrolizumab (n = 45), ipilimumab (n = 17), atezolizumab (n = 2), and avelumab (n = 1). The prevalence of any grade and grade ≥ 3 irAE hepatitis was 8.4% (17/202) and 4.0% (8/202), respectively. irAE hepatitis occurred at a median duration of 42 days in any grade and 36 days in grade ≥ 3 after ICI initiation. The clinical course of grade ≥ 3 irAE hepatitis was generally favorable; however, 50% required corticosteroid treatment and two patients required additional mycophenolate mofetil. Female sex and history of ICI treatment were significantly associated with the incidence of grade ≥ 3 irAE hepatitis. CONCLUSIONS: Grade ≥ 3 irAE hepatitis was observed in 4.0% of the patients who were treated with ICI. Female sex and history of ICI treatment were significantly associated with the incidence of grade ≥ 3 irAE hepatitis.
  • Impact of single-heterozygous UGT1A1 on the clinical outcomes of irinotecan monotherapy after fluoropyrimidine and platinum-based combination therapy for gastric cancer: a multicenter retrospective study.
    Shintaro Nakano; Satoshi Yuki; Yasuyuki Kawamoto; Hiroshi Nakatsumi; Takayuki Ando; Shinya Kajiura; Ayumu Yoshikawa; Kazuaki Harada; Kazuteru Hatanaka; Aya Tanimoto; Atsushi Ishiguro; Takuya Honda; Masayoshi Dazai; Takahide Sasaki; Naoya Sakamoto; Yoshito Komatsu
    International journal of clinical oncology, 25, 10, 1800, 1806, 2020年10月, [国内誌]
    英語, 研究論文(学術雑誌), BACKGROUND: It is unclear whether the UGT1A1 status, single heterozygous (SH) or wild type (WT), is associated with the efficacy and toxicity of irinotecan monotherapy in advanced gastric cancer (AGC). We investigated the association between clinical outcomes (efficacy and safety) and UGT1A1 status in patients who received irinotecan monotherapy. METHODS: We evaluated AGC patients who received irinotecan monotherapy between January 2011 and December 2017. Efficacy was assessed according to overall survival (OS) and progression-free survival (PFS). Toxicity was graded using the Common Toxicity Criteria for Adverse Events (version 4.0). RESULTS: A total of 100 patients were evaluated (62 and 38 patients with UGT1A1 WT and SH, respectively). In the WT and SH groups, the irinotecan dose was reduced in 19 (30.6%) and 18 (47.2%) patients (p = 0.135), respectively; treatment was delayed due to adverse events (AEs) in 19 (30.6%) and 13 (34.2%) patients (p = 0.826), respectively; the median PFS was 3.15 and 3.25 months (HR, 0.734; 95% CI 0.465-1.158; p = 0.184), respectively; and the median OS was 10.4 and 7.26 months (HR, 1.137; 95% CI 0.752-1.721; p = 0.543), respectively. Severe hematological AEs (Grade ≥ 3) were significantly more frequent in the SH group than in the WT group (63% vs. 36%; p = 0.008), while severe non-hematological AEs was not significantly different (16.0% vs. 6.5%; p = 0.173). CONCLUSION: There was no significant difference in the efficacy of irinotecan monotherapy between UGT1A1 WT and UGT1A1 SH, but UGT1A1 SH was associated with a high frequency of severe hematological toxicity.
  • Association between the use of antibiotics and efficacy of gemcitabine plus nab-paclitaxel in advanced pancreatic cancer.
    Shintaro Nakano; Yoshito Komatsu; Yasuyuki Kawamoto; Rika Saito; Ken Ito; Hiroshi Nakatsumi; Satoshi Yuki; Naoya Sakamoto
    Medicine, 99, 39, e22250, 2020年09月25日, [国際誌]
    英語, 研究論文(学術雑誌), It is unclear whether the use of antibiotics is related to the efficacy of gemcitabine plus nab-paclitaxel (GnP). Therefore, we investigated the association between the use of antibiotics and efficacy of GnP.We conducted a retrospective single center study from January 2014 to December 2018 in Hokkaido University Hospital.Ninety-nine patients were eligible for the study. Thirty-seven used antibiotics (U) and 62 did not use antibiotics (NU) during GnP therapy. In the U group, 15 patients used β-lactam antibiotics, 21 used new quinolones, and 1 used carbapenem. The median progression-free survival was 5.8 and 2.7 months (hazards ratio [HR] .602, 95% confidence interval [CI] .391-.928, P = .022) and the median overall survival was 11.0 and 8.4 months (HR .768, 95% CI .491-1.202, P = .248) in the U and not use antibiotics groups, respectively. Antibiotic use (HR .489, 95% CI .287-.832, P = .008) and locally advanced pancreatic cancer (HR 1.808, 95% CI 1.051-3.112, P = .032) were independent prognostic factors for progression-free survival.Antibiotic use was associated with a higher efficacy of GnP, and therefore, it may be employed as a novel treatment strategy.
  • 大腸がん薬物療法における免疫チェックポイント阻害薬の役割 マイクロサテライト不安定性のない(MMS)切除可能直腸癌症例に対する術前化学放射線療法(CRT)後の逐次治療としてのニボルマブ(nivo)療法の検討VOLTAGE試験
    加藤 健志; 坂東 英明; 植村 守; 小松 嘉人; 本間 重紀; 塚田 祐一郎; 伊藤 雅昭; 吉野 孝之
    日本大腸肛門病学会雑誌, 73, 9, A50, A50, (一社)日本大腸肛門病学会, 2020年09月
    日本語
  • Clinical impact of a cancer genomic profiling test using an in-house comprehensive targeted sequencing system.
    Hideyuki Hayashi; Shigeki Tanishima; Kyoko Fujii; Ryo Mori; Chihiro Okada; Emmy Yanagita; Yuka Shibata; Ryosuke Matsuoka; Toraji Amano; Takahiro Yamada; Ichiro Yabe; Ichiro Kinoshita; Yoshito Komatsu; Hirotoshi Dosaka-Akita; Hiroshi Nishihara
    Cancer science, 111, 10, 3926, 3937, 2020年08月08日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Precision medicine is a promising strategy for cancer treatment. In this study, we developed an in-house clinical sequencing system to perform a comprehensive cancer genomic profiling test as a clinical examination and analyzed the utility of this system. Genomic DNA was extracted from tumor tissues and peripheral blood cells collected from 161 patients with different stages and types of cancer. A comprehensive targeted amplicon exome sequencing for 160 cancer-related genes was performed using next-generation sequencing (NGS). The sequencing data were analyzed using an original bioinformatics pipeline, and multiple cancer-specific gene alterations were identified. The success rate of our test was 99% (160/161), while re-biopsy was required for 24% (39/161) of the cases. Potentially actionable and actionable gene alterations were detected in 91% (145/160) and 46% (73/160) of the patients, respectively. The actionable gene alterations were frequently detected in PIK3CA (9%), ERBB2 (8%), and EGFR (4%). High tumor mutation burden (TMB) (≥10 mut/Mb) was observed in 12% (19/160) of the patients. The secondary findings in germline variants considered to be associated with hereditary tumors were detected in 9% (15/160) of the patients. Seventeen patients (11%, 17/160) were treated with genotype-matched therapeutic agents, and the response rate was 47% (8/17). The median turnaround time for physicians was 20 days, and the median survival time after the initial visit was 8.7 months. The results of the present study prove the feasibility of implementing in-house clinical sequencing as a promising laboratory examination technique for precision cancer medicine.
  • Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer.
    Masaaki Miyo; Takeshi Kato; Takayuki Yoshino; Takeharu Yamanaka; Hideaki Bando; Hironaga Satake; Kentaro Yamazaki; Hiroya Taniguchi; Eiji Oki; Masahito Kotaka; Koji Oba; Yoshinori Miyata; Kei Muro; Yoshito Komatsu; Hideo Baba; Akihito Tsuji
    BMC cancer, 20, 1, 687, 687, 2020年07月23日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: First-line treatment with FOLFOXIRI plus bevacizumab (BEV) is highly effective and regarded as one of the standards-of-care for patients with metastatic colorectal cancer (mCRC), despite the high incidence of neutropenia and diarrhea as side effects. AXEPT, an Asian phase III study, showed that modified CAPIRI+BEV [capecitabine (CAP: 1600 mg/m2), irinotecan (IRI: 200 mg/m2), and BEV (7.5 mg/m2)] was non-inferior to FOLFIRI+BEV as a second-line therapy for mCRC patients and was associated with a lower incidence of hematologic toxicities. Thus, a reduced dose of the CAP and IRI regimen in combination with oxaliplatin (OX) and BEV (CAPOXIRI+BEV) may be more feasible than FOLFOXIRI+BEV, without compromising efficacy. METHODS: QUATTRO-II is an open-label, multicenter, randomized phase II study. In Step 1, the recommended doses of OX and IRI will be investigated as a safety lead-in. In Step 2, patients will be randomized to the recommended dose of either CAPOXIRI+BEV or FOLFOXIRI+BEV. Induction triplet chemotherapy plus BEV treatments will be administered for up to 4 months followed by fluoropyrimidine plus BEV maintenance. The primary endpoint is progression-free survival (PFS). The similarity in PFS between the two arms will be evaluated by observing whether the point estimate of hazard ratio (HR) for PFS falls between 0.80 and 1.25. Ensuring a 70% probability that the observed HR will be "0.8 < HR < 1.25" under the assumption of the true HR of 1.0, and 100 patients will be evaluated during the 3-year study period. Secondary endpoints include overall survival, overall response rate, safety, and patient reported outcome (PRO) (FACT/GOG-Ntx4). DISCUSSION: Considering the lower incidence of hematologic toxicities with modified CAPIRI+BEV than with FOLFIRI+BEV, CAPOXIRI+BEV may be a promising treatment option if sufficient efficacy and lower hematologic toxicities are indicated in this study. Additionally, a lower incidence of peripheral sensory neuropathy (PSN) reported following CAPEOX treatment compared to that after FOLFOX in ACHIEVE, an adjuvant phase III trial, suggest that CAPOXIRI+BEV can mitigate OX-induced PSN. TRIAL REGISTRATION: Clinicaltrials.gov NCT04097444 . Registered September 20, 2019, https://clinicaltrials.gov/ct2/show/study/NCT04097444 / Japan Registry of Clinical Trials jRCTs041190072. Registered October 9, 2019.
  • Multicenter phase 1/2 Trial of napabucasin and pembrolizumab in patients with metastatic colorectal cancer (EPOC1503/SCOOP Trial).
    Akihito Kawazoe; Yasutoshi Kuboki; Eiji Shinozaki; Hiroki Hara; Tomohiro Nishina; Yoshito Komatsu; Satoshi Yuki; Masashi Wakabayashi; Shogo Nomura; Akihiro Sato; Takeshi Kuwata; Masahito Kawazu; Hiroyuki Mano; Yosuke Togashi; Hiroyoshi Nishikawa; Takayuki Yoshino
    Clinical cancer research : an official journal of the American Association for Cancer Research, 26, 22, 5887, 5894, 2020年07月21日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), PURPOSE: This is a phase 1/2 trial of napabucasin plus pembrolizumab for metastatic colorectal cancer (mCRC). EXPERIMENTAL DESIGN: Phase 1 was conducted to determine the recommended phase 2 dose (RP2D) in a dose escalation design of napabucasin (240mg to 480 mg twice daily) with 200mg pembrolizumab every 3 weeks. Phase 2 included cohort A (n = 10, microsatellite instability high) and cohort B (n = 40, microsatellite stable). The primary endpoint was immune-related objective response rate (irORR). PD-L1 combined positive score (CPS), genomic profiles and the consensus molecular subtypes (CMS) of colorectal cancer were assessed. RESULTS: A total of 55 patients were enrolled in this study. In phase 1, no patients experienced dose-limiting toxicities and napabucasin 480 mg was determined as RP2D. The irORR was 50.0% in cohort A and 10.0% in cohort B. In cohort B, the irORR was 0%, 5.3%, and 42.9% in CPS <1, 1≤ CPS <10 and CPS ≥10, respectively. Patients with objective response tended to have higher tumor mutation burden than those without. Of evaluable 18 patients for CMS classification in cohort B, the irORR was 33.3%, 0%, 33.3% and 33.3% in CMS1, CMS2, CMS3 and CMS4, respectively. The common grade 3 or higher treatment-related adverse events included fever (10.0%) in cohort A and decreased appetite (7.5%) and diarrhea (5.0%) in cohort B. CONCLUSIONS: Napabucasin with pembrolizumab showed anti-tumor activity with acceptable toxicities for MSS mCRC patients as well as MSI-H mCRC, although it did not meet the primary end point.
  • Phase Ib/II Study of Biweekly TAS-102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS study).
    Hironaga Satake; Takeshi Kato; Koji Oba; Masahito Kotaka; Yoshinori Kagawa; Hisateru Yasui; Masato Nakamura; Takanori Watanabe; Toshihiko Matsumoto; Akayuki Kii; Tetsuji Terazawa; Akitaka Makiyama; Nao Takano; Mitsuru Yokota; Yoshihiro Okita; Koreatsu Matoba; Hiroko Hasegawa; Akihito Tsuji; Yoshito Komatsu; Takayuki Yoshino; Kentaro Yamazaki; Hideyuki Mishima; Eiji Oki; Naoki Nagata; Junichi Sakamoto
    The oncologist, 25, 12, e1855-e1863, 2020年07月14日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), LESSONS LEARNED: A biweekly TAS-102 plus BEV schedule in patients with heavily pretreated mCRC showed equivalent efficacy with less toxicity compared with the current schedule of TAS-102 plus BEV combination. Biweekly TAS-102 plus BEV combination could reduce unnecessary dose reduction of TAS-102, maintain higher doses, and possibly be effective even in cases without CIN. The pre-specified subgroup analysis of this study showed an obvious association between CIN within the first two cycles and prognosis of biweekly TAS-102 plus BEV. BACKGROUND: TAS-102 (trifluridine/tipiracil) plus bevacizumab (BEV) combination therapy has shown promising activity in patients with metastatic colorectal cancer (mCRC). However, the previously reported dose and schedule for the TAS-102 (70mg/m2 /day on day 1-5 and 8-12, every 4 weeks) plus BEV (5mg/kg, day1, every 2 weeks) regimen is complicated by severe hematological toxicities and difficult administration schedules. Here, we evaluated the efficacy and safety of a more convenient biweekly TAS-102 plus BEV combination. METHODS: Patients with mCRC who were refractory or intolerant to standard chemotherapies were enrolled. Patients received biweekly TAS-102 (twice daily, on days 1-5, every 2 weeks) with BEV (5mg/kg, day1, every 2 weeks). The primary endpoint was progression-free survival rate at 16 weeks (16-w PFS rate). RESULTS: From October 2017 to January 2018, 46 patients were enrolled. The recommended phase II dose was determined to be TAS-102 (70mg/m2 /day). Of the 44 eligible patients, 16-w PFS rate was 40.9% (95% confidence interval: 26.3% to 56.8%) and the null hypothesis was rejected (p < 0.0001). Median PFS and overall survival was 4.29 months and 10.86 months, respectively. Disease control rate was 59.1%. Common grade 3 or higher adverse events were hypertension (40.9%), neutropenia (15.9%) and leucopenia (15.9%). CONCLUSION: Biweekly TAS-102 plus BEV showed promising anti-tumor activity with safety.
  • Multicenter Cohort Study to Assess the Association between Changes on Imaging and Outcome after Regorafenib Treatment (KSCC1603).
    Eiji Oki; Masahiro Kawahira; Tetsuya Kusumoto; Satoshi Yuki; Kazuteru Hatanaka; Yoshimitsu Kobayashi; Akihiro Nishie; Satoshi Kawanami; Akitaka Makiyama; Hiroshi Saeki; Sanae Sakamoto; Yoshito Komatsu; Mototsugu Shimokawa; Masaki Mori; Taito Esaki
    Oncology, 98, 10, 1, 8, 2020年07月08日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Molecular targeted drugs having angiogenesis-inhibiting properties allow the induction of necrosis inside tumors. We retrospectively investigated the relationship between changes on imaging associated with regorafenib (REGO) and treatment outcomes using real-world data. PATIENTS AND METHODS: The eligibility criteria included an ECOG PS of 0-1, a starting dose of 120 or 160 mg/day of REGO, and a duration of treatment of at least 35 days. Regarding changes on imaging, cavitation in lung lesions (CLL), morphologic response of liver lesions (MRL), and change of liver metastasis density (CLD) were evaluated. RESULTS: We finally screened 671 cases, and 226 cases were eligible. In total, 172 and 145 patients had lung and liver metastases, respectively. Among the patients with lung metastasis, CLL was found in 69 patients (40.0%). The median progression-free survival (PFS) of the patients with and those without CLL was 3.2 and 2.4 months, respectively (hazard ratio [HR] = 0.758; 95% confidence interval [CI]: 0.529-1.087), and the median overall survival (OS) of these groups was 10.5 and 8.9 months, respectively (HR = 0.862; 95% CI: 0.579-1.285). MRL and CLD of liver metastasis were analyzed in 145 and 90 patients, respectively. The median OS with and without MRL was 8.9 and 8.2 months, respectively, whereas the median OS with and without CLD was 11.6 and 7.7 months, respectively (HR = 0.523; 95% CI: 0.275-0.992). CONCLUSION: CLL may predict PFS but not OS among patients with lung metastasis. CLD was predictive of favorable outcomes for REGO in patients with liver metastasis.
  • Correction: A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer.
    Hideaki Bando; Yoshinori Kagawa; Takeshi Kato; Kiwamu Akagi; Tadamichi Denda; Tomohiro Nishina; Yoshito Komatsu; Eiji Oki; Toshihiro Kudo; Hiroshi Kumamoto; Takeharu Yamanaka; Takayuki Yoshino
    British journal of cancer, 122, 8, 1271, 1271, 2020年04月, [国際誌]
    英語, An amendment to this paper has been published and can be accessed via a link at the top of the paper.
  • Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS study.
    Toshikazu Moriwaki; Shota Fukuoka; Toshiki Masuishi; Atsuo Takashima; Yosuke Kumekawa; Takeshi Kajiwara; Kentaro Yamazaki; Taito Esaki; Akitaka Makiyama; Tadamichi Denda; Yukimasa Hatachi; Takeshi Suto; Naotoshi Sugimoto; Masanobu Enomoto; Toshiaki Ishikawa; Tomomi Kashiwada; Eiji Oki; Yoshito Komatsu; Akihito Tsuji; Kenji Tsuchihashi; Daisuke Sakai; Hideki Ueno; Takao Tamura; Kimihiro Yamashita; Yasuhiro Shimada
    International journal of clinical oncology, 25, 4, 614, 621, 2020年04月, [査読有り], [国内誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Although regorafenib or trifluridine/tipiracil (FTD/TPI) has been recognized as a later-line standard treatment in patients with metastatic colorectal cancer (mCRC), not all patients have beneficial outcomes. This study aimed to develop a prognostic scoring system for evaluating the overall survival (OS) benefit. METHODS: Patients included in the REGOTAS study, which comprised 489 patients (regorafenib group: 199; FTD/TPI group: 290 patients), were evaluated. OS was analyzed using multivariate Cox proportional model. The prognostic score was calculated using the worst four individual factors weighted by hazard ratio, and the total scores were categorized as low-, moderate-, and high-OS benefit. RESULTS: The worst four factors in the regorafenib group were AST > 40 IU/dL (point, + 3), CRP ≥ 1.0 mg/dL (+ 2), number of metastatic organ site ≥ 3 (+ 2), and duration from initiation of 1st-line chemotherapy < 18 months (+ 2), while they were AST (+ 2), CRP (+ 2), CA19-9 > 37.0 U/mL (+ 2), and ECOG PS ≥ 1 (+ 2) in the FTD/TPI group. These corresponded to a total prognostic score of > 5, 2-4, and 0 points in the regorafenib group and 8, 2-6, and 0 points in the FTD/TPI group. The median OS in the low, moderate, and high OS benefit group was 3.3 (95% CI 3.0-3.7), 8.1 (95% CI 6.4-9.7), and 12.6 months (95% CI 10.6-14.6) in the regorafenib group and 2.8 (95% CI 2.0-3.5), 7.5 (95% CI 6.6-8.3), and 15.4 months (95% CI 9.7-21.2) in the FTD/TPI group. CONCLUSION: These prognostic scores are useful for identifying patients with mCRC who will obtain survival benefits from these drugs.
  • Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study.
    Akihito Kawazoe; Kensei Yamaguchi; Hisateru Yasui; Yuji Negoro; Mizutomo Azuma; Kenji Amagai; Hiroki Hara; Hideo Baba; Masahiro Tsuda; Hisashi Hosaka; Hisato Kawakami; Takashi Oshima; Yasushi Omuro; Nozomu Machida; Taito Esaki; Kazuhiro Yoshida; Tomohiro Nishina; Yoshito Komatsu; Shi R Han; Shinichi Shiratori; Kohei Shitara
    European journal of cancer (Oxford, England : 1990), 129, 97, 106, 2020年04月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), AIM: The KEYNOTE-659 study evaluated the efficacy and safety of pembrolizumab in combination with chemotherapy as the first-line treatment in Japanese patients with advanced gastric/gastroesophageal junction (G/GEJ) cancer. In this paper, we report results from cohort 1 (S-1 plus oxaliplatin [SOX] with pembrolizumab). METHODS: This was a non-randomised, multicentre, open-label phase IIb study in patients with advanced programmed death-ligand 1 (PD-L1)-positive, human epidermal growth factor receptor 2-negative G/GEJ tumours. The primary endpoint was the objective response rate (ORR) assessed by blinded independent central review (BICR). Secondary endpoints were duration of response (DOR), disease control rate (DCR), time to response (TTR), progression-free survival (PFS), overall survival (OS) and safety. Exploratory analyses were performed based on the PD-L1 combined positive score (CPS) status. RESULTS: Fifty-four patients were evaluated. The median follow-up was 10.1 months. ORR and DCR by BICR were 72.2% (95% confidence interval [CI] 58.4-83.5) and 96.3% (95% CI 87.3-99.5), respectively. Median DOR, TTR, PFS and OS were as follows: not reached, 1.5 months, 9.4 months and not reached. The ORR was 73.9% in patients with CPS ≥1 to <10 and 71.0% in those with CPS ≥10. Grade ≥3 treatment-related adverse events (TRAEs) were reported by 57.4% of patients. The most common grade ≥3 TRAEs were decreased platelet count (14.8%), decreased neutrophil count (13.0%), colitis (5.6%) and adrenal insufficiency (5.6%). CONCLUSIONS: SOX with pembrolizumab showed encouraging efficacy and a manageable safety profile for the first-line treatment of advanced G/GEJ cancer. TRIAL REGISTRATION: NCT03382600/JapicCTI-183829.
  • ペムブロリズマブが奏効した高頻度マイクロサテライト不安定性の肝内胆管癌の1例
    斎藤 里佳; 伊藤 憲; 中野 真太郎; 川本 泰之; 中積 宏之; 結城 敏志; 小松 嘉人; 坂本 直哉
    日本消化器病学会北海道支部例会プログラム・抄録集, 126回, 41, 41, 日本消化器病学会-北海道支部, 2020年03月
    日本語
  • 進行膵癌における化学療法施行例の予後因子解析
    中野 真太郎; 小松 嘉人; 斉藤 里佳; 伊藤 憲; 川本 泰之; 中積 宏之; 結城 敏志; 坂本 直哉
    日本消化器病学会北海道支部例会プログラム・抄録集, 126回, 58, 58, 日本消化器病学会-北海道支部, 2020年03月
    日本語
  • 【肝・胆・膵がんの薬物療法】胆道がん 進行胆道がんに対する分子標的治療薬と免疫チェックポイント阻害薬
    川本 泰之; 小松 嘉人
    腫瘍内科, 25, 2, 159, 166, (有)科学評論社, 2020年02月
    日本語
  • S-1またはカペシタビンを含む標準治療に不応・不耐の胃癌に対するbolus 5-FU/I-LV療法の多施設共同第II相試験 前治療別の解析
    村中 徹人; 小松 嘉人; 結城 敏志; 中野 真太郎; 澤田 憲太郎; 川本 泰之; 中積 宏之; 原田 一顕; 宮城島 拓人; 畑中 一映; 太宰 昌佳; 植田 亮; 笹木 祐介; 辻 靖; 西本 尚樹; 坂田 優; 坂本 直哉
    日本消化管学会雑誌, 4, Suppl., 262, 262, (一社)日本消化管学会, 2020年01月
    日本語
  • Adherence to the guidelines and the pathological diagnosis of high-risk gastrointestinal stromal tumors in the real world
    Toshirou Nishida; Yoshiharu Sakai; Masakazu Takagi; Masato Ozaka; Yuko Kitagawa; Yukinori Kurokawa; Toru Masuzawa; Yoichi Naito; Tatsuo Kagimura; Seiichi Hirota; Takuro Saito; Yoshito Komatsu; Masato Kondo; Tsutomu Hayashi; Naoto Gotoda; Nobuhiro Takiguchi; Atsuhiko Maki; Hideo Baba; Hajime Orita; Hiroshi Yabusaki; Gaku Chiguchi; Dai Manaka; Kazuhito Nabeshima; Hiromitsu Akabane; Koichi Ono; Norihito Wada; Masahide Kaji; Kazuhiro Yoshida; Ikuo Takahashi; Kazumasa Fujitani; Sohei Matsumoto; Yutaka Tamamori; Hiroaki Saito; Shugo Ueda; Masahiro Yamamura; Hirofumi Fujii; Shigefumi Yoshino; Akihiro Suzuki; Eigo Otsuji; Shigeyuki Kawachi; Tsuyoshi Takahashi; Kazuya Muguruma; Suguru Ishikawa; Masaaki Mitsutsuji; Hiroshi Takamori; Takashi Kaiho; Akihiro Sako; Seiji Ito; Masahiro Mori; Makoto Tokuhara; Yoshihiko Kawaguchi; Naoki Hirabayashi; Motohira Yoshida; Masazumi Takahashi; Shiro Takase; Keishi Yamashita; Yoshiaki Iwasaki; Yutaka Ozeki; Yasunori Nishida; Keisuke Koeda; Toshimasa Tsujinaka; Hiroshi Kanie; Shinji Hato; Junya Morimoto; Hiroshi Honda; Hirotaka Tashiro; Yoshihiro Kakeji; Hiroaki Hata; Toshiro Sugiyama; Takayuki Nobuoka; Ryoji Fukushima; Katsuro Sugiyama; Junichi Hasegawa; Tsunehiro Yoshimura; Atsuo Takashima; Chikara Kunisaki; Hiroharu Shinozaki; Naoto Senmaru; Hiroshi Imamura; Satoshi Otsu; Daisuke Kobayashi; Akinori Noguchi; Akinori Takagane; Atsushi Mitsunaga; Shigeyuki Tamura; Jin Matsuyama; Yoshio Oka; Kiyoshi Kajiyama; Takuji Yamada; Sumito Hoshino; Hideki Ohdan; Tomokazu Kakishita; Katsuhiko Yanaga; Yasushi Rino; Takayuki Takahashi; Hisahiro Matsubara; Masahiro Ishizaki; Songtae Kim; Noriyuki Inaki; Noriyuki Hirahara
    Gastric Cancer, 23, 1, 118, 125, 2020年01月01日
    研究論文(学術雑誌)
  • Pharmaceutical Care Contributes to the Advanced Management of Patients Receiving Immune Checkpoint Inhibitors.
    Yoshitaka Saito; Kazuki Uchiyama; Tatsuhiko Sakamoto; Kojiro Yamazaki; Kosei Kubota; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
    Biological & pharmaceutical bulletin, 43, 12, 1969, 1974, 2020年, [国内誌]
    英語, 研究論文(学術雑誌), We previously reported that successive pharmaceutical care by oncology pharmacy specialists contributes to quality outpatient chemotherapy. However, there are a few reports regarding such care during immune checkpoint inhibitors (ICIs) treatment, despite increasing patients being treated with ICIs and the profile of immune-related adverse events being quite different from that of the adverse effects of cytotoxic agents. We retrospectively evaluated the effectiveness of continuous pharmaceutical care in outpatient ICI treatment, focusing especially on the period of providing pharmaceutical recommendations. The adoption rate, efficacy, and period of pharmaceutical interventions, such as prescription questions and pharmaceutical recommendations, were evaluated. A total of 3597 ICI administrations (366 patients) were evaluated. We performed 2625 face-to-face medication counseling. A total of 282 prescription questions and 147 pharmaceutical recommendations were conducted. Approximately 70% of the questions were regarding ordering of laboratory examination, and 86.5% of these questions were adopted. Pharmaceutical recommendations were categorized into medication recommendations (81.1%), examination recommendations (10.8%), and recommendation of expert consultation (8.1%). The adoption rate of pharmaceutical recommendations was 96.0, and 70% of the medication recommendations attenuated the symptoms. Finally, the provision rate of pharmaceutical recommendations was significantly higher in the first 3 months after ICI treatment initiation. We found that pharmaceutical care contributes to an improved quality of outpatient ICI treatment, and face-to-face pharmaceutical counseling up to 3 months after ICI treatment initiation is the most important.
  • BIG BANG study (EPOC1703): multicentre, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy with binimetinib, encorafenib and cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer.
    Daisuke Kotani; Hideaki Bando; Hiroya Taniguchi; Toshiki Masuishi; Yoshito Komatsu; Kensei Yamaguchi; Takako Nakajima; Taroh Satoh; Tomohiro Nishina; Taito Esaki; Shogo Nomura; Koji Takahashi; Shinobu Iida; Seiko Matsuda; Shinya Motonaga; Nozomu Fuse; Akihiro Sato; Satoshi Fujii; Atsushi Ohtsu; Hiromichi Ebi; Takayuki Yoshino
    ESMO open, 5, 1, e000624, 2020年, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: While the BRAF V600E mutation occurs in 5%-15% of metastatic colorectal cancer (mCRC), BRAF non-V600E mutations were recently reported to range from 1.6% to 5.1%. We have previously reported that BRAF non-V600E mutations could have a negative impact on efficacy outcomes as well as BRAF V600E mutation for antiepidermal growth factor receptor (EGFR) antibody treatment for pretreated patients with mCRC. Recently, simultaneous inhibitions of mitogen-activated protein kinase kinase (MEK), BRAF and EGFR exhibited relevant antitumour activities in patients with BRAF V600E mutant and also in BRAF non-V600E mutant but only in the preclinical model. TRIAL DESIGN: The BIG BANG (study is a multicentre, phase II study to assess the efficacy, safety and proof of concept of the combinations of binimetinib+encorafenib+cetuximab in patients with BRAF non-V600E mutated mCRC, identified by either tumour tissue (tumour tissue group) or blood samples (liquid biopsy group). Key eligibility criteria include Eastern Cooperative Oncology Group Performance Status of ≤1, mCRC with BRAF non-V600E mutant and RAS wild type, refractory or intolerant to at least one fluoropyrimidine-based regimen and no prior history of regorafenib, and no prior history of anti-EGFR antibody treatment (primary analysis cohort and liquid biopsy cohort) or refractory to prior anti-EGFR antibody treatment in patients with class 3 BRAF mutations (anti-EGFR antibody refractory class three cohort). Enrolled patients receive binimetinib (45 mg, two times per day), encorafenib (300 mg, once a day) and cetuximab (initially 400 mg/m2 and subsequently 250 mg/m2, once per week). The primary endpoint is the confirmed objective response rate in the primary analysis cohort. TRIAL REGISTRATION NUMBERS: UMIN000031857 and 000031860.
  • Impact of sex and histology on the therapeutic effects of fluoropyrimidines and oxaliplatin plus bevacizumab for patients with metastatic colorectal cancer in the SOFT trial
    Yasuhide Yamada; Kei Muro; Keiichi Takahashi; Hideo Baba; Yoshito Komatsu; Taroh Satoh; Masahiro Goto; Hideyuki Mishima; Masahiko Watanabe; Yuh Sakata; Satoshi Morita; Yasuhiro Shimada; Naruhito Takenaka; Tadashi Hirooka; Kenichi Sugihara
    Global Health & Medicine, 2, 4, 240, 246, National Center for Global Health and Medicine (JST), 2020年, [査読有り], [国内誌]
    英語, 研究論文(学術雑誌), Mechanisms accounting for sex differences in the incidence of adverse events caused by fluoropyrimidine treatments, and histologic differences in efficacy are insufficiently understood. We determined differences between the sexes in terms of the safety of S-1 plus oxaliplatin (SOX)/bevacizumab-versus-l-leucovorin, 5-fluorouracil (5-FU) and oxaliplatin (FOLFOX)/bevacizumab, and the impact of histology on their therapeutic effects, in 512 unresectable metastatic colorectal cancer patients from the SOFT phase III study. Nausea (OR: 2.88, P < 0.001) and vomiting (OR: 3.04, P = 0.005) occurred more frequently in females than males treated with SOX/bevacizumab, while nausea (OR: 2.12, P = 0.006), vomiting (OR: 3.26, P = 0.004), leukopenia (OR: 2.61, P < 0.001), neutropenia (OR: 2.92, P < 0.001), and alopecia (OR: 4.13, P < 0.001) were higher in females on FOLFOX/bevacizumab. Mean relative dose intensities (RDIs) of S-1 during all cycles of SOX/bevacizumab were significantly lower in females (73.9%) than males (81.5%) (P < 0.001), while RDIs of continuous infusion of 5-FU in the FOLFOX/bevacizumab regimen were 75.0% in females and 80.5% in males (P = 0.005). No significant differences in efficacy with regard to overall survival (OS) and progression-free survival (PFS) were identified between the sexes for either SOX/bevacizumab or FOLFOX/bevacizumab treatment. Patients with poorly-differentiated adenocarcinoma had significantly worse OS (HR: 2.72, 95% CI: 1.67-4.44, P < 0.0001) and PFS (HR: 1.89, 95% CI: 1.18-3.02, P = 0.0079) than patients with well- or moderately-differentiated adenocarcinoma. Female patients experienced more frequent and severe adverse reactions to SOX/bevacizumab and FOLFOX/bevacizumab and a worse prognosis for poorly-differentiated adenocarcinoma were confirmed in this phase III study. This warrants further translational research to identify the responsible mechanisms.
  • Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials.
    T Yoshino; J M Cleary; E Van Cutsem; R J Mayer; A Ohtsu; E Shinozaki; A Falcone; K Yamazaki; T Nishina; R Garcia-Carbonero; Y Komatsu; H Baba; G Argilés; A Tsuji; A Sobrero; K Yamaguchi; M Peeters; K Muro; A Zaniboni; N Sugimoto; Y Shimada; Y Tsuji; H S Hochster; T Moriwaki; B Tran; T Esaki; C Hamada; T Tanase; F Benedetti; L Makris; F Yamashita; H-J Lenz
    Annals of oncology : official journal of the European Society for Medical Oncology, 31, 1, 88, 95, 2020年01月, [査読有り], [国際誌]
    英語, BACKGROUND: The phase II J003 (N = 169) and phase III RECOURSE (N = 800) trials demonstrated a significant improvement in survival with trifluridine (FTD)/tipiracil (TPI) versus placebo in patients with refractory metastatic colorectal cancer. This post hoc analysis investigated pharmacokinetic data of FTD/TPI exposure and pharmacodynamic markers, such as chemotherapy-induced neutropenia (CIN) and clinical outcomes. PATIENTS AND METHODS: A total of 210 patients from RECOURSE were enrolled in this substudy. A limited sampling approach was used, with three pharmacokinetic samples drawn on day 12 of cycle 1. Patients were categorized as being above or below the median area under the plasma concentration-time curve (AUC) for FTD and TPI. We conducted a post hoc analysis using the entire RECOURSE population to determine the correlations between CIN and clinical outcome. We then carried out a similar analysis on the J003 trial to validate the results. RESULTS: In the RECOURSE subset, patients in the high FTD AUC group had a significantly increased CIN risk. Analyses of the entire population demonstrated that FTD/TPI-treated patients with CIN of any grade in cycles 1 and 2 had significantly longer median overall survival (OS) and progression-free survival (PFS) than patients who did not develop CIN and patients in the placebo group. Patients who required an FTD/TPI treatment delay had increased OS and PFS versus those in the placebo group and those who did not develop CIN. Similar results were obtained in the J003 cohort. CONCLUSIONS: In RECOURSE, patients with higher FTD drug exposure had an increased CIN risk. FTD/TPI-treated patients who developed CIN had improved OS and PFS versus those in the placebo group and those who did not develop CIN. Similar findings were reported in the J003 cohort, thus validating the RECOURSE results. The occurrence of CIN may be a useful predictor of treatment outcomes for FTD/TPI-treated patients. CLINICALTRIALS. GOV IDENTIFIER: NCT01607957 (RECOURSE). JAPAN PHARMACEUTICAL INFORMATION CENTER NUMBER: JapicCTI-090880 (J003).
  • Multicenter phase II study of SOX plus trastuzumab for patients with HER2+ metastatic or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS 1501B.
    Satoshi Yuki; Katsunori Shinozaki; Tomomi Kashiwada; Tetsuya Kusumoto; Masaaki Iwatsuki; Hironaga Satake; Kazuma Kobayashi; Taito Esaki; Yuichiro Nakashima; Hirofumi Kawanaka; Yasunori Emi; Yoshito Komatsu; Mototsugu Shimokawa; Akitaka Makiyama; Hiroshi Saeki; Eiji Oki; Hideo Baba; Masaki Mori
    Cancer chemotherapy and pharmacology, 85, 1, 217, 223, 2020年01月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Trastuzumab (T-mab) combined with cisplatin and fluoropyrimidines is a standard first-line treatment for HER2+ advanced gastric cancer (AGC). We conducted the first phase II trial among four Japanese study groups to assess the efficacy and safety of T-mab + S-1 and oxaliplatin (T-SOX130) for HER2+ AGC or recurrent gastric cancer. METHODS: Patients with IHC 3+ or IHC 2+/FISH+ tumors received 80 mg/m2 (80-120 mg/day) oral S-1 on days 1-14, 130 mg/m2 intravenous oxaliplatin on day 1, and intravenous T-mab (8 mg/kg loading dose, 6 mg/kg thereafter) on day 1 of a 21-day cycle. The primary endpoint was centrally assessed response rate (RR). Adverse events were based on the Common Terminology Criteria for Adverse Events (CTCAE) Ver.4.0. RESULTS: We enrolled 42 patients from June 2015 to May 2016. Efficacy and safety analyses were conducted for 39 patients. The data cutoff was May 31, 2018. The confirmed RR was 82.1% (32/39; 90% CI 70.0-90.0); the disease control rate was 87.2% (34/39; 95% CI 73.3-94.4). Nine patients underwent curative surgery after T-SOX130. Median Time to treatment failure (TTF), Progression-free survival (PFS) and Overall survival (OS) was 5.7 (95% CI 4.6-7.0), 7.0 (95% CI 5.5-14.1), and 27.6 (95% CI 15.6-Not reached) months, respectively. Incidences of grade 3-4 adverse events > 10% were thrombocytopenia (17.9%), anorexia (17.9%), anemia (12.8%), neutropenia (10.3%), and hyponatremia (10.3%). CONCLUSIONS: T-SOX130 showed promising response and survival with a favorable safety profile and should be considered for patients with HER2+ AGC.
  • 【遺伝子・免疫異常に伴う消化管病変-最新のトピックスを中心に】免疫チェックポイント阻害薬関連消化管病変
    長島 一哲; 桂田 武彦; 大塚 拓也; 西田 睦; 表原 里実; 桜井 健介; 小田切 信介; 山梨 香菜; 小松 嘉人; 三橋 智子; 坂本 直哉
    胃と腸, 54, 13, 1723, 1732, (株)医学書院, 2019年12月
    日本語
  • One-Day Versus Three-Day Dexamethasone in Combination with Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Individual Patient Data-Based Meta-Analysis.
    Okada Y; Oba K; Furukawa N; Kosaka Y; Okita K; Yuki S; Komatsu Y; Celio L; Aapro M
    The oncologist, 24, 12, 1593, 1600, 2019年12月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: A dexamethasone-sparing regimen consisting of palonosetron plus 1-day dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) has been studied previously. Here, we evaluate the noninferiority of the dexamethasone-sparing regimen in overall antiemetic control using a meta-analysis based on individual patient data (IPD). MATERIALS AND METHODS: We conducted a systematic review for randomized trials reporting CINV outcomes for the comparison of palonosetron plus 1-day dexamethasone (d1 arm) versus the same regimen followed by dexamethasone on days 2-3 after chemotherapy (d3 arm) in chemotherapy-naïve adult patients undergoing either moderately emetogenic chemotherapy (MEC) or anthracycline plus cyclophosphamide (AC)-containing chemotherapy. PubMed and MEDLINE were searched electronically. A manual search was also conducted. The primary endpoint was complete response (CR; no emesis and no rescue medication) in the overall 5-day study period. The noninferiority margin was set at -8.0% (d1 arm-d3 arm). RESULTS: Five studies (n = 1,194) were eligible for analysis and all IPD was collected. In the overall study period, the d1 arm showed noninferiority to the d3 arm for CR as well as complete control (pooled risk difference in CR rate - 1.5%, 95% confidence interval [CI] -7.1 to 4.0%, I2 = 0%; in complete control rate - 2.4%, 95% CI -7.7 to 2.9%, I2 = 0%). There was no significant interaction between dexamethasone regimen and risk factors (type of chemotherapy, sex, age, and alcohol consumption). CONCLUSION: This IPD meta-analysis indicates that the dexamethasone-sparing regimen is not associated with a significant loss in overall antiemetic control in patients undergoing MEC or AC-containing chemotherapy, irrespective of known risk factors for CINV. IMPLICATIONS FOR PRACTICE: Although dexamethasone in combination with other antiemetic agents has been used to prevent chemotherapy-induced nausea and vomiting (CINV), it is of clinical importance to minimize total dose of dexamethasone in patients undergoing multiple cycles of emetogenic chemotherapy. This individual-patient-data meta-analysis from five randomized controlled trials (1,194 patients) demonstrated a noninferiority of the dexamethasone-sparing regimen for complete response and complete control of CINV. The outcomes were comparable across patients with different characteristics. These findings thus help physicians minimize use of the steroid and further reduce the burden of dexamethasone-related side effects in patients undergoing multiple consecutive courses of emetogenic chemotherapy.
  • 胸部食道扁平上皮癌に対する術前補助化学療法・根治切除術および根治的化学放射線療法についての後方視的検討
    中積 宏之; 村中 徹人; 川本 泰之; 小松 嘉人; 結城 敏志; 中野 真太郎; 澤田 憲太郎; 坂本 直哉; 打浪 雄介; 田口 大志; 白土 博樹; 海老原 裕磨; 七戸 俊明; 平野 聡
    北海道医学雑誌, 94, 2, 120, 121, 北海道医学会, 2019年11月
    日本語
  • Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer.
    Tetsuya Hamaguchi; Tadamichi Denda; Toshihiro Kudo; Naotoshi Sugimoto; Takashi Ura; Kentaro Yamazaki; Hirofumi Fujii; Takeshi Kajiwara; Takako Eguchi Nakajima; Shin Takahashi; Satoshi Otsu; Yoshito Komatsu; Fumio Nagashima; Toshikazu Moriwaki; Taito Esaki; Takeo Sato; Michio Itabashi; Eiji Oki; Toru Sasaki; Marielle Chiron; Takayuki Yoshino
    Cancer science, 110, 11, 3565, 3572, 2019年11月, [国際誌]
    英語, 研究論文(学術雑誌), Aflibercept plus 5-fluorouracil/levofolinate/irinotecan (FOLFIRI) is a second-line treatment for metastatic colorectal cancer. This ancillary exploratory analysis of data in Japanese people was aimed at exploring the relationship between a set of potential prognostic biomarkers and efficacy endpoints following aflibercept plus FOLFIRI therapy. Sixty-two patients with metastatic colorectal cancer received aflibercept (4 mg/kg) plus FOLFIRI every 2 weeks. Seventy-eight potential protein biomarkers were chosen for analysis based on their roles in angiogenesis, tumor progression, and tumor-stroma interaction. Plasma levels of biomarkers at baseline and at pre-dose 3 (day 1 of treatment cycle 3) were measured in all patients by ELISA. Relationships between these levels and efficacy endpoints were assessed. Ten potential biomarkers had a ±30% change from baseline to pre-dose 3 (adjusted P < .001), with the greatest changes occurring in placental growth factor (median: +4716%) and vascular endothelial growth factor receptor 1 (+2171%). Baseline levels of eight potential biomarkers correlated with overall survival in a univariate Cox regression analysis: extracellular newly identified receptor for advanced glycation end-products binding protein, insulin-like growth factor-binding protein 1, interleukin-8, kallikrein 5, pulmonary surfactant-associated protein D, tissue inhibitor of metalloproteinases 1, tenascin-C, and tumor necrosis factor receptor 2. None correlated with progression-free survival or maximum tumor shrinkage. Pre-dose 3 levels did not correlate with any efficacy endpoints. Preliminary data show that these eight biomarkers could be associated with overall survival. ClinicalTrials.gov identifier: NCT01882868.
  • Impact of tumour growth rate during preceding treatment on tumour response to regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer.
    Toshiki Masuishi; Hiroya Taniguchi; Takeshi Kawakami; Yasuyuki Kawamoto; Shigenori Kadowaki; Yusuke Onozawa; Tetsuhito Muranaka; Masahiro Tajika; Hirofumi Yasui; Hiroshi Nakatsumi; Satoshi Yuki; Kei Muro; Katsuhiro Omae; Yoshito Komatsu; Kentaro Yamazaki
    ESMO open, 4, 6, 2019年11月, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Although regorafenib (REG) and trifluridine/tipiracil (FTD/TPI) have been recognised as standard treatments in metastatic colorectal cancer (mCRC), the best option remains unclear. Pretreatment tumour growth rate (TGR) is associated with radiotherapeutic efficacy in laryngeal cancer. However, no reports are available on the association between TGR during preceding treatment and the efficacy of REG or FTD/TPI. PATIENTS AND METHODS: We retrospectively analysed the data of consecutive mCRC patients treated with REG or FTD/TPI and classified them into slow-growing or rapid-growing (SG or RG) groups according to TGR and emergence of new lesion (NL+) or their absence (NL-) during preceding treatment period [SG: NL- with low TGR (<0.33%/day); RG: NL+ or high TGR (≥0.33%/day)]. RESULTS: A total of 244 patients (RG/SG, 133/111; REG/FTD/TPI, 132/112) were eligible. The RG proportion with a long duration from first-line chemotherapy and the SG proportion with elevated alkaline phosphatase were higher in REG, whereas the SG proportion with performance status 2 was higher in FTD/TPI. The disease control rates (DCRs) were similar between REG and FTD/TPI (24%/30%; OR: 0.74; p=0.44; adjusted OR: 0.73; p=0.47) in the RG, whereas the DCR was significantly higher for FTD/TPI than for REG (47%/26%; OR: 2.56; p=0.029; adjusted OR: 3.38; p=0.01) in the SG. CONCLUSIONS: TGR and NL during preceding treatment may be helpful for drug selection in refractory mCRC patients to be treated with REG or FTD/TPI. However, further studies are needed to confirm the value of TGR for drug selection.
  • Efficacy and safety of TAS-116, an oral inhibitor of heat shock protein 90, in patients with metastatic or unresectable gastrointestinal stromal tumour refractory to imatinib, sunitinib and regorafenib: a phase II, single-arm trial.
    Toshihiko Doi; Yukinori Kurokawa; Akira Sawaki; Yoshito Komatsu; Masato Ozaka; Tsuyoshi Takahashi; Yoichi Naito; Shuichi Ohkubo; Toshirou Nishida
    European journal of cancer (Oxford, England : 1990), 121, 29, 39, 2019年11月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), AIM: We evaluated the efficacy and safety of TAS-116, a novel class of an orally active selective inhibitor of heat shock protein 90, in patients with advanced gastrointestinal stromal tumour (GIST) after failure of three or more lines of standard treatment with imatinib, sunitinib and regorafenib. METHODS: In this single-arm phase II study, patients received 160 mg/day oral TAS-116 for five consecutive days, followed by a 2-day rest. The primary end-point was centrally assessed progression-free survival (PFS). The secondary end-points were objective response rate, disease control rate, overall survival (OS), metabolic response rate, safety, pharmacokinetics and pharmacogenomics. RESULTS: Forty-one patients were enrolled in Japan, and 40 patients underwent efficacy and safety evaluation. At the cut-off date, the median PFS was 4.4 months (95% confidence interval [CI], 2.8-6.0) and 12-week progression-free rate was 73.4% (95% CI, 58.1-88.7). Thirty-four patients (85.0%) had stable disease for ≥ 6 weeks. The median OS was 11.5 months (95% CI, 7.0-not reached). All patients experienced at least one treatment-related adverse event (AE), including diarrhoea (80.0%), decreased appetite (45.0%) and increase in blood creatinine level (42.5%). Grade ≥3 AEs and treatment-related grade ≥3 AEs occurred in 23 (57.5%) and 21 (52.5%) patients, respectively. All AEs resolved after dose modification, and no TAS-116-related AEs led to treatment discontinuation. CONCLUSION: TAS-116 showed significant activity in advanced GIST refractory to standard treatment. Further development of TAS-116 is warranted. TRIAL REGISTRATION: JapicCTI-163182.
  • TRICOLORE試験(大腸癌第3相試験:mFOLFOX6/CapeOX+Bev vs S-1/CPT-11+Bev)のQOL解析
    佐藤 温; 高島 淳生; 傳田 忠道; 蒲生 真紀夫; 高畑 武功; 天貝 賢二; 倉持 英和; 近藤 仁; 的場 周一郎; 有岡 仁; 小松 嘉人; 山口 達郎; 嶋田 顕; 森田 智視; 石岡 千加史
    日本癌治療学会学術集会抄録集, 57回, O38, 1, (一社)日本癌治療学会, 2019年10月
    英語
  • The impact of late-line treatment on overall survival (OS) from the initiation of first-line chemotherapy (CT) for patients (pts) with metastatic colorectal cancer (mCRC)
    T. Kawakami; T. Masuishi; Y. Kawamoto; H. Go; H. Shirasu; K. Kato; R. Kumanishi; K. Sawada; K. Yamamoto; S. Yuki; Y. Komatsu; H. Yasui; K. Muro; T. Yamanaka; K. Yamazaki
    Annals of Oncology, 30, v222, v222, Elsevier BV, 2019年10月
    研究論文(学術雑誌)
  • 経口フッ化ピリミジン不応の胃がんに対するRPMI療法(HGCSG1502試験)OS・QOL解析結果
    太宰 昌佳; 村中 徹人; 川本 泰之; 中積 宏之; 原田 一顕; 宮城島 拓人; 畑中 一映; 植田 亮; 加藤 総介; 笹木 有佑; 結城 敏志; 坂本 直哉; 西本 尚樹; 坂田 優; 小松 嘉人
    日本癌治療学会学術集会抄録集, 57回, P69, 1, (一社)日本癌治療学会, 2019年10月
    英語
  • 転移を有する膵癌に対する化学療法薬剤使用歴と治療成績の関係の検討
    川本 泰之; 斎藤 里佳; 伊藤 憲; 中野 真太郎; 中積 宏之; 結城 敏志; 小松 嘉人; 坂本 直哉
    日本癌治療学会学術集会抄録集, 57回, P86, 7, (一社)日本癌治療学会, 2019年10月
    英語
  • TRICOLORE試験に基づいた転移を有する大腸癌に対する一次治療の費用効果分析
    後藤 励; 高島 淳生; 傳田 忠道; 蒲生 真紀夫; 倉持 英和; 天貝 賢二; 近藤 仁; 杉山 克郎; 中村 路夫; 畑中 一映; 石岡 千加史; 小松 嘉人; 山口 達郎; 嶋田 顕; 森田 智視
    日本癌治療学会学術集会抄録集, 57回, O38, 2, (一社)日本癌治療学会, 2019年10月
    英語
  • 局所進行膵癌における化学療法および化学放射線療法の検討
    中野 真太郎; 小松 嘉人; 川本 泰之; 斎藤 里佳; 伊藤 憲; 中積 宏之; 結城 敏志; 坂本 直哉
    日本消化器病学会北海道支部例会プログラム・抄録集, 125回, 55, 55, 日本消化器病学会-北海道支部, 2019年09月
    日本語
  • mFOLFIRINOX療法にて完全奏効が得られた進行膵癌の2例
    伊藤 憲; 小松 嘉人; 結城 敏志; 中積 宏之; 川本 泰之; 中野 真太郎; 齋藤 里佳
    日本消化器病学会北海道支部例会プログラム・抄録集, 125回, 55, 55, 日本消化器病学会-北海道支部, 2019年09月
    日本語
  • Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors.
    Kohei Shitara; Taroh Satoh; Satoru Iwasa; Kensei Yamaguchi; Kei Muro; Yoshito Komatsu; Tomohiro Nishina; Taito Esaki; Jun Hasegawa; Yasuyuki Kakurai; Emi Kamiyama; Tomoko Nakata; Kota Nakamura; Hayato Sakaki; Ichinosuke Hyodo
    Journal for immunotherapy of cancer, 7, 1, 219, 219, 2019年08月14日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Erythropoietin-producing hepatocellular receptor A2 (EPHA2) is overexpressed on the cell surface in many cancers and predicts poor prognosis. DS-8895a is a humanized anti-EPHA2 IgG1 monoclonal antibody afucosylated to enhance antibody-dependent cellular cytotoxicity activity. We conducted a two-step, phase I, multicenter, open-label study to determine the safety, tolerability, and pharmacokinetics of DS-8895a in patients with advanced solid tumors. METHODS: Step 1 was a dose escalation cohort in advanced solid tumor patients (six dose levels, 0.1-20 mg/kg) to determine Step 2 dosing. Step 2 was a dose expansion cohort in EPHA2-positive esophageal and gastric cancer patients. DS-8895a was intravenously administered every 2 weeks for the duration of the study, with a 28-day period to assess dose-limiting toxicity (DLT). Safety, pharmacokinetics, tumor response, and potential biomarkers were evaluated. RESULTS: Thirty-seven patients (Step 1: 22, Step 2: 15 [9: gastric cancer, 6: esophageal cancer]) were enrolled. Although one DLT (Grade 4 platelet count decreased) was observed in Step 1 (dose level 6, 20 mg/kg), the maximum tolerated dose was not reached; the highest dose (20 mg/kg) was used in Step 2. Of the 37 patients, 24 (64.9%) experienced drug-related adverse events (AEs) including three (8.1%) with Grade ≥ 3 AEs. Infusion-related reactions occurred in 19 patients (51.4%) but were manageable. All patients discontinued the study (evident disease progression, 33; AEs, 4). Maximum and trough serum DS-8895a concentrations increased dose-dependently. One gastric cancer patient achieved partial response and 13 patients achieved stable disease. Serum inflammatory cytokines transiently increased at completion of and 4 h after the start of DS-8895a administration. The proportion of CD16-positive natural killer (NK) cells (CD3-CD56+CD16+) decreased 4 h after the start of DS-8895a administration, and the ratio of CD3-CD56+CD137+ to CD3-CD56+CD16+ cells increased on day 3. CONCLUSIONS: Twenty mg/kg DS-8895a infused intravenously every 2 weeks was generally safe and well tolerated in patients (n = 21) with advanced solid tumors. The exposure of DS-8895a seemed to increase dose-dependently and induce activated NK cells. TRIAL REGISTRATION: Phase 1 Study of DS-8895a in patients with advanced solid tumors ( NCT02004717 ; 7 November 2013 to 2 February 2017); retrospectively registered on 9 December 2013.
  • A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer.
    Hideaki Bando; Yoshinori Kagawa; Takeshi Kato; Kiwamu Akagi; Tadamichi Denda; Tomohiro Nishina; Yoshito Komatsu; Eiji Oki; Toshihiro Kudo; Hiroshi Kumamoto; Takeharu Yamanaka; Takayuki Yoshino
    British journal of cancer, 120, 10, 982, 986, 2019年05月, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: OncoBEAMTM RAS CRC kit using BEAMing technology is a circulating tumour DNA (ctDNA) test for detecting plasma RAS mutational status in metastatic colorectal cancer (mCRC). We conducted a multicentre, prospective study to investigate the concordance of the RAS mutational status between plasma ctDNA and tumour tissue DNA. METHODS: mCRC patients without prior anti-EGFR antibodies or regorafenib treatment were enroled. Plasma- and tissue-based RAS mutational status were determined by BEAMing, respectively. RESULTS: A total of 280 patients from eight institutions were eligible. The overall agreement between plasma- and tissue-based analyses was 86.4%, with a positive percent agreement of 82.1% and negative percent agreement of 90.4%. From logistic regression analysis, lung metastasis alone indicated the most significant factor associated with discordance. The agreement between plasma- and tissue-based analyses was 64.5% in patients with lung metastasis alone (n = 31) indicating lower amount of ctDNA. Among the cases with lung metastasis alone, all plasma- and tissue-based analyses were perfectly concordant in cases with ≥20 mm of maximum lesion diameter or ≥10 lesions. CONCLUSION: The clinical validity of OncoBEAMTM RAS CRC kit was confirmed. Careful attention should be paid for mCRC patients with lung metastases alone having fewer metastases or smaller diameter lesions.
  • Predictive factors for early mortality after initiation of regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer.
    Masuishi, Toshiki; Moriwaki, Toshikazu; Fukuoka, Shota; Takashima, Atsuo; Kumekawa, Yosuke; Kajiwara, Takeshi; Yamazaki, Kentaro; Esaki, Taito; Makiyama, Akitaka; Denda, Tadamichi; Satake, Hironaga; Suto, Takeshi; Sugimoto, Naotoshi; Katsumata, Kenji; Ishikawa, Toshiaki; Kashiwada, Tomomi; Oki, Eiji; Komatsu, Yoshito; Yoshimura, Kenichi; Shimada, Yasuhiro
    JOURNAL OF CLINICAL ONCOLOGY, 37, 15::S, AMER SOC CLINICAL ONCOLOGY, 2019年05月
    英語, 研究論文(国際会議プロシーディングス)
  • Microsatellite instability status in metastatic colorectal cancer and effect of immune checkpoint inhibitors on survival in MSI-high metastatic colorectal cancer.
    Okamoto, Wataru; Nakamura, Yoshiaki; Shiozawa, Manabu; Komatsu, Yoshito; Denda, Tadamichi; Hara, Hiroki; Kagawa, Yoshinori; Narita, Yukiya; Kawakami, Hisato; Esaki, Taito; Nishina, Tomohiro; Izawa, Naoki; Ando, Koji; Moriwaki, Toshikazu; Kato, Takeshi; Nagashima, Fumio; Satoh, Taroh; Nomura, Shogo; Yoshino, Takayuki; Akagi, Kiwamu
    JOURNAL OF CLINICAL ONCOLOGY, 37, 15::S, AMER SOC CLINICAL ONCOLOGY, 2019年05月
    英語, 研究論文(国際会議プロシーディングス)
  • 免疫チェックポイント阻害薬関連大腸炎3例の超音波所見
    表原 里実; 西田 睦; 長島 一哲; 桂田 武彦; 村中 徹人; 小松 嘉人; 澁谷 斉; 秋沢 宏次; 杉田 純一; 豊嶋 崇徳
    超音波医学, 46, Suppl., S650, S650, (公社)日本超音波医学会, 2019年04月
    日本語
  • 下部直腸癌に対する術前治療 切除可能局所進行性直腸癌患者における術前化学放射線療法後のnivolumab単剤療法とその後の広汎切除術に関する多施設共同第Ib/II相研究 VOLTAGE試験(Multicenter phase Ib/II study of nivolumab monotherapy and subsequent radical surgery following pre-operative chemoradiotherapy in patients with resectable locally advanced rectal cancer:VOLTAGE trial)
    塚田 祐一郎; 坂東 英明; 稲守 宏治; 佐々木 剛志; 西澤 祐吏; 若林 将史; 小嶋 基寛; 結城 敏志; 小松 嘉人; 吉田 雅; 市川 伸樹; 本間 重紀; 畑中 豊; 松野 吉宏; 植村 守; 三宅 正和; 加藤 健志; 関本 貢嗣; 佐藤 暁洋; 伊藤 雅昭; 吉野 孝之
    日本外科学会定期学術集会抄録集, 119回, PD, 7, (一社)日本外科学会, 2019年04月
    英語
  • Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy.
    Harada K; Okamoto W; Mimaki S; Kawamoto Y; Bando H; Yamashita R; Yuki S; Yoshino T; Komatsu Y; Ohtsu A; Sakamoto N; Tsuchihara K
    BMC cancer, 19, 1, 255, 255, 2019年03月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: In the era of genome-guided personalized cancer treatment, we must understand chemotherapy-induced genomic changes in tumors. This study evaluated whether adjuvant FOLFOX chemotherapy modifies the mutational profile of recurrent colorectal cancer (CRC). METHODS: Whole exome sequencing was performed on samples from primary CRC tumors, untreated metastatic tumors, and recurrent tumors following adjuvant FOLFOX chemotherapy. The samples were resected from four patients. RESULTS: The number of mutations or the mutation spectrum in individual patients was nearly identical. Copy number variants persisted regardless of FOLFOX therapy administration. The genomic signature of oxaliplatin exposure (G > T/C > A, T > A/A > T) was not enriched after FOLFOX chemotherapy. Overlapping single nucleotide variants (SNVs) and indels remained in 26-65% of the patient-matched tumor samples. One patient harbored an AKT1 E17K mutation in the recurrent tumor, whereas PIK3CA E542K and E88Q mutations were detected in the primary and untreated metastatic tumor samples. Genes related to intracellular Ca2+ homeostasis were enriched among the genes uniquely mutated after FOLFOX chemotherapy. CONCLUSIONS: We found that the mutation rates, mutation spectrum, and copy number variants were nearly identical regardless of the administration of FOLFOX therapy in the four CRC cases. The mutational discordance between the patient-matched tumor samples is likely caused by tumor heterogeneity and chemotherapy-induced clonal selection. These findings might be useful as pilot data for larger studies to clarify the changes in the mutational landscape induced by adjuvant FOLFOX chemotherapy.
  • Treatment guidelines
    Muranaka Tetsuhito; Yoshito Komatsu
    Gastrointestinal Stromal Tumor: Research and Practice, 79, 87, Springer Singapore, 2019年02月20日
    英語, 論文集(書籍)内論文
  • Rationale and design of the BRAVERY study (EPOC1701): a multicentre phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer.
    Masuishi T; Taniguchi H; Kotani D; Bando H; Komatsu Y; Shinozaki E; Nakajima TE; Satoh T; Nishina T; Esaki T; Wakabayashi M; Nomura S; Takahashi K; Ono H; Hirano N; Fujishiro N; Fuse N; Sato A; Ohtsu A; Yoshino T
    ESMO open, 4, 6, e000590, 2019年, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Background: BRAF V600E mutations are associated with aggressive biology and limited response to standard chemotherapy, especially during second-line and beyond therapies. BRAF V600E mutant and wild-type colorectal cancers (CRCs) differ in their expression profiles, and preclinical evidence suggests that microtubule inhibitors have an antitumour effect on xenograft models of BRAF V600E mutant CRCs. Eribulin has the best growth inhibitory activity in vitro of the microtubule inhibitors. Also, we have evidenced a hint of activity for patients with BRAF V600E mutant metastatic CRC (mCRC) with tumour shrinkage following eribulin treatment. Trial design: The BRAVERY study is a multicentre phase II study to evaluate the efficacy and safety of eribulin in patients with BRAF V600E mutant mCRC detected in either tumour tissues (primary analysis part) or circulating tumour DNA assays (liquid biopsy part). Key eligibility criteria are refractoriness and intolerance to at least one regimen (including irinotecan or oxaliplatin) containing fluoropyrimidine and Eastern Cooperative Oncology Group performance status of 0-1. Eribulin is to be administered intravenously at a dose of 1.4 mg/m2 on days 1 and 8 and repeated every 21 days. The primary endpoint is the confirmed objective response rate (ORR) by investigator's assessment. We calculated the sample size of the primary analysis part at 27 patients using a two-stage design with 25% ORR deemed promising and 5% unacceptable (one-sided α, 0.05; β, 0.1). Secondary endpoints include disease control rate, progression-free survival, overall survival and adverse events. Moreover, we will collect pretreated tissue and serial blood samples for biomarker analyses, focusing on gene expression associated with BRAF mutant-like CRC to find predictive markers and acquired gene alterations to detect resistance mechanisms to eribulin. We initiated patient enrolment in March 2018, completed the primary analysis on May 2019, and are currently continuing with the liquid biopsy part. Trial registration number: UMIN000031221 and 000031552.
  • Large-Scale, Prospective Observational Study of Regorafenib in Japanese Patients with Metastatic Colorectal Cancer in a Real-World Clinical Setting.
    Yamaguchi K; Komatsu Y; Satoh T; Uetake H; Yoshino T; Nishida T; Yamazaki N; Takikawa H; Morimoto T; Chosa M; Sunaya T; Hamada Y; Muro K; Sugihara K
    The oncologist, 24, 7, e450-e457, 2019年01月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Regorafenib improved the overall survival (OS) of patients with metastatic colorectal cancer (mCRC) who progress after standard therapies in two phase III trials. The present large-scale prospective observational study evaluated the safety and effectiveness of regorafenib administered to Japanese patients with mCRC in real-life setting. MATERIALS AND METHODS: Patients with mCRC were prospectively registered and initially received ≤160 mg oral regorafenib daily, at the investigator's discretion, for weeks 1-3 of each 4-week cycle. The study's primary aim was to assess safety, particularly unexpected clinically significant adverse drug reactions (ADRs). A Cox's proportional hazards model was used to evaluate the association between OS, hand-foot skin reaction (HFSR), and baseline characteristics. RESULTS: We evaluated 1,227 of 1,301 patients (enrolled from March 2013 to May 2015). ADRs occurred in 89.3% of patients (mostly within the first 4 weeks) and were a major reason for discontinuing treatment. The most frequent ADRs were HFSR, liver injury, and hypertension. The cumulative incidence of HFSR and liver injury was higher in patients who initially received 160 mg than in those who received ≤120 mg. The incidence of hypertension and fatigue was similar between groups. Median OS was 6.9 months (95% confidential interval, 6.4-7.4). OS was associated with early onset of HFSR and good performance status (PS) but not with the initial dose. CONCLUSION: The outcomes of this study were consistent with those of clinical trials. There were no new safety concerns. Regorafenib treatment would not be recommended for patients with higher PS. IMPLICATIONS FOR PRACTICE: Previous clinical trials demonstrated regorafenib improved overall survival in patients with metastatic colorectal cancer who progress after standard chemotherapies. Because the eligibility criteria of the trials were restricted compared with a real-world setting, the data from the trials may not fully represent the profiles of regorafenib in clinical practice. This large-scale observational study showed that the safety and effectiveness of regorafenib in clinical practice were generally consistent with previous trials. The majority of patients reported adverse drug reactions within the first 4 weeks, most commonly hand-foot skin reaction. Regorafenib treatment would not be recommended for patients with higher performance status.
  • Phase II trial of aflibercept with FOLFIRI as a 2nd-line treatment for Japanese patients with metastatic colorectal cancer.
    Denda T; Sakai D; Hamaguchi T; Sugimoto N; Ura T; Yamazaki K; Fujii H; Kajiwara T; Nakajima TE; Takahashi S; Otsu S; Komatsu Y; Nagashima F; Moriwaki T; Esaki T; Sato T; Itabashi M; Oki E; Sasaki T; Sunaga Y; Ziti-Ljajic S; Brillac C; Yoshino T
    Cancer science, 110, 3, 1032, 1043, 2019年01月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Aflibercept targets vascular endothelial growth factor. The present study involved assessing the efficacy, safety and pharmacokinetics of aflibercept plus 5-fluorouracil/levofolinate/irinotecan (FOLFIRI) as a second-line treatment for metastatic colorectal cancer (mCRC) in Japanese patients. Aflibercept (4 mg/kg) plus FOLFIRI was administered every 2 weeks in 62 patients with mCRC until disease progression, unacceptable toxicity or patient withdrawal. Tumors were imaged every 6 weeks. The primary endpoint was objective response rate (ORR); secondary endpoints were progression-free survival, overall survival, safety, and pharmacokinetics of aflibercept, irinotecan and 5-fluorouracil. A total of 60 patients were evaluated for ORR; 50 had received prior bevacizumab. The ORR was 8.3% (95% confidence interval [CI]: 1.3%-15.3%), and the disease control rate (DCR) was 80.0% (69.9%-90.1%). The median progression-free survival was 5.42 months (4.14-6.70 months) and the median overall survival was 15.59 months (11.20-19.81 months). No treatment-related deaths were observed, and no significant drug-drug interactions were found. The most common treatment-emergent adverse events were neutropenia and decreased appetite. Free aflibercept had a mean maximum concentration (coefficient of variation) of 73.2 μg/mL (15%), clearance of 0.805 L/d (22%) and volume of distribution of 6.2 L (18%); aflibercept bound with vascular endothelial growth factor had a clearance of 0.162 L/d (9%) (N = 62). Aflibercept did not significantly affect the pharmacokinetics of irinotecan or 5-fluorouracil: The clearance was 11.1 L/h/m2 (28%) for irinotecan and, at steady state, 72.6 L/h/m2 (56%) for 5-fluorouracil (N = 10). Adding aflibercept to FOLFIRI was shown to be beneficial and well-tolerated in Japanese patients with mCRC. ClinicalTrials.gov Identifier: NCT01882868.
  • Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer.
    Kenji Tsuchihashi; Mamoru Ito; Toshikazu Moriwaki; Shota Fukuoka; Hiroya Taniguchi; Atsuo Takashima; Yosuke Kumekawa; Takeshi Kajiwara; Kentaro Yamazaki; Taito Esaki; Akitaka Makiyama; Tadamichi Denda; Hironaga Satake; Takeshi Suto; Naotoshi Sugimoto; Kenji Katsumata; Toshiaki Ishikawa; Tomomi Kashiwada; Eiji Oki; Yoshito Komatsu; Hiroyuki Okuyama; Daisuke Sakai; Hideki Ueno; Takao Tamura; Kimihiro Yamashita; Junji Kishimoto; Yasuhiro Shimada; Eishi Baba
    Clinical colorectal cancer, 17, 4, e687-e697, 2018年12月, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Assessment of patient factors is essential for selecting later-line chemotherapy in patients with metastatic colorectal cancer (mCRC). The efficacy, prognosis, and safety of each treatment regimen according to nutritional and inflammatory status still remain to be elucidated. PATIENTS AND METHODS: A total of 550 patients with mCRC who were registered in the REGOTAS study (Regorafenib versus TAS-102 as Salvage-line in patients with colorectal cancer refractory to standard chemotherapies: a multicenter observational study, UMIN 000020416) and treated with trifluridine/tipiracil (TFTD) or regorafenib as a later-line therapy were retrospectively stratified according to the modified Glasgow Prognostic Score (mGPS), which divided patients into mGPS 0 to 2 by serum albumin and C-reactive protein, and compared. RESULTS: The median overall survival (OS) of patients with mGPS 0, 1, and 2 was 10.0 months (95% confidence interval [CI], 9.2-11.6 months), 6.5 months (95% CI, 5.3-7.1 months), and 3.9 months (95% CI, 3.3-4.9 months), respectively. The median progression-free survival (PFS) with mGPS 0, 1, and 2 was 2.5 months (95% CI, 2.1-3.0 months), 2.0 months (95% CI, 1.9-2.3 months), and 1.7 months (95% CI, 1.4-1.9 months), respectively. There were significant differences by mGPS in both OS and PFS (all P < .001). No significant differences in OS and PFS were observed between the patient groups treated with TFTD and regorafenib in each mGPS group. In patients aged ≥ 65 years with mGPS 2, the OS and PFS were worse with regorafenib than with TFTD (OS: hazard ratio, 1.45; 95% CI, 0.93-2.25; P = .097; PFS: hazard ratio, 1.57, 95% CI, 1.01-2.44; P = .047), but there were no consistent trends observed as mGPS increased. The frequency of grade 3 and more adverse events was generally similar in each mGPS group. The multivariate analyses showed that mGPS was the strongest predictive factor for OS. CONCLUSIONS: The mGPS before later-line chemotherapy is strongly correlated with survival in patients with mCRC.
  • Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial.
    Doi T; Iwasa S; Muro K; Satoh T; Hironaka S; Esaki T; Nishina T; Hara H; Machida N; Komatsu Y; Shimada Y; Otsu S; Shimizu S; Watanabe M
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 22, 4, 817, 827, 2018年12月, [査読有り], [国内誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Avelumab is a human anti-PD-L1 IgG1 monoclonal antibody that has shown antitumor activity in several advanced cancers. We report results from JAVELIN Solid Tumor JPN, a phase 1 trial of avelumab in Japanese patients with advanced solid tumors with expansion in patients with advanced gastric cancer/gastroesophageal junction cancer. METHODS: In the dose-escalation part, eligible patients had various previously treated metastatic or advanced solid tumors. In the dose-expansion part, patients had stage IV gastric cancer/gastroesophageal junction adenocarcinoma and disease progression after prior therapy that included a platinum and fluoropyrimidine agent. Patients received avelumab every 2 weeks intravenously at 3, 10, or 20 mg/kg during dose escalation and 10 mg/kg during dose expansion. RESULTS: Among 17 patients who received avelumab in the dose-escalation part, no dose-limiting toxicities occurred, and the maximum tolerated dose was not reached. 40 patients were enrolled in the dose-expansion part, of whom 21 (52.5%) had received ≥ 3 prior lines of therapy for advanced disease. In these patients, the objective response rate was 10.0% (95% CI, 2.8-23.7%) and median overall survival was 9.1 months (95% CI, 7.2-11.2 months). Three of 40 patients (7.5%) had a grade 3 treatment-related adverse event (alanine aminotransferase increase, anemia, and hyponatremia), and no grade ≥ 4 treatment-related adverse events occurred. Five patients (12.5%) had an immune-related adverse event (all grade 1/2). CONCLUSIONS: Avelumab showed acceptable safety in Japanese patients with advanced solid tumors and clinical activity in patients with advanced gastric cancer/gastroesophageal junction cancer and disease progression after chemotherapy.
  • A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy re
    Kato K; Satoh T; Muro K; Yoshikawa T; Tamura T; Hamamoto Y; Chin K; Minashi K; Tsuda M; Yamaguchi K; Machida N; Esaki T; Goto M; Komatsu Y; Nakajima TE; Sugimoto N; Yoshida K; Oki E; Nishina T; Tsuji A; Fujii H; Kunieda K; Saitoh S; Omuro Y; Azuma M; Iwamoto Y; Taku K; Fushida S; Chen LT; Kang YK; Boku N
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 22, 2, 344, 354, 2018年12月, [査読有り], [国内誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Nivolumab, an anti-programmed death-1 agent, showed survival benefits in Asian patients, including Japanese, with gastric/gastro-esophageal junction (G/GEJ) cancer. We report the analysis of the Japanese subpopulation from ATTRACTION-2 that evaluated nivolumab versus placebo in unresectable advanced or recurrent G/GEJ cancer after ≥ 2 chemotherapy regimens. METHODS: Data from the Japanese subpopulation in the randomized, double-blind, placebo-controlled, phase 3 trial were analyzed (data cutoff, February 25, 2017). Primary endpoint was overall survival (OS); secondary endpoints included progression-free survival (PFS) and objective response rate (ORR). RESULTS: Among the overall study population of 493 patients, 226 (nivolumab 152; placebo 74) were enrolled from 28 sites in Japan. In the Japanese subset, median OS was longer with nivolumab versus placebo (5.4 months, 95% CI 4.6-7.4 versus 3.6 months, 95% CI 2.8-5.0). The risk of death was lower in the nivolumab versus placebo group (hazard ratio 0.58, 95% CI 0.42-0.78; p = 0.0002). Incidences of serious adverse events were 23% (35/152) and 25% (18/72) in the nivolumab and placebo groups, respectively. In the Japanese ITT population, 22% of nivolumab-treated and 28% of placebo-treated patients received prior ramucirumab treatment. Overall, clinical activity of nivolumab was observed regardless of prior ramucirumab use. In the nivolumab group, ORR and PFS were numerically higher in patients with prior ramucirumab use than in those without. CONCLUSIONS: In the Japanese subpopulation, patients receiving nivolumab had longer OS, similar to the overall population, with a manageable safety profile. The interaction between nivolumab and ramucirumab will be clarified in ongoing clinical trials.
  • 外来化学療法におけるがん専門薬剤師による長期継続的な薬学的患者管理の有用性の検討
    齋藤 佳敬; 原田 幸子; 小林 正紀; 植田 孝介; 山崎 浩二郎; 熊井 正貴; 宮本 剛典; 笠師 久美子; 山田 武宏; 小松 嘉人; 井関 健
    薬学雑誌, 138, 11, 1409, 1416, (公社)日本薬学会, 2018年11月, [査読有り], [国内誌]
    日本語, 研究論文(学術雑誌), がん専門薬剤師による外来がん化学療法施行患者に対する長期継続的な薬学的管理の有用性について評価した。当院にてがん専門薬剤師が専従配置された2016年5月から2017年5月を各種調査期間に設定し、疑義照会数及び処方提案数、それらの内訳や実施時期について検討した。治療当日に実施された疑義照会件数は約25〜50件/月で変動し、処方提案件数は概ね経時的に増加した。がん専門薬剤師専従配置後の疑義照会は、必要薬剤の処方漏れ、治療当日の患者の検査値用量、治療レジメン内容に関するものの順で多く、疑義照会による処方変更率は約73%であった。一方、処方提案については、悪心・嘔吐、皮膚障害、口内炎、排便コントロールに関するものの順で多く、その採択率は約98%であった。全処方に占める全薬学的介入件数は、専従配置以前(2015年4月〜2016年4月)に対し、専従配置後で有意に増加した。また、提案薬剤による該当症状の改善効果は、約70%の症例で認められた。がん専門薬剤師専従配置後における薬学的介入の実施時期について検討すると、全薬学的介入のうち初回・2回目治療時に実施されたものが約40%を占め、約60%の薬学的介入が治療3回目以降に、約20%が治療10回以降に実施された。処方提案に関しては、3回目以降の治療時に実施されたものが約半数を占め、6回目以降の治療時に実施されたものが約20%認められた。
  • 外来化学療法におけるがん専門薬剤師による長期継続的な薬学的患者管理の有用性の検討
    齋藤 佳敬; 原田 幸子; 小林 正紀; 植田 孝介; 山崎 浩二郎; 熊井 正貴; 宮本 剛典; 笠師 久美子; 山田 武宏; 小松 嘉人; 井関 健
    薬学雑誌, 138, 11, 1409, 1416, (公社)日本薬学会, 2018年11月
    日本語, It is important that pharmacists ensure safe chemotherapy implementation. In addition to inspecting chemotherapeutic prescriptions according to patient condition and drug-drug interactions, the management of chemotherapy-induced adverse effects and associated pharmaceutical intervention is one of the most important responsibilities of pharmacists in medical care teams. In May 2016, an oncology pharmacist was set responsible for the specialized, long-term, and successive pharmaceutical care, including instructions about appropriate use of medication at an outpatient chemotherapy center. We evaluated the effectiveness of the continuous pharmaceutical care. The number of medication counseling and associated pharmaceutical interventions increased with time. Specifically, the number of pharmaceutical interventions (prescription questions and pharmaceutical proposals) was 745 (459 and 286, respectively) in the surveillance period, which significantly increased compared to that observed within the same duration before posting an oncology pharmacist. The adoption rate was approximately 70% for prescription questions and 98% for pharmaceutical proposals. We also found that approximately 70% of the proposals attenuated the painful symptoms. Furthermore, approximately 60% of all pharmaceutical interventions were established after the third visit; in particular, approximately 20% of the pharmaceutical proposals were suggested after the sixth visit, indicating that continuous medication counseling results in an increase in pharmaceutical proposals. In conclusion, long-term and successive pharmaceutical care by oncology pharmacy specialists in outpatient chemotherapy contributes to a safe and less onerous chemotherapy implementation, as it has been highly adopted, is effective in many cases, and has been proven to be important for risk management in chemotherapy.
  • TRICOLORE追跡結果 大腸癌一次治療のS-1/CPT-11+Bevの有用性を検証する第3相試験
    高橋 信; 沖田 南津子; 傳田 忠道; 蒲生 真紀夫; 中村 路夫; 杉山 克郎; 岩指 元; 武藤 理; 佐藤 敏彦; 濱田 和幸; 小松 嘉人; 山口 達郎; 嶋田 顕; 森田 智視; 石岡 千加史
    日本癌治療学会学術集会抄録集, 56回, O47, 1, (一社)日本癌治療学会, 2018年10月
    英語
  • The Effect of Everolimus on Refractory Hypoglycemia in a Patient with Inoperable Metastatic Insulinoma Evaluated by Continuous Glucose Monitoring.
    Yanagiya S; Cho KY; Nakamura A; Nomoto H; Kawamoto Y; Kawakubo K; Komatsu Y; Mitsuhashi T; Miyoshi H; Atsumi T
    Internal medicine (Tokyo, Japan), 57, 17, 2527, 2531, 2018年09月, [査読有り], [国内誌]
    英語, 研究論文(学術雑誌), An 84-year-old Japanese woman with metastatic insulinoma suffered from frequent hypoglycemic events. Continuous glucose monitoring (CGM) confirmed severe and frequent symptomatic/asymptomatic hypoglycemia. After the initiation of everolimus treatment, the hypoglycemic events were rapidly eliminated. CGM revealed that her blood glucose levels were maintained without hypoglycemia throughout the day. Furthermore, everolimus reduced the duration of time above the upper limit (>180 mg/dL) along with the standard deviation and mean amplitude of glycemic excursions. This case shows the potential effects of everolimus on hypoglycemia and glycemic control in a patient with inoperable metastatic insulinoma evaluated by CGM.
  • Prognostic and Predictive Value of HER2 Amplification in Patients With Metastatic Colorectal Cancer.
    Sawada K; Nakamura Y; Yamanaka T; Kuboki Y; Yamaguchi D; Yuki S; Yoshino T; Komatsu Y; Sakamoto N; Okamoto W; Fujii S
    Clinical colorectal cancer, 17, 3, 198, 205, 2018年09月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), PURPOSE: To evaluate a prognostic and predictive value of HER2 amplification in patients with metastatic colorectal cancer (mCRC). PATIENTS AND METHODS: Patients with mCRC who underwent surgical resection of the primary tumor and who received best supportive care with or without palliative chemotherapy between 2005 and 2015 were included. HER2 immunohistochemistry was performed using formalin-fixed, paraffin-embedded primary tumor specimens. HER2 amplification was confirmed by fluorescence in-situ hybridization. The RAS and BRAFV600E mutations were centrally assessed using a PCR-based method. Patients were divided into 4 subgroups: R (RAS mutant), B (BRAFV600E mutant), H (wild-type RAS/BRAF with HER2 amplification), and W (wild-type RAS/BRAF without HER2 amplification). Overall survival (OS) and progression-free survival of anti-epidermal growth factor receptor (EGFR) therapy were assessed. RESULTS: Among 370 eligible patients, data of 359 were successfully analyzed. Fifteen tumors harbored HER2 amplifications, including 4 tumors with concomitant RAS mutation (group R). The number of patients in groups R, B, H, and W was 204, 13, 11, and 131, respectively. The median OS was 27.4 months, and the median follow-up time was 63.2 months. The median OS for groups R, B, H, and W was 24.0, 14.2, 19.9, and 39.1 months, respectively. The number of patients who received anti-EGFR therapy in groups R, B, H, and W was 17, 4, 5, and 49, respectively. Progression-free survival of anti-EGFR therapy was significantly shorter in groups R, B, and H than in group W. CONCLUSION: HER2 amplification was predictive of anti-EGFR therapy response and appeared to be prognostic in mCRC patients.
  • Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
    Kohei Shitara; Mustafa Özgüroğlu; Yung-Jue Bang; Maria Di Bartolomeo; Mario Mandalà; Min-Hee Ryu; Lorenzo Fornaro; Tomasz Olesiński; Christian Caglevic; Hyun C Chung; Kei Muro; Eray Goekkurt; Wasat Mansoor; Raymond S McDermott; Einat Shacham-Shmueli; Xinqun Chen; Carlos Mayo; S Peter Kang; Atsushi Ohtsu; Charles S Fuchs; Guillermo Lerzo; Juan Manuel O'Connor; Guillermo Ariel Mendez; James Lynam; Niall Tebbutt; Mark Wong; Andrew Strickland; Chris Karapetis; David Goldstein; Paul Vasey; Jean-Luc Van Laethem; Eric Van Cutsem; Scott Berry; Mark Vincent; Bettina Muller; Felipe Rey; Angela Zambrano; Joaquin Guerra; Merete Krogh; Lene Baeksgaard; Mette Yilmaz; Anneli Elme; Andrus Magi; Paivi Auvinen; Tuomo Alanko; Markus Moehler; Volker Kunzmann; Thomas Seufferlein; Peter Thuss-Patience; Thomas Hoehler; Georg Haag; Salah-Eddin Al-Batran; Hugo Castro; Karla Lopez; Mynor Aguilar Vasquez; Mario Sandoval; Ka On Lam; Sinead Cuffe; Cathy Kelly; Ravit Geva; Ayala Hubert; Alex Beny; Baruch Brenner; Aprile Giuseppe; Alfredo Falcone; Evaristo Maiello; Rodolfo Passalacqua; Vincenzo Montesarchio; Hiroki Hara; Keisho Chin; Tomohiro Nishina; Yoshito Komatsu; Nozumo Machida; Shuichi Hironaka; Taroh Satoh; Takao Tamura; Naotaoshi Sugimoto; Haruhiko Cho; Yashushi Omuro; Ken Kato; Masahiro Goto; Ichinosuke Hyodo; Kazuhiro Yoshida; Hideo Baba; Taito Esaki; Junji Furuse; Wan Zamaniah Wan Mohammed; Carlos Hernandez Hernandez; Juan Casas Garcia; Adriana Dominguez Andrade; Katriona Clarke; Geir Hjortland; Nils Glenjen; Tomasz Kubiatowski; Jassem Jacek; Marek Wojtukiewicz; Sergey Lazarev; Yuri Lancukhay; Sergey Afanasayev; Vladimir Moiseyenko; Vladimir Kostorov; Svetlana Protsenko; Vadim Shirinkin; Dina Sakaeva; Natalia Fadeeva; Wei Peng Yong; Chau Hsien Matthew Ng; Barbara Robertson; Bernardo Rapaport; Graham Cohen; Lydia Dreosti; Paul Ruff; Conrad Jacobs; Gregory Landers; Waldemar Szpak; Sang-Young Roh; Jeeyun Lee; Yeul Hong Kim; Yung-Jue Bang; Min-Hee Ryu; Maria Alsina Maqueda; Federico Longo Munoz; Andres Cervantes Aguilar; Enrique Aranda Aguilar; Pilar Garcia Alfonso; Fernando Rivera; Jaime Feliu Batle; Roberto Pazo Cid; Kun-Huei Yeh; Jen-Shi Chen; Yee Chao; Chia-Jui Yen; Mustafa Özgüroğlu; Oguz Kara; Suayib Yalcin; Daniel Hochhauser; Ian Chau; Al Benson; Veena Shankaran; Walid Shaib; Philip Philip; Vivek Sharma; Robert Siegel; Weijing Sun; Zev Wainberg; Ben George; Andrea Bullock; Samuel Myrick; Josephine Faruol; Richard Siegel; Timothy Larson; Carlos Becerra; Suresh Ratnam; Donald A. Richards; Stephen L. Riche; KEYNOTE-061 investigators
    The Lancet, 392, 10142, 123, 133, Elsevier B.V., 2018年07月14日
    英語, 研究論文(学術雑誌)
  • Genomic testing for pancreatic cancer in clinical practice as real-world evidence.
    Hayashi H; Tanishima S; Fujii K; Mori R; Okamura Y; Yanagita E; Matsuoka R; Amano T; Kinoshita I; Komatsu Y; Dosaka-Akita H; Nishihara H
    Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 18, 6, 647, 654, 2018年07月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Precision medicine guided by comprehensive genome sequencing represents a potential treatment strategy for pancreatic cancer. However, clinical sequencing for pancreatic cancer entails several practical difficulties. We have launched an in-house clinical sequencing system and started genomic testing for patients with cancer in clinical practice. We have analyzed the clinical utility of this system in pancreatic cancer. METHODS: We retrospectively reviewed 20 patients with pancreatic cancer who visited our division. Genomic DNA was extracted from both tumor tissue and peripheral blood mononuclear cells obtained from the patients. We performed a comprehensive genomic testing using targeted amplicon sequencing for 160 cancer-related genes. The primary endpoints were the detection rates of potential actionable and druggable gene alterations. The secondary endpoints were the detection rate of secondary germline findings, the rate of re-biopsy required for genome sequencing, survival time after the initial visit (post-sequencing survival time), and turnaround time. RESULTS: Although re-biopsy was required for 25% (5/20) of all patients, genomic testing was performed in all patients. Actionable and druggable gene alterations were detected in 100% (20/20) and 35% (7/20) of patients, respectively, whereas secondary germline findings were detected in 5% (1/20) of patients. The median turnaround times for physicians and patients were 20 and 26 days, respectively. The median post-sequencing survival time was 10.3 months. Only 10% (2/20) of all patients were treated with therapeutic agents based on the outcomes of genomic testing. CONCLUSIONS: The clinical application of comprehensive genomic testing for pancreatic cancer was feasible and promising in clinical practice.
  • Relationship Between Thymidine Kinase 1 Expression and Trifluridine/Tipiracil Therapy in Refractory Metastatic Colorectal Cancer: A Pooled Analysis of 2 Randomized Clinical Trials.
    Yoshino T; Yamazaki K; Shinozaki E; Komatsu Y; Nishina T; Baba H; Tsuji A; Tsuji Y; Yamaguchi K; Sugimoto N; Denda T; Muro K; Takayama T; Esaki T; Hamamoto Y; Moriwaki T; Shimada Y; Goto M; Nakayama N; Fujii H; Tanase T; Ohtsu A
    Clinical colorectal cancer, 17, 4, e719-e732, 2018年07月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: High thymidine kinase 1 (TK1) activity increases the incorporation of trifluridine (FTD) into DNA; thus, FTD antitumor activity is likely to increase in patients with high tumoral TK1 activity. To date, no established predictive biomarker to indicate the clinical benefit of FTD/tipiracil (TPI) has been identified. We aimed to determine the relationship between TK1 expression and FTD/TPI efficacy in refractory metastatic colorectal cancer. PATIENTS AND METHODS: Individual patient data from 2 randomized placebo-controlled trials were analyzed. We measured TK1 protein expression in tumor tissue samples and its relationship with FTD/TPI clinical efficacy using overall survival (OS), progression-free survival, and disease control rate. RESULTS: This study comprised 329 patients (FTD/TPI, 224; placebo, 105). FTD/TPI significantly improved OS versus placebo in the high-expression (cutoff ≥ 15%) TK1 group (median OS, 7.8 vs. 6.8 months; hazard ratio = 0.65; 95% confidence interval, 0.46-0.93; P = .018). The low-expression (cutoff < 15%) TK1 group experienced a smaller OS benefit (9.3 vs. 7.4 months; hazard ratio = 0.88; 95% confidence interval, 0.63-1.23; P = .45). For patients who received placebo, the high-expression TK1 group had a slightly worse prognosis than the low-expression TK1 group. The tendency of FTD/TPI efficacy concerning progression-free survival and disease control rate was not similar to that concerning OS between groups. CONCLUSION: Patients with high TK1 expression showed an improvement in OS when treated with FTD/TPI. Further investigations are warranted to confirm this relationship.
  • Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm.
    Akira Sawaki; Yasuhide Yamada; Kensei Yamaguchi; Tomohiro Nishina; Toshihiko Doi; Taroh Satoh; Keisho Chin; Narikazu Boku; Yasushi Omuro; Yoshito Komatsu; Yasuo Hamamoto; Wasaburo Koizumi; Shigehira Saji; Manish A Shah; Eric Van Cutsem; Yoon-Koo Kang; Junko Iwasaki; Hiroshi Kuriki; Wataru Ohtsuka; Atsushi Ohtsu
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 21, 3, 429, 438, 2018年05月, [査読有り], [国内誌]
    英語, 研究論文(学術雑誌), BACKGROUND: AVAGAST was an international, randomized, placebo-controlled phase III study of chemotherapy with or without bevacizumab as first-line therapy for patients with advanced gastric cancer. We performed exploratory analyses to evaluate regional differences observed in the trial. METHODS: Analyses were performed in the placebo plus chemotherapy arm (intention-to-treat population). Chemotherapy was cisplatin 80 mg/m2 for six cycles plus capecitabine (1000 mg/m2 orally bid days 1-14) or 5-fluorouracil (800 mg/m2/day continuous IV infusion days 1-5) every 3 weeks until disease progression or unacceptable toxicity. RESULTS: Overall, 387 patients were assigned to placebo plus chemotherapy (eastern Europe/South America, n = 118; USA/western Europe, n = 81; Korea/other Asia, n = 94; Japan, n = 94). At baseline, poor performance status, liver metastases, and larger tumors were most frequent in eastern Europe/South America and least frequent in Japan. Patients received subsequent chemotherapy after disease progression as follows: eastern Europe/South America (14%); USA/western Europe (37%); Korea/other Asia (61%); and Japan (77%). Hazard ratios for overall survival versus USA/western Europe were 1.47 (95% CI, 1.09-1.99) for eastern Europe/South America, 0.91 (95% CI, 0.67-1.25) for Korea/other Asia, and 0.87 (95% CI, 0.64-1.19) for Japan. CONCLUSIONS: Regional differences in the healthcare environment may have contributed to the differences in overall survival observed in the AVAGAST study.
  • S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial.
    Yamada Y; Denda T; Gamoh M; Iwanaga I; Yuki S; Shimodaira H; Nakamura M; Yamaguchi T; Ohori H; Kobayashi K; Tsuda M; Kobayashi Y; Miyamoto Y; Kotake M; Shimada K; Sato A; Morita S; Takahashi S; Komatsu Y; Ishioka C
    Annals of oncology : official journal of the European Society for Medical Oncology, 29, 3, 624, 631, 2018年03月, [査読有り]
  • A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer
    Hideaki Bando; Hideki Shimodaira; Kazumasa Fujitani; Atsuo Takashima; Kensei Yamaguchi; Norisuke Nakayama; Takehiro Takahashi; Eiji Oki; Mizutomo Azuma; Tomohiro Nishina; Shuichi Hironaka; Yoshito Komatsu; Kohei Shitara
    European Journal of Cancer, 91, 86, 91, Elsevier Ltd, 2018年03月01日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • BIG BANG study: A multicenter phase II study of the MEK inhibitor binimetinib + BRAF inhibitor encorafenib + anti-EGFR antibody cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer (EPOC 1703)
    Kotani, D.; Bando, H.; Masuishi, T.; Komatsu, Y.; Yamaguchi, K.; Nakajima, T.E.; Satoh, T.; Nishina, T.; Esaki, T.; Nomura, S.; Sakamoto, S.; Iida, S.; Matsuda, S.; Yonemura, M.; Fuse, N.; Sato, A.; Fujii, S.; Ebi, H.; Ohtsu, A.; Yoshino, T.
    Annals of oncology : official journal of the European Society for Medical Oncology, 29, 2018年
    研究論文(学術雑誌)
  • BRAVERY study: A multicenter phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer (EPOC1701)
    Masuishi, T.; Taniguchi, H.; Kotani, D.; Bando, H.; Komatsu, Y.; Yamaguchi, K.; Nakajima, T.E.; Satoh, T.; Nishina, T.; Esaki, T.; Wakabayashi, M.; Nomura, S.; Sakamoto, S.; Ono, H.; Hirano, N.; Fujishiro, N.; Fuse, N.; Sato, A.; Ohtsu, A.; Yoshino, T.
    Annals of oncology : official journal of the European Society for Medical Oncology, 29, 2018年
    研究論文(学術雑誌)
  • Prophylactic Effect of Dexamethasone on Regorafenib-Related Fatigue and/or Malaise: A Randomized, Placebo-Controlled, Double-Blind Clinical Study in Patients with Unresectable Metastatic Colorectal Cancer (KSCC1402/HGCSG1402)
    Tanioka H; Miyamoto Y; Tsuji A; Asayama M; Shiraishi T; Yuki S; Kotaka M; Makiyama A; Shimokawa M; Shimose T; Masuda S; Yamaguchi T; Komatsu Y; Saeki H; Emi Y; Baba H; Oki E; Maehara Y; Kyushu Study; Group of Clinical Cancer; KSC
    Oncology, 94, 5, 289, 296, 2018年, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Regorafenib is an oral multikinase inhibitor with a proven survival benefit for metastatic colorectal cancer patients. The KSCC1402/HGCSG1402 study investigated the prophylactic effect of oral dexamethasone (DEX) on regorafenib-related fatigue and/or malaise. PATIENTS AND METHODS: Patients who progressed after standard chemotherapy were randomized 1: 1 to a DEX group (2 mg/day; days 1-28) with regorafenib or a placebo group with regorafenib. The primary endpoint was the incidence of fatigue and/or malaise, based on version 4.0 of the National Cancer Institute's CTCAE (Common Terminology Criteria for Adverse Events). One of the secondary endpoints was the in-cidence of fatigue and/or malaise based on the CTCAE assessed by patient-reported outcome (PRO). RESULTS: The incidence of any grade of fatigue and/or malaise assessed by the investigators was 58.8% in the DEX group and 61.1% in the placebo group (p = 0.8101), and that assessed by PRO was 47.2 and 58.3%, respectively (p = 0.3450). The incidence of grade ≥2 fatigue and/or malaise, as assessed by the investigators, was 19.4% for the DEX group and 38.9% for the placebo group (p = 0.0695), and that assessed by PRO was 27.8 and 52.8%, respectively (p = 0.0306). CONCLUSION: Our results suggest that prophylactic oral DEX is clinically effective in improving regorafenib-related fatigue and/or malaise.
  • [Survey of the Efficacy of Long-term and Successive Pharmaceutical Care in Outpatient Chemotherapy by Oncology Pharmacy Specialists].
    Saito Y; Harada S; Kobayashi M; Ueda K; Yamazaki K; Kumai M; Miyamoto T; Kasashi K; Yamada T; Komatsu Y; Iseki K
    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 138, 11, 1409, 1416, 公益社団法人 日本薬学会, 2018年, [査読有り]
    日本語, It is important that pharmacists ensure safe chemotherapy implementation. In addition to inspecting chemotherapeutic prescriptions according to patient condition and drug-drug interactions, the management of chemotherapy-induced adverse effects and associated pharmaceutical intervention is one of the most important responsibilities of pharmacists in medical care teams. In May 2016, an oncology pharmacist was set responsible for the specialized, long-term, and successive pharmaceutical care, including instructions about appropriate use of medication at an outpatient chemotherapy center. We evaluated the effectiveness of the continuous pharmaceutical care. The number of medication counseling and associated pharmaceutical interventions increased with time. Specifically, the number of pharmaceutical interventions (prescription questions and pharmaceutical proposals) was 745 (459 and 286, respectively) in the surveillance period, which significantly increased compared to that observed within the same duration before posting an oncology pharmacist. The adoption rate was approximately 70% for prescription questions and 98% for pharmaceutical proposals. We also found that approximately 70% of the proposals attenuated the painful symptoms. Furthermore, approximately 60% of all pharmaceutical interventions were established after the third visit; in particular, approximately 20% of the pharmaceutical proposals were suggested after the sixth visit, indicating that continuous medication counseling results in an increase in pharmaceutical proposals. In conclusion, long-term and successive pharmaceutical care by oncology pharmacy specialists in outpatient chemotherapy contributes to a safe and less onerous chemotherapy implementation, as it has been highly adopted, is effective in many cases, and has been proven to be important for risk management in chemotherapy.
  • Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study
    Toshikazu Moriwaki; Shota Fukuoka; Hiroya Taniguchi; Atsuo Takashima; Yusuke Kumekawa; Takeshi Kajiwara; Kentaro Yamazaki; Taito Esaki; Chinatsu Makiyama; Tadamichi Denda; Hironaga Satake; Takeshi Suto; Naotoshi Sugimoto; Masanobu Enomoto; Toshiaki Ishikawa; Tomomi Kashiwada; Masahiko Sugiyama; Yoshito Komatsu; Hiroyuki Okuyama; Eishi Baba; Daisuke Sakai; Tomoki Watanabe; Takao Tamura; Kimihiro Yamashita; Masahiko Gosho; Yasuhiro Shimada
    Oncologist, 23, 1, 7, 15, Wiley-Blackwell, 2018年01月01日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer
    Daisuke Sakai; Hyun Cheol Chung; Do-Youn Oh; Se Hoon Park; Shigenori Kadowaki; Yeul Hong Kim; Akihito Tsuji; Yoshito Komatsu; Yoon-Koo Kang; Kazunori Uenaka; Sameera R. Wijayawardana; Volker Wacheck; Xuejing Wang; Ayuko Yamamura; Toshihiko Doi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 80, 6, 1197, 1207, 2017年12月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Study protocol of HGCSG1404 SNOW study: a phase I/II trial of combined chemotherapy of S-1, nab-paclitaxel and oxaliplatin administered biweekly to patients with advanced gastric cancer
    Yasuyuki Kawamoto; Yoshito Komatsu; Satoshi Yuki; Kentaro Sawada; Tetsuhito Muranaka; Kazuaki Harada; Hiroshi Nakatsumi; Hiraku Fukushima; Atsushi Ishiguro; Masayoshi Dazai; Kazuteru Hatanaka; Michio Nakamura; Ichiro Iwanaga; Minoru Uebayashi; Susumu Sogabe; Yoshimitsu Kobayashi; Takuto Miyagishima; Kota Ono; Naoya Sakamoto; Yuh Sakata
    BMC CANCER, 17, 1, 837, 837, 2017年12月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Fibroblast growth factor-2-mediated FGFR/Erk signaling supports maintenance of cancer stem-like cells in esophageal squamous cell carcinoma
    Osamu Maehara; Goki Suda; Mitsuteru Natsuizaka; Shunsuke Ohnishi; Yoshito Komatsu; Fumiyuki Sato; Masato Nakai; Takuya Sho; Kenichi Morikawa; Koji Ogawa; Tomoe Shimazaki; Megumi Kimura; Ayaka Asano; Yoshiyuki Fujimoto; Shinya Ohashi; Shingo Kagawa; Hideaki Kinugasa; Seiji Naganuma; Kelly A. Whelan; Hiroshi Nakagawa; Koji Nakagawa; Hiroshi Takeda; Naoya Sakamoto
    CARCINOGENESIS, 38, 11, 1073, 1083, 2017年11月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • A Phase 1/1b tolerability study of rilotumumab alone or in combination with cisplatin and capecitabine in Japanese patients with gastric cancer
    Toshihiko Doi; Kensei Yamaguchi; Yoshito Komatsu; Kei Muro; Tomohiro Nishina; Takako Eguchi Nakajima; Rui Tang; Hui Yang; Yilong Zhang; A. Scott Jung; Agnes Ang; Hirofumi Yasui
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 47, 11, 1002, 1009, 2017年11月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • 前治療における腫瘍増殖速度がレゴラフェニブとTAS-102の抗腫瘍効果に与える影響
    舛石 俊樹; 谷口 浩也; 川上 武志; 川本 泰之; 門脇 重憲; 小野澤 祐輔; 村中 徹人; 田近 正洋; 安井 博史; 中積 宏之; 結城 敏志; 室 圭; 大前 勝弘; 小松 嘉人; 山崎 健太郎
    日本癌治療学会学術集会抄録集, 55回, O31, 6, (一社)日本癌治療学会, 2017年10月
    日本語
  • Phase II study of TAS-116, an oral inhibitor of heat shock protein 90 (HSP90), in metastatic or unresectable gastrointestinal stromal tumor refractory to imatinib, sunitinib and regorafenib
    Y. Kurokawa; T. Doi; A. Sawaki; Y. Komatsu; M. Ozaka; T. Takahashi; Y. Naito; S. Okubo; T. Nishida
    ANNALS OF ONCOLOGY, 28, 2017年09月, [査読有り]
    英語
  • HGCSG 1201: Phase II study of trastuzumab with irinotecan in HER2-positive metastatic or advanced gastric cancer patients previously treated with trastuzumab
    Sasaki Takahide; Kawamoto Yasuyuki; Yuki Satoshi; Meguro Takashi; Hatanaka Kazuteru; Uebayashi Minoru; Iwanaga Ichiro; Nakamura Michio; Eto Kazunori; Okuda Hiroyuki; Abe Masakazu; Oba Ayane; Abe Nobuhiko; Sato Atsushi; Nakatsumi Hiroshi; Harada Kazuaki; Muranaka Tetsuhito; Yagisawa Masataka; Oba Koji; Sakata Yuh; Komatsu Yoshito
    ANNALS OF ONCOLOGY, 28, 2017年06月, [査読有り]
    英語
  • Rationale for and Design of the PARADIGM Study: Randomized Phase III Study of mFOLFOX6 Plus Bevacizumab or Panitumumab in Chemotherapy-naive Patients With RAS (KRAS/NRAS) Wild-type, Metastatic Colorectal Cancer
    Takayuki Yoshino; Hiroyuki Uetake; Katsuya Tsuchihara; Kohei Shitara; Kentaro Yamazaki; Eiji Oki; Takeo Sato; Takeshi Naitoh; Yoshito Komatsu; Takeshi Kato; Kazunori Yamanaka; Kouji Iwasaki; Jumpei Soeda; Masamitsu Hihara; Takeharu Yamanaka; Atsushi Ochiai; Kei Muro
    CLINICAL COLORECTAL CANCER, 16, 2, 158, 163, 2017年06月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer
    Tetsuhito Muranaka; Masaki Kuwatani; Yoshito Komatsu; Kentaro Sawada; Hiroshi Nakatsumi; Yasuyuki Kawamoto; Satoshi Yuki; Yoshimasa Kubota; Kimitoshi Kubo; Shuhei Kawahata; Kazumichi Kawakubo; Hiroshi Kawakami; Naoya Sakamoto
    Journal of Gastrointestinal Oncology, 8, 3, 566, 571, AME Publishing Company, 2017年06月01日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Systematic review and individual patient data based meta-analysis of palonosetron trials for chemotherapy induced nausea and vomiting.
    Yuki Okada; Koji Oba; Naoto Furukawa; Yoshito Komatsu; Yoshimasa Kosaka; Kenji Okita; Satoshi Yuki; Luigi Celio; Matti S. Aapro
    JOURNAL OF CLINICAL ONCOLOGY, 35, 2017年05月, [査読有り]
    英語
  • Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer.
    Hideyuki Hayashi; Takashi Kohno; Hideki Ueno; Nobuyoshi Hiraoka; Shunsuke Kondo; Motonobu Saito; Yoko Shimada; Hitoshi Ichikawa; Mamoru Kato; Tatsuhiro Shibata; Chigusa Morizane; Yasunari Sakamoto; Kazuaki Shimada; Yoshito Komatsu; Naoya Sakamoto; Takuji Okusaka
    Pancreas, 46, 3, 335, 340, 2017年03月, [査読有り], [国際誌]
    英語
  • Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer
    Hideyuki Hayashi; Takashi Kohno; Hideki Ueno; Nobuyoshi Hiraoka; Shunsuke Kondo; Motonobu Saito; Yoko Shimada; Hitoshi Ichikawa; Mamoru Kato; Tatsuhiro Shibata; Chigusa Morizane; Yasunari Sakamoto; Kazuaki Shimada; Yoshito Komatsu; Naoya Sakamoto; Takuji Okusaka
    PANCREAS, 46, 3, 335, 340, 2017年03月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Decreased RNA-binding motif 5 expression is associated with tumor progression in gastric cancer
    Takahiko Kobayashi; Junich Ishida; Yuichi Shimizu; Hiroshi Kawakami; Goki Suda; Tetsuhito Muranaka; Yoshito Komatsu; Masahiro Asaka; Naoya Sakamoto
    TUMOR BIOLOGY, 39, 3, 1010428317694547, 1010428317694547, 2017年03月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer
    T. Ioka; Y. Komatsu; N. Mizuno; A. Tsuji; S. Ohkawa; M. Tanaka; H. Iguchi; A. Ishiguro; M. Kitano; T. Satoh; T. Yamaguchi; K. Takeda; M. Kida; K. Eguchi; T. Ito; M. Munakata; T. Itoi; J. Furuse; C. Hamada; Y. Sakata
    British Journal of Cancer, 116, 4, 464, 471, Nature Publishing Group, 2017年02月14日, [査読有り]
    英語, 研究論文(学術雑誌)
  • A phase II study of panitumumab with FOLFOX or FOLFIRI as first-line chemotherapy for KRAS-wild type metastatic colorectal cancer: The PaFF-J study.
    Eiji Shinozaki; Megumi Ishiguro; Eiji Nakatani; Tatsuro Yamaguchi; Masato Nakamura; Yuji Miyamoto; Hitoshi Ojima; Yoshitaka Honma; Masahiro Gotoh; Toshiaki Ishikawa; Keiichi Takahashi; Yasuhiro Shimada; Kazuhiro Yoshida; Nobuyuki Mizunuma; Kei Muro; Yoshito Komatsu; Kensei Yamaguchi; Hiroshi Nakano; Junki Koike; Kenichi Sugihara
    JOURNAL OF CLINICAL ONCOLOGY, 35, 4, 2017年02月
    英語
  • Effect of thymidine kinase 1 expression on prognosis and treatment outcomes in refractory metastatic colorectal cancer: Results from two randomized studies of TAS-102 versus a placebo.
    Yoshino Takayuki; Shinozaki Eiji; Yamazaki Kentaro; Komatsu Yoshito; Nishina Tomohiro; Baba Hideo; Tsuji Akihito; Tsuji Yasushi; Yamaguchi Kensei; Sugimoto Naotoshi; Denda Tadamichi; Muro Kei; Takayama Tetsuji; Esaki Taito; Hamamoto Yasuo; Moriwaki Toshikazu; Shimada Yasuhiro; Goto Masahiro; Tanase Takanori; Ohtsu Atsushi
    JOURNAL OF CLINICAL ONCOLOGY, 35, 4, 2017年02月01日, [査読有り]
    英語
  • A Prospective Observational Study on Effect of Short-Term Periodic Steroid Premedication on Bone Metabolism in Gastrointestinal Cancer (ESPRESSO-01)
    Michio Nakamura; Atsushi Ishiguro; Tetsuhito Muranaka; Hiraku Fukushima; Satoshi Yuki; Kota Ono; Taichi Murai; Chika Matsuda; Ayane Oba; Kazufumi Itaya; Takayuki Sone; Masataka Yagisawa; Yuta Koike; Ayana Endo; Yoko Tsukuda; Yuji Ono; Takahiko Kudo; Atsushi Nagasaka; Shuji Nishikawa; Yoshito Komatsu
    ONCOLOGIST, 22, 5, 592, 600, 2017年, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study.
    Hideo Baba; Yasuhide Yamada; Daisuke Takahari; Hiroshi Matsumoto; Kazuhiro Yoshida; Masato Nakamura; Motoki Yoshida; Shigeyoshi Iwamoto; Ken Shimada; Yoshito Komatsu; Yasutsuna Sasaki; Taroh Satoh; Keiichi Takahashi; Hideyuki Mishima; Kei Muro; Masahiko Watanabe; Yuh Sakata; Satoshi Morita; Yasuhiro Shimada; Kenichi Sugihara
    ESMO open, 2, 1, e000135, 2017年, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), OBJECTIVE: The SOFT study previously demonstrated that S-1 and oxaliplatin (SOX) plus bevacizumab was non-inferior to l-leucovorin, fluorouracil and oxaliplatin (mFOLFOX6) plus bevacizumab in terms of the primary end point of progression-free survival (PFS) as first-line chemotherapy for metastatic colorectal cancer (mCRC). The overall survival (OS) data were immature at the time of the primary analysis. METHODS: A total of 512 patients were enrolled and randomly assigned to receive either mFOLFOX6 plus bevacizumab (5 mg/kg of bevacizumab, followed by 200 mg/m2 of l-leucovorin given simultaneously with 85 mg/m2 of oxaliplatin, followed by a 400 mg/m2 bolus of 5-FU on day 1 and then 2400 mg/m2 of 5-FU as an intravenous infusion over the course of 46 hours, every 2 weeks) or SOX plus bevacizumab (7.5 mg/kg of bevacizumab, 130 mg/m2 of oxaliplatin on day 1 and 40-60 mg of S-1 two times per day for 2 weeks, followed by a 1-week rest). The primary end point was PFS. After the primary analysis, the follow-up survey was cut-off on 30 September 2013, and the final OS data were analysed. RESULTS: With a median follow-up of 37.7 months, the median survival time (MST) was 29.7 months with mFOLFOX6 plus bevacizumab and 29.6 months with SOX plus bevacizumab (HR, 1.018; 95% CI 0.823 to 1.258). Median PFS was 11.7 months in the mFOLFOX6 plus bevacizumab group and 12.2 months in the SOX plus bevacizumab group (HR, 1.051; 95% CI 0.876 to 1.262; pnon-inferiority=0.0115). CONCLUSION: Our results reconfirmed that SOX plus bevacizumab is non-inferior to mFOLFOX6 plus bevacizumab in terms of PFS. MST did not differ between the groups. SOX plus bevacizumab is considered an effective regimen for first-line chemotherapy in patients with mCRC and can be used instead of mFOLFOX6 plus bevacizumab. TRIAL REGISTRATION NUMBER: JapicCTI-090699.
  • Proxies of quality of life in metastatic colorectal cancer: analyses in the RECOURSE trial.
    Van Cutsem E; Falcone A; Garcia-Carbonero R; Komatsu Y; Pastorino A; Peeters M; Shimada Y; Yamazaki K; Yoshino T; Zaniboni A; Amellal N; Kanehisa A; Winkler R; Makris L; Mayer RJ; Ohtsu A; Tabernero J
    ESMO open, 2, 5, e000261, 2017年, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Background: In the pivotal phase III, randomised, double-blind, placebo-controlled RECOURSE study, treatment with trifluridine/tipiracil was well tolerated and associated with prolonged progression-free and overall survival in patients with metastatic colorectal cancer (mCRC). There was no formal analysis of quality of life (QoL) in RECOURSE. The aim of the present analysis was to assess proxies of QoL during the RECOURSE treatment period, in terms of adverse events (AEs) likely to affect QoL and Eastern Cooperative Oncology Group performance status (ECOG PS). Patients and methods: Enrolled patients had documented, previously treated (≥2 prior chemotherapy lines) mCRC and an ECOG PS of 0 or 1. Patients received best supportive care plus trifluridine/tipiracil 35 mg/m2 twice daily (n=534) or placebo (n=266) in a 28-day cycle. AEs analysed included nausea, vomiting, diarrhoea, dysgeusia and fatigue/asthenia. ECOG PS was determined at baseline, on day 1 of each treatment cycle, at treatment end and 30 days post-treatment discontinuation. Results: AEs that affect QoL were more frequent in patients treated with trifluridine/tipiracil than placebo. Median treatment duration for patients experiencing at least one of these AEs was longer than that observed for the overall RECOURSE population (trifluridine/tipiracil: 12 vs 7 weeks; placebo: 10 vs 6 weeks). Versus placebo, the duration of most AEs was longer in trifluridine/tipiracil recipients; however, all AEs except nausea and vomiting occupied a lower proportion of the total treatment period. Of the patients who had their PS recorded at discontinuation, PS was maintained in 67% and 63% of trifluridine/tipiracil and placebo recipients, and 84% and 81% of the trifluridine/tipiracil and placebo patients remained at a PS of 0 or 1 at discontinuation. Conclusions: Analysis of ECOG PS and AEs thought to affect QoL in the RECOURSE patient population suggests that trifluridine/tipiracil treatment does not result in a deterioration of patient QoL versus placebo.
  • Recommendations for the Prophylactic Management of Skin Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in Patients With Solid Tumors
    Ralf-Dieter Hofheinz; Gael Deplanque; Yoshito Komatsu; Yoshimitsu Kobayashi; Janja Ocvirk; Patrizia Racca; Silke Guenther; Jun Zhang; Mario E. Lacouture; Aminah Jatoi
    ONCOLOGIST, 21, 12, 1483, 1491, 2016年12月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Cytomegalovirus colitis in a patient undergoing postoperative adjuvant chemotherapy for lung adenocarcinoma with uracil-tegafur
    Hideyuki Hayashi; Yoshito Komatsu; Takumi Uchida; Nobuhiko Abe; Ken Ito; Kouji Hirata; Kana Matsuda; Akira Fujinaga
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 22, 12, 826, 829, 2016年12月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • [III. The Association between Location and Colorectal Cancer Characteristics].
    Komatsu Y
    Gan to kagaku ryoho. Cancer & chemotherapy, 43, 11, 1357, 1360, 2016年11月, [査読有り], [国内誌]
    日本語, 研究論文(学術雑誌)
  • Efficacy and Safety of Bolus 5-Fluorouracil and L-Leucovorin as Salvage Chemotherapy for Oral Fluoropyrimidine-Resistant Unresectable or Recurrent Gastric Cancer: A Single Center Experience
    Tetsuhito Muranaka; Satoshi Yuki; Yoshito Komatsu; Kentaro Sawada; Kazuaki Harada; Yasuyuki Kawamoto; Hiroshi Nakatsumi; Naoya Sakamoto
    JOURNAL OF GASTRIC CANCER, 16, 3, 177, 181, 2016年09月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer
    Kohei Shitara; Kei Muro; Yasuhiro Shimada; Shuichi Hironaka; Naotoshi Sugimoto; Yoshito Komatsu; Tomohiro Nishina; Kensei Yamaguchi; Yoshihiko Segawa; Yasushi Omuro; Takao Tamura; Toshihiko Doi; Seigo Yukisawa; Hirofumi Yasui; Fumio Nagashima; Masahiro Gotoh; Taito Esaki; Michael Emig; Kumari Chandrawansa; Astra M. Liepa; Hansjochen Wilke; Yukako Ichimiya; Atsushi Ohtsu
    GASTRIC CANCER, 19, 3, 927, 938, 2016年07月, [査読有り], [国内誌]
    英語, 研究論文(学術雑誌)
  • The adjuvant therapy for high risk GIST patients after complete resection in the clinical practice.
    Nishida Toshirou; Takagi Masakazu; Ozaka Masato; Kitagawa Yuko; Kurokawa Yukinori; Komatsu Yoshito; Ishioka Chikashi; Doi Toshihiko; Cho Haruhiko; Kanda Tetsuo; Sugiyama Toshiro; Sawaki Akira; Kakeji Yoshihiro; Hirai Toshihiro; Hato Shinji; Baba Hideo; Shirao Kuniaki; Hirota Seiichi; Kagimura Tatsuo; Masuzawa Toru
    JOURNAL OF CLINICAL ONCOLOGY, 34, 15, 2016年05月20日, [査読有り]
  • A randomized, double-blind, placebo-controlled phase II study of prophylactic dexamethasone (dex) therapy for fatigue and malaise due to regorafenib in patient (pts) with metastatic colorectal cancer (mCRC): (KSCC1402/HGCSG1402).
    Yuji Miyamoto; Satoshi Yuki; Mototsugu Shimokawa; Hiroaki Tanioka; Akihito Tsuji; Masako Asayama; Takeshi Shiraishi; Masahito Kotaka; Akitaka Makiyama; Yoshito Komatsu; Satohiro Masuda; Takuhiro Yamaguchi; Hiroshi Saeki; Eiji Oki; Yasunori Emi; Hideo Baba; Yoshihiko Maehara
    JOURNAL OF CLINICAL ONCOLOGY, 34, 15, 2016年05月, [査読有り]
    英語
  • Onset of neutropenia as an indicator of treatment response in the randomized phase II of TAS-102 vs placebo in Japanese patients with metastatic colorectal cancer (Study J003-10040030).
    Tomohiro Nishina; Takayuki Yoshino; Eiji Shinozaki; Kentaro Yamazaki; Yoshito Komatsu; Hideo Baba; Akihito Tsuji; Kensei Yamaguchi; Kei Muro; Naotoshi Sugimoto; Yasushi Tsuji; Toshikazu Moriwaki; Taito Esaki; Chikuma Hamada; Takanori Tanase; Atsushi Ohtsu
    JOURNAL OF CLINICAL ONCOLOGY, 34, 15, 2016年05月, [査読有り]
    英語
  • A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer
    M. Ueno; T. Okusaka; Y. Omuro; H. Isayama; A. Fukutomi; M. Ikeda; N. Mizuno; K. Fukuzawa; M. Furukawa; H. Iguchi; K. Sugimori; J. Furuse; K. Shimada; T. Ioka; S. Nakamori; H. Baba; Y. Komatsu; M. Takeuchi; I. Hyodo; N. Boku
    ANNALS OF ONCOLOGY, 27, 3, 502, 508, 2016年03月
    英語, 研究論文(学術雑誌)
  • Clinicopathological features of ruptured GIST in the ReGISTry study of high risk GIST patients after complete resection in Japan
    Toshirou Nishida; Masato Kondo; Masato Ozaka; Haruhiko Cho; Yoshito Komatsu; Toshihiko Doi; Hideo Baba; Yuko Kitagawa; Yukinori Kurokawa; Tetsuo Kanda; Toshiro Sugiyama; Akira Sawaki; Yoshihiro Kakeji; Toshihiro Hirai; Shinji Hato; Kuniaki Shirao; Chikashi Ishioka; Seiichi Hirota; Tatsuo Kagimura; Masakazu Takagi
    JOURNAL OF CLINICAL ONCOLOGY, 34, 4, 2016年02月, [査読有り]
    英語
  • Observational cohort study of first-line bevacizumab with oxaliplatin or irinotecan and fluoropyrimidines in metastatic colorectal cancer: HGCSG0802-Analysis of early tumor shrinkage (ETS).
    Yuki Satoshi; Nakatsumi Hiroshi; Sawada Kentaro; Kato Takashi; Meguro Takashi; Nakamura Michio; Iwanaga Ichiro; Ehira Nobuyuki; Sonoda Norikazu; Kudo Mineo; Kato Kanji; Sogabe Susumu; Amano Toraji; Ono Kota; Sakamoto Keita; Miyamoto Noriyuki; Kudo Kohsuke; Sakamoto Naoya; Sakata Yuh; Komatsu Yoshito
    JOURNAL OF CLINICAL ONCOLOGY, 34, 4, 2016年02月01日, [査読有り]
  • S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial
    Shuichi Hironaka; Naotoshi Sugimoto; Kensei Yamaguchi; Toshikazu Moriwaki; Yoshito Komatsu; Tomohiro Nishina; Akihito Tsuji; Takako Eguchi Nakajima; Masahiro Gotoh; Nozomu Machida; Hideaki Bando; Taito Esaki; Yasunori Emi; Takashi Sekikawa; Shigemi Matsumoto; Masahiro Takeuchi; Narikazu Boku; Hideo Baba; Ichinosuke Hyodo
    LANCET ONCOLOGY, 17, 1, 99, 108, 2016年01月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Safety, efficacy and prognostic analyses of sunitinib in the post-marketing surveillance study of Japanese patients with gastrointestinal stromal tumor
    Yoshito Komatsu; Emiko Ohki; Naomi Ueno; Ai Yoshida; Yasuharu Toyoshima; Eiji Ueda; Hiroyuki Houzawa; Kanae Togo; Toshirou Nishida
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 45, 11, 1016, 1022, 2015年11月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • A pivotal role of Kruppel-like factor 5 in regulation of cancer stem-like cells in hepatocellular carcinoma
    Osamu Maehara; Fumiyuki Sato; Mitsuteru Natsuizaka; Ayaka Asano; Yoshimasa Kubota; Jun Itoh; Seiji Tsunematsu; Katsumi Terashita; Yoko Tsukuda; Masato Nakai; Takuya Sho; Goki Suda; Kenichi Morikawa; Koji Ogawa; Makoto Chuma; Koji Nakagawa; Shunsuke Ohnishi; Yoshito Komatsu; Kelly A. Whelan; Hiroshi Nakagawa; Hiroshi Takeda; Naoya Sakamoto
    CANCER BIOLOGY & THERAPY, 16, 10, 1453, 1461, 2015年10月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer
    Taroh Satoh; Kyung Hee Lee; Sun Young Rha; Yasutsuna Sasaki; Se Hoon Park; Yoshito Komatsu; Hirofumi Yasui; Tae-You Kim; Kensei Yamaguchi; Nozomu Fuse; Yasuhide Yamada; Takashi Ura; Si-Young Kim; Masaki Munakata; Soh Saitoh; Kazuto Nishio; Satoshi Morita; Eriko Yamamoto; Qingwei Zhang; Jung-mi Kim; Yeul Hong Kim; Yuh Sakata
    GASTRIC CANCER, 18, 4, 824, 832, 2015年10月, [査読有り], [国内誌]
    英語, 研究論文(学術雑誌)
  • Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial
    Yoshito Komatsu; Toshihiko Doi; Akira Sawaki; Tatsuo Kanda; Yasuhide Yamada; Iris Kuss; George D. Demetri; Toshirou Nishida
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 20, 5, 905, 912, 2015年10月, [査読有り], [国内誌]
    英語, 研究論文(学術雑誌)
  • Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer
    Yoshito Komatsu; Chikashi Ishioka; Ken Shimada; Yasuhide Yamada; Makio Gamoh; Atsushi Sato; Tatsuro Yamaguchi; Satoshi Yuki; Satoshi Morita; Shin Takahashi; Rei Goto; Minoru Kurihara
    BMC CANCER, 15, 626, 626, 2015年09月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with Palonosetron.
    Yoshito Komatsu; Kenji Okita; Satoshi Yuki; Tomohisa Furuhata; Hiraku Fukushima; Hiroyuki Masuko; Yasuyuki Kawamoto; Hiroshi Isobe; Takuto Miyagishima; Kazuaki Sasaki; Michio Nakamura; Yoshinobu Ohsaki; Junta Nakajima; Miki Tateyama; Kazunori Eto; Shinya Minami; Ryoji Yokoyama; Ichiro Iwanaga; Hitoshi Shibuya; Mineo Kudo; Koji Oba; Yasuo Takahashi
    Cancer science, 106, 7, 891, 5, 2015年07月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), The purpose of this study is to compare the efficacy of a single administration of dexamethasone (DEX) on day 1 against DEX administration on days 1-3 in combination with palonosetron (PALO), a second-generation 5-HT3 receptor antagonist, for chemotherapy-induced nausea and vomiting (CINV) in non-anthracycline and cyclophosphamide (AC) moderately-emetogenic chemotherapy (MEC). This phase III trial was conducted with a multi-center, randomized, open-label, non-inferiority design. Patients who received non-AC MEC as an initial chemotherapy were randomly assigned to either a group administered PALO (0.75 mg, i.v.) and DEX (9.9 mg, i.v.) prior to chemotherapy (study treatment group), or a group administered additional DEX (8 mg, i.v. or p.o.) on days 2-3 (control group). The primary endpoint was complete response (CR) rate. The CR rate difference was estimated by logistic regression with allocation factors as covariates. The non-inferiority margin was set at -15% (study treatment group - control group). From April 2011 to March 2013, 305 patients who received non-AC MEC were randomly allocated to one of two study groups. Overall, the CR rate was 66.2% in the study treatment group (N = 151) and 63.6% in the control group (N = 154). PALO plus DEX day 1 was non-inferior to PALO plus DEX days 1-3 (difference, 2.5%; 95% confidence interval [CI]: -7.8%-12.8%; P-value for non-inferiority test = 0.0004). There were no differences between the two groups in terms of complete control rate (64.9 vs 61.7%) and total control rate (49.7% vs 47.4%). Anti-emetic DEX administration on days 2-3 may be eliminated when used in combination with PALO in patients receiving non-AC MEC.
  • EGFR inhibitors prevent induction of cancer stem-like cells in esophageal squamous cell carcinoma by suppressing epithelial-mesenchymal transition
    Fumiyuki Sato; Yoshimasa Kubota; Mitsuteru Natsuizaka; Osamu Maehara; Yutaka Hatanaka; Katsuji Marukawa; Katsumi Terashita; Goki Suda; Shunsuke Ohnishi; Yuichi Shimizu; Yoshito Komatsu; Shinya Ohashi; Shingo Kagawa; Hideaki Kinugasa; Kelly A. Whelan; Hiroshi Nakagawa; Naoya Sakamoto
    CANCER BIOLOGY & THERAPY, 16, 6, 933, 940, 2015年06月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations
    Takayuki Yoshino; Yoshito Komatsu; Yasuhide Yamada; Kentaro Yamazaki; Akihito Tsuji; Takashi Ura; Axel Grothey; Eric Van Cutsem; Andrea Wagner; Frank Cihon; Yoko Hamada; Atsushi Ohtsu
    INVESTIGATIONAL NEW DRUGS, 33, 3, 740, 750, 2015年06月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • ReGISTry Study of High Risk GIST Patients After Complete Resection: The adjuvant therapy and pathological diagnosis in Japan.
    Nishida Toshirou; Kitagawa Yuko; Kurokawa Yukinori; Komatsu Yoshito; Ishioka Chikashi; Doi Toshihiko; Yamada Yasuhide; Ozaka Masato; Cho Haruhiko; Kanda Tetsuo; Sugiyama Toshiro; Sawaki Akira; Kakeji Yoshihiro; Hirai Toshihiro; Hato Shinji; Baba Hideo; Shirao Kuniaki; Hirota Seiichi; Kagimura Tatsuo
    JOURNAL OF CLINICAL ONCOLOGY, 33, 15, 2015年05月20日, [査読有り]
  • Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
    Robert J. Mayer; Eric Van Cutsem; Alfredo Falcone; Takayuki Yoshino; Rocio Garcia-Carbonero; Nobuyuki Mizunuma; Kentaro Yamazaki; Yasuhiro Shimada; Josep Tabernero; Yoshito Komatsu; Alberto Sobrero; Eveline Boucher; Marc Peeters; Ben Tran; Heinz-Josef Lenz; Alberto Zaniboni; Howard Hochster; James M. Cleary; Hans Prenen; Fabio Benedetti; Hirokazu Mizuguchi; Lukas Makris; Masanobu Ito; Atsushi Ohtsu
    NEW ENGLAND JOURNAL OF MEDICINE, 372, 20, 1909, 1919, 2015年05月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • [Somatostatin analog].
    Muranaka T; Yuki S; Komatsu Y
    Nihon rinsho. Japanese journal of clinical medicine, 73 Suppl 2, 286, 290, 2015年02月, [査読有り], [国内誌]
    日本語, 研究論文(学術雑誌)
  • [Gastrointestinal ulcer, gastrointestinal perforation].
    Nakatsumi H; Komatsu Y
    Nihon rinsho. Japanese journal of clinical medicine, 73 Suppl 2, 380, 383, 2015年02月, [査読有り], [国内誌]
    日本語, 研究論文(学術雑誌)
  • Association of morphologic response with progression free survival in patients with metastatic colorectal cancer treated with bevacizumab-based chemotherapy: HGCSG0802.
    Yuki Satoshi; Nakatsumi Hiroshi; Hayashi Hideyuki; Fukushima Hiraku; Kato Takashi; Meguro Takashi; Nakamura Michio; Iwanaga Ichiro; Eto Kazunori; Sato Atsushi; Okuda Hiroyuki; Oba Ayane; Miyagishima Takuto; Muto Osamu; Yabusaki Satoshi; Miyamoto Noriyuki; Kudo Kohsuke; Sakamoto Naoya; Sakata Yuh; Komatsu Yoshito
    JOURNAL OF CLINICAL ONCOLOGY, 33, 3, 2015年01月20日, [査読有り]
  • Association of early tumor shrinkage with progression-free survival in patients with metastatic colorectal cancer treated with bevacizumab-based chemotherapy: HGCSG0802.
    Nakatsumi Hiroshi; Yuki Satoshi; Muranaka Tetsuhito; Fukushima Hiraku; Kato Takashi; Meguro Takashi; Nakamura Michio; Iwanaga Ichiro; Ehira Nobuyuki; Sonoda Norikazu; Kudo Mineo; Kato Kanji; Miyashita Kencho; Abe Masakazu; Miyamoto Noriyuki; Sakamoto Keita; Kudo Kohsuke; Sakamoto Naoya; Sakata Yuh; Komatsu Yoshito
    JOURNAL OF CLINICAL ONCOLOGY, 33, 3, 2015年01月20日, [査読有り]
  • P0988-23-AM オキサリプラチンによる血管痛発現における患者背景の調査(がん薬物療法(他の副作用対策)2,ポスター,一般演題,医療薬学の進歩と未来-次の四半世紀に向けて-)
    坂本 和央; 柴山 良彦; 小林 正紀; 井関 健; 久保田 康生; 速水 章一; 大江 利治; 齋藤 佳敬; 熊井 正貴; 笠師 久美子; 山田 武宏; 小松 嘉人
    日本医療薬学会年会講演要旨集, 25, 0, 430, 430, 一般社団法人 日本医療薬学会, 2015年, [査読有り]
    日本語
  • The SOFT trial: a Phase III study of the dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 and oxaliplatin (SOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer
    Masato Nakamura; Yasuhide Yamada; Kei Muro; Keiichi Takahashi; Hideo Baba; Yasutsuna Sasaki; Yoshito Komatsu; Taroh Satoh; Hideyuki Mishima; Masahiko Watanabe; Yuh Sakata; Satoshi Morita; Yasuhiro Shimada; Kenichi Sugihara
    FUTURE ONCOLOGY, 11, 10, 1471, 1478, 2015年, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study
    Hirofumi Yasui; Kei Muro; Yasuhiro Shimada; Akihito Tsuji; Shinichi Sameshima; Hideo Baba; Taroh Satoh; Tadamichi Denda; Kenji Ina; Tomohiro Nishina; Kensei Yamaguchi; Taito Esaki; Shinya Tokunaga; Hiroyuki Kuwano; Narikazu Boku; Yoshito Komatsu; Masahiko Watanabe; Ichinosuke Hyodo; Satoshi Morita; Kenichi Sugihara
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 141, 1, 153, 160, 2015年01月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Serum HER2 levels and HER2 status in tumor cells in advanced gastric cancer patients
    Takahide Sasaki; Nozomu Fuse; Takeshi Kuwata; Shogo Nomura; Kazuhiro Kaneko; Toshihiko Doi; Takayuki Yoshino; Hiromichi Asano; Atsushi Ochiai; Yoshito Komatsu; Naoya Sakamoto; Atsushi Ohtsu
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 45, 1, 43, 48, 2015年01月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPP.
    Yoshimitsu Kobayashi; Yoshito Komatsu; Satoshi Yuki; Hiraku Fukushima; Takahide Sasaki; Ichiro Iwanaga; Minoru Uebayashi; Hiroyuki Okuda; Takaya Kusumi; Takuto Miyagishima; Susumu Sogabe; Miki Tateyama; Kazuteru Hatanaka; Yasushi Tsuji; Michio Nakamura; Jun Konno; Fumiyasu Yamamoto; Manabu Onodera; Kazuhiro Iwai; Yuh Sakata; Riichiro Abe; Koji Oba; Naoya Sakamoto
    Future oncology (London, England), 11, 4, 617, 27, 4, 2015年, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), AIM: We planned a randomized, open-label trial to evaluate differences between pre-emptive and reactive skin treatment for panitumumab (Pmab)-associated skin toxicities in Japanese patients with metastatic colorectal cancer. PATIENTS & METHODS: Patients receiving third-line Pmab-containing regimens were randomized to pre-emptive or reactive treatment. The primary end point was the cumulative incidence of ≥grade 2 skin toxicities during 6 weeks. Retrospectively, a dermatologist reviewed skin toxicities, in a blinded manner. RESULTS: A total of 95 patients were enrolled (pre-emptive: 47, reactive: 48). The primary end point was achieved (21.3 and 62.5% [risk ratio: 0.34; p < 0.001], for pre-emptive and reactive treatment, respectively). A similar trend was observed in central review. CONCLUSION: Pre-emptive skin treatment could reduce the severity of Pmab-associated skin toxicities in Japanese metastatic colorectal cancer patients.
  • Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
    Hansjochen Wilke; Kei Muro; Eric Van Cutsem; Sang-Cheul Oh; Gyoergy Bodoky; Yasuhiro Shimada; Shuichi Hironaka; Naotoshi Sugimoto; Oleg Lipatov; Tae-You Kim; David Cunningham; Philippe Rougier; Yoshito Komatsu; Jaffer Ajani; Michael Emig; Roberto Carlesi; David Ferry; Kumari Chandrawansa; Jonathan D. Schwartz; Atsushi Ohtsu
    LANCET ONCOLOGY, 15, 11, 1224, 1235, 2014年10月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer
    Yoshito Komatsu; Takayuki Yoshino; Kentaro Yamazaki; Satoshi Yuki; Nozomu Machida; Takahide Sasaki; Ichinosuke Hyodo; Yutaka Yachi; Hiroshi Onuma; Atsushi Ohtsu
    INVESTIGATIONAL NEW DRUGS, 32, 3, 473, 480, 2014年06月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Randomized controlled trial on the skin toxicity of panitumumab in third-line treatment of KRAS wild-type metastatic colorectal cancer: HGSGl001 (Japanese Skin Toxicity Evaluation Protocol with Panitumumab: J-STEPP)-Additional analysis of antitumor effica
    Kobayashi Yoshimitsu; Komatsu Yoshito; Yuki Satoshi; Nakatsumi Hiroshi; Fukushima Hiraku; Miyagishima Takuto; Ehira Nobuyuki; Iwanaga Ichiro; Okuda Hiroyuki; Kusumi Takaya; Tateyama Miki; Tsuji Yasushi; Hatanaka Kazuteru; Nakamura Michio; Kudo Mineo; Takagi Tomofumi; Hisai Hiroyuki; Abe Riichiro; Oba Koji; Sakata Yuh
    JOURNAL OF CLINICAL ONCOLOGY, 32, 15, 2014年05月20日, [査読有り]
  • Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1)
    Y. Kurokawa; N. Sugimoto; H. Miwa; M. Tsuda; S. Nishina; H. Okuda; H. Imamura; M. Gamoh; D. Sakai; T. Shimokawa; Y. Komatsu; Y. Doki; T. Tsujinaka; H. Furukawa
    BRITISH JOURNAL OF CANCER, 110, 5, 1163, 1168, 2014年03月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Randomized controlled trial on the skin toxicity of panitumumab in third-line treatment of KRAS wild-type metastatic colorectal cancer: HGCSG1001 (Japanese Skin Toxicity Evaluation Protocol with Panitumumab; J-STEPP).
    Iwanaga Ichiro; Komatsu Yoshito; Yuki Satoshi; Kobayashi Yoshimitsu; Sakamoto Naoya; Uebayashi Minoru; Okuda Hiroyuki; Kusumi Takaya; Sogabe Susumu; Miyagishima Takuto; Tateyama Miki; Tsuji Yasushi; Hatanaka Kazuteru; Nakamura Michio; Konno Jun; Yamamoto Fumiyasu; Iwai Kazuhiro; Onodera Manabu; Oba Koji; Sakata Yuh
    JOURNAL OF CLINICAL ONCOLOGY, 32, 3, 2014年01月20日, [査読有り]
  • Updated analysis of HERBIS-1: A phase ll study of trastuzumab (T-mab) in combination with tri-weekly S-1 plus CDDP in HER2-positive advanced gastric cancer.
    Gamoh Makio; Sugimoto Naotoshi; Miwa Hiroto; Tsuda Masahiro; Nishina Shinichi; Okuda Hiroyuki; Imamura Hiroshi; Matsuyama Jin; Shimokawa Toshio; Sakai Daisuke; Kurokawa Yukinori; Komatsu Yoshito; Tsujinaka Toshimasa; Ishioka Chikashi; Furukawa Hiroshi
    JOURNAL OF CLINICAL ONCOLOGY, 32, 3, 2014年01月20日, [査読有り]
    英語
  • Impact of Rechallenge with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib
    Akira Sawaki; Tatsuo Kanda; Yoshito Komatsu; Toshirou Nishida
    GASTROENTEROLOGY RESEARCH AND PRACTICE, 2014, 342986, 342986, 2014年, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • [New molecular targeting drugs for metastatic colorectal cancer].
    Komatsu Y; Harada K; Fukushima H; Yuki S
    Nihon rinsho. Japanese journal of clinical medicine, 72, 1, 120, 126, 1, 2014年01月, [査読有り], [国内誌]
    日本語, 研究論文(学術雑誌), I explain an outline of the molecular target of new drugs for colorectal cancer. First, regorafenib is an orally active, multikinase inhibitor. Second, as angiogenesis inhibitors, aflibercept and ramucirumab. Aflibercept is the second anti-angiogenic agent after bevacizumab with a FDA approval for metastatic colorectal cancer. Ramucirumab is a fully human mAb that binds human VEGFR-2, thus blocking VEGF binding and inhibiting angiogenesis. Finally, I introduce a new combination chemotherapy regimen with molecular targetting drugs.
  • Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial
    Yasuhide Yamada; Daisuke Takahari; Hiroshi Matsumoto; Hideo Baba; Masato Nakamura; Kazuhiro Yoshida; Motoki Yoshida; Shigeyoshi Iwamoto; Ken Shimada; Yoshito Komatsu; Yasutsuna Sasaki; Taroh Satoh; Keiichi Takahashi; Hideyuki Mishima; Kei Muro; Masahiko Watanabe; Yuh Sakata; Satoshi Morita; Yasuhiro Shimada; Kenichi Sugihara
    LANCET ONCOLOGY, 14, 13, 1278, 1286, 2013年12月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • 【大腸癌肝転移;Consensus & Controversy】
    有井 滋樹; 小松 嘉人; 島田 安博; 椎名 秀一朗
    肝胆膵, 67, 4, 605, 619, (株)アークメディア, 2013年10月
    日本語
  • Pharmacokinetic assessment of irinotecan, SN-38, and SN-38-glucuronide: A substudy of the FIRIS study
    Taroh Satoh; Hirofumi Yasui; Kei Muro; Yoshito Komatsu; Shinichi Sameshima; Kensei Yamaguchi; Kenichi Sugihara
    Anticancer Research, 33, 9, 3845, 3854, 9, 2013年09月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • 【分子標的治療薬の選び方、使い方】 分子標的治療薬の選び方、使い方 レゴラフェニブ
    小松 嘉人; 結城 敏志; 福島 拓
    臨床腫瘍プラクティス, 9, 3, 280, 281, (株)ヴァンメディカル, 2013年08月
    日本語
  • Randomized phase III clinical study comparing postoperative UFT/LV, UFT plus LV/UFT and UFT plus LV plus PSK/UFT plus PSK as adjuvant therapy for curatively resected stage III colorectal cancer HGCSG-CAD study
    Shichinohe Toshiaki; Komatsu Yoshito; Akazawa Kohei; Yuki Satoshi; Fukushima Hiraku; Ohno Kouichi; Nakamura Fumitaka; Kusumi Takaya; Morita Takayuki; Senmaru Naoto; Kumagai Naoko; Hirano Satoshi
    JOURNAL OF CLINICAL ONCOLOGY, 31, 15, 2013年05月20日, [査読有り]
  • Erratum: Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: Subset analyses of the AVAGAST study and the ToGA study (Gastric Cancer DOI: 10.1007/s10120-012-0167-0)
    Kensei Yamaguchi; Akira Sawaki; Toshihiko Doi; Taroh Satoh; Yasuhide Yamada; Yasushi Omuro; Tomohiro Nishina; Narikazu Boku; Keisho Chin; Yasuo Hamamoto; Hiroya Takiuchi; Yoshito Komatsu; Shigehira Saji; Wasaburo Koizumi; Yoshinori Miyata; Atsushi Sato; Eishi Baba; Takao Tamura; Takashi Abe; Atsushi Ohtsu
    Gastric Cancer, 16, 2, 183, 184, 2013年04月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study
    Kensei Yamaguchi; Akira Sawaki; Toshihiko Doi; Taroh Satoh; Yasuhide Yamada; Yasushi Omuro; Tomohiro Nishina; Narikazu Boku; Keisho Chin; Yasuo Hamamoto; Hiroya Takiuchi; Yoshito Komatsu; Shigehira Saji; Wasaburo Koizumi; Yoshinori Miyata; Atsushi Sato; Eishi Baba; Takao Tamura; Takashi Abe; Atsushi Ohtsu
    GASTRIC CANCER, 16, 2, 175, 182, 2013年04月, [査読有り], [国内誌]
    英語, 研究論文(学術雑誌)
  • Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy
    Kohei Shitara; Satoshi Yuki; Kentaro Yamazaki; Yoichi Naito; Hiraku Fukushima; Yoshito Komatsu; Hirofumi Yasui; Toshimi Takano; Kei Muro
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 139, 4, 595, 603, 2013年04月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Randomized phase II trial of S-1 versus S-1 plus irinotecan (IRIS) in patients with gemcitabine-refractory pancreatic cancer
    Nobumasa Mizuno; Kenji Yamao; Yoshito Komatsu; Masaki Munakata; Atsushi Ishiguro; Taketo Yamaguchi; Shinichi Ohkawa; Mitsuhiro Kida; Tatsuya Ioka; Koji Takeda; Toshihiro Kudo; Masayuki Kitano; Haruo Iguchi; Akihito Tsuji; Tetsuhide Ito; Masao Tanaka; Junji Furuse; Chikuma Hamada; Yuh Sakata
    JOURNAL OF CLINICAL ONCOLOGY, 31, 4, 2013年02月, [査読有り]
    英語
  • A phase II study of trastuzumab in combination with triweekly S-1 plus CDDP in HER2-positive advanced gastric cancer (HERBIS-1)
    Sugimoto Naotoshi; Tanaka Junji; Tsuda Masahiro; Okamoto Wataru; Okuda Hiroyuki; Lmamura Hiroshi; Shimokawa Toshio; Sakai Daisuke; Kurokawa Yukinori; Komatsu Yoshito; Ishioka Chikashi; Tsujinaka Toshimasa; Takiuchi Hiroya; Furukawa Hiroshi
    JOURNAL OF CLINICAL ONCOLOGY, 31, 4, 2013年02月01日, [査読有り]
    英語
  • Adjuvant therapy with imatinib mesylate after resection of primary high-risk gastrointestinal stromal tumors in Japanese patients
    Tatsuo Kanda; Toshirou Nishida; Norihito Wada; Osamu Kobayashi; Masakazu Yamamoto; Akira Sawaki; Narikazu Boku; Masato Koseki; Toshihiko Doi; Yasushi Toh; Yoshihiro Kakeji; Toshiro Sugiyama; Yoshito Komatsu; Shojiro Kikuchi; Kyoji Ogoshi; Hitoshi Katai; Kazuhito Miyachi; Seiichi Hirota; Atsushi Ohtsu
    International Journal of Clinical Oncology, 18, 1, 38, 45, 1, 2013年02月, [査読有り], [国内誌]
    英語, 研究論文(学術雑誌)
  • Phase I dose-escalating study of panobinostat (LBH589) Administered intravenously to Japanese patients with advanced solid tumors
    Sachi Morita; Satoshi Oizumi; Hironobu Minami; Koichi Kitagawa; Yoshito Komatsu; Yutaka Fujiwara; Megumi Inada; Satoshi Yuki; Naomi Kiyota; Ayako Mitsuma; Masataka Sawaki; Hiromi Tanii; Junko Kimura; Yuichi Ando
    INVESTIGATIONAL NEW DRUGS, 30, 5, 1950, 1957, 2012年10月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial
    Takayuki Yoshino; Nobuyuki Mizunuma; Kentaro Yamazaki; Tomohiro Nishina; Yoshito Komatsu; Hideo Baba; Akihito Tsuji; Kensei Yamaguchi; Kei Muro; Naotoshi Sugimoto; Yasushi Tsuji; Toshikazu Moriwaki; Taito Esaki; Chikuma Hamada; Takanori Tanase; Atsushi Ohtsu
    LANCET ONCOLOGY, 13, 10, 993, 1001, 2012年10月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer
    Yoshito Komatsu; Satoshi Yuki; Susumu Sogabe; Hiraku Fukushima; Hiroshi Nakatsumi; Yoshimitsu Kobayashi; Ichiro Iwanaga; Michio Nakamura; Kazuteru Hatanaka; Takuto Miyagishima; Mineo Kudo; Masaki Munakata; Takashi Meguro; Miki Tateyama; Yuh Sakata
    ACTA ONCOLOGICA, 51, 7, 867, 872, 2012年09月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • 研修医からの質問Q&A 転移臓器の臨床症状に乏しい進行大腸癌症例にも、初回よりセツキシマブを用いるべきか?
    結城 敏志; 小松 嘉人
    臨床腫瘍プラクティス, 8, 3, 305, 305, (株)ヴァンメディカル, 2012年08月
    日本語
  • First-line sunitinib plus FOLFIRI in Japanese patients with unresectable/metastatic colorectal cancer: A phase II study
    Yasushi Tsuji; Taroh Satoh; Akihito Tsuji; Kei Muro; Motoki Yoshida; Tomohiro Nishina; Michitaka Nagase; Yoshito Komatsu; Takeshi Kato; Yoshinori Miyata; Naoko Mizutani; Satoshi Hashigaki; Maria Jose Lechuga; Tadamichi Denda
    CANCER SCIENCE, 103, 8, 1502, 1507, 2012年08月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer
    Y. Kawamoto; K. Tsuchihara; T. Yoshino; N. Ogasawara; M. Kojima; M. Takahashi; A. Ochiai; H. Bando; N. Fuse; M. Tahara; T. Doi; H. Esumi; Y. Komatsu; A. Ohtsu
    British Journal of Cancer, 107, 2, 340, 344, 2012年07月10日, [査読有り]
    英語, 研究論文(学術雑誌)
  • Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
    Kohei Shitara; Satoshi Yuki; Motoki Yoshida; Daisuke Takahari; Setsuo Utsunomiya; Tomoya Yokota; Yozo Sato; Yoshitaka Inaba; Masahiro Tajika; Hiroki Kawai; Hidekazu Yamaura; Mina Kato; Kentaro Yamazaki; Yoshito Komatsu; Kei Muro
    INVESTIGATIONAL NEW DRUGS, 30, 2, 787, 793, 2012年04月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Therapeutic effect of TAS-102 (A) in patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard chemotherapy by the Kohne model (Km).
    Tomohiro Nishina; Takayuki Yoshino; Nobuyuki Mizunuma; Kentaro Yamazaki; Yoshito Komatsu; Hideo Baba; Akihito Tsuji; Kensei Yamaguchi
    JOURNAL OF CLINICAL ONCOLOGY, 30, 4, 2012年02月, [査読有り]
    英語
  • Retrospective cohort study on the risk factors of admission due to serious adverse events during S-1 (tegaful, gimeracil, oteracil potassium) containing chemotherapy for gastric cancer.
    Kawamoto Yasuyuki; Yuki Satoshi; Kobayashi Yoshimitsu; Oba Koji; Hayashi Hideyuki; Nakatsumi Hiroshi; Komatsu Yoshito
    JOURNAL OF CLINICAL ONCOLOGY, 30, 4, 2012年02月01日, [査読有り]
  • Optimal dose period for indisetron tablets for preventing chemotherapy-induced nausea and vomiting with modified FOLFOX6: a randomized pilot study.
    Hiroshi Nakatsumi; Yoshito Komatsu; Satoshi Yuki; Susumu Sogabe; Miki Tateyama; Shuichi Muto; Mineo Kudo; Kanji Kato; Takuto Miyagishima; Minoru Uebayashi; Takashi Meguro; Koji Oba; Masahiro Asaka
    Chemotherapy, 58, 6, 439, 44, 6, 2012年, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Indisetron is a serotonin (5-hydroxytryptamine type 3) receptor antagonist that also antagonizes 5-hydroxytryptamine type 4 receptors. We designed a pilot study in order to explore the optimal dosing period for indisetron during modified FOLFOX6 (mFOLFOX6). PATIENTS AND METHODS: Forty-two chemotherapy-naive patients with advanced colorectal cancer scheduled to receive mFOLFOX6 were randomly assigned to either a 1- or 3-day indisetron regimen arm. The primary endpoint was complete protection from vomiting. RESULTS: Proportions of patients with complete protection from vomiting were 85.7% [95% confidence interval (CI) 63.7-97.0] with the 3-day regimen and 81.0% (95% CI 58.1-94.6) with the 1-day regimen. Proportions of patients with complete protection from nausea were 47.6% in each arm (95% CI 25.7-70.2). No rescue therapy rates were 66.7% (95% CI 43.0-85.4) versus 57.1% (95% CI 34.0-78.2). No severe adverse events were observed in either arm. CONCLUSION: Both 1- and 3-day indisetron regimens were feasible for preventing nausea and vomiting induced by mFOLFOX6.
  • Sensitivity to previous irinotecan treatment does not predict the efficacy of combination chemotherapy with cetuximab plus irinotecan for wild-type KRAS metastatic colorectal cancer
    Kohei Shitara; Takashi Ura; Keitaro Matsuo; Daisuke Takahari; Tomoya Yokota; Satoshi Yuki; Motoki Yoshida; Setsuo Utsunomiya; Yozo Sato; Hidekazu Yamaura; Mina Kato; Yoshitaka Inaba; Masahiro Tajika; Hiroki Kawai; Kentaro Yamazaki; Yoshito Komatsu; Kei Muro
    EUROPEAN JOURNAL OF CANCER, 47, 18, 2673, 2680, 2011年12月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • PHASE II STUDY OF CHEMORADIOTHERAPY WITH 5-FLUOROURACIL AND CISPLATIN FOR STAGE II-III ESOPHAGEAL SQUAMOUS CELL CARCINOMA: JCOG TRIAL (JCOG 9906)
    Ken Kato; Kei Muro; Keiko Minashi; Atsushi Ohtsu; Satoshi Ishikura; Narikazu Boku; Hiroya Takiuchi; Yoshito Komatsu; Yoshinori Miyata; Haruhiko Fukuda
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81, 3, 684, 690, 2011年11月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Phase 2 Study of Nilotinib as Third-Line Therapy for Patients With Gastrointestinal Stromal Tumor
    Akira Sawaki; Toshirou Nishida; Toshihiko Doi; Yasuhide Yamada; Yoshito Komatsu; Tatsuo Kanda; Yoshihiro Kakeji; Yusuke Onozawa; Makoto Yamasaki; Atsushi Ohtsu
    CANCER, 117, 20, 4633, 4641, 2011年10月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Randomized phase II trial of first-line treatment with tailored irinotecan and S-1 therapy versus S-1 monotherapy for advanced or recurrent gastric carcinoma (JFMC31-0301)
    Yoshito Komatsu; Yutaka Takahashi; Yutaka Kimura; Hisashi Oda; Yusuke Tajima; Shigeyuki Tamura; Jo Sakurai; Takehiro Wakasugi; Shigeru Tatebe; Masahiro Takahashi; Yuh Sakata; Masaki Kitajima; Junichi Sakamoto; Shigetoyo Saji
    ANTI-CANCER DRUGS, 22, 6, 576, 583, 2011年07月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Retrospective Cohort Study on the Safety and Efficacy of Bevacizumab with Chemotherapy for Metastatic Colorectal Cancer Patients: The HGCSG0801 Study
    Susumu Sogabe; Yoshito Komatsu; Satoshi Yuki; Takaya Kusumi; Kazuteru Hatanaka; Michio Nakamura; Takashi Kato; Takuto Miyagishima; Ayumu Hosokawa; Ichiro Iwanaga; Yuh Sakata; Masahiro Asaka
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 41, 4, 490, 497, 2011年04月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • [Colorectal cancer chemotherapy and QOL (benefits and problems of outpatient-chemotherapy)].
    Nakatsumi H; Yuki S; Kobayashi Y; Komatsu Y
    Nihon rinsho. Japanese journal of clinical medicine, 69 Suppl 3, 585, 588, 2011年04月, [査読有り], [国内誌]
    日本語, 研究論文(学術雑誌)
  • A case of sigmoid colon cancer with temporary dysarthria associated with irinotecan
    Susumu Sogabe; Satoshi Yuki; Hironobu Takano; Yoshimitsu Kobayashi; Hiroshi Nakatsumi; Takahide Sasaki; Yasuyuki Kawamoto; Hiraku Fukushima; Ichiro Iwanaga; Yasuko Uehata; Yoshito Komatsu; Masahiro Asaka
    Japanese Journal of Cancer and Chemotherapy, 38, 8, 1375, 1377, Japanese Journal of Cancer and Chemotherapy Publishers Inc., 2011年, [査読有り], [国内誌]
    日本語, 研究論文(学術雑誌)
  • Phase I / II study of XELOX plus bevacizumab in Japanese patients with metastatic colorectal cancer (JO19380): Evaluation of long-term treatment cases
    Atsushi Sato; Toshihiko Doi; Narikazu Boku; Ken Kato; Yoshito Komatsu; Kensei Yamaguchi; Kei Muro; Yasuo Hamamoto; Wasaburo Koizumi; Nobuyuki Mizunuma; Hiroya Takiuchi
    Japanese Journal of Cancer and Chemotherapy, 38, 4, 561, 569, Japanese Journal of Cancer and Chemotherapy Publishers Inc., 2011年, [査読有り], [国内誌]
    日本語, 研究論文(学術雑誌)
  • Phase II Study of Combined Treatment with Irinotecan and S-1 (IRIS) in Patients with Inoperable or Recurrent Advanced Colorectal Cancer (HGCSG0302)
    Yoshito Komatsu; Satoshi Yuki; Susumu Sogabe; Hiraku Fukushima; Ichiro Iwanaga; Mineo Kudo; Miki Tateyama; Takashi Meguro; Minoru Uebayashi; Akiyoshi Saga; Yuh Sakata; Masahiro Asaka
    ONCOLOGY, 80, 1-2, 70, 75, 2011年, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate
    Kuniaki Shirao; Toshirou Nishida; Toshihiko Doi; Yoshito Komatsu; Kei Muro; Yinhua Li; Eiji Ueda; Atsushi Ohtsu
    INVESTIGATIONAL NEW DRUGS, 28, 6, 866, 875, 2010年12月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • FIRIS STUDY: A RANDOMIZED PHASE III NON-INFERIORITY STUDY OF FOLFIRI VS. IRIS AS SECOND-LINE CHEMOTHERAPY OF MCRC
    Taroh Satoh; Kei Muro; Hirofumi Yasui; Yasuhiro Shimada; Akihito Tsuji; Tadamichi Denda; Kenji Ina; Tomohiro Nishina; Kensei Yamaguchi; Hiroya Takiuchi; Taito Esaki; Shinya Tokunaga; Yoshito Komatsu; Hisateru Yasui; Kenichi Sugihara
    ANNALS OF ONCOLOGY, 21, 13, 14, 2010年11月, [査読有り]
    英語
  • Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study)
    Kei Muro; Narikazu Boku; Yasuhiro Shimada; Akihito Tsuji; Shinichi Sameshima; Hideo Baba; Taroh Satoh; Tadamichi Denda; Kenji Ina; Tomohiro Nishina; Kensei Yamaguchi; Hiroya Takiuchi; Taito Esaki; Shinya Tokunaga; Hiroyuki Kuwano; Yoshito Komatsu; Masahiko Watanabe; Ichinosuke Hyodo; Satoshi Morita; Kenichi Sugihara
    LANCET ONCOLOGY, 11, 9, 853, 860, 2010年09月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Phase 1/2 Clinical Study of Irinotecan and Oral S-1 (IRIS) in Patients with Advanced Gastric Cancer
    Yoshito Komatsu; Satoshi Yuki; Nozomu Fuse; Takashi Kato; Takuto Miyagishima; Mineo Kudo; Yasuyuki Kunieda; Miki Tateyama; Osamu Wakahama; Takashi Meguro; Yuh Sakata; Masahiro Asaka
    ADVANCES IN THERAPY, 27, 7, 483, 492, 2010年07月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Phase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylate
    Akira Sawaki; Yasuhide Yamada; Yoshito Komatsu; Tatsuo Kanda; Toshihiko Doi; Masato Koseki; Hideo Baba; Yu-Nien Sun; Koji Murakami; Toshirou Nishida
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 65, 5, 961, 967, 2010年04月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Multicenter Phase II Study of Everolimus in Patients With Previously Treated Metastatic Gastric Cancer
    Toshihiko Doi; Kei Muro; Narikazu Boku; Yasuhide Yamada; Tomohiro Nishina; Hiroya Takiuchi; Yoshito Komatsu; Yasuo Hamamoto; Nobutsugu Ohno; Yoshie Fujita; Matthew Robson; Atsushi Ohtsu
    JOURNAL OF CLINICAL ONCOLOGY, 28, 11, 1904, 1910, 2010年04月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Long-term treatment of localized gastric marginal zone B-cell mucosa associated lymphoid tissue lymphoma including incidence of metachronous gastric cancer
    Shouko Ono; Mototsugu Kato; Kikuko Takagi; Junichi Kodaira; Kanako Kubota; Yoshihiro Matsuno; Yoshito Komatsu; Masahiro Asaka
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 25, 4, 804, 809, 2010年04月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • A case of sigmoid colon cancer with lymphangitis carcinomatosa successfully treated with chemotherapies including molecular targeting drugs
    Susumu Sogabe; Satoshi Yuki; Tomofumi Takagi; Takuji Miyazaki; Hironobu Takano; Yasuyuki Kawamoto; Hiroshi Nakatsumi; Takahide Sasaki; Ichiro Iwanaga; Yasuko Uehata; Masahiro Asaka; Yoshito Komatsu
    Japanese Journal of Cancer and Chemotherapy, 37, 3, 535, 538, Japanese Journal of Cancer and Chemotherapy Publishers Inc., 2010年03月06日, [査読有り], [国内誌]
    日本語, 研究論文(学術雑誌)
  • Sunitinib
    Yoshito Komatsu; Ichiro Iwanaga; Satoshi Yuuki; Susumu Sogabe; Hiroshi Nakatsumi; Takahide Sasaki
    Biotherapy, 24, 2, 172, 177, 2010年03月
    日本語, 研究論文(国際会議プロシーディングス)
  • Modified-Irinotecan/Fluorouracil/Levoleucovorin Therapy as Ambulatory Treatment for Metastatic Colorectal Cancer Results of Phase I and II Studies
    Satoshi Yuuki; Yoshito Komatsu; Nozomu Fuse; Takashi Kato; Takuto Miyagishima; Mineo Kudo; Masao Watanabe; Miki Tateyama; Yasuyuki Kunieda; Osamu Wakahama; Yu Sakata; Masahiro Asaka
    CLINICAL DRUG INVESTIGATION, 30, 4, 243, 249, 2010年, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Second-line chemotherapy for colorectal cancer
    Yoshito Komatsu; Susumu Sogabe; Yasuyuki Kawamoto; Ichiro Iwanaga; Yasuko Uehata; Satoshi Yuki; Masahiro Asaka
    Japanese Journal of Cancer and Chemotherapy, 36, 5, 721, 725, Japanese Journal of Cancer and Chemotherapy Publishers Inc., 2009年, [査読有り], [国内誌]
    日本語, 研究論文(学術雑誌)
  • Pilot study of combination chemotherapy using irinotecan plus S-1 for metastatic pancreatic cancer
    Kohei Shitara; Yoshito Komatsu; Satoshi Yuki; Masaki Munakata; Osamu Muto; Sen Shimaya; Yuh Sakata
    ONCOLOGY, 75, 1-2, 67, 70, 2008年, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Eradication of Helicobacter pylori for primary gastric cancer and secondary gastric cancer after endoscopic mucosal resection
    Motosugu Kato; Masahiro Asaka; Shouko Ono; Manabu Nakagawa; Souichi Nakagawa; Yuichi Shimizu; Makoto Chuma; Hiroshi Kawakami; Yoshito Komatsu; Shuhei Hige; Hiroshi Takeda
    JOURNAL OF GASTROENTEROLOGY, 42, 16, 20, 2007年01月, [査読有り], [国内誌]
    英語, 研究論文(学術雑誌)
  • 【S-1の基礎と臨床】 大腸癌に対するCPT-11+S-1併用(IRIS)療法 S-12週投薬法
    小松 嘉人; 結城 敏志; 舘山 美樹; 工藤 峰生; 浅香 正博
    癌と化学療法, 33, Suppl.I, 131, 134, (株)癌と化学療法社, 2006年06月
    日本語
  • 【S-1の基礎と臨床】 胃癌に対するCPT-11+S-1併用(IRIS)療法 S-1 2週投薬法
    小松 嘉人; 結城 敏志; 宮城島 拓人; 浅香 正博
    癌と化学療法, 33, Suppl.I, 75, 78, (株)癌と化学療法社, 2006年06月
    日本語
  • [Irinotecan plus oral S-1 in patients with advanced gastric cancer-biweekly IRIS regimen].
    Komatsu Y; Yuki S; Miyagishima T; Asaka M
    Gan to kagaku ryoho. Cancer & chemotherapy, 33 Suppl 1, 75, 78, 2006年06月, [査読有り], [国内誌]
    日本語, 研究論文(学術雑誌), We reported the results of phase I study with CPT-11 and S-1 (IRIS) in advanced gastric cancer (AGC) patients at ASCO 2002. Now I present an outline of this phase I/II trial. A combined treatment of IRIS (CPT-11 + S-1) was given to the AGC patients who had not received prior chemotherapy. S-1 was orally administered twice a day for 14 days, and CPT-11 was administered as a 90-minute intravenous infusion on days 1 and 15. This schedule was repeated every 4 weeks. Fifteen patients were registered in this phase I study and 9 patients were added in this phase II study. Non-hematological toxicities were almost classified as grade 2 or lower, except for grade 3 nausea and grade 3 dermatitis of level 2. These adverse events were manageable by administering anti-emetic drugs and a drug rest. As for hematological toxicities, grade 4 neutropenia occurred with one patient at level 1 and level 2 in phase I. And grade 4 neutropenia occurred with four patients at level 2 in phase II. However, they recovered after the drug rest, and we could continue the administration based on the standard dose modifications. These side effects were tolerable, and the overall response rate was 54.2%. MST of this regimen is 581 days. The IRIS treatment is effective and tolerable for outpatient treatments.
  • [Irinotecan plus oral S-1 in patients with advanced colorectal cancer--biweekly IRIS regimen].
    Komatsu Y; Yuki S; Tateyama M; Kudo M; Asaka M
    Gan to kagaku ryoho. Cancer & chemotherapy, 33 Suppl 1, 131, 134, 2006年06月, [査読有り], [国内誌]
    日本語, 研究論文(学術雑誌), We planned to conduct a phase II clinical study of combination therapy with CPT-11 and S-1. The antitumor effect was the primary endpoint, while the safety, progression-free survival time, and median survival time were the secondary endpoints. The subjects were untreated patients with inoperable advanced colorectal cancer aged 20-75 years. Based on the results of our previous phase I/II study in patients with gastric cancer, the dosage was established in consideration of safety for outpatient therapy. CPT-11 was administered at a dose of 100 mg/m2 (on days 1 and 15) as an intravenous infusion over 90 minutes, and oral S-1 (40 mg/m2) was administered after breakfast and dinner and then withdrawn for 2 weeks. No other serious adverse reactions occurred (either hematological or non-hematological), and all patients could receive therapy safely on an outpatient basis. Interim analysis suggested excellent results, with a response rate of 50%. Combination therapy with CPT-11 and S-1 achieved a high response rate and could be given safely. These findings suggest that the therapy has potential as first-line treatment for inoperable advanced recurrent colorectal cancer.
  • Phase I-II study of biweekly paclitaxel administration with fixed-dose-rate cisplatin in advanced gastric cancer
    Kensei Yamaguchi; Tomotaka Shimamura; Yoshito Komatsu; Akinori Takagane; Takashi Yoshioka; Soh Saitoh; Masaki Munakata; Yu Sakata; Tsukasa Sato; Tatsuhiro Arai; Hiroshi Saitoh
    Gastric Cancer, 9, 1, 36, 43, 1, 2006年02月, [査読有り], [国内誌]
    英語, 研究論文(学術雑誌)
  • 症例提示 切除不能進行胃がんに対する塩酸イリノテカン+ティーエスワン併用療法によって著効であった2例 Hokkaido Gastrointestinal Cancer Study Group(HGCSG0303)
    結城 敏志; 小松 嘉人; 宮城島 拓人; 若浜 理; 浅香 正博; 坂田 優
    臨床腫瘍プラクティス, 1, 1, 101, 104, (株)ヴァンメディカル, 2005年08月
    日本語, 切除不能進行胃癌に対する塩酸イリノテカン(以下,CPT-11)+ティーエスワン(以下,S-1)併用療法が著効した2例(61歳男性,69歳男性)を報告した.レジメンは,CPT-11を100mg/m2でday1・15に,S-1は体表面積に応じた用量をday1〜14に投与し,28日間を1コースとしたものであった
  • Treatment of a Gilbert's syndrome patient with irinotecan, leucovorin and 5-fluorouracil
    Y Komatsu; M Takei; S Yuki; N Fuse; S Furukawa; T Kato; H Takeda; M Kato; M Asaka
    JOURNAL OF CHEMOTHERAPY, 17, 1, 111, 114, 2005年02月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Phase II study of oral S-1 plus irinotecan in patients with advanced colorectal cancer: Hokkaido gastrointestinal cancer study group HGCSG0302
    Y Komatsu; S Yuuki; N Fuse; M Takei; T Kato; T Miyagishima; M Kudo; Y Kunieda; M Tateyama; O Wakahama; T Meguro; H Ohizumi; M Watanabe; H Akita; Y Sakata; M Asaka
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 35, 2, 88, 89, 2005年02月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Endoscopic clip application for closure of esophageal perforations caused by EMR
    Y Shimizu; M Kato; J Yamamoto; S Nakagawa; Y Komatsu; H Tsukagoshi; M Fujita; M Hosokawa; M Asaka
    GASTROINTESTINAL ENDOSCOPY, 60, 4, 636, 639, 2004年10月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • A randomized phase II clinical trial of tailored CPT-11+S-1 vs S-1 in patients with advanced or recurrent gastric carcinoma as the first line chemotherapy
    Y Takahashi; J Sakamoto; T Takeuchi; M Mai; T Kubota; M Kitajima; Y Tanigawara; Y Komatsu; T Toge; S Saji
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 34, 6, 342, 345, 2004年06月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • 【胃・十二指腸潰瘍 基礎・臨床の最新動向】 診断学の進歩 H.pylori感染診断・評価 ガイドライン後の新しい検査法 免疫学的迅速ウレアーゼ試験法
    加藤 元嗣; 中川 宗一; 清水 勇一; 結城 敏志; 布施 望; 武居 正明; 古川 滋; Perez-Aldana LA; 鄭 日男; 小松 嘉人; 斎藤 永仁; 武田 宏司; 杉山 敏郎; 浅香 正博
    日本臨床, 62, 3, 470, 476, (株)日本臨床社, 2004年03月
    日本語
  • [Immunological rapid urease test].
    Kato M; Nakagawa S; Shimizu Y; Yuki S; Fuse N; Takei M; Furukawa S; Perez-Aldana LA; Rinan Z; Komatsu Y; Saito N; Takeda H; Sugiyama T; Asaka M
    Nihon rinsho. Japanese journal of clinical medicine, 62, 3, 470, 476, 3, 2004年03月, [査読有り], [国内誌]
    日本語, 研究論文(学術雑誌), Immunological rapid urease test for detection of Helicobacter pylori infection, composed of a solid-phase tip coated with monoclonal antibody against H. pylori's urease and ion-sensitive field transistor (ISFT)-based pH sensor system, was developed. The monoclonal antibody against H. pylori's urease was useful to avoid the contamination of urease activity in other bacteria. Because ISFTT had high ability to detect pH change, the sensitivity and specificity of immunological rapid urease test was significantly improved comparing with that of conventional rapid urease test. The utility of immunological rapid urease test was evaluated in some clinical studies.
  • 【消化管悪性リンパ腫に対する治療法の選択】 H.pylori陰性胃MALTリンパ腫の治療方針
    小平 純一; 結城 敏志; 布施 望; 武居 正明; 小野 尚子; 森 康明; 山本 純司; 中川 学; 古川 滋; 河原崎 暢; 小松 嘉人; 武田 宏司; 杉山 敏郎; 浅香 正博; 中川 宗一; 清水 勇一; 加藤 元嗣
    消化器科, 38, 1, 6, 12, (有)科学評論社, 2004年01月
    日本語
  • Spontaneous resolution of cap polyposis: case report
    T Ohkawara; M Kato; S Nakagawa; M Nakamura; M Takei; Y Komatsu; Y Shimizu; H Takeda; T Sugiyama; M Asaka
    GASTROINTESTINAL ENDOSCOPY, 57, 4, 599, 602, 2003年04月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • [Rapid urease test].
    Kato M; Shimizu Y; Kobayashi T; Komatsu Y; Takeda H; Sugiyama T; Asaka M
    Nihon rinsho. Japanese journal of clinical medicine, 61, 1, 72, 78, 1, 2003年01月, [査読有り], [国内誌]
    日本語, 研究論文(学術雑誌), Rapid urease test(RUT) is one of the invasive methods for detection of H. pylori infection. H. pylori in the biopsy specimen splits the urea to ammonia in the test container. Elevation of pH by ammonium hydroxide are detected as color change of pH indicator. The advantage of RUT are low-priced, easy-to-use, and rapid time to diagnosis. The disadvantage of RUT are necessity of endoscopy performance and occurrence of false negative. RUT is useful for diagnosis of H. pylori infection before and after eradication treatment. However, the sensitivity of RUT is comparatively low within 6 months after completion of eradication.
  • The relationship between consumption of antimicrobial agents and the prevalence of primary Helicobacter pylori resistance
    LP Aldana; M Kato; S Nakagawa; M Kawarasaki; T Nagasako; T Mizushima; H Oda; J Kodaira; Y Shimizu; Y Komatsu; R Zheng; H Takeda; T Sugiyama; M Asaka
    HELICOBACTER, 7, 5, 306, 309, 2002年10月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Intense F-18FDG accumulation in the stomach in a patient with Menetrier's disease
    T Kato; Y Komatsu; E Tsukamoto; M Takei; T Takei; F Yamamoto; Y Kuge; M Asaka; N Tamaki
    CLINICAL NUCLEAR MEDICINE, 27, 5, 376, 377, 2002年05月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • [Clinical significance of serum antibodies against Helicobacter pylori VacA protein].
    Komatsu Y
    [Hokkaido igaku zasshi] The Hokkaido journal of medical science, 77, 2, 185, 192, 2, 2002年03月, [査読有り], [国内誌]
    日本語, 研究論文(学術雑誌)
  • [Guidelines for the management of Helicobacter pylori infection in Japan].
    Kato M; Shimizu Y; Komatsu Y; Takeda H; Sugiyama T; Asaka M
    Nihon rinsho. Japanese journal of clinical medicine, 60 Suppl 2, 397, 402, 2002年02月, [査読有り], [国内誌]
    日本語, 研究論文(学術雑誌)
  • Decreased adherence of cagG-deleted Helicobacter pylori to gastric epithelial cells in Japanese clinical isolates
    T Mizushima; T Sugiyama; T Kobayashi; Y Komatsu; J Ishizuka; M Kato; M Asaka
    HELICOBACTER, 7, 1, 22, 29, 2002年02月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • [Analysis of H. pylori eradicated patients during more-than-5-year follow-up].
    Kato M; Shimizu Y; Nakagawa S; Kodaira J; Takei M; Furukawa S; Yamamoto F; Takano M; Nagasako T; Nakaya H; Kato T; Oda H; Okawara T; Mizushima T; Komatsu Y; Takeda H; Sugiyama T; Asaka M
    Nihon rinsho. Japanese journal of clinical medicine, 60 Suppl 2, 491, 496, 2002年02月, [査読有り], [国内誌]
    日本語, 研究論文(学術雑誌)
  • Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism
    K Hokari; T Sugiyama; M Kato; M Saito; T Miyagishima; M Kudo; K Nishikawa; J Ishizuka; Y Komatsu; T Mizushima; H Kagaya; S Hige; H Takeda; M Asaka
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 15, 9, 1479, 1484, 2001年09月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Clinical relevance of the babA2 genotype of Helicobacter pylori in Japanese clinical isolates
    T Mizushima; T Sugiyama; Y Komatsu; J Ishizuka; M Kato; M Asaka
    JOURNAL OF CLINICAL MICROBIOLOGY, 39, 7, 2463, 2465, 2001年07月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Attributable risk of H. pylori in peptic ulcer disease - Does declining prevalence of infection in general population explain increasing frequency of non-H. pylori ulcers?
    T Sugiyama; K Nishikawa; Y Komatsu; J Ishizuka; T Mizushima; A Kumagai; M Kato; N Saito; H Takeda; M Asaka; JW Freston
    DIGESTIVE DISEASES AND SCIENCES, 46, 2, 307, 310, 2001年02月, [査読有り]
    英語, 研究論文(学術雑誌)
  • High-dose ecabet sodium improves the eradication rate of Helicobacter pylori in dual therapy with lansoprazole and amoxicillin
    H Kagaya; M Kato; Y Komatsu; T Mizushima; M Sukegawa; K Nishikawa; K Hokari; H Takeda; T Sugiyama; M Asaka
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 14, 11, 1523, 1527, 2000年11月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Characterization of C-terminal-truncated urinary metabolites of a recombinant hirudin in rats
    Y. Komatsu; H. Hayashi
    Peptides, 20, 12, 1401, 1409, 1999年12月
    英語, 研究論文(学術雑誌)
  • Eradication of Helicobacter pylori using 30 mg or 60 mg lansoprazole combined with amoxicillin and metronidazole: one and two weeks of a new triple therapy
    K Nishikawa; T Sugiyama; J Ishizuka; T Kudo; Y Komatsu; M Katagiri; M Sukegawa; H Kagaya; M Kudo; M Kato; H Takeda; J Toyota; M Asaka
    JOURNAL OF GASTROENTEROLOGY, 34, 72, 75, 1999年12月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Ten minute C-13-urea breath test for the diagnosis of Helicobacter pylori infection
    M Kato; M Asaka; T Kudo; M Katagiri; Y Komatsu; F Sato; M Sukegawa; T Kobayashi; H Kagaya; K Nishikawa; M Kudo; K Hokari; S Hige; M Watanabe; H Takeda; T Sugiyama
    JOURNAL OF GASTROENTEROLOGY, 33, 40, 43, 1998年11月, [査読有り]
    英語, 研究論文(学術雑誌)
  • 早期胃癌切除後に腸間膜デスモイド腫瘍の合併が認められた1例.
    馬場秀雄; 横田敏広; 横山正; 斉藤大三; 小松嘉人; 木場崇剛; 小野裕之; 山尾剛一; 白尾国昭; 近藤仁; 山口肇; 小黒八七郎; 石川勉; 杉原健一; 下田忠和
    消化器内視鏡の進歩 Prog Dig Endosc, 47, 228, 229, 1995年07月, [査読有り]
  • 食道粘膜癌に対する内視鏡的粘膜切除の検討.
    木場崇剛; 山口肇; 白尾国昭; 近藤仁; 小野裕之; 佃博; 小松嘉人; 清水靖仁; 平山敦; 小黒八七郎; 加藤抱一; 日月裕司; 渡辺寛; 中西幸浩; 落合淳志; 下田忠和
    消化器内視鏡の進歩 Prog Dig Endosc, 47, 52, 55, 1995年07月, [査読有り]
■ その他活動・業績
■ 書籍等出版物
■ 主な担当授業
  • 医学総論, 2024年, 博士後期課程, 医学研究科
  • 基本医学研究, 2024年, 修士課程, 医学院
  • 基本医学総論, 2024年, 修士課程, 医学院
  • 医学総論, 2024年, 博士後期課程, 医学院
  • 基盤医学研究, 2024年, 博士後期課程, 医学院
  • 臨床医学研究, 2024年, 博士後期課程, 医学院
■ 所属学協会
  • 日本緩和医療学会
  • 日本胃癌学会
  • 米国臨床腫瘍学会
  • 日本大腸肛門病学会
  • 日本消化器病学会
  • 日本癌学会
  • 食道癌研究会
  • GIST研究会
  • 欧州臨床腫瘍学会
  • 日本内科学会
  • 日本消化器学会
  • 北海道食道癌研究会
  • 北海道消化器癌化学療法研究会
  • American Society of Clinical Oncology
  • European Society for Medical Oncology
  • 日本がん予防学会
  • 日本消化器内視鏡学会
  • 日本消化管学会
  • 北海道癌治療研究会
■ Works(作品等)
  • 『CPT-11を用いた消化器癌化学療法』
    2002年
  • 札幌薬剤師会学術講演会『消化器癌に対する薬物療法』
    2002年
■ 共同研究・競争的資金等の研究課題
  • KRAS変異を標的とした膵管癌に対する新規腫瘍免疫療法の開発
    科学研究費助成事業
    2026年04月01日 - 2029年03月31日
    小松 嘉人; 桑谷 将城; 川久保 和道
    日本学術振興会, 基盤研究(C), 北海道大学, 26K10204
  • 肝癌幹細胞におけるPARP阻害剤耐性メカニズムの解明およびその克服
    科学研究費助成事業
    2022年04月01日 - 2025年03月31日
    小松 嘉人; 川久保 和道; 須田 剛生
    日本学術振興会, 基盤研究(C), 北海道大学, 22K08023
  • 食道癌三次元培養モデルを用いた癌幹細胞ニッチの解析
    科学研究費助成事業 基盤研究(C)
    2014年04月01日 - 2017年03月31日
    小松 嘉人; 夏井坂 光輝
    本研究では食道3次元培養モデルを用いて食道扁平上皮癌(ESCC)の癌幹細胞ニッチ解析を行った。ESCCにおいては腫瘍浸潤部において癌幹細胞ニッチが形成されており、上皮間葉転換(EMT)が癌幹細胞の維持において重要な役割を有していた。間質の線維芽細胞より放出されるEGFはEMTを誘導し、腫瘍浸潤部において癌幹細胞を増幅した。EGFR阻害剤を用いることで、癌幹細胞ニッチの形成が阻害され、癌幹細胞が抑制されることを3次元培養モデルを用いて示した。
    日本学術振興会, 基盤研究(C), 北海道大学, 26460933
  • RNA結合蛋白を介した上皮間葉転換制御による抗癌剤耐性克服療法の開発
    科学研究費助成事業 基盤研究(C)
    2013年04月01日 - 2016年03月31日
    小林 隆彦; 小松 嘉人
    上皮間葉転換(EMT)は癌細胞の浸潤能亢進などに関連している。本研究では、RNA結合蛋白であるRBM5がEMTを介して抗癌剤感受性に与える影響を検討した。癌細胞においてRBM5をノックダウンさせるとEMT転写因子Snailの発現量が増加した。一方でRBM5を発現誘導するとSnailの発現量は減少した。5FU耐性癌細胞ではRBM5の発現量は減少しSnailの発現量は亢進していた。またRBM5をノックダウンさせると5FU感受性を低下させ、RBM5を発現誘導すると5FUに対する感受性を亢進させた。これらよりRBM5はSnailの発現制御を介して薬剤感受性に影響を与えていることが示唆された。
    日本学術振興会, 基盤研究(C), 北海道大学, 25460921
  • 消化器癌の化学療法 固形癌の化学療法
    競争的資金
  • GI oncology Cancer Chemotherapy Clinical Study
    競争的資金